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Abstract 
Heart valve disease can affect people of all ages, and can be treated by either 
valve repair or valve replacement surgery. Currently available replacement heart 
valves, including mechanical prostheses, bioprostheses, autografts and allografts 
improve patient survival and quality of life, but have limitations. Key limitations 
include the risk of immunological reaction and the lack of growth potential and 
regeneration, which is of particular importance in young patients. To address these 
limitations, low concentration sodium dodecyl sulphate (SDS) decellularised human 
aortic, human pulmonary, porcine aortic and porcine pulmonary heart valve roots 
have been developed. Decellularisation of allografts would potentially reduce the risk 
of immunological reaction, and the development of a decellularised porcine 
pulmonary heart valve root would potentially provide an option for right ventricular 
outflow reconstruction in younger patients who have undergone the Ross Procedure. 
Before moving to clinical trials, the functional performance of decellularised heart 
valve roots needs to be pre-clinically assessed appropriately to determine mechanical 
safety. Whilst there are recommended test methods in place for the in vitro 
functional performance assessment of newly manufactured and modified surgical 
replacement heart valves, they need to be optimised or replaced with novel methods 
suitable for decellularised heart valve roots, due to their time dependent viscoelastic 
properties.  
The main aim of this research was to optimise in vitro hydrodynamic and 
biomechanical performance test methods and develop a novel real time fatigue test 
method for biological heart valve roots. The secondary aim was to apply the 
developed in vitro test methods to cellular and decellularised (human and porcine) 
heart valve roots to evaluate the effect of decellularisation, prior to the decellularised 
heart valve roots being implanted in patients for clinical trials. 
In collaboration with NHS Blood and Transplant, Tissue and Eye Services, in vitro 
biomechanical and hydrodynamic performance of decellularised human aortic and 
pulmonary heart valve roots was evaluated for the first time in this research. This 
research determined that the hydrodynamic and functional biomechanical 
vi 
performance of human aortic and pulmonary heart valve roots was not affected by 
decellularisation treatment. Decellularisation, however, significantly altered some of 
the directional material properties of pulmonary and aortic heart valve root leaflets.  
To support clinical translation of decellularised porcine pulmonary heart valve 
roots, material properties of pulmonary heart valve roots was evaluated following 12 
months implantation in sheep. In addition, the effect of the processing steps of 
cryopreservation and decellularisation on the material properties of porcine 
pulmonary heart valve roots was investigated. Cryopreservation was shown not to 
alter the material properties of cellular porcine pulmonary heart valve roots, 
however, decellularisation did have an effect on the material properties of the 
porcine pulmonary heart valve root wall. Following 12 months implantation in sheep, 
the decellularised porcine pulmonary heart valve root wall and leaflets showed a 
trend for decreasing stiffness and strength; becoming more like the cellular ovine, 
potentially indicating constructive remodelling. 
 A novel method was developed to investigate the real time fatigue of biological 
heart valve roots, which was then applied to porcine cellular aortic heart valve roots 
and porcine decellularised aortic heart valve roots at 120 bpm under physiological 
cyclic pressures for a maximum of 1.2 million cycles. The results showed no fatigue 
difference between the cellular and decellularised heart valve roots. 
Overall, a portfolio of in vitro pre-clinical test methods were developed, 
optimised and applied to assess the hydrodynamic, biomechanical and fatigue 
performance of biological heart valve roots including decellularised human and 
porcine heart valve roots. The in vitro pre-clinical test methods developed in this 
study will lead to the refinement of in vivo large animal studies and revision of 
international standards; and the data will help in the development of the next 
generation of replacement biological heart valve roots, such as decellularised heart 
valve roots.  
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 Introduction and Literature Review 
1.1 Introduction 
Heart valve disease affects all population ages as a result of rheumatic fever in 
young adults, atherosclerosis in elderly patients, or by congenital malformation of 
the heart valve in children (Boudoulas et al., 2013). In severe heart valve disease, 
replacement of the native heart valve is the most effective solution and is currently 
performed over 300,000 times each year worldwide (Lei et al., 2018). The available 
options for heart valve replacement include mechanical heart valves (Gott et al., 
2003), bioprosthetic heart valves (Starr et al., 2002), allograft heart valves (Fukushima 
et al., 2014), and the pulmonary autograft for the diseased aortic valve (Ross 
procedure) (Yacoub et al., 2006, Ross et al., 1991).  
The choice of heart valve replacement in older patients (age ≥ 70 years) is less 
critical than the choice in young patients, because bioprosthetic heart valves are 
durable in this age group (Bourguignon et al., 2015, David et al., 2010, Pupello et al., 
1992). However, the choice of replacement heart valve is complex in young patients 
due to longer life expectancy and patient growth (Alsoufi et al., 2009). Despite more 
than 55 years of development and use of replacement heart valves, no ideal heart 
valve replacement option is available for young patients. Bioprosthetic heart valves 
are an option due to superior haemodynamic performance but at the cost of 
accelerated valvular degeneration (Gao et al., 2004). Mechanical heart valves are 
durable but carry the risk of thromboembolism and require lifetime anticoagulation 
therapy (Gott et al., 2003). Regeneration and growth is a major problem with both 
heart valve replacements. Allograft and autograft heart valves do not require 
anticoagulation therapy and have good hemodynamic performance, but allograft, in 
contrast to autograft heart valves do not increase in size with child growth. Root 
dilation (David et al., 2000, Carr-White et al., 2001) and regurgitation (Sampath 
Kumar et al., 2006) have been reported with the use of autograft heart valves. In 
addition, the Ross procedure is a surgically demanding operation, and both the 
autograft in the aortic position and the valve replacement in the right ventricular 
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outflow tract (RVOT) suffer structural degeneration over time (da Costa et al., 2005, 
Dignan et al., 2003). 
In order to minimise the immune response to allograft heart valves and hence 
overcome the limitations of degeneration over time, decellularised allograft heart 
valve roots have been developed (Elkins et al., 2001, da Costa et al., 2005, Cebotari 
et al., 2011, Vafaee et al., 2016). Decellularised allograft heart valve roots have shown 
remarkable favourable initial in vivo results (Elkins et al., 2001, Lichtenberg et al., 
2006, da Costa et al., 2010, Dohmen, 2012). Decellularised allograft heart valve roots, 
however, suffer from limitations of availability in sizes adequate for young patients. 
To address this problem, “off the shelf” decellularised porcine heart valve roots in a 
range of sizes have been investigated by several groups (Luo, 2011, Knight et al., 
2005, Choe et al., 2018). Initial clinical translation of decellularised porcine heart 
valve roots however proved disastrous (Simon et al., 2003, Cicha et al., 2011), and 
subsequent findings reported that incomplete decellularisation was one of the main 
reasons for failure of decellularised porcine heart valves. 
In addition to complete decellularisation, the success of the replacement heart 
valve roots relies heavily on an understanding of the biomechanics, hydrodynamics 
and fatigue performance of the heart valve roots before implanting them in a human 
body. Such in vitro performance evaluation is one of the approval criteria specified 
by ISO 5840 (2015) and FDA (2010) for the newly manufactured and modified surgical 
replacement heart valves. However, the in vitro performance assessment methods 
described by the ISO 5840 (2015) standard were developed on the basis of existing 
mechanical and chemically fixed bioprosthetic heart valves (excluding allografts 
which are not classified as a manufactured valve) and need to be optimised or 
replaced with novel methods suitable for decellularised heart valve roots. In 
particular, the accelerated fatigue assessment method is not suitable for 
decellularised heart valve roots as the decellularised heart valve roots have time 
dependent viscoelastic properties and fatigue performance must be assessed in real 
time. The real time fatigue assessment under physiologic conditions (e.g. heart rates 
<200 bpm), to cycle counts less than 200 million cycles is recommended by ISO 5840 
(2015) for replacement heart valves which have components manufactured from 
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viscoelastic materials. However, the ISO 5840 (2015) standard does not define either 
the test equipment or detail the test method for real time fatigue assessment.  
This chapter will examine: the function of semilunar human cellular heart valve 
roots; the current heart valve replacement options, their advantages and 
disadvantages; next generation tissue engineered heart valves for heart valve 
replacement; in vitro biomechanical, hydrodynamic and fatigue performance 
assessment methods for current replacement heart valves and decellularised heart 
valve roots and the limitations of each; in vitro performance of replacement heart 
valves with the emphasis on in vitro performance of decellularised heart valve roots. 
The aim of this thesis was to develop, optimise and apply in vitro pre-clinical test 
methods to determine the hydrodynamic, biomechanical and fatigue performance of 
biological heart valve roots (including decellularised heart valve roots), to predict 
their safety and reliability before they can be used in clinical studies.  
1.2 The Heart  
The human heart is a pump circulating blood in the body. The pumping system 
of the heart is coordinated by a series of synchronised contractions. A contraction is 
generated by electrical activation, spread by a wave of bioelectricity that propagates 
throughout the heart in a coordinated manner. The human heart contracts 70 times 
per minute on average, equating to 100,800 cycles per day, and 36 million cycles per 
year (Roberts and Mitchelmore, 1985). 
The heart is composed of four chambers (right atrium, right ventricle, left 
atrium and left ventricle) and four valves (tricuspid, pulmonary, mitral and aortic 
valves) (Klabunde, 2005). The anatomy of the human heart is shown in Figure 1.1. 
The atrioventricular valves (tricuspid and mitral valve) are located between the 
atria and ventricles; the tricuspid valve resides between the right atrium and the right 
ventricle, and the mitral valve is between the left atrium and the left ventricle. The 
semilunar valves (pulmonary and aortic valve) are located between the ventricles and 
arteries; the pulmonary valve resides between the right ventricle and pulmonary 
artery, and the aortic valve is between the left ventricle and aorta (Bateman et al., 
2013). 
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Figure 1.1 Schematic Diagram of the Structure of the Heart (figure derived 
from http://www.sorin.com/anatomy ) 
All the heart valves, except for the mitral valve, consist of three leaflets. The 
mitral valve has two leaflets and tendinous chords. The right atrium receives 
deoxygenated blood from the systemic circulation. The right ventricle pumps 
deoxygenated blood to the pulmonary network where the lungs replenish the oxygen 
in the blood. The left atrium receives oxygenated blood from the pulmonary network 
and the left ventricle then pumps oxygenated blood through the rest of the body.  
1.3 Cardiac Cycle 
A cardiac cycle consists of two phases named ventricle systole and ventricle 
diastole (Figure 1.2). The ventricle systole phase consists of ventricular contraction 
and blood outflow, whereas the ventricle diastole phase comprises ventricular 
relaxation and blood inflow.  
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Figure 1.2 The Cardiac Cycle. Adapted from (Stehle and Iorga, 2010) 
  Ventricular Systole  
The ventricular systole phase, also known as isovolumetric contraction 
(Klabunde, 2011), is divided into two stages. Firstly, the ventricles of the heart 
undergo contraction. During this stage, the blood pressure inside the ventricles is not 
high enough to open the semilunar (aortic and pulmonary) valves. The second stage 
of systole is when the blood flows out. As the pressure in the ventricles increases, the 
semilunar valves are forced open, and blood is expelled from the ventricles very 
rapidly. The ejection of blood from the ventricle gradually decreases. The decrease in 
strength from the ejection of blood is directly correlated to the reduction in strength 
of the ventricular contraction near the end of systole. As the ejection weakens, the 
rate of blood leaving the ventricles and the heart is less than the rate of blood leaving 
the aorta, thus decreasing the pressure in the aorta. The amount of blood in a single 
cycle/beat ejected from the heart is called the stroke volume (Milnor, 1990). The 
stroke volume multiplied by the number of beats per minute (heart rate) is the 
cardiac output (Klabunde, 2005). 
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  Ventricular Diastole 
Ventricular diastole begins with a period of ventricular relaxation. In this period, 
the outflow of blood is prevented by the closure of semilunar valves, and the influx 
of blood is stopped by the closed atrioventricular (mitral and tricuspid) valves. Once 
the ventricles have relaxed even further, the atrioventricular valves open. Diastole 
ends when the atria contracts to assist in the timely filling of the ventricles (Milnor, 
1990).  
1.4 Characteristics of Semilunar (Aortic and Pulmonary) Heart Valve Roots 
 The term ‘aortic heart valve root’ refers to the aortic valve from its position at 
the left ventricular outlet to its junction with the ascending portion of the aorta (Ho, 
2009). Anatomically, this whole structure is the aortic heart valve root. The aortic 
heart valve has four anatomic components: the aortic annulus, the aortic leaflets, the 
aortic sinuses or sinuses of Valsalva, and the sinotubular junction [Figure 1.3 (a)] 
(Bateman et al., 2013).  
The aortic annulus is the attachment between the aortic heart valve root and 
the left ventricle. The aortic heart valve root is attached to the ventricular 
myocardium throughout 45% of its circumference and to the anterior leaflet of the 
mitral valve and the membranous septum in the remaining 55%. The aortic annulus 
forms a superior border of the left ventricular outflow tract. The three leaflets (left, 
right and non-coronary leaflets) of the aortic heart valve root are named after their 
coronary arteries that branch from the sinus of Valsalva, which supply blood to the 
left and right side of the heart. The sinotubular junction is above the commissures 
and is functionally important for the aortic heart valve root as the sinotubular 
junction on the commissure suspends the aortic leaflets. The aortic sinuses are 
described as the arterial walls contained between the aortic annulus and sinotubular 
junction. The aortic sinuses facilitate coronary artery blood flow during the cardiac 
cycle while maintaining eddies and currents to facilitate closure of the aortic leaflets 
during diastole. 
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Figure 1.3 Defined Terminology for the (a) Aortic and (b) Pulmonary Heart 
Valve Root Components 
The structural components of the pulmonary heart valve root are similar to the 
aortic heart valve root. The pulmonary heart valve root also consists of a valve with 
three leaflets, three sinuses of Valsalva, a crown-shaped annulus and commissures 
[Figure 1.3(b)]. The pulmonary valve leaflets are named according to their position 
with respect to the aortic valve. Two leaflets face towards the right coronary and left 
coronary aortic leaflets are known as right and left leaflets respectively. The third 
leaflet (the non-facing leaflet), being the most anterior is known as the anterior 
leaflet (Bateman et al., 2013).  
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Figure 1.4 Semilunar Heart Valve Leaflet Region (Dawidowska, 2016) 
In vitro studies have shown that native aortic and pulmonary heart valve roots 
undergo rapid, complex conformational changes during opening/closing. The valve 
opens from the belly region to the free edge (Figure 1.4) while during closing both 
the free edge and circumferential section close together indicating important 
differences between the opening and closing phases.  
 
Figure 1.5 Schematic Diagram of the Multi-Layered Structure of Heart Valve 
Root Leaflet (Rippel et al., 2012) 
Heart valve leaflets are multi-layered structures with complex architecture. 
They have functionally adapted cells and an anisotropic arrangement of extracellular 
matrix (ECM) (Ho, 2009). Heart valve leaflets have three major layers, which together 
have the necessary material properties to withstand cyclic loading (Figure 1.5). Each 
layer’s composition and function is displayed in Table 1.1. 
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Table 1.1 Composition and Function of Each Leaflet Layer (Vesely and 
Noseworthy, 1992, Schoen and Levy, 1999). 
Layer Matrix Composition Function 
Fibrosa – on the 
outflow/backward 
flow side,  
Consists of macroscopic 
collagen bundles arranged in a 
circumferential manner where 
the collagen fibers run parallel 
to the leaflet free edge ; elastin 
Maintain durability and 
stiffness to withstand 
pressure gradient 
(Chester et al., 2014) 
Spongiosa – the 
centrally arranged 
layer between 
fibrosa and 
ventricularis  
Consists of loosely arranged 
collagen fibers along with 
abundant glycosaminoglycans 
(GAGs). 
Allows shearing between 
the ventricularis and 
fibrosa during cardiac 
valve cycle (Chester et al., 
2014) 
Ventricularis - on 
the inflow side  
 
Consists of densely packed 
collagen; radially aligned elastin 
fibers 
Maintains valve 
resilience, allows stretch 
in response to pressure 
change (Chester et al., 
2014) 
  
The leaflets of the heart valve root exhibit highly nonlinear stress-strain 
relationships, are anisotropic, and have significant time dependent viscoelastic 
features exhibiting behaviours that combine features of elastic solids and viscous 
fluids. The viscoelastic response of the leaflets has often been attributed to the 
glycosaminoglycan (GAG) component of the ECM (Tseng et al., 2013). Indeed, there 
is evidence that the GAG rich spongiosa layer acts as a damper, to reduce the impact 
created by sudden changes in pressure gradient (Luo, 2011).  
The aortic and pulmonary heart valve root wall consists of three separate layers 
(Figure 1.6) as described in Table 1.2. 
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Figure 1.6 Schematic Diagram of the Multi-Layered Structure of Heart Valve 
Root Wall (McCloskey et al., 2014)   
Table 1.2 Composition and Function of Each Wall Layer (Tsamis et al., 2013, 
Pak et al., 2007) 
Layer Matrix Composition Function 
Intima – inner 
layer, in contact 
with blood  
A single layer of 
endothelial cells which 
create a lining along the 
wall 
Becomes mechanically significant 
with ageing and the associated 
onset of arteriosclerosis (Holzapfel 
et al., 2005) 
Media – middle 
thickest layer 
Made up of a complex 
network of both elastin 
and collagen fiber 
bundles  
Allows wall to resist loads in both 
the circumferential and 
longitudinal directions. (Tsamis et 
al., 2013, Pak et al., 2007) 
Adventitia – 
external 
thinnest layer 
of connective 
tissues 
Consists of fibroblasts 
and fibrocytes, which are 
cells that produce 
collagen and elastin 
respectively 
Under high pressures, the collagen 
fibers are engaged creating an 
extremely stiff structure in order 
to help resist rupture (Tsamis et 
al., 2013, Pak et al., 2007) 
 
The elastic property of heart valve root walls is mediated by elastin, whereas 
the stiffer collagen contributes to wall strength (van Soldt et al., 2015). The dynamic 
circumferential movement (dilation) of the heart valve root wall enhances leaflet 
closure at the end of systole and protects the leaflets from wall impact during systole. 
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In addition, movement of the annulus changes the tension/length relationships of the 
leaflets to enhance function (Hopkins, 2003). 
1.5 Function of Semilunar (Aortic and Pulmonary) Heart Valve Roots 
The aortic and pulmonary heart valve roots are compliant biological structures 
experiencing dynamic cyclic loading and permit the blood flow in one direction only. 
When the ventricles contract (ventricular systole), the aortic and pulmonary valve 
leaflets are pushed open by the blood flow from the ventricles to the aorta and 
pulmonary artery respectively. When the ventricles are at rest (ventricular diastole) 
the aortic and pulmonary valve leaflets are pushed closed by blood rebounding off 
the walls of the aorta and pulmonary artery respectively, effectively preventing the 
blood flowing back into the ventricles (Bateman et al., 2013). Although the leaflets 
are the most dynamic parts of the aortic and pulmonary heart valve root, the motion 
of other associated structures such as the heart valve root wall and the expansion of 
the entire valve root structure itself also play important role (Thubrikar, 2018). 
Moreover, the aortic heart valve root wall dilation is assumed to prevent the 
leaflets from sticking to the wall of the aorta (Hopkins, 2003) and to transmit the 
stress from the leaflets to the wall (Thubrikar, 2018). The dynamic aortic heart valve 
root wall anatomy has been described as designed to reduce leaflet stresses and 
thereby fatigue and eventual structural failure of the valve leaflets (Sutton et al., 
1995). During diastole, when the aortic valve is closed, a part of each leaflet coapts 
against the other two leaflets. The coaptation surface serves two important 
functions; it provides a safety margin for the valve to close without regurgitation or 
leakage, and it transfers the load on the leaflets to the commissures (Thubrikar, 
2018). During the closed phase, the aortic valve leaflets experience a tensile stretch, 
which stretches the elastin within the ventricularis layer, while the crimp and un-
crimp action of the collagen heavy fibrosa layer enables opening and closing of the 
leaflet.  
The action of the heart valve root may be explained on the basis of local 
pressure gradients in the regions of the aortic heart valve root. The transvalvular 
pressure difference across the open aortic heart valve is less than 10 mmHg in a 
healthy aortic heart valve root, typical closing pressures are 80 - 100 mmHg 
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(Chandran et al., 2012). The aortic heart valve is highly affected by diseases more 
than the pulmonary heart valve due to the fact that the aortic valve (100 mmHg) 
carries higher pressure than the pulmonary valve (30 mmHg) (Yoganathan et al., 
2004).  
The pulmonary heart valve leaflets respond in the same manner in response to 
relaxation and contraction of the right ventricle in moving de-oxygenated blood into 
the pulmonary artery and hence to the lungs for re-oxygenation.  
1.6 Valvular Disease  
Heart valve disease is defined as the improper function of one or more heart 
valves (Boudoulas et al., 2013). Heart valve disease affects more than 100 million 
people worldwide and is a growing problem because of the high incidence of 
rheumatic heart disease in developing countries (Carapetis et al., 2005). Almost 
500,000 people die every year from rheumatic heart disease, with most deaths 
occurring during childhood or early adulthood (Carapetis et al., 2005). The other main 
causes of valvular disease include calcification of the valve as people age (Kodali et 
al., 2018), congenital defects (a malformation during pregnancy)(Lincoln and Yutzey, 
2011) and  valvular infections (called endocarditis) (Torpy et al., 2007). In some 
instances the valve does not function properly due to deterioration of valvular 
supportive tissue (loose valve sealing) or due to aortic aneurysm (the dilated aorta). 
Deficit in the function of any heart valve reduces the effectiveness of the heart, and 
can eventually lead to heart failure and death. In adults, the prevalence of valvular 
heart disease increases dramatically with age reaching 13% of patients who are 
75 years old and older (Nkomo et al., 2006, Roger et al., 2012). The most common 
treatment option for a severely damaged heart valve is heart valve replacement, 
comprising of approximately 300,000 surgeries per year (Lei et al., 2018). It is also 
expected for the number of patients requiring heart valve replacement to triple from 
approximately 290,000 in 2003 to over 850,000 by 2050 (Cheung et al., 2015). 
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1.7 Replacement Heart Valves 
  Mechanical Heart Valves 
Mechanical heart valves are made totally of mechanical parts and have evolved 
through several design changes since 1952 (Gott et al., 2003). There have been 
numerous repetitions of these valves with multiple designs, including mono leaflet, 
bileaflet, and ball-in-cage models. The bileaflet valve is the most common type of 
mechanical valve used today. The bileaflet valve has two semicircular leaflets 
attached to the ring on pivots (Suh et al., 2015). The advantage of mechanical valves 
is their excellent long-term durability. However, patients require lifelong 
anticoagulation treatment to manage risks of thromboembolism (due to foreign body 
response) and haemorrhage (from too much anticoagulation) (Schoen and Levy, 
1999). Another disadvantage with the mechanical valve is the mechanical clicking 
sound resulting from the opening and closing of the valve leaflets, which can be 
disturbing for some patients. Moreover, pregnancy in patients with mechanical 
valves may present a high risk due to the need for anticoagulation (Ashour et al., 
2000).  
  Bioprosthetic Heart Valves 
The term “bioprosthetic” commonly denotes an organic valve which is a 
chemically treated stented or stentless valve (Meuris and Flameng, 2008). 
Bioprosthetic heart valves have leaflets produced of animal tissue (Pibarot and 
Dumesnil, 2009) and were first commercialised in the 1970’s but continue to face 
durability issues resulting from a variety of causes. Bioprosthetic heart valves do have 
an advantage of lower thrombogenicity compared to mechanical valves, and do not 
subject the recipient to a lifetime of anticoagulant therapy (Yadava, 2013). Another 
advantage in comparison with mechanical valves is the absence of the mechanical 
clicking sound. The major disadvantage of biological alternatives is the risk of 
structural deterioration and malfunction of the valve, which is accelerated in younger 
patients (Gao et al., 2004, Applegate et al., 2017). Tears and calcification of the 
leaflets can occur and the risk of failure (stenosis or regurgitation) and limited 
durability increases with time. Recent models of these types of bioprosthetic heart 
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valves have demonstrated good durability and last for 10–15 years in elderly patients 
over 70 years of age (Siddiqui et al., 2009, Gao et al., 2004).  
  Allografts (Homograft) Heart Valve Roots 
Allograft heart valve roots are aseptically recovered from cadavers and treated 
with antibiotics before cryopreservation (Shaddy and Hawkins, 2002, O'Brien et al., 
2001). The allografts are implanted as a freehand subcoronary implantation or as a 
full heart valve root replacement in place of a diseased heart valve (Koolbergen et al., 
2002). The advantages of using allografts in heart valve replacement surgery include 
the excellent hemodynamic performance, low risk of thromboembolism, and possibly 
a reduction in the risk of prosthetic valve infection (O'Brien et al., 2001, Staab et al., 
1998, Park et al., 2012, Elkins et al., 2001, Fukushima et al., 2014). In addition, these 
heart valve roots do not have any rigid stent mounting like most prosthetic heart 
valves, which is helpful for good haemodynamic characteristics of these heart valves. 
However, allograft heart valve roots fail due to progressive degenerative changes 
resulting from immunologically mediated inflammation and calcification (Hoekstra et 
al., 1996, Oei et al., 2002, Homann et al., 2000, Penta et al., 1984, da Costa et al., 
2005). In addition, the limited availability of allograft heart valve roots due to donor 
shortages, especially for small sized heart valve roots for young patients, is a 
significant disadvantage (Delmo Walter et al., 2012). In addition, donor human heart 
valve roots of consistent quality are often limited. 
  Autograft Heart Valves 
The autograft heart valve is the pulmonary heart valve translocated within the 
same patient to the aortic position. The autograft valve replacement procedure 
requires the pulmonary heart valve to be replaced with a pulmonary allograft, and 
this surgical procedure is referred to as the “Ross operation” or the “Ross procedure” 
(Ross et al., 1991). The Ross procedure has proven a good option for younger patients 
due to its ability to grow with the child, and can result in long term complication free 
survival for patients with aortic heart valve disease (Yacoub et al., 2006, Ross et al., 
1991). The Ross procedure has shown higher survival rates in comparison with 
mechanical heart valves, largely due to improved hemodynamic performance and 
lack of anticoagulation therapy (Alsoufi et al., 2009, Mazine et al., 2018, Nagy and 
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Watterson, 2008). However, a progressive dilation of the pulmonary autograft has 
been observed after aortic heart valve root replacement (Hokken et al., 1997, David 
et al., 2000, Takkenberg et al., 2006). In addition, the heart valve substitute in the 
pulmonary position often fails, compounding the problem of reoperations in patients 
with failed Ross procedure (Mokhles et al., 2012, Luciani et al., 2012). The use of 
autograft valves requires longer operation times and a requirement of very high 
levels of surgical skill.  
  Tissue Engineered Heart Valves 
In spite of all the existing heart valve replacement options (Section 1.7.1, 1.7.2 
1.7.3, 1.7.4), there is still a need for a better living replacement heart valve with the 
capacity to grow, repair and integrate in a biological environment. Most importantly, 
none of the current replacement heart valve options available are adequate for 
young patients, as most heart valve replacement options cannot grow with patients 
and patients may need to go through multiple revision surgeries during their life. 
The goal of heart valve tissue engineering requires the design of a scaffold that 
essentially acts as an artificial extracellular matrix (ECM) to support cell migration, 
attachment, proliferation, differentiation and tissue regeneration (Mooradian, 2016, 
Sacks et al., 2009, Mendelson and Schoen, 2006). Two main types of scaffolds have 
been developed: 
 Biodegradable synthetic scaffolds (Hoerstrup et al., 2000, Sodian et al., 2000, 
Robinson et al., 2008, Syedain et al., 2015)  
 Decellularised heart valve scaffolds from allogeneic (a genetically non-identical 
donor of the same species) or xenogeneic (animal) sources (Luo et al., 2014, da 
Costa et al., 2005, Vafaee et al., 2016, Paniagua Gutierrez et al., 2015, Elkins et 
al., 2001, Ozawa et al., 2018).    
Besides choosing the appropriate scaffold material, the choice of a right cell 
source is essential for the creation of a functional tissue engineered heart valve. The 
approaches to tissue-engineered heart valves can be divided into the in vitro and the 
in vivo tissue engineering approach (Kluin et al., 2017). The in vivo tissue engineering 
approach is, also known as ‘in situ tissue engineering’ or ‘guided tissue regeneration’ 
approach. 
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The in vitro heart valve tissue engineering approach aims to create a new viable 
three-dimensional heart valve in vitro. In this approach cells from individual cellular 
components are isolated, expanded and subsequently seeded on an appropriate 
(biodegradable) scaffold. The seeded scaffold is exposed to stimulation transmitted 
via a culture medium (biochemical stimuli) or via ‘mechanical conditioning’ of the 
tissue (mechanical stimuli) (Bader et al., 1998, Lichtenberg et al., 2006, Cicha et al., 
2011, Rippel et al., 2012, Roosens et al., 2017) prior to in vivo implantation. Different 
cell types have been investigated for the ability to synthesize extracellular matrix 
(ECM) for tissue engineered heart valves. Myofibroblasts are an interesting cell 
source because of their capacity for fast proliferation and collagen synthesis (Maish 
et al., 2003). These cells can be isolated from the vasculature of the patient, involving 
surgical intervention to obtain a tissue sample. To prevent multiple surgical 
interventions, alternative cell sources have been investigated, such as bone marrow 
stem cells (Hoerstrup et al., 2000), adipose tissue derived stem cells (Roosens et al., 
2017), amniotic fluid stem cells (Schmidt et al., 2007), endothelial progenitor cells 
from peripheral blood (Lichtenberg et al., 2006) and umbilical cord blood (Sodian et 
al., 2000).  
The in vivo heart valve tissue engineering approach is based on the use of the 
natural regenerative potential of the body for tissue maturation. In this approach, 
decellularised (xenografts, allografts) and synthetic scaffold (either with or without 
autologous cells) are directly implanted into the patient. This in vivo tissue 
engineering approach could be attractive for clinical application due to off-the-shelf 
availability, lack of the in vitro maturation phase (in vitro conditioning phase) and the 
regulatory process prior to implantation is likely to be more straightforward 
(especially if cells do not have to be expanded). 
1.7.5.1 Synthetic Scaffolds 
To increase the potential for growth and remodelling biodegradable synthetic 
polymers [polyglycolic acid (PGA), polylactic acid (PLA), poly-4-hydroxybutyrate 
(P4HB) and polycaprolactone (PCL)] are being widely investigated as scaffold 
materials to fabricate tissue engineered heart valves (Stock and Mayer, 2001, Hong 
et al., 2009, Santoro et al., 2017, Kluin et al., 2017, Mayer et al., 1997, Cascone et al., 
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2001). All the biodegradable synthetic polymer materials have characteristics such as 
a large surface to volume ratio, high porosity with small pore size, biocompatible, 
adequate mechanical properties, low cost of production, consistency, and long shelf 
life (Hutmacher, 2001). However, biodegradable synthetic scaffolds face cell 
adhesion and tissue reorganisation challenges since such materials are usually 
isotropic and ECM proteins are not usual constituents of synthetic scaffolds. Some 
limitations are encountered due to degradation of the scaffolding material being 
faster than the ECM production, leading to early structural incompetency. PGA 
degrades at the fastest rate, in weeks, while PCL degrades over years. Slow or 
incomplete polymer degradation, in contrast, may result in excessive chronic local 
tissue inflammation, possibly leading to fibrosis (scar) and hampered valve function 
(Cheung et al., 2015). 
1.7.5.2 Allogenic and Xenogenic Scaffolds 
Scaffolds derived from allogenic and xenogenic heart valves can be used as in 
tissue engineered heart valves because they have a geometry and structure that is 
closer to native human heart valves, with similar material constituents and functional 
properties and there are no potentially toxic by-products from polymer 
biodegradation. However, both xenogenic and allogenic heart valve replacements 
increase the risk of immunogenic reactions. Moreover, using native (unfixed) 
biological material, particularly xenogenic scaffolds, exposes the recipient to the risk 
of disease transmissions. These risks can be mitigated by chemical crosslinking or 
decellularisation of the tissue. Chemically crosslinked xenograft and allograft heart 
valves inhibit cellular deterioration, enhance mechanical stability, and makes it 
possible to carry an inventory of different sized heart valves (Mooradian, 2016). As 
crosslinked valves are fixed, inanimate and non-degrading scaffolds, they cannot 
grow and remodel, and thus are not suitable for heart valve tissue engineering. On 
the other hand, decellularisation of biological tissues decreases adverse 
immunological response without limiting the remodelling capacity (Luo et al., 2014, 
Wilcox et al., 2005). Several decellularisation methods have been developed to 
produce decellularised heart valves using enzymatic digestion and detergent cell 
extraction techniques. None of the currently used decellularisation techniques are 
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capable of removing 100% of cellular material. However, it has been suggested that 
the decellularisation technique has to satisfy a set minimal criteria; double-
stranded DNA content below 50 ng/mg ECM (dry weight), DNA fragments less than 
a maximum length of 200 bp, and no nuclear material visible with 6-diamidino-2-
phenylindole (DAPI) or  haematoxylin and eosin (HE) staining (Crapo et al., 2011). 
Enzymatic techniques for heart valve decellularisation include the use of 
protease digestion and nucleases. Trypsin is a highly specific enzyme that breaks the 
peptide bonds or cell matrix attachments and washes the cells from the native tissue 
(Grauss et al., 2005). Steinhoff et al. (2000), demonstrated that a 48-hour trypsin/ 
ethylene diamine tetra-acetic acid (EDTA) treatment resulted in a decellularised 
ovine pulmonary heart valve root. The procedure revealed an almost complete 
removal of cells while the static reseeding of the upper surface with autologous 
myofibroblasts and endothelial cells showed a limited and patchy coverage. This 
protocol was later applied to human aortic and pulmonary allograft valves, resulting 
in decellularisation (Cebotari et al., 2002). However, incomplete decellularisation of 
porcine aortic and pulmonary heart valve roots was reported even though the same 
trypsin/EDTA protocol was used (Kasimir et al., 2003, Rieder et al., 2004). 
Detergents are amphipathic molecules, consisting of a polar head group and a 
hydrophobic chain (or tail), which can solubilize amphiphilic cell membranes and 
separate DNA from proteins by disrupting lipid-lipid and lipid-DNA interactions. For 
heart valve decellularisation, the most commonly used non-ionic detergent is Triton 
X-100 (tert-octylphenylpolyoxyethylen) and ionic detergents are sodium dodecyl 
sulphate (SDS) and sodium deoxycholate (SDC). Non-ionic detergents are relatively 
mild detergents as they break lipid–lipid and lipid-protein interactions, but leave 
protein–protein interactions intact (Seddon et al., 2004). The ionic detergents are 
known to solubilize cell and nucleic membranes, but tend to denature proteins 
(Gilbert, 2012). Bader et al. (1998) was the first to use non-ionic detergent Triton X-
100 for the decellularisation of porcine aortic valves. Numata et al. (2004) showed 
successful decellularisation of porcine pulmonary heart valve roots with Triton X-100 
treatment. However, Booth et al. (2002) did not achieve complete decellularisation 
of porcine aortic valve roots after Triton X-100 treatment. 
19 
Chapter 1 
Several authors have demonstrated complete decellularisation of porcine 
pulmonary (Luo et al., 2014, Tudorache et al., 2007) and aortic (Paniagua Gutierrez 
et al., 2015, Korossis et al., 2002) heart valve roots using the ionic detergent, SDS. 
Booth et al. (2002) used 0.03 – 1% (w/v) SDS and 0.5 – 2% (w/v) deoxycholic acid to 
decellularise porcine aortic heart valve root leaflets. Concentrations of SDS of 0.1% 
(w/v) facilitated the removal of cellular material without causing substantial damage 
to the ECM (Booth et al., 2002) and this concentration was subsequently adopted in 
the Leeds proprietary decellularisation treatment protocol. Concentrations of SDS of 
1% (w/v) and higher have been found to change the biomechanical properties of 
tissues in some studies (Nakayama et al., 2010, Wollmann et al., 2011). Korossis et al. 
(2002) used the Leeds proprietary decellularisation treatment to decellularise 
porcine aortic heart valve leaflets and reported that the 0.1 % SDS decellularised 
porcine aortic leaflet retained its natural structure, biochemical composition, 
mechanical strength and function but decellularisation altered leaflet stiffness. These 
changes may have been due to the significant reduction of GAGs and removal of cells 
(Vafaee et al., 2016, Luo, 2011). The loss of GAGs in the decellularised leaflets, may 
have led to loosening of the fibrous structure, and uncrimping of the circumferentially 
aligned collagen fibers. Although the SDS treatment was successful in the 
decellularisation of aortic valve leaflets, it was not effective alone for 
decellularisation of the aortic wall component of whole aortic heart valve roots and, 
a modified protocol was developed by including a 1.25% (w/v) trypsin digestion step, 
applied only to the surfaces of the aortic root wall. Again, in this protocol, SDS was 
used at a concentration of 0.1% (w/v) (Wilcox et al., 2005, Luo et al., 2014).  
Porcine pulmonary heart valve roots have also been decellularised using SDS 
0.1% (w/v) with trypsin. No significant difference in the tensile properties of the 
decellularised wall and leaflet specimens compared with cellular specimens were 
found, except for a significant decrease in the elastin phase slope in both the 
circumferential and axial directions of the decellularised heart valve root wall 
specimens (Luo et al., 2014).  
Subsequently the Leeds proprietary decellularisation process comprising 
washes in hypotonic buffer, 0.1% (w/v) SDS and nuclease digestion was applied to 
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human donor aortic and pulmonary heart valve roots and this has been reported to 
remove 97% of the DNA (Vafaee et al., 2016). DNA levels are a good indicator of the 
degree of cell removal (Crapo et al., 2011). However, although the process described 
by da Costa et al. (2010) also used 0.1% (w/v) SDS, the use of nuclease was not 
described. The decellularisation technology used by da Costa et al. (2010) was 
developed at Pontificia Universidade Católica do Paraná (PUCPR), in conjunction with 
the research team from the University of Leeds, United Kingdom. The Haverich group 
(Lichtenberg et al., 2006, Neumann et al., 2014) used harsher detergent treatment 
[0.5% (w/v) SDC plus 0.5 % (w/v) SDS] to decellularise human donor pulmonary heart 
valve roots but again did not appear to incorporate a nuclease treatment (Cebotari 
et al., 2011). 
1.7.5.3 Clinical Experience with Decellularised Heart Valve Roots 
Clinical implantation of decellularised allograft heart valve roots has shown 
promising success in recent years. SynerGraft® (CryoLife, Kennesaw, GA) 
decellularised cryopreserved aortic and pulmonary allograft heart valve roots were 
introduced in 2000. The allograft heart valve roots were decellularised using a 
SynerGraft proprietary decellularisation process involving incubation of the tissue 
in sterile water to promote cell lysis. The allografts are then exposed to 
deoxyribonuclease and are repeatedly washed in an isotonic solution prior to 
cryopreservation. Clinical studies of the CryoValve SG™ pulmonary allograft heart 
valve roots in young patients and adults undergoing Ross procedures and RVOT 
reconstructions have reported comparable or improved performance relative to 
cryopreserved pulmonary allograft heart valve roots in the short to medium-term 
(Bechtel et al., 2008, Brown et al., 2010, Burch et al., 2010, Brown et al., 2011, Elkins 
et al., 2001, Zehr et al., 2005). Most of the studies reported either no valve related or 
operative death (Sievers et al., 2003, Brown et al., 2011, Burch et al., 2010, Elkins et 
al., 2001) and no significant difference in death or survival (Bechtel et al., 2008, 
Tavakkol et al., 2005). However, some of these studies reported evidence of 
structural deterioration, although Dohmen et al. (2007) reported no structural 
deterioration at a mean of 4 years post-implantation. In addition, most of these 
clinical studies are focused solely on heart valve function and do not have clear 
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information about inclusion and exclusion criteria in their clinical outcome 
assessment methods. For example, the dysfunction or failure of the decellularised 
heart valve root was not specified to be structural or non-structural. Brown et al. 
(2010) stated that no significant differences were found between CryoValve SG™ 
decellularised pulmonary heart valve roots and the control group of heart valve roots 
in terms of non-structural valve dysfunction.  
Despite these promising reports on the benefits of using decellularised allograft 
heart valve roots, some studies (Bechtel et al., 2005, Bechtel et al., 2008) which have 
compared CryoValve SG™ pulmonary allograft heart valve roots with conventional 
cryopreserved pulmonary allograft heart valve roots have found no significant 
difference in heart valve root longevity, with only slight trends toward improved peak 
pressure gradients in smaller CryoValve SG™ pulmonary allograft heart valve roots in 
maximum 5 years follow up time. The results showed freedom from heart valve root 
dysfunction was significantly worse at 10 years in the cryopreserved allograft heart 
valve roots (58%) than in the CryoValve SG™ pulmonary heart valve roots 
(83%, p <0.001). Adventitial fibrosis, degeneration, and calcification have been 
reported for most explanted decellularised heart valve roots (Helder et al., 2016). 
Other noticeable studies on decellularised allograft heart valve roots have been 
performed by the Hannover group (Cebotari et al., 2011, Tudorache et al., 2016) and 
the da Costa group (da Costa et al., 2010, da Costa et al., 2018) from Brazil using 0.5% 
(w/v) SDS plus 0.5% (w/v) SDC and 0.1% (w/v) SDS respectively to achieve 
decellularisation. They reported short to medium term success with decellularised 
pulmonary allograft heart valve roots (Cebotari et al., 2011, da Costa et al., 2005, da 
Costa et al., 2014, da Costa et al., 2018) and decellularised aortic allograft heart valve 
roots (da Costa et al., 2010, Kneib et al., 2012). da Costa et al. (2009) reported good 
results in RVOT in the Ross procedure (up to 4 years) in patients with a mean age of 
30 ± 11 years using decellularised pulmonary allograft heart valve roots. Clinical 
studies of decellularised aortic valve allograft heart valve roots implanted in  patients 
with a median age of 34 years (range, 0.1 to 71) showed stable structural integrity, 
low rate of calcification and adequate haemodynamics in a mean follow-up of 19 
months (range, 1 to 53) (da Costa et al., 2010).   
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Tudorache et al. (2016) analysed results of 69 decellularised aortic allograft 
implants in children and young patients. Hemodynamic performance of these 
decellularised allografts was excellent up to 7.6 years of follow up. Most importantly, 
this study showed clinical data of decellularised aortic allograft implanted in 16 
patients younger than 10 years (Tudorache et al., 2016). Cebotari et al. (2006) 
reported normal physiological growth of decellularised human pulmonary heart valve 
roots in the pulmonary position in two paediatric patients (aged 11 and 13 years old) 
in a 3.5 years follow up. The human pulmonary heart valve roots were decellularised 
using trypsin/EDTA and seeded with endothelial progenitor cells (Cebotari et al., 
2006). In another study by same the research group (Cebotari et al., 2011), the in vivo 
performance of decellularised pulmonary allografts was investigated in 38 patients 
(mean age at implantation 16.4 ± 11.4 years) and compared with glutaraldehyde-
fixed bovine jugular vein and cryopreserved allografts in children and young adults. 
The heart valves were decellularised using the harsher detergent treatment (0.5% 
SDC plus 0.5% SDS). The decellularised pulmonary allograft heart valves showed very 
promising early results (no development of high pressure gradients, rare insufficiency 
observations, no revision surgery) in a maximum of 5 years follow up (Cebotari et al., 
2011). In a more recent study Sarikouch et al. (2016) reported 100 % freedom from 
surgical replacement after ten years of follow-up with decellularised pulmonary 
allograft heart valve roots using the same harsher detergent treatment (0.5% SDC 
plus 0.5% SDS) in young patients (n=93) with mean age 15.8 ± 10.2 years at 
implantation. However, the mean short term follow up, small number of patients and 
complex surgical procedure in these young patients, limit the discussion of the 
results. Despite the fact that these decellularised allograft heart valves have been 
implanted into patients, details of DNA levels in these decellularised human donor 
valve allografts is lacking. Overall the results from these studies in young patients 
(Sarikouch et al., 2016, Cebotari et al., 2011, Tudorache et al., 2016, Lichtenberg et 
al., 2006) are promising; even though the decellularisation protocols were different.  
These studies (Tudorache et al., 2016, Cebotari et al., 2011, da Costa et al., 
2005, da Costa et al., 2014, da Costa et al., 2018) suggested that the short-term and 
mid-term performance of decellularised allograft heart valve roots was superior or 
similar to that of cryopreserved allograft heart valve roots which usually last 8-12 
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years without issues (Fukushima et al., 2014, Homann et al., 2000). Hence, studies 
comparing decellularised heart valve roots with cryopreserved allograft heart valve 
roots which are less than 10 years would not be expected to show any differences. 
Further long-term follow-up is needed to see whether this decellularisation process 
improves long-term durability of allograft heart valve roots.  
Although clinical performance of the decellularised allograft heart valve roots is 
satisfactory, only four decellularised allograft heart valve roots [Espoir PV  
(decellularised human pulmonary) by CorLife GbH (Hannover, Germany), Arise AV 
(decellularised human aortic) by CorLife GbH (Hannover, Germany),  CryoValve SG™ 
(decellularised pulmonary) by CryoLife (CryoLife Inc), CryoValve Aortic (decellularised 
aortic) by CryoLife  (CryoLife Inc)] are commercially available. 
Although decellularised heart valve roots are commercially available and have 
been in clinical use in some countries for more than 10 years, they are not yet 
routinely available in the UK. However, the decellularised human heart valve roots 
were used in the UK and as a part of the European Commission funded clinical trial 
studies [European clinical study for the application of regenerative heart valves 
(ESPOIR) (http://www.espoir-clinicaltrial.eu) and Aortic Valve Replacement using 
Individualised Regenerative Allografts (ARISE) (http://www.arise-clinicaltrial.eu)] 
which was started in 2012 to evaluate performance of the decellularised pulmonary 
and aortic allograft heart valve roots in young patients. These studies are conducted 
in collaboration with seven leading European clinics (London, Leiden, Padua, Zürich, 
Leuven, Chisinau and Hannover), four European tissue banks (European Homograft 
Bank, Deutsche Gesellschaft für Gewebetransplantation, Fondazione Banca dei 
Tessuti di Treviso and Euro Heart Valve Bank), and a bio-tech company, Corlife GbH, 
Germany). Heart valve roots were supplied by the tissue banks, decellularised by 
Corlife oHG, and subsequently transplanted at one of the clinical centres. Currently, 
240 patients are documented within this registry with the aim of a 10 year follow-up 
for all patients.  
The lack of availability of decellularised allograft heart valve roots, particularly 
in smaller sizes suitable for young patients, led to the proposal of decellularised 
xenogenic “off the shelf” aortic and pulmonary heart valves in a range of sizes. 
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However, to date clinical performance of these decellularised xenogenic heart valve 
roots has been disappointing (Cicha et al., 2011, Simon et al., 2003). Simon et al. 
(2003) reported failures of the FDA-approved SynerGraft® (Model 500 and 700; 
Cryolife Inc., USA) decellularised porcine pulmonary heart valve roots, leading to the 
death of three out of four male children (age 2.5-11 years). Post-implant examination 
of failed heart valve roots revealed incomplete decellularisation, lack of cell 
repopulation, lack of endothelialization with severe inflammation, fibrous sheath 
creation inside and outside the graft, foreign body reaction, calcification, and severe 
degeneration of leaflets and wall.  
Dohmen et al. (2002) reported the first successful implantation of a 1 % 
deoxycholic acid decellularised cryopreserved pulmonary allograft (AutoTissue Ltd™ 
process) seeded with autologous vascular endothelial cells in the RVOT of a 43 year 
old patient that underwent the Ross procedure. The results showed good clinical 
outcome at one year of follow-up. Subsequently, porcine heart valve roots were 
decellularised using a modification of the AutoTissue Ltd™ decellularisation method 
(with the addition of ethanol 70 % to the protocol). The decellularised porcine heart 
valve roots (Matrix P™ and Matrix P Plus™ valves; AutoTissue GmbH, Berlin, 
Germany) were implanted in 93 patients that underwent the Ross operation. A total 
of 33 patients (35.5%) experienced conduit failure, and conduit dysfunction occurred 
in 27 (29%) of the patients. The most common reason for conduit failure was stenosis 
in 20 cases (60%). Histological examination showed inflammatory giant-type cells and 
poor autologous recellularisation in all explanted valves (Cicha et al., 2011, Perri et 
al., 2012).  
1.8 In vitro Pre - Clinical Assessment of Functional Performance 
Decellularised heart valve roots have demonstrated promising results in both 
pre-clinical (Berry et al., 2017, Baraki et al., 2009, Syedain et al., 2015, Goecke et al., 
2018) and clinical (da Costa et al., 2005, da Costa et al., 2014, Bechtel et al., 2008, 
Bibevski et al., 2017) trials, however their clinical approval is limited as many primary 
challenges remain. These include key scientific questions to enable the safe clinical 
translation and logistical, technical, and infrastructural challenges for the production 
and commercialisation of such decellularised heart valve roots. Although the studies 
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outlined above have indicated that decellularisation processes do not affect the in 
vivo short or mid-term performance of allogeneic heart valve roots; the longer‐term 
outcome may differ depending upon the specific decellularisation process. Therefore 
it is important to understand the effects of specific decellularisation processes on the 
functional characteristics of allogeneic heart valves. The newly manufactured and 
modified surgical replacement heart valve roots should be performed in accordance 
to the appropriate international standards [e.g., ISO 13485 (2016): Medical Devices - 
Quality Management System - Requirements for Regulatory Purposes; ISO 10993-13 
(2009): Biological Evaluation of Medical Devices, ISO 5840 (2015): Cardiovascular 
Implants - Cardiac Valve Prosthesis (part 1 and part 2)] and the product should be 
evaluated by an accredited notified body. These standards are helpful to achieve the 
quality and effectiveness of replacement heart valves for use in patients and 
worldwide commercialisation.  
The United States Food and Drug Administration (FDA) classification of medical 
devices is based upon the level of control required to assure safety and effectiveness 
of a device (Zuckerman et al., 2011). Device classification in the European Union is 
similar to that of the United States FDA system. There are three regulatory classes for 
devices. Class I devices are defined as non-life sustaining. These products are the least 
complicated of the three classes, and their failure poses little risk to patients. Class II 
devices are more complicated than Class I devices, and present increased, but non-
life sustaining, risk to users. Class III devices sustain or support life, hence their failure 
is life threatening. The majority of heart valve replacements (mechanical and 
bioprosthetic heart valves) are considered to be Class III medical devices. However, 
classification of a tissue engineered heart valve is complex. In particular, and 
importantly, medical devices containing living cells are usually classified by the FDA 
as biological or pharmaceutical products due to their pharmacological, 
immunological, or metabolic function upon implantation. The CryoValve SynerGraft® 
allograft heart valve roots are marketed as an unclassified medical device but in 
October 2014 the FDA recommendation is to reclassify them to a class III medical 
device and the requirements will not fully apply until 26th May 2020 for Medical 
Devices. Similar discrepancies also exist in the European classification for tissue 
engineered products. According to the medical device regulation (MDR) (Regulation, 
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2017/745), all non-living (i.e., decellularised and fixed) products, such as 
decellularised allograft or xenograft heart valve roots, will be categorised as medical 
devices from 26th May 2020. 
Decellularised heart valve roots are expected to undergo remodelling and 
regeneration in vivo. For this reason, in vitro investigations alone are not sufficient to 
provide information about the clinical safety and efficacy of the device because of 
the modifications that will occur upon in vivo implantation. The remodelling potential 
of decellularised heart valve roots should be investigated in animal models for proof-
of-concept, efficacy, and safety evaluation. In addition,  in vitro investigations can be 
used to assess the individual components of decellularised heart valve roots such as 
scaffold degradation rate, cytotoxicity and biocompatibility by following  ISO 10993-
13 (2009) (Biological Evaluation of Medical Devices). Also the scaffold of the 
decellularised heart valve roots is an essential part and, therefore, its chemical and 
physical properties (e.g., porosity, stiffness, topography, hydrophilicity, and 
biodegradation) should be characterised according to ISO 10993-13 (2009). 
Subsequently, the performance and efficacy of decellularised heart valve roots 
should be evaluated as per the international standard ISO 5840 (2015) to ensure that 
the decellularised heart valve roots will be able to function upon implantation. ISO 
5840 (2015) includes investigations of material property (biomechanical 
performance), function (hydrodynamic performance), as well as structural 
performance assurance, device durability and component fatigue assessments. 
However, application of this standard to decellularised heart valve roots may be 
challenging, as indeed the ISO 5840 (2015) standard was designed to assess the 
performance of mechanical and biological heart valve prostheses and therefore the 
extrapolation to decellularised heart valve roots may be difficult, especially as the 
decellularised heart valve root leaflets have time dependent viscoelastic properties 
(Wilczek et al., 2018).  
Various studies have evaluated the pre-clinical functional performance of 
mechanical and bioprosthetic heart valves through the assessment of mechanical 
(Luo, 2011, Sauren et al., 1983, Zhang et al., 2015, Stella et al., 2007), hydrodynamic 
(Nagy et al., 2000, Jennings et al., 2002, Yoganathan, 1989) and fatigue (Iwasaki et 
27 
Chapter 1 
al., 2002, Butterfield and Fisher, 2000) performance. The ability of in vitro 
performance assessment methods to predict structural failure in the clinical setting 
is still questionable. There are some mechanical heart valve prostheses which 
showed post-market failure such as thromboembolism (Medtronic Parallel) (Bodnar, 
1996) or strut fracture (Björk-Shiley) (Harrison et al., 2013) or chronic inflammatory 
reaction due to a toxic reaction to the silver-coated sewing cuff (St. Jude Medical 
Silzone) (Tozzi et al., 2001) even though in vitro performance was assessed. Clinical 
failures have been reported for both mono leaflet mechanical valves (Omnicarbon, 
Björk–Shiley) (Kornberg et al., 1999, Ericsson et al., 1992) and bileaflet mechanical 
valves (Edward –Duromedics, TRI technologies) (Hemmer et al., 2000, Bottio et al., 
2003). The most striking example is the Björk-Shiley convexo-concave valve, which 
was implanted in 86,000 patients between 1978 and 1986 before being withdrawn 
from the market because of outlet strut fracture and embolisation of the disc. With 
the valve in the aortic position, the result was massive aortic regurgitation and often 
death (>90% of cases) (Blot William et al., 2005). 
In the past, this kind of post-market failure has also been observed in 
bioprosthetic heart valves. The first generation bovine pericardial valves (Ionescu-
Shiley bovine pericardial valve and Hancock pericardial xenografts) were withdrawn 
from the market, because of poor clinical results and a high rate of deterioration 
characterized by leaflet tears and valve incompetence (Gallo et al., 1985, Bortolotti 
et al., 1991). The limited durability of the Ionescu-Shiley bovine pericardial valve was 
due to factors related to its design, that is, abrasion-related damage at the alignment 
suture (Schoen et al., 1987).  Much of this insight came from clinical outcomes. It is 
possible that this failure could have been identified in pre-clinical in vitro or in vivo 
animal studies if such studies had been performed. 
Clinical implantation of the first decellularised porcine heart valve roots 
[SynerGraft®; Cryolife Inc., Kennesaw, GA, USA] resulted in patient mortality. The 
SynerGraft® heart valve roots were implanted into 4 children; two were homograft 
(donor organ) replacements and two as part of a Ross operation (Simon et al., 2003). 
Despite normal function of the heart valve roots after surgery, 3 of the 4 children died 
due to valve failure (Simon et al., 2003). Two children died suddenly at 6 weeks and 
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1 year after implantation due to severely degenerated SynerGraft® heart valve roots. 
The third child died at day 7 due to a SynerGraft® heart valve rupture. The fourth 
heart valve root was explanted 2 days after implantation. Histological analysis of the 
SynerGraft® heart valve roots showed incomplete decellularisation of the valves and 
calcified deposits (Simon et al., 2003).  
These post market catastrophic failures of mechanical, bioprosthetic and 
decellularised porcine heart valve roots illustrate the importance of assessing heart 
valve reliability, verifying safety requirements, and identifying weak points in the 
design before introducing heart valve products into clinical practice. This leads to the 
requirement for robust pre-clinical in vitro investigations of the products.  
 Biomechanical Performance 
From a biomechanical perspective, replacement heart valve roots have to 
function under enormous dynamic in vivo loads immediately upon implantation in 
the patient. The in vivo loads are imposed cyclically on the heart valve leaflets as the 
valve opens (flexure), permits blood to pass (shear), closes (flexure), and prevents the 
reverse flow of blood (tension and compression). The dynamic movement (dilation) 
of the heart valve root wall enhances leaflet closure at the end of systole and protects 
leaflets from wall impact during systole (Hopkins, 2003). Therefore, successful 
development of these replacement heart valve roots will require that the whole heart 
valve root structure (wall and leaflets) exhibit and maintain mechanical properties 
similar to those of native heart valve roots (Hasan et al., 2014). Native heart valve 
tissue exhibits nonlinear and anisotropic behaviour under quasi-static and dynamic 
load due to its structure and specific morphology (Carew et al., 2000).  
The material properties of the wall and leaflets of human aortic and pulmonary 
heart valve roots can be determined using quasi-static uniaxial or biaxial loading test 
methods. The material properties of human cellular heart valves have rarely been 
investigated in the literature due to the limited availability of fresh cellular human 
heart valves (Clark, 1973, Stradins et al., 2004), while a substantial number of studies 
have investigated the material properties of cellular xenogeneic heart valves 
(Anssari-Benam et al., 2011, Luo, 2011, Korossis et al., 2002, Sauren et al., 1983, 
Sacks, 2000, Hoerstrup et al., 2000). In addition, the ability to predict biomechanical 
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performance could be hampered by significant levels of biological variability present 
in human heart valve roots and quality of donor human heart valve roots. 
Uniaxial tensile testing of the wall and leaflets of heart valve roots has proved a 
more common method to determine stress-strain characteristics and failure loads, 
due to it being relatively straightforward to perform. However, this information is not 
sufficient to fully understand heart valve tissue biomechanics, in that they rarely fail 
catastrophically. The main concern is that the leaflets must have adequate 
biomechanical properties to allow the leaflets to remain compliant and co-apted 
when closed during diastole, which are biaxial properties. Because of these 
considerations, the native leaflet response to diastolic pressure is often examined 
mechanically by biaxial tensile testing of the belly region of heart valve leaflets (Billiar 
and Sacks, 2000, Wells and Sacks, 2002). During biaxial tensile testing, the applied 
load and amount of strain in each direction (axial and circumferential) can be 
controlled, similar to the experience of the leaflets in vivo. However, there are several 
limitations with biaxial tensile testing including the difficulty in clamping the tissue 
specimen without damaging it, and the stress calculation requires the assumption of 
homogeneity whereas heart valve tissues are heterogeneous (Sacks and Sun, 2003).  
 
Figure 1.7 Typical Stress-Strain Behaviour Curve for Heart Valve Tissue 
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The typical shape of the stress-strain behaviour curve of heart valve tissue (wall 
and leaflet) is shown in Figure 1.7 (Sauren et al., 1983). During the initial phase (Phase 
I, Figure 1.7), the bundle of collagen fibers are rearranged in the principal direction 
of loading and the elastin fibers are a significant determinant of the initial tissue 
stiffness. During the transitional phase (Phase II, Figure 1.7), the stiffness begins to 
rise rapidly, as the fiber recruitment concludes the high stiffness collagen bundles 
begin to bear load. At the end of the final phase (Phase III, Figure 1.7), the collagen 
network begins to slip and rupture, the slope of the stress curve falls until complete 
failure is observed (Natali et al., 2008). 
There have been many reports of the tensile testing of heart valve tissue to 
determine mechanical properties, although there are many inconsistencies between 
methods. Several studies (Korossis et al., 2002, Fitzpatrick et al., 2010, David et al., 
1994) have preconditioned heart valve tissue during uniaxial tensile testing when 
determining the material parameters (collagen and elastin phase stiffness, ultimate 
tensile stress and strain) as it is believed that this generates a consistent stress-stress 
response. Preconditioning typically involves the repeated loading and unloading 
cycles for a certain number of times prior to actual tests, to overcome history 
dependency of soft tissues (Quinn and Winkelstein, 2011). However, the exact 
mechanisms of preconditioning are unknown and it is the least studied area (Sacks, 
2000). Carew et al. (2000) tested porcine aortic leaflets and suggested that 
preconditioning must be accompanied by an adequate period of viscoelastic material 
recovery in order to fully reset strain history as preconditioning without an adequate 
rest period may actually increase the complexity of the strain history and may be 
worse than a rest period without any preconditioning. However, no study has directly 
quantified the reorganisation of collagen fibers in heart valve tissue following 
preconditioning and assessed its correlation with any altered mechanical response of 
the tissue. Martin and Sun (2012) investigated biomechanical properties of human 
aortic heart valve leaflets and reported reduced hysteresis and a stable mechanical 
response after a 60 second rest period between two preconditioning cycles. In 
summary, while some studies explained that preconditioning is necessary, protocols 
for the determination of the mechanical properties of heart valve tissue have not yet 
been standardised. 
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In addition to preconditioning, it is also important to consider the strain rate 
while determining material properties of heart valve tissue using tensile testing. 
During tensile testing of heart valve leaflets, the majority of studies have used 
relatively slower strain rates [0.6 mm.min-1 (Sokolis et al., 2002), 1 mm.min-1 (Casado 
et al., 2012), 10 mm.min-1 (Lee et al., 1984, Luo et al., 2014, Duprey et al., 2010, 
Seebacher et al., 2008), 300 mm.min-1(Tseng et al., 2013)] than physiological strain 
rates [1800 mm.min-1 to 2400 mm.min-1 (Duncan et al., 1997, Leeson-Dietrich et al., 
1995)] often due to the constraints of tensile testing equipment. Additionally, Lendon 
et al. (1993) indicated that slow strain rate helped to capture the full characteristics 
of the material behaviour and it allows time for the biological tissue constituents to 
adapt, realign and fill spaces between the tissue structural components, therefore 
reducing the force at a given extension. However, it has been reported that stress-
strain characteristics of heart valve leaflets are insensitive to strain rates (Sauren et 
al., 1983).  
There are other factors such as, the clamping of heart valve tissue specimens 
and the test specimen geometry that may contribute to the variation in material 
properties of the heart valve tissue specimens, observed by different laboratories. 
Studies have used mainly either dog bone shaped (Helder et al., 2016, Garcia-Herrera 
et al., 2012, Seebacher et al., 2008) or rectangular shaped wall specimens (Sauren et 
al., 1983, Mavrilas and Missirlis, 1991, Luo et al., 2014, Korossis et al., 2002, 
Patwardhan and Vaideeswar, 2004, Kalejs et al., 2009). Dog bone shaped samples 
have been avoided for heart valve leaflet specimens as the tissue tends to distort 
under the cutting blade pressure of the punch, making it difficult to cut precise 
curves. The reason for using a dog bone shaped heart valve wall tissue specimen is to 
ensure that the highest stress concentrations do not build up at the grip ends. 
Whereas rectangular-shaped specimens are easier to cut from both wall and leaflet 
of the heart valve root and permit the calculation of the strain from the grip-to-grip 
displacement (gauge length), which is not possible using the dog-bone shaped 
specimen.  
There are further reasons for treating the results of uniaxial tensile testing with 
caution, as there are several practical challenges such as specimen clamping and 
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gauge length measurement. Many efforts have been made to prevent grip-specimen 
slippage during testing, namely the use of specially designed hydraulic or pneumatic 
clamps (Elenes and Hunter, 2014), serrated jaws (Jennings et al., 2001), sandpaper 
(Warnock et al., 2010, Sokolis et al., 2002), tissue paper (Seebacher et al., 2008), etc. 
Also, it is very important to measure the cross-sectional area as accurately as 
possible, because the calculation of stress relies on it. Particularly with a soft 
biological tensile specimen, it is more difficult to determine thickness due to the 
compressive nature of specimen tissue (Lee and Langdon, 1996). Also heart valve 
leaflet thicknesses are non-uniform due to collagen fiber distributions and 
orientations (Clark and Finke, 1974, Li et al., 2001). Hence different studies (Vesely, 
1998, Seebacher et al., 2008, Sacks and Yoganathan, 2007) have used “tension”, that 
is, force per unit width of tissue specimen and have expressed the results purely in 
terms of load to overcome the problem of measuring the thickness.  
A final point to consider is the environmental conditions during tensile testing. 
In some studies specimens have been immersed in saline at 37 °C (Lee et al., 1984, 
David et al., 1994) whilst Sauren et al. (1983) dripped saline onto specimens to keep 
them hydrated to prevent mechanical artefacts due to tissue drying. 
To add further insight to heart valve tissue material properties, flexural 
assessment of heart valve leaflets has been used in many studies (Vesely and 
Boughner, 1989, Mirnajafi et al., 2006, Thubrikar et al., 1982, Narine et al., 2006), 
particularly when subjected to different modes of deformation (bending and creep) 
that are not included in uniaxial and biaxial extension. Various methods have been 
used to derive flexure properties of heart valve leaflets such as three-point bending 
(Engelmayr et al., 2005, Williams et al., 2009), macro-indentation test (Narine et al., 
2006) and cantilever bending (Mirnajafi et al., 2006). In the flexural macro-
indentation test method, the excised valve tissue is clamped over a round opening 
and indented with a ball probe, resulting in a load versus depth of indentation curve 
(Narine et al., 2006). Whereas, a three-point bending test measures the flexural 
response of the entire leaflet, as opposed to cut-out strips from the leaflet, whose 
behaviour is dependent on the direction in which they are cut. Although the entire 
valve leaflets were used in the three point bending flexure test method, the flexural 
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behaviour of the belly region was evaluated, as the commissural region remained 
inside the clamped part (Engelmayr et al., 2005). Furthermore, flexural testing allows 
the determination of the effect of compressive forces on heart valve leaflets in a 
bending configuration. The compressive flexure stresses are believed to impact the 
degradation of bioprosthetic heart valve tissues (Thubrikar et al., 1982, Vesely and 
Boughner, 1989). The flexural deformation mode not only represents a major 
deformation mode of heart valve leaflets, but also allows direct examination of 
individual layer responses in tension and compression. Mirnajafi et al. (2006) used 
the flexural method to derive the layer specific mechanical properties of heart valve 
tissue in the low stress-strain region.  
There is an alternative to testing excised tissue of simple geometry to derive the 
biomechanical response of the heart valve root wall under more physiological 
conditions, which is to test whole heart valve roots. For aortic and pulmonary heart 
valve roots, the circumferential expansion (dilation) can be measured with respect to 
different internal static pressures (Jennings et al., 2001, Nagy et al., 2000). The 
function of the replacement heart valve root leaflets is dependent on the dilation of 
the heart valve root and when the dilation was reduced to non-physiological levels, 
open leaflet bending strains were higher (Butterfield et al., 1991, Lockie et al., 1993). 
In open heart valve surgery, replacement heart valves are typically sutured to 
the annulus which is left in situ when the native valve is removed; suture line 
breakdown can lead to paravalvular leakage or separation of the replacement heart 
valve from the annulus (valve dehiscence). Risk factors for replacement heart valve 
dehiscence include bacterial endocarditis, aneurysm of the ascending aorta, 
degenerative regurgitation, and severe calcification of the valve (Rizzoli et al., 1984). 
In order to determine whether the sutures and replacement heart valve tissue are 
strong enough to withstand in vivo load, studies (Pierce et al., 2016, Walraevens et 
al., 2008, Choe et al., 2018, McGregor et al., 2016) have reported upon in vitro suture 
pull out tests. These investigations were aimed at quantifying the suture retention 
strength, often referred to as anastomotic strength, which is “the force necessary to 
pull a suture from the replacement heart valve”. The test methods usually involve 
34 
Chapter 1 
pulling a suture loop until the suture pulled through the heart valve specimen (wall 
and/or myocardium) using a uniaxial tensile tester (Walraevens et al., 2008). 
The chemical treatments used to treat animal and human heart valve tissue for 
producing bioprosthetic and decellularised heart valves have been shown to affect 
the biomechanical and viscoelastic properties of the tissue. Generally, viscoelasticity 
is manifested by a number of different features, including hysteresis, 
preconditioning, stress relaxation and creep. Glutaraldehyde fixation of bioprosthetic 
heart valves reduces the immune response and prevents leaflet degradation but can 
induce ECM cross-links and other structural changes (Vesely and Noseworthy, 1992, 
Golomb et al., 1987) that reduce radial stiffness and increase extensibility as well as 
reduce creep and stress relaxation (Lee et al., 1984, Vesely et al., 1995, Rousseau et 
al., 1983). The effects of decellularisation treatment on viscoelasticity have been 
reported in some studies (Jiao et al., 2011, Spina et al., 2003). Spina et al. (2003) 
reported no change in relaxation behaviour of porcine aortic valve leaflets following 
decellularisation using Triton X-100. Jiao et al. (2011) also reported no change in 
ovine pulmonary and aortic leaflet viscoelasticity under torsional loading following 
decellularisation using Triton X-100. Conversely, the decellularisation treatment 
using Triton X-100 resulted in significant changes to the stress relaxation behaviour 
of pulmonary heart valve leaflets, but, the creep behaviour remained 
unchanged (Converse et al., 2012). The difference seen in these studies (Quinn et al., 
2012, Spina et al., 2003, Jiao et al., 2011) may be due to the use of different types of 
heart valve leaflets. 
Several reports of the effects of decellularisation on the quasi-static material 
properties of heart valve tissues are available in the literature (Korossis et al., 2002, 
Seebacher et al., 2008, Liao et al., 2008, Tudorache et al., 2007). Korossis et al. (2002) 
and Luo et al. (2014) found no difference in the ultimate tensile strength of porcine 
aortic and pulmonary heart valve root leaflets respectively following 0.1% (w/v) SDS 
decellularisation treatment. However, Korossis et al. (2002) did report a significant 
decrease in elastin phase stiffness of porcine aortic leaflets following 0.1% (w/v) SDS 
decellularisation treatment. Seebacher et al. (2008) reported no change in the tensile 
strength and failure strain of porcine pulmonary heart valve roots in uniaxial tension 
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following detergent based decellularisation, though stiffness values were not 
reported. Liao et al. (2008) investigated the effects of multiple decellularisation 
protocols [SDS, trypsin, and a Triton X-100] on the biomechanical performance of 
porcine aortic valve leaflets and reported decreased flexural stiffness regardless of 
the decellularisation protocol used. Another study by Tudorache et al. (2007) et al. 
evaluated the effect of multiple decellularisation protocols [1% SDC, 1% SDS, or 
0.05% trypsin/0.02% EDTA] under uniaxial loading conditions and found a decrease 
in tensile strength and stiffness in the elastin phase region for decellularised (1% 
SD, 1% SDS) pulmonary heart valve root wall axial specimens with the exception of 
trypsin/0.02% EDTA decellularised porcine pulmonary heart valve root wall 
specimens. However, the detergent/enzymatic decellularised ovine pulmonary 
heart valve root wall specimens Quinn et al. (2012) showed increased stiffness in 
the elastin phase region under biaxial loading conditions (Buse et al., 2016). The 
changes in material properties may have been due to different decellularisation 
protocols and heart valve root species. 
Only one study (Elkins et al., 2001) investigated and compared biomechanical 
properties of cellular and decellularised human pulmonary heart valve roots to 
determine the effect of decellularisation. In this study, the heart valve roots were 
tested mechanically using uniaxial tensile (wall and leaflets) and suture retention 
(wall and myocardium) test protocols. No differences in biomechanical properties 
were detected between the cellular and decellularised human pulmonary heart valve 
roots.  
 Hydrodynamic Performance  
The evaluation of the functional performance of heart valve replacements 
under pulsatile flow is a useful indicator of predicted clinical performance. The 
hydrodynamic performance of replacement heart valves can be assessed in terms of 
transvalvular pressure difference and forward flow performance, expressed as valve 
effective office area (EOA), and regurgitatant volumes. Various designs of pulsatile 
flow simulators (or duplicators) have been used to gain information on the functional 
performance of replacement heart valves under physiological pulsatile flow 
conditions by many different laboratories (Jennings et al., 2001, Walker and 
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Yoganathan, 1992, Heiliger et al., 1987, Fisher et al., 1986). Commercial pulse 
duplicators include the Vivitro pulse duplicator (ViVitro Labs Inc., Victoria, BC), 
Dynatek Dalta MP3® (Dynatek Dalta®, Galena, MO, USA) hydrodynamic pulse 
duplicator and BDC Heart valve pulse duplicator system (Model: HDT-500 and HDTi-
500; BDC laboratories, USA). All these pulse duplicator systems are designed with 
current prosthetic heart valve designs in mind. The pulsatile flow duplicator simulates 
and recreates the pressure and flow conditions that exist in the left or right side of 
the heart. The majority of pulse duplicator systems consist of aortic and mitral 
sections containing the valve under test, a compliance chamber, peripheral 
resistance and atrial reservoir, pulsatile pump and data collection instrumentation. 
These systems allow measurements of pressure and flow to assess hydrodynamic 
performance of the heart valve root under pulsatile flow in terms of the following key 
parameters: 
 Mean transvalvular pressure difference (ΔP):  the average value of the pressure 
difference (ventricle pressure – aortic pressure) across a valve during systolic 
ejection. This is a flow dependent quantity and is dependent on the internal 
diameter and orifice size.  
 Effective orifice area (EOA): relates to pressure gradient and volumetric flow rate 
for an estimation of heart valve efficiency (Gorlin and Gorlin, 1951).  
EOA is also a standard measure of clinical assessment, measured using 
Doppler echocardiography to investigate the effectiveness of heart valve opening 
during the forward flow phase (Dasi et al., 2009). 
 Regurgitation volume: the sum of the closing volume and the leakage (closed) 
volume. The closing volume is the volume of fluid flowing retrograde through the 
valve during closure. Any fluid accumulation after valve closure results from 
leakage and is referred to as the leakage volume (Figure 1.8). 
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Figure 1.8 Representative Flow Waveform for Cardiac Cycle where (a) Forward 
Flow Volume (b) Closing Volume and (c) Leakage Volume (ISO 5840, 2015) 
The resistance to blood flow has a significant effect on the circulatory system. 
The body has the ability to change the resistance to flow by contracting or dilating 
the arteries. To adjust this resistance in the pulse duplicator system, a simple 
restrictor clamp has been used in many previous studies (Jennings et al., 2001, 
Korossis et al., 2002, Schichl and Affeld, 1993). Donovan (1975) used a bellows 
operated valve with a metal plate which rotated about a pivot to change the cross 
sectional area of the flow tube.  This technique was useful for achieving lower 
resistance, especially for the testing of pulmonary heart valves. The method used by 
Liu et al. (2005) used a porous material which had appropriate permeability to 
represent compliance and peripheral resistance. The resistance value was achieved 
by moving a slide plate over porous material to block and unblock some of the pores.  
One of the key factors to making the pulsatile flow simulator representative of 
the physiological system is to have variable arterial compliance so that the pressure 
and flow waveforms adequately simulate that of the human body. The most common 
design for producing compliance in the pulse duplicator system is to simply have a 
cylindrical chamber downstream filled with circulating test fluid and air (Jennings et 
al., 2001, Donovan, 1975, Korossis et al., 2002, Fisher et al., 1986). The compliance 
chamber and variable resistance in the pulsatile flow simulator reproduced the elastic 
characteristic of the heart valve root. Also, the type of test fluid to be used during 
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testing can be quite important, particularly when evaluating materials such as 
polyester and polyurethanes whose viscoelastic properties are affected by blood 
(Campo-Deaño et al., 2013). Bazan and Ortiz (2016) used a glycerol-water mixture 
with 47.6% by volume of glycerin solution in water (with normal saline solution to 
allow the electromagnetic flowmeter operation) to validate the pulsatile flow 
simulator design with a bileaflet mechanical valve. However, the disadvantage of 
using glycerol in the pulsatile flow simulator makes the system difficult to clean due 
to its viscous nature. Hence most studies (Rahmani et al., 2017, Jennings et al., 2001, 
Luo, 2011) have used saline to test replacement heart valves in the pulsatile flow 
simulator. 
In addition to pulsatile flow studies, limited studies (Leo et al., 2006, Loger et 
al., 2014, Jennings, 2001) have used a static leakage flow test to assess valve 
competency in terms of leakage flow rate of the closed valve under static back 
pressure. The test set up consisted of a vertical column of test fluid which was able 
to apply back pressure on the heart valves (Loger et al., 2014, Jennings, 2001). Loger 
et al. (2014) and Leo et al. (2006) measured competency of a transcatheter 
mechanical heart valve with Nitinol leaflets and bileaflet mechanical heart valves (St. 
Jude Medical Inc) respectively. Whereas Jennings (2001) used static leakage flow test 
method to measure competency of cellular and glutaraldehyde fixed porcine aortic 
and pulmonary heart valve roots. The static leakage flow test did not give quantitative 
values regarding overall valve performance.  
The hydrodynamic performance of decellularised xenogenic heart valve roots 
has been reported in some studies (Bottio et al., 2010, Dohmen et al., 2002, Luo et 
al., 2014), however, only one study (Elkins et al., 2001) investigated hydrodynamic 
performance of decellularised (CryoValve SG) human heart valve roots. Elkins et al. 
(2001) showed no difference in hydrodynamic performance between cellular and 
decellularised human pulmonary heart valve roots.  
 Dohmen et al. (2002) investigated the in vitro hydrodynamic performance of 
decellularised porcine pulmonary heart valves in the pulsatile flow simulator and 
compared it with glutaraldehyde fixed xenogenic and polyurethane heart valves. The 
decellularised pulmonary porcine heart valves showed the same performance as 
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polyurethane heart valves, which were superior to the glutaraldehyde fixed 
xenograft. Bottio et al. (2010) investigated the in vitro hydrodynamic performance of 
porcine aortic heart valve roots, before and after decellularisation with sodium 
cholate (TRI-COL), SDC , 0.03% SDS, and 0.1% SDS. The results showed that except for 
0.03%, SDS, the other three decellularisation protocols modified the hydrodynamic 
performance of porcine aortic heart valve roots. SDC and TRI-COL-treated porcine 
aortic heart valve roots exhibited decreased transvalvular pressure difference and an 
increased EOA. However, compared to SDC and TRI-COL, the SDS decellularisation 
treatments showed contrasting results. The decellularised porcine aortic heart valve 
roots treated with 0.1% SDS resulted in a significantly increased transvalvular 
gradient and a reduced EOA. However, Luo et al. (2014) reported that hydrodynamic 
performance and leaflet kinematics of the 0.1% (w/v) SDS decellularised porcine 
pulmonary heart roots were similar to cellular porcine pulmonary heart valve roots. 
No significant difference was observed for either EOA or leaflet dynamics between 
the decellularised and cellular porcine pulmonary heart valve roots. 
 Fatigue/Durability Performance  
During the cardiac cycle, native heart valve roots are subjected to relatively high 
mechanical stresses (Dasi et al., 2009, Sacks et al., 2009). For this reason, any heart 
valve replacement must be capable of resisting these stresses to prevent structural 
fatigue and failure.   
The FDA (2010) and ISO 5840 (2015) standards prescribe guidelines for 
accelerated fatigue test methods applied to mechanical and bioprosthetic heart 
valves. These standards require that a targeted minimum peak transvalvular pressure 
must be established across the closed test heart valves for at least 5% of each cycle, 
and this should be maintained for 95 % or more of all test cycles. The ISO 5840 (2015) 
[clause 7.2.4.2 Device durability assessment; ISO 5840:2-Part 2] standard requires 
that mechanical heart valves must be tested for at least 400 million cycles (equivalent 
to 15 years in vivo), and due to short term clinical expectations, bioprosthetic heart 
valves must be tested at least for 200 million cycles (equivalent to 5 years in vivo) in 
pulsatile flow prior to clinical application. In addition to accelerated fatigue 
assessment, real time wear assessment under physiologic conditions (e.g. heart rates 
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<200 bpm), to cycle counts less than 200 million cycles is recommended for 
replacement heart valves which have components manufactured from viscoelastic 
materials. However, the ISO 5840 (2015) standard does not define the test 
equipment, test conditions or test method for real time wear assessment.  
In order to predict structural fatigue, equivalent to its expectancy in vivo, it is 
not practical to perform in vitro fatigue tests for the same period of time. To reduce 
the in vitro testing time period, accelerated fatigue testing of replacement heart 
valves has been performed in numerous studies (Iwasaki et al., 2002, Butterfield and 
Fisher, 2000, Vesely, 1995, Bezuidenhout et al., 2015, Arokiaraj et al., 2016, Raghav 
et al., 2016). The assessment of durability by accelerated cycling has been widely 
accepted as a major component in the development stage of heart valve 
replacements. The typical duration of accelerated fatigue testing for an equivalent of 
10 years in vivo is approximately 8 months at 15 Hz which is fifteen times faster than 
the normal heart rate producing dynamic loads different to those physiologically 
experienced. However, in the case of decellularised heart valve roots, the optimal 
protocol for predicting fatigue failure has yet to be established. Biologically derived 
products are not generally tested in an accelerated rate because the differences in 
physiological and accelerated rate environments influence the durability of the 
biological or decellularised heart valve roots due to viscoelastic properties of the 
heart valve tissue.  
The viscoelastic behaviour of heart valve root leaflets, as determined by the 
strain rate sensitivity of the stress-strain curve or stress relaxation (Tseng et al., 
2013), requires attention when accelerated fatigue testing is being considered. 
Broom (1977) and Stella et al. (2007) showed the stress-strain behaviour of such 
tissue to be insensitive to different non physiological and physiological strain rates. 
On the other hand, Vesely et al. (1995) has shown such tissue to be sensitive to strain 
rates. However, the strain rates investigated by Vesely et al. (1995) were lower than 
physiological strain rates. Vesely et al. (1995) further explained that due to the 
viscoelasticity of porcine heart valve leaflets, during durability testing in the 
accelerated fatigue tester, the heart valve leaflets may not have enough time to relax 
with reduced stress-relaxation, resulting in a higher preload for each subsequent 
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cycle. Accelerated fatigue testing would then under-estimate the valve durability. On 
the contrary, Vesely et al. (1995) explained that valve durability may be 
overestimated due to insufficient leaflet tissue relaxation between two consecutive 
cycles, since the valve would be under lower cyclic stresses than in vivo. When the 
viscoelastic material is exposed to cyclic loading, during each loading cycle the 
material undergoes a combination of the creep and relaxation process. At 
accelerated cyclic conditions the retardation process between two loading cycles 
cannot be fully completed. Consequently, strain starts to accumulate, which leads 
to hardening of the material and ultimately to failure of the material. The rate of this 
strain accumulation is dependent on the applied peak pressure and the period of time 
for which peak pressure is applied on the closed valve. This process has a greater 
effect on more compliant tissue, which has been demonstrated by the work of 
Butterfield and Fisher (2000) who investigating the fatigue of photo oxidised bovine 
pericardial heart valves (Butterfield and Fisher, 2000). This study showed that in vitro 
accelerated fatigue testing failed to replicate the in vivo failure of photo oxidised 
bovine pericardial heart valve, as the accelerated fatigue test did not replicate in vivo 
pressure and time per cycle. D'Souza et al. (2003) further explained that the leaflet 
kinematics, bending strains in the leaflet belly, the strain time integral and proportion 
of time that the valve fully closed or open were dependent on cycle rate. Iwasaki et 
al. (2002) tested a polymer valve (Jellyfish valve), in attempting to identify an ideal 
method to predict heart valve prosthesis durability and identified that the valve was 
less durable in accelerated fatigue testing than in vivo. The study also identified that 
there might be variation in dynamic pressures experienced by the heart valve leaflets 
between various designs of accelerated fatigue testers and that these factors may 
influence valve fatigue. 
Frame mounted glutaraldehyde fixed pericardial and porcine xenograft 
bioprosthetic heart valves which failed mechanically in an accelerated fatigue tester 
have been shown to fail in vivo as well (Gabbay et al., 1984, Schuster and Wagner, 
1989, Wheatley et al., 1987, Fisher, 1986, Ishihara et al., 1981). Mechanical 
degeneration was responsible for a large percentage of bioprosthetic heart valve 
failures. Bioprosthetic heart valve leaflets experience high transient stresses during 
valve closure, and cyclic flexural and compressive stresses during valve opening. It 
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was believed that tensile stresses induced during valve closure were responsible for 
leaflet tearing; studies have shown that tissue rupture is related to flexure 
fatigue (Ishihara et al., 1981, Vesely et al., 1988, Vesely et al., 2001) and the 
compressive stresses on the inner surface of the leaflets (Krucinski et al., 1993). In 
addition, Thubrikar et al. (1983) reported that the cyclic compressive stressing of the 
valve leaflets disrupted the collagen architecture. Studies (Christie, 1992, Wells and 
Sacks, 2002) indicated that accelerated fatigue testing underestimates the effects of 
long-term cycling on biomechanical performance of zero pressure-fixed bioprosthetic 
valves. Hence, studies (Sacks and Smith, 1998, Wells and Sacks, 2002) have 
determined the effects of in vitro accelerated cyclic loading on bioprosthetic valves 
by subsequent use of biaxial testing to quantify the changes in collagen fiber 
architecture. 
Studies (Syedain et al., 2013, Costa et al., 2005, Lim et al., 2015) reported in 
vitro real time fatigue assessment of frame mounted tissue engineered heart valves 
under cyclic physiological test conditions. Syedain et al. (2013) and Lim et al. (2015) 
used custom made pulsatile flow simulators which were able to test one sample at a 
time, whereas Costa et al. (2005) tested four pericardial bioprostheses (three 
decellularised and one glutaraldehyde fixed) using a Shelhigh FTS 300 accelerated 
fatigue tester (Shelhigh Inc., Springfield, NJ, USA). Costa et al. (2005)  fatigue tested 
three 0.3% EDTA decellularised pericardial bioprostheses and one glutaraldehyde 
bovine pericardial bioprostheses (control) at mean heart rate 80 bpm for 150 million 
cycles. The test was interrupted at every 50 x 106 cycles to assess the hydrodynamic 
performance and showed that the decellularised bovine pericardial bioprostheses 
had similar hydrodynamic performance to the glutaraldehyde bovine pericardial 
bioprosthesis. However, fatigue of decellularised porcine pericardial bioprostheses 
was compared with only one control valve which limits critical analysis of this study. 
Syedain et al. (2013) performed a short term (maximum 2 million cycle) fatigue test 
at 120 bpm on two tissue engineered tubular heart valves under pulmonary heart 
conditions (average 8 mmHg end of diastolic pressure drop). To prevent bacterial 
contamination during testing antibiotics (penicillin and streptomycin) were added to 
the test fluid (PBS). The tissue engineered heart valves were made by moulding fibrin 
gel with fibroblasts into a tubular shape, culturing the tube within a bioreactor for 5 
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weeks, decellularising with 1 % SDS and then mounting on PEEK frame. No 
macroscopic tissue damage was observed in the end of test visual examination. 
However, there was evidence of leaflet thinning after 2 million cycles. Lim et al. 
(2015) tested frame mounted Triton X-100 decellularised and immunologically 
modified with α-galactosidase porcine aortic heart valves with pulsatile pressure of 
120/80 mmHg and heart rate of 60 bpm for 8 million cycles and no macroscopic 
leaflet failure was observed.   
The fatigue test methods used in these studies (Syedain et al., 2013, Costa et 
al., 2005, Lim et al., 2015) were not suitable for decellularised heart valve roots as 
the studies investigated fatigue of frame mounted heart valves and hence elastic 
effects of the aorta were not included. More commonly, the fatigue of decellularised 
heart valve roots has been investigated in the in vivo juvenile sheep model (Dohmen 
et al., 2003, Quinn et al., 2011, Baraki et al., 2009, Goecke et al., 2018, Berry et al., 
2017). Animal models are essential in the development of heart valve replacement 
to derive the effects (calcification, cytotoxicity, and biocompatibility) of the host 
environment, however, they are expensive and do not always represent the wide 
variation of size and morphology seen in the human population. In addition, sheep 
have normal blood pressure, but the majority of human patients suffering from heart 
valve disease have high blood pressure.  
The clinical use of decellularised heart valve roots is increasing. Due to the lack 
of an in vitro real time fatigue method and corresponding lack of in vitro real time 
fatigue data for decellularised heart valve roots, there is an unmet need to develop a 
predictive in vitro real time cyclic fatigue method for decellularised heart valve roots. 
The decellularised heart valve root wall and leaflets are integral components and 
when implanted in vivo, both experience cyclic loading. Therefore it is appropriate to 
include wall dynamics in addition to leaflet dynamics for fatigue assessment. It is also 
important during the assessment to control transvalvular pressure across the closed 
valve to achieve radial expansion of the leaflets and dilation pressure within the heart 
valve root to maintain physiological function of the heart valve root (Lockie et al., 
1993). 
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1.9 Project Rationale 
Heart valve disease is a major health burden, treated by either valve repair or 
valve replacement, depending on the affected valve. Approximately, 290,000 heart 
valve replacements are performed worldwide and this number is expected to triple 
by the year 2050 (Cheung et al., 2015). Furthermore, an average of 10 out of every 
1000 children are born with congenital cardiac defects (Hoffman, 2013) and every 
fifth of these needs a heart valve replacement (Yankah et al., 2010). Despite the life-
saving benefits of available replacement heart valves, including mechanical 
prostheses, bioprosthetic valves, autografts (Ross Procedure) and allografts they 
have several disadvantages, such as calcification, the need for anticoagulation 
therapies, lack of any remodelling and regenerative capacity and inability to grow. 
Therefore, the quest for a better heart valve replacement goes on, particularly for 
young patients. 
A review of the literature indicates that in the surgical treatment of heart valve 
disease, decellularised allograft and xenograft heart valve roots have the potential to 
offer good hemodynamic, and low thrombogenicity characteristics, with the 
potential for regeneration, remodelling and capacity to grow with the patient 
(Sarikouch et al., 2016, Cebotari et al., 2011, Tudorache et al., 2016, Lichtenberg et 
al., 2006, da Costa et al., 2010).  
The production and pre-clinical assessment of the prosthetic heart valves 
(mechanical and bioprosthetic) must conform to international standards [e.g., ISO 
ISO 13485 (2016): Medical Devices - Quality Management System - Requirements for 
Regulatory Purposes; ISO 10993-13 (2009): Biological Evaluation of Medical Devices, 
ISO 5840 (2015): Cardiovascular Implants - Cardiac Valve Prosthesis Part 1 and Part 
2], evaluating in vitro mechanical and biological performance. The ISO 5840 (2015) 
standard was developed on the basis of existing mechanical and bioprosthetic heart 
valves and is not entirely appropriate to investigate the in vitro performance of 
decellularised heart valve roots, more specifically in vitro fatigue of decellularised 
heart valve roots. The literature review critically reviewed the test methods used to 
evaluate biomechanical, hydrodynamic and fatigue performance of native and 
replacement heart valves. The uniaxial tensile testing of biological heart valve roots 
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was criticised due to the technical challenges involved in clamping the specimens and 
cross sectional area measurement; and the hydrodynamic pulsatile performance 
assessment method due to heart valve root mounting in the pulsatile flow simulator. 
In addition, it was identified that there was no ideal physiological test method or test 
equipment which can be used to assess fatigue or durability of biological heart valve 
roots (including decellularised heart valve roots) which have viscoelastic properties. 
A lack of repeatable, robust and physiological in vitro biomechanical and 
hydrodynamic performance assessment test methods for biological heart valve roots, 
in addition to a lack of in vitro real time fatigue assessment test method for biological 
heart valve roots (including decellularised heart valve roots), has been identified as a 
target for study.  
In addition, decellularised allograft heart valve roots (Sarikouch et al., 2016, 
Cebotari et al., 2011, Tudorache et al., 2016, Lichtenberg et al., 2006, da Costa et al., 
2010) and decellularised xenogenic heart valve roots (Berry et al., 2017, Goecke et 
al., 2018) have shown promising results clinically and pre-clinically respectively; even 
though the decellularisation protocols are different. It is therefore essential to 
understand the effects of specific decellularisation processes on the in vitro fatigue 
in addition to hydrodynamic and biomechanical performance of allogeneic or 
xenogeneic heart valve roots. However, only a few studies have evaluated in vitro 
functional performance of decellularised allograft and xenogenic heart valve roots.  
The University of Leeds have developed a decellularisation protocol using low 
concentration SDS and applied it to human and porcine aortic and pulmonary heart 
valve roots (Korossis et al., 2002, Vafaee et al., 2016, 2014). The decellularised human 
aortic and pulmonary heart valve roots were developed with a view to use clinically 
as heart valve replacements through a partnership with NHS BT TES, Speke, Liverpool. 
The decellularised human heart valve roots suffer from limitations of availability in 
sizes suitable for young patients. To address this problem, decellularised porcine 
pulmonary heart valve roots in a range of sizes were investigated and the biological, 
biomechanical and hydrodynamic performance of these heart valve roots has been 
evaluated (Luo, 2011). Subsequently, an in vivo proof of concept study of 
decellularised porcine pulmonary heart valve roots was conducted in collaboration 
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with Professor Francisco Da Costa, Pontificia Universidade Catolica do Parana, 
Curitiba, Brazil (Berry et al., 2017). The decellularised porcine heart valve roots were 
implanted in the orthotopic position (RVOT) of 3 months old juvenile sheep.  
Before translating these decellularised human and porcine heart valve roots 
into clinical use it is important to understand the effects of decellularisation 
processes on the functional performance of the heart valves. Therefore, prior to in 
vivo clinical trials of the low concentration SDS decellularised human and porcine 
aortic and pulmonary heart valve roots, the effect of decellularisation on fatigue in 
addition to hydrodynamic and biomechanical performance will be investigated in this 
research.  
1.10 Aims and Objectives 
The primary aim of this research was to optimise in vitro hydrodynamic and 
biomechanical performance test methods and develop a novel real time fatigue test 
method using a real time wear tester (RWT) for biological heart valve roots. The 
secondary aim was to apply the developed in vitro test methods to decellularised 
human and porcine (aortic and pulmonary) heart valve roots to evaluate their in vitro 
functional performance and compare with cellular human and porcine heart valve 
roots. 
The objectives for this research were as follows: 
1. Optimise existing in vitro test methods to determine hydrodynamic and 
biomechanical performance of biological heart valve roots (Figure 1.9).  
 
Figure 1.9 Outline of Objective 1 
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 Key novel improvements to the test methods will be performed to optimise 
repeatability and robust in vitro functional performance assessment of biological 
heart valve roots. 
 Competency test method: modification of static leakage rig will enable 
measurements of the leakage flow rate of a closed valve (aortic and 
pulmonary) 
 Pulsatile flow test method: optimisation of pulsatile flow simulator by 
replacing the existing instrumentation with the latest available 
instrumentation, the mounting technique of cellular and decellularised 
human heart valve roots in the pulsatile flow simulator and  leakage free 
pulsatile flow simulation during functional performance assessment  
 Uniaxial tensile test method: a novel clamping technique of the heart valve 
root specimens (wall and leaflets) and cross sectional area measurement of 
the heart valve root specimens 
 Dilation test method: development of cylindrical Perspex tubes to 
accommodate different sizes of heart valve roots enabling the measurement 
of wall circumferential compliance  
2. Develop a novel robust repeatable in vitro test method to determine the fatigue 
of biological heart valve roots (Figure 1.10). 
 
Figure 1.10 Outline of Objective 2 
3. Evaluate the developed or optimised in vitro hydrodynamic, biomechanical and 
fatigue performance assessment test methods described in Objectives 1 and 2 
using cellular porcine aortic and pulmonary heart valve roots to ensure the 
methods produced results that were consistent with existing data in the literature 
(Figure 1.11). 
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Figure 1.11 Outline of Objective 3 
4. Apply the developed in vitro hydrodynamic (competency, pulsatile flow) and 
biomechanical (dilation, tensile, suture pull-out) performance assessment test 
methods described in Objective 1 to cellular and decellularised human aortic and 
pulmonary heart valve roots to investigate the effects of low concentration SDS 
decellularisation on human aortic heart valve roots [(Figure 1.12 (a)].  
 
 
(a) 
 
(b) 
Figure 1.12 Outline of Objective 4 (a) and (b) 
In addition, investigate the influence of a specific processing step (scraping) used 
during the decellularisation of human pulmonary heart valve roots on the 
functional biomechanical performance (competency, dilation) of cellular and 
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decellularised (scraped and un-scraped) pulmonary heart valve roots (in a paired 
comparison) [(Figure 1.12 (b)]. This will be the first full report comparing in vitro 
biomechanical and hydrodynamic performance of decellularised cryopreserved 
aortic and pulmonary human allograft heart valve roots with conventionally used 
cryopreserved human aortic and pulmonary allograft heart valve roots. 
5. Investigate the effects of low concentration SDS decellularisation and 
cryopreservation on the material properties of porcine pulmonary heart valve 
root wall and leaflet specimens and determine the material properties of 
decellularised porcine pulmonary heart valve root wall and leaflet specimens 
following 12 months implantation in 3 months old sheep (Figure 1.13).  
 
 
Figure 1.13 Outline of Objective 5 
6. Investigate the effects of decellularisation on in vitro real time fatigue of porcine 
aortic heart valve roots under physiological cyclic pressures and heart rate 
conditions and determine the effect of cyclic loading conditions on competency, 
pulsatile flow performance and leaflet material properties of decellularised 
porcine aortic heart valve roots (Figure 1.14).  
 
Figure 1.14 Outline of Objective 6 
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 Materials and Methods 
In this chapter the materials and methods used to characterise biological heart 
valve roots for hydrodynamic and biomechanical performance are described. First, 
the methodologies for the assessment of hydrodynamic performance of heart valve 
roots under static and pulsatile flow conditions are described. Secondly, the 
experimental methodologies for assessment of biomechanical performance of the 
heart valve roots in terms of circumferential expansion and material properties are 
described.  
2.1 Introduction 
Heart valves are complex structures consisting of cells and extracellular matrix 
(ECM) with a glycosaminoglycan content, collagen and elastin fibres (Chen and 
Simmons, 2011). The ECM plays a biomechanical role; it is responsible for the 
mechanical behaviour of the valve tissue and thus the overall valve function. 
Therefore, the development of decellularised heart valve roots for use in 
regenerative medicine requires the preservation of the valvular extracellular matrix 
(ECM). Hence, functional performance, safety and durability of these decellularised 
heart valve roots should be evaluated prior to their use in clinical studies. In vitro 
experimental test setups provide a way to test replacement heart valves in a 
controlled environment and minimised animal studies. Also, it is one of the main 
regulatory approval requirements to address key issues for safety and efficiency of 
the newly manufactured and modified surgical replacement heart valves. 
The mechanical strength and elasticity of heart valve roots, which includes their 
ability to withstand physiological pressures and flow rates for the duration of usage, 
contributes significantly to the heart valve root's performance, safety and durability. 
During systole, the outward flexion of the heart valve root wall supports the opening 
of the leaflets. Therefore, mechanical function testing of each of the heart valve root 
components (wall and leaflets) is important and it is essential to assess how the 
component mechanical properties affect the function of the valve as a whole. 
Another important consideration is the efficiency of the whole heart valve root 
structure from the perspective of cardiovascular flow dynamics. Consequently, it is 
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important to derive in vitro performance of heart valve roots under steady and 
pulsatile flow conditions. These methods determine whether a valve is either stenotic 
or regurgitant. Various in vitro test methods have been used to assess both the 
mechanical properties of valve tissue such as flexural (Engelmayr et al., 2005, Sacks 
et al., 2009), local indentation (Cox et al., 2006), biaxial tensile (Fisher et al., 1986, 
Billiar and Sacks, 2000, Williams et al., 2009) uniaxial tensile (Korossis et al., 2002, 
Anssari-Benam et al., 2011, 2014), suture pull-out (Edwards et al., 2005, Walraevens 
et al., 2008), and dilation (Jennings et al., 2002, Wilcox et al., 2005) testing as well as 
hydrodynamic performance of the valves under physiological flow conditions (Fisher 
et al., 1986, Jennings et al., 2002, Syedain et al., 2013, Reimer et al., 2015). While 
biomechanical and hydrodynamic parameters may be estimated by a variety of 
methods, calculation of these parameters relies on test method reliability and test 
variables. The ideal test methods should be robust and reproducible. The most 
evident example of this scenario is uniaxial tensile testing. Uniaxial tensile testing of 
biological heart valve roots has however been criticised because of the technical 
challenges involving gripping the specimens, cross sectional area measurement of 
specimens and specimen hydration during testing. Another key issue is heart valve 
root mounting difficulty in the pulsatile flow simulator to derive hydrodynamic 
performance of the heart valve root. These issues have been examined and 
addressed in this Chapter. In addition, in vitro hydrodynamic properties of xenograft 
valves have been determined in various studies (Korossis et al., 2002, Schenke-
Layland et al., 2003, Lichtenberg et al., 2006, Tudorache et al., 2007, 2014). Due to 
limited availability of fresh human hearts, repeatability of test methods and lack of 
physiological test conditions, there have been a limited number of studies 
investigating the hydrodynamic properties of human valves (Goldstein et al., 2000, 
Elkins et al., 2001). Even though the biomechanical and hydrodynamic properties of 
stented and stentless bioprosthetic xenograft valves are well defined, newer and 
upgraded measurement techniques can continuously improve the available data. 
Therefore, the approach was to take existing methods, critically review them and 
optimise certain processes, more specifically for biological heart valve roots. The 
developed hydrodynamic and biomechanical methods were then applied to different 
types of biological heart valve roots [cellular porcine aortic and pulmonary (Chapter 
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3), cryopreserved cellular and decellularised human aortic (Chapter 4) and pulmonary 
(Chapter 5), cellular ovine pulmonary (Chapter 6), explanted decellularised porcine 
pulmonary (Chapter 6), decellularised and cryopreserved porcine pulmonary 
(Chapter 6), cellular and decellularised porcine aortic (Chapter 8)], and the results are 
presented and discussed. 
In addition to hydrodynamic and biomechanical performance, the durability or 
fatigue of the decellularised human and porcine heart valve roots will be critical to 
their success, and there is a need for this to be evaluated prior to being implanted in 
patients. A methodology for fatigue assessment of the heart valve roots is addressed 
in Chapter 7. 
2.2 Aim and Objectives 
The aim of this chapter was to develop robust and repeatable methods to 
determine hydrodynamic and biomechanical performance of porcine and human 
(cellular and decellularised) aortic and pulmonary heart valve roots.  
The specific objectives were: 
1. Develop a test method to assess aortic and pulmonary heart valve root 
competency under static physiological back pressures. 
2. Develop a method to determine the hydrodynamic performance of the aortic and 
pulmonary heart valve roots. 
3. Develop a method to determine the circumferential compliance of the aortic and 
pulmonary heart valve root walls under static internal pressures. 
4. Develop a uniaxial tensile test method to derive material parameters for the wall 
and leaflets of the aortic and pulmonary heart valve roots. 
5. Develop a suture pull-out test method to derive suture pull-out properties of the 
wall and myocardium of the aortic and pulmonary heart valve roots. 
2.3 Materials 
  Chemicals and General Stock Solutions 
The chemicals and general stock solutions used during this project are listed in 
Table 2.1. 
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Table 2.1 The Chemicals and General Stock Solutions used during this Study  
Chemicals/ General stock 
solutions 
Supplier Product Code 
Saline (0.9%) Leeds Pharmaceutical Ltd 31-58-736 
Phosphate buffered saline 
(PBS): Ten PBS tablets were 
dissolved in 1L of distilled 
water 
MP Biomedicals, LLC 092810305 
Tissue marking dye (Thermo Fisher Scientific, UK) 5000BL/ 
5000R 
Cambridge antibiotic solution 
with agitation 80 rpm 
Source BioScience 04-301 
Sodium azide 1 % (w/v) 
solution 
Severn Biotech Ltd 40-2000-01 
Amphotericin B Sigma-Aldrich Company Ltd. A2942 
Aprotinin (10000 KIU.mr-1) Mayfair house AP012 
Ethylenediaminetetraacetic 
acid 
Thermo Fisher Scientific, UK) E/P140/53 
Glutaraldehyde Solution  Sigma-Aldrich Company Ltd, UK 49629-250 mL 
  Porcine and Human Cellular Heart Valve Roots 
Porcine heart valve roots were used to evaluate the test methods before 
applying said methods to human heart valve roots. The cellular porcine aortic and 
pulmonary heart valve roots used in this study were dissected from porcine hearts. 
The hearts were from approximately 24-28 week old pigs, slaughtered and supplied 
within 24 hours by M & C Meats, Crossgates, Leeds and John Penny & Sons, Rawdon, 
Leeds, UK.  
The human aortic and pulmonary heart valve roots used in this study were 
provided by NHS Blood and Transplant Tissue and Eye Services (NHS BT TES), 
Liverpool, L24 8RB, UK. Ethics approval was obtained for the study from the Yorkshire 
and the Humber committee – Leeds West, UK under the REC reference 09/H1307/82. 
All the heart valve roots were visually examined and any roots with severe tissue 
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calcification were excluded from further processing. The size of the valves were 
measured with obturators (Figure 2.1). 
 
Figure 2.1 Valve Sizing Obturator Set 
  Björk-Shiley mono leaflet valve (BSM; Shiley Corporation Incorporated, 
USA)…………. 
A 23 mm Björk-Shiley mono leaflet mechanical valve (BSM; Shiley Corporation 
Incorporated, USA) was used as a control to validate static leakage rig and pulsatile 
flow simulator. 
  Imaging System 
The imaging system was used during pulsatile flow and real time fatigue testing 
to capture video of the heart valve root leaflets. It consisted of a high speed video 
camera (S-PRI Model, AOS Technologies, Inc), imaging software (AOS Imaging studio 
V3), Navitar high speed lens (50 mm focal length) and SCHOTT cold light lamp (model 
no: KL1500-T). The imaging software controlled the video capture speed and the 
quality of the videos. The high speed video camera was placed on a tripod. The cold 
light lamp was used to illuminate the leaflets of the test valves. A 2 second video clip 
was captured at rate of 500 frames.s-1 to record high speed video of leaflets’ motion.  
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2.4 Methods 
 Decellularisation 
The porcine and human heart valve roots were decellularised using a 
proprietary low concentration sodium dodecyl sulphate (SDS) based protocol (Booth 
C, 2001). The details of decellularised protocol for porcine aortic and pulmonary heart 
valve roots are descried in various studies (Korossis et al., 2002, 2014). The details of 
the optimised decellularisation protocol for human aortic and pulmonary heart valve 
roots are described by Vafaee et al. (2016). Both the cellular and decellularised 
human aortic and pulmonary heart valve roots were cryopreserved using the 
standard NHS BT TES process. Each root was placed in a nylon bag containing 100 mL 
heart valve cryopreservation medium [Hank's Balanced Salt Solution (HBSS); 16% v/v 
dimethyl sulfoxide (DMSO), 25 mM N-2-hydroxyethylpiperazine-N-2-ethane sulfonic 
acid (HEPES); product code 04-311, Inverclyde Biologicals]. The bag was then heat-
sealed and placed into a second foil bag. The outer bag was also heat-sealed. The 
sealed foil bag was placed into a jiffy bag before storing at -80°C. The heart valve 
roots were removed from the bag 24 hours before testing, thawed, and stored at 4°C 
in Cambridge antibiotic solution. 
 Glutaraldehyde Fixation  
Glutaraldehyde fixed porcine aortic heart valve roots were used for both the 
initial real time fatigue test method development stage and as a control to 
understand any potential confounding factors caused during biological heart valve 
root testing. The aortic heart valve roots were used because they are well supported 
with thick myocardium, easy to handle and larger in size than pulmonary heart valve 
roots. Also pulmonary heart valve roots have an arch whereas aortic heart valve roots 
are a straight tubular shape, so it was more straightforward to use aortic heart valve 
roots for method development.   
As described in Section 2.3.2, the cellular porcine aortic heart valve roots used 
in this study were harvested from porcine hearts, obtained from the local abattoir. 
The heart valve roots were stored in PBS at 4°C. The heart valve roots were then 
tested or fixed as necessary within 36 hours.  
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Figure 2.2 Schematic Drawing of Glutaraldehyde Fixation of Porcine Aortic 
Heart Valve Roots 
Before the fixation process, the arteries of the aortic heart valve roots were 
ligated with surgical sutures. In the fixation process the aortic heart valve roots were 
treated with 0.5% glutaraldehyde solution (diluted in PBS). During the fixation 
process the valve was kept closed and a cylindrical tube was inserted from the wall 
side with 0.5% glutaraldehyde solution to keep aorta dilated to its original diameter 
(Figure 2.2). 150 mL of fixative was used for one heart valve root. Fixation was 
considered complete after 72 hours. 
 Antibiotic and Antifungal Treatment  
All the cellular porcine aortic heart valve roots were treated with Cambridge 
antibiotic solution and amphotericin B to minimise growth of contaminating bacteria 
and fungi for real time fatigue testing in the real time wear tester (RWT). Before the 
antibiotic treatment, the arteries of the aortic heart valve roots were ligated with 
surgical sutures. The heart valve root was submersed in treatment solution (150 mL 
Cambridge antibiotic + 2.5 mL amphotericin B) for 3 hours at 37°C temperature. An 
Optima™ T 100 heated circulating bath was used to maintain 37°C temperature.   
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 Heart Valve Root Storage and Defrosting Procedure 
Following dissection, the cellular porcine heart valve roots were stored in 150 
mL PBS and used straight away for testing or stored in 150 mL PBS individually at -
20oC until required. A day before testing, the frozen roots were defrosted by leaving 
them at room temperature for maximum 12 hours. 
All the human cellular and decellularised heart valve roots were cryopreserved 
using the standard NHS BT TES process and stored at -80oC prior to use. A day before 
testing, each heart valve root was thawed as per standard Leeds procedure. Briefly, 
the package containing the cryopreserved heart valve root was gently agitated in 
warm saline (37 oC) to dissolve ice crystals and soften the heart valve root. The outer 
and inner bags were cut open and the contents were placed into a sterile 2 L beaker. 
The cryopreservation solution was diluted by the successive addition of 200, 400, 800 
mL PBS after 5, 10 and 15 minutes. The heart valve root was transferred to a sterile 
beaker containing 200 mL sterile PBS was solution (PBS plus 2.7 mM 
ethylenediaminetetraacetic acid disodium salt (EDTA) and 10 KIU.mL-1 aprotinin). 
Then the thawed heart valve roots were disinfected in 200 mL Cambridge antibiotic 
solution with agitation at 80 rpm for 3 hours at 37oC in an incubator and stored at 
4oC. Prior to testing. The heart valve root was washed with two changes of PBS 
solution (250 mL) for 5-15 min (twice). 
 Dimensional Measurement  
All the cellular and decellularised human pulmonary heart valve roots were 
measured before and after decellularisation and also after the scraping procedure. 
The set up for measuring the dimensions of the heart valve roots is shown in Figure 
2.3.  
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Figure 2.3 Dimension Measurement Set Up 
Great care was taken during measurement and analysis when comparing the 
effect of decellularisation on tissue dimension. The camera (Canon digital SLR 550 D) 
was set up perpendicular to the heart valve root and a scale was kept in same plane 
as the heart valve root for calibration purposes. Images for all the pulmonary heart 
valve roots (cellular, cellular scraped, un-scraped decellularised and scraped 
decellularised) were captured. 
2.4.5.1  Data Analysis of Dimensional Measurements 
All the images were uploaded into ImageJ, a Java-based open source image 
processing software ImageJ (NIH, Bethesda, MD), for analysis. ImageJ line tool was 
used to take measurements W1 near annulus and W2 in the wall region as shown in 
Figure 2.4. 
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Figure 2.4 Dimension Measurement with ImageJ 
The width W1 and W2 was measured for each heart valve root before and after 
the treatments (scraping and decellularisation). The formula shown below was used 
to measure percentage change in the widths W1 and W2 for un- scraped 
decellularised relative to un- scraped cellular and scraped decellularised relative to 
cellular scraped.  
% 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑊 =  
W(before treatment) − W(after treatment) 
W(before treatment)
 × 100 
2.4.5.2  Dimension Measurement Technique Validation   
To validate the measurement approach the dimensions of a cellular porcine 
pulmonary heart valve root were measured over two consecutive days. An image of 
the porcine pulmonary heart valve root was taken three times at every two hours on 
each day. The heart valve root was stored in PBS at 4°C in between measurements. 
These images of porcine valves were captured and processed with ImageJ, keeping 
all the conditions and the procedures same as human pulmonary heart valve roots. 
The widths W1 near the annulus and W2 in the wall region (Figure 2.4) were 
measured and are displayed in Table 2.2. 
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Table 2.2 Dimensions of the Cellular Porcine Pulmonary Heart Valve Root 
Measured On Two Consecutive Days 
 Width W1 mm Width W2 mm 
 Day 1 Day 2 Day 1 Day 2 
 
2.62 2.76 2.48 2.62 
 2.66 2.76 2.55 2.66 
 
2.60 2.74 2.47 2.61 
Mean ± 95 % 
Confidence Limit 
2.63 ± 0.08 2.75 ± 0.03 2.50 ± 0.11 2.62 ± 0.01 
% Change in Width 
Between Two Days 
4.50% 4. 80% 
 
 From this experiment, the accuracy of the valve dimension measurement with 
ImageJ was estimated to be to 5 %. 
 Hydrodynamic Performance I: Competency under Static Back Pressure 
Competency tests were performed to assess valve closure and quantify 
regurgitant flow rate under a range of physiological static back pressures. This section 
describes the modification of the static leakage rig, the use of the modified static 
leakage rig to conduct the tests, the process to validate the rig and the procedure for 
determining the competency of the heart valve roots.  
2.4.6.1 Static Leakage Rig 
A static leakage rig was used to assess valve competency under static 
physiological back pressures. The rig enabled measurements of leakage flow rate of 
a closed valve. This information about valve behaviour during diastole, when the 
valve was closed, could expose the existence of regurgitation problems. A static 
leakage rig was used in previous study (Jennings, 2001) to measure leakage flow rates 
of porcine pulmonary heart valve roots. The rig consisted of a 1.56 meter high 
cylindrical Perspex column able to apply pressure of 100 mmHg when saline was used 
as a test fluid. However, this study also required testing of aortic heart valve roots 
with a pressure of 120 mmHg. Therefore, it was necessary to modify the static 
leakage rig.  
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2.4.6.1.1 Modification of Static Leakage Rig 
The static leakage test rig (Jennings, 2001) was modified to enable testing of 
aortic heart valve roots with a pressure 120 mmHg. The vertical cylindrical Perspex 
column was replaced with a longer vertical Perspex column which was applied a 
pressure of 120 mmHg.  
 
Figure 2.5 Static Leakage Rig (not drawn to scale) 
The modified test rig (Figure 2.5) consisted of an 1832 mm tall cylindrical 
Perspex column with an internal diameter of 60 mm, housed vertically in a 
rectangular Perspex block. The column was marked at intervals of 20 mmHg up to 
120 mmHg applicable for the test fluid of saline. It could be drained via an outlet 
drainage pipe at the base of the block (Figure 2.5). The rig was placed on the floor 
into a large stainless tray and the Perspex column secured vertically to a work bench 
with a G clamp.   
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2.4.6.1.2 Validation of Static Leakage Rig  
The static leakage rig was validated by recording the time taken for the pressure 
head to leak test fluid of 0.9 % (w/v) saline from 120 mmHg to 80 mmHg through a 1 
mm diameter hole. The test was repeated 6 times, leakage times and leakage 
volumes were recorded for each iteration. An externally calibrated Hanhart 
Mesotron Quartz stop clock (serial number 6558CLK) was used to record leakage 
times. The mean volume of test fluid was calculated to be 1534 mL, which enabled 
the flow rate to be calculated, recorded leakage times and leakage volumes were 
within a range of ± 5 % the mean values. 
A baseline value (control data) for the static leakage rate of a heart valve was 
established using a 23 mm Björk-Shiley mono leaflet valve (BSM; Shiley Corporation 
Incorporated, USA) with the static leakage rig. A 23 mm BSM valve was placed in a 
closed position in a valve holder at the bottom of the leakage tester, as shown in 
Figure 2.6. 
 
Figure 2.6 Test Set-up to Derive Leakage Flow Rate under Static Back Pressure 
for Mechanical Valve 
The rig was filled with a 0.9 % (w/v) saline solution to the 120 mmHg pressure 
mark. The leakage time was measured for the pressure head to leak the test fluid 
from 120 mmHg to 80 mmHg. Five runs were performed to ensure repeatability. After 
63 
Chapter 2 
two runs, the valve holder was removed from the rig and the mechanical valve 
opened and closed again to allow possible leaflet alignment variation upon closure.  
Table 2.3 Static Leakage Results for the Mechanical Valve 
Test 
Run 
Static Leakage 
Time (s) 
Static Leakage Flow 
Rate (mL.s-1) 
1 205 5.03 
2 347 4.42 
3 430 3.56 
4 349 4.39 
5 223 7.33 
 
Table 2.3 shows the results of the static leakage tests. The mean leakage flow 
rate with 95% confidence limits of the 23 mm BSM valve was 4.95 ± 1.78 mL.s-1. 
2.4.6.1.3 Test Procedure – Biological Heart Valve Roots 
The heart valve root was secured to the rig spigot with a cable tie, and mounted 
into the Perspex plate with gasket seal. The Perspex mounting plate and spigot 
assembly were attached to the rectangular Perspex block with 4 screws (Figure 2.7). 
The desired maximum (systolic) pressure was achieved by filling the Perspex 
column with 0.9% (w/v) saline solution. The leakage time, i.e. time taken by the test 
fluid to drop from the systolic limit to the desired minimum (diastolic) pressure, was 
documented. The maximum applied pressure was 120 mmHg for all the aortic heart 
valve roots and 60 mmHg for all the pulmonary heart valve roots. The times taken for 
this test fluid to drop to 80 mmHg (for all aortic) and 20 mmHg (for all pulmonary) 
were recorded. An externally calibrated Hanhart Mesotron Quartz stop clock (serial 
number 6558CLK) was used to record leakage times. 
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Figure 2.7 Test Set-up for Static Leakage Testing of Heart Valve Roots 
2.4.6.1.4 Data Analysis 
The mean flow rate was determined with the formula: Q = V/t [flow rate (Q) = 
volume of test fluid (V) /leakage time (t)]. This volume (V) of test fluid was measured 
as 1534 mL in all iterations. A vernier caliper was used to measure heart valve root 
diameter D near to the sino tubular junction at the maximum pressure limit. The root 
was considered to be competent if the pressure head had not dropped to 80 mmHg 
(for aortic) or 20 mmHg (for pulmonary) within a cut-off period of 30 minutes for 
aortic and 20 minutes for pulmonary heart valve roots. 
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  Hydrodynamic Performance II: Pulsatile Flow Testing 
Quantitative hydrodynamic performance of the heart valve roots was assessed 
by testing the root under physiological pressure and flow conditions similar to those 
occurring in a human heart in a pulsatile flow simulator.  
Table 2.4 The Major Performance Specifications required during optimisation 
of the Pulsatile Flow Simulator 
No Specification 
1 Easy mounting and removal of the heart valve roots without causing damage 
2 Able to clean thoroughly with disinfectant  
3 Able to capture valve images during testing 
4 Accurate measurement of the flow and pressure 
5 Leakage free 
 
The pulsatile flow simulator has been widely used in previous studies (Fisher et 
al., 1986, Jennings, 2001, 2014) to access hydrodynamic performance of the heart 
valve roots. However, the instrumentation for this pulsatile flow simulator was 
relatively old and difficult to use. The simulator had the potential to work, but 
suffered frequent failures of the flow meter, pump controller and waveform 
generator. Replacing these units with the most recently available versions of the units 
was an ideal solution. In addition, another key requirement of the new pulsatile flow 
simulator was the capability to mount a cellular and decellularised human heart valve 
root into the loop in the position of the aortic valve. The major performance 
specifications for the optimised pulsatile flow simulator are described in Table 2.4. 
2.4.7.1 Optimisation of Pulsatile Flow Simulator 
To satisfy the performance specifications described in Table 2.4, the pulsatile 
flow simulator used by Fisher et al. (1986) was upgraded and optimised to make 
certain processes easier and more practical. For instance, it used to take a long time 
to mount a heart valve root into the existing flow loop and there were risks of 
damaging the heart valve root during mounting. Therefore, the heart valve root 
mounting technique in the simulator was optimised (Section 2.4.7.3) which greatly 
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increased the ease in which studies could be carried out in the simulator. In addition, 
new gaskets and O-rings were implemented into the new flow loop to prevent leaks. 
The newer versions of instrumentations and flow loop were improved. A schematic 
diagram of the optimised pulsatile flow simulator is shown in Figure 2.8.  
   
 
 
6
7
 
 
 
Figure 2.8 Pulsatile Flow Simulator Schematic Diagram used to assess Hydrodynamic Performance of the Heart Valve Roots
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The simulator replicated the function of either side (left or right) of the heart. 
The simulator consisted of a positive displacement pulsatile pump, SuperPump 
(Vivitro Systems Inc, Victoria BC, Canada), a viscoelastic impedance adapter (VIA), 
two test chambers for testing valves in the aortic/pulmonary or mitral/tricuspid valve 
positions, a ventricular and an atrial chamber, a compliance chamber (after load), 
silicon tubing simulating the peripheral circulation, a peripheral resistance tap, and 
the pressure and flow measurement (Vivitro Systems Inc, Victoria BC, Canada) 
instruments. The simulator was controlled and monitored by a data acquisition 
system and the ViviTest software (Vivitro Systems Inc, Victoria BC, Canada) installed 
on an attached computer. 
 
Figure 2.9 Pulsatile Flow Simulator Showing the Test Chambers with 
Supporting Tables 
All the test chambers had supporting tables for easy specimen mounting and 
cleaning as shown in Figure 2.9. 
2.4.7.1.1 SuperPump and Viscoelastic Impedance Adapter (VIA) 
The SuperPump (AR Series, Vivitro Systems Inc, Victoria BC, Canada) was a 
microprocessor controlled piston-in-cylinder pump that creates physiological cardiac 
flows (Figure 2.10). The SuperPump system consisted of an amplifier, a linear 
actuator, a pump head, and interconnecting cables. The amplifier had a capacity to 
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store five programmable physiological waveforms at different heart rates ranging 
from 30 to 200 bpm. Additional user defined waveforms could be programmed in the 
amplifier using the ViViGen software. The amplitude of the input waveforms, in terms 
of stroke volume, was controllable by an amplitude switch on the amplifier. A 
sinusoidal (S50) input waveform was used to drive the SuperPump throughout this 
study as this waveform was found to produce smoother pressure waveforms for the 
biological heart valve roots (Jennings, 2001).  
 
Figure 2.10 SuperPump System used for Pulsatile Flow Simulator 
A viscoelastic impedance adapter (VIA), (VIA 7991, Vivitro Systems Inc, Victoria 
BC, Canada) (Figure 2.11) was placed between the SuperPump and the ventricle test 
chamber. It added resistance and compliance to pump waveforms to produce 
physiological pressure and flow waveforms. A diaphragm separated the VIA from the 
ventricle chamber and the pump to prevent the test fluid (saline) from entering the 
VIA. 
The VIA consisted of a fixed resistive element and adjustable compliance 
chambers, simulating ventricular viscoelastic behaviour. The VIA was adjusted to 
maximum compliance by setting air volumes to 60 mL and 125 mL on the output and 
input side respectively. 
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Figure 2.11 A Viscoelastic Impedance Adapter 
Minimum compliance was achieved by completely filling the VIA with distilled 
water. Adjusting the VIA to maximum compliance reduced the oscillations in the 
ventricle pressure and provided the smoothest possible flow waveforms, similar to 
those seen on porcine cellular heart valve roots tested in the pulse duplicator 
simulator by Jennings et al. (2001). 
2.4.7.1.2 Aortic Test Section  
The aortic test section comprised of a ventricle chamber and aorta. In the 
human body, the left ventricle is responsible for pumping blood through the aortic 
valve, on to the ascending aorta, and out to the rest of the body. In this experimental 
flow loop, the ventricle was powered by a pulsatile positive displacement pump to 
push fluid through the system.  
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2.4.7.1.3 Compliance Chamber 
Compliance is characterised by the ability of the walls of a heart to contract and 
expand as the interior pressure changes. In the simulator, the compliance chamber is 
the section of the flow loop that compensates for the requirement to expand and 
contract according to the arterial pressure and maintains the physiological nature of 
the waveforms produced by the device. After leaving the aortic valve and passing 
through the flow probe, the test solution (saline) enters the compliance chamber.  
This compliance chamber consisted of a long vertical cylindrical Perspex column 
partially filled with air, an analogue pressure gauge and a rubber tubing with a clamp. 
The clamp on the flexible rubber tubing was used to control the resistance and the 
level of saline inside the cylindrical Perspex column. 
2.4.7.1.4 Mitral Valve Test Section  
The mitral valve test section consisted of two parts:  the atrium and ventricle, 
with the mitral valve positioned between them. The outlet of the test section was 
connected to the ventricle section. The atrium chamber primarily served as a 
reservoir that held excess saline not used by the system. Saline supplied to the flow 
loop enters the system through the atrium. The atrium chamber was designed with 
a cavity on top to tolerate fluctuations in volume without causing a drastic increase 
in pressure through the rest of the system. A 29 mm Björk-Shiley mono-leaflet 
mechanical valve was used throughout the study as the standard valve in the mitral 
position. 
2.4.7.1.5 Measuring Instruments  
The flow measuring system consisted of a Carolina Medical electromagnetic 
variable range analogue flow meter (model: FM501, Carolina Medical Electronics, Inc) 
and electromagnetic flow probe (EP688, Carolina Medical Electronics, Inc). The flow 
meter had a range from 5 mL.min-1 to 19.99 L. min-1 depending on probe selected. 
72  
Chapter 2  
 
Figure 2.12 Flow Probe Mounting Arrangements  
The flow probe works on the principle of electromagnetic induction. The probe 
had an internal diameter of 28 mm and probe factor was 53800 provided by the 
manufacturer. The probe factor was useful to adjust flowmeter gain and permitted 
full scale direct reading on the flow meter display in millilitres or litre per minute. It 
was held between two Delrin spigots, as shown in Figure 2.12, and mounted at an 
angle between the aortic test section and the compliance chamber.  
To measure the pressure in the system, several small ports were built into the 
chambers at various locations. These ports consisted of small through holes running 
inside a chamber to the exterior and attached to three way connectors. Pressure 
transducers were attached to the three way connectors. Pressure was measured 
directly upstream and downstream of the test heart valve root using Vivitro pressure 
transducers (Model: HCM018, Vivitro Systems Inc, Victoria BC, Canada). The pressure 
transducers had a range of -50 to +300 mmHg with 5 µV/V/mmHg. Data from the 
transducers was filtered by the attached amplifier unit. Each transducer was filled 
with saline, and bubbles were removed before every experiment for accurate 
pressure measurement.  
2.4.7.1.6 Data Acquisition  
A 12 bit digital data acquisition device was used to acquire data from the piston 
position sensor, the flow meter, and the three pressure transducers. Data was 
sampled at a rate of 300 Hz. Low pass filters with cut-off of 30 Hz and 10 Hz were set 
for the pressure and flow sensors respectively to remove excessive electrical 
interference from the pressure and flow output waveforms. This filter settings 
73  
Chapter 2  
allowed smoother pressure and flow waveforms. The ViViTest software (Vivitro 
Systems Inc, Victoria BC, Canada) was used to monitor, collect, and analyse the 
pressure and flow data which is explained in detail in the Section 2.4.7.5 .  
2.4.7.2 Calibration and Verification of Pulsatile Flow Simulator Components 
Stroke volume verification: The accuracy and consistency of the stroke volume 
measured by the pump controller and recorded by the ViViTest software was verified 
as follows: 
 
Figure 2.13 Stroke Volume Verification Setup 
The volume of fluid displaced by the piston in a single stroke is the output data 
of the pump controller. This stroke volume value was verified using an analogue dial 
test indicator (DTI) connected to the pump as shown in Figure 2.13. The pump was 
adjusted to displace 60 mL of fluid per stroke for a corresponding heart rate of 60 
bpm with a sine waveform. The movement of the DTI plunger for the forward stroke 
was recorded. The stroke volume (SV) is the amount of blood the left ventricle pumps 
through the aortic valve with each heartbeat. The volume of test fluid being pumped 
in each stroke was calculated using the formula shown below: 
𝑆𝑡𝑟𝑜𝑘𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑆𝑉) = 𝐴𝑟𝑒𝑎 𝑥 [𝑠𝑡𝑟𝑜𝑘𝑒 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒] 
Where Area 𝐴 = 𝜋𝑟2 = 38.32 cm2 (provided by manufacturer) 
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This process was repeated three times under the same test conditions and the 
mean of the three results was used. The data output of the pump controller and value 
displayed by the ViViTest software were within ± 0.2 mL of the calculated stroke 
volume. 
Flow meter calibration: The flow meter was calibrated using the ViViTest 
software. An open spacer ring was mounted in the aortic site and an occluding solid 
plug in the mitral site. The pump was adjusted for 60 bpm and 60 mL stroke volume 
with sine wave. The calibration wizard steps of ViViTest software were followed. The 
stroke volume automatically adjusted calibration factor to equate the flow meter 
signal with pump displacement signal. 
Pressure transducer calibration: Three digital pressure transducers were used 
to measure pressure at various locations in the pulsatile flow simulator. A two point 
pressure calibration, guided by ViViTest software, was performed with each of the 
pressure transducers using the following procedure: A transducer was kept open to 
the atmosphere, without any external pressure, to record the initial base value - the 
output voltage of the transducer. Pressure equivalent to 200 mmHg was then applied 
to the transducer with an external digital pressure transducer (S/N: 63204/3, Comark 
Instruments, Inc). The resulting output voltage of the transducer was recorded. At 
the end of this calibration process, a calibrated value in mV/mmHg was calculated for 
each pressure transducer by ViViTest software. These values were compared with 
their historical values.  
2.4.7.3 Heart Valve Root Mounting in Pulsatile Flow Simulator 
One of the key aspects of the modification of the pulsatile flow simulator was 
the capability to mount cellular and decellularised human roots into the flow loop in 
the position of the aortic valve. The problem with testing these roots was that they 
were well hydrated and soft, so they slipped off the spigot with clamping fittings due 
to pulsatile forces during the testing. In addition, in this study the same root was 
tested for multiple test conditions and multiple test procedures. Therefore, it was 
essential not to damage the heart valve root even after completion of this test 
procedure. 
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 The heart valve roots were positioned and clamped at the downstream end of 
ventricular chamber and upstream end of the aorta as shown in Figure 2.14. 
 
Figure 2.14 Schematic Diagram of Heart Valve Root Position and Mounting in 
Pulsatile Flow Simulator 
All the cellular and decellularised roots under test were mounted on Delrin 
mounting spigots and secured with cable ties as shown in Figure 2.15.   
 
Figure 2.15 Heart Valve Root Mounting in Pulsatile Flow Simulator 
It was a requirement to tighten the cable ties without damaging the heart valve 
root. A cable tie gun (part no: STHV, Panduit Europe Ltd) (Figure 2.16) was used to 
tension and cut the cable ties. The cable ties were sufficiently tight to prevent axial 
movement along the heart valve root and push them out under pulsatile flow 
conditions.  
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Figure 2.16 Cable Tie Gun 
2.4.7.4 Test Procedure 
The hydrodynamic performance of the heart valve roots was assessed using this 
upgraded Leeds pulsatile flow simulator. A Viscoelastic Impedance Adapter (VIA) 
(Vivitro System Inc., Victoria BC, Canada) was used to deliver physiological ventricle 
pressure and flow waveform to the simulator. This simulator system allowed for 
physiological pressure and flow waveforms as well as high speed video recording of 
leaflet motion as described in detail by Jennings et al. (Jennings et al., 2001). As 
described in Section 2.4.7.3, a test heart valve root was mounted in the aortic 
position. It was a two stage testing procedure for biological heart valve roots due to 
the nature of their compliance. Firstly, at minimum VIA compliance, the simulator 
was adjusted for with heart rates 60, 72, 80 and 100 bpm with corresponding stroke 
volumes 60, 72, 70 and 80 mL.  The systemic pressure was held between 120 to 80 
mmHg for aortic heart valve roots and between 45 to 15 mmHg for pulmonary heart 
valve roots to represent in vivo conditions of the heart. The process was repeated 
with the VIA adjusted to its maximum compliance setting, with 125 mL air in the 
source chamber and 60 mL in the output chamber to produce physiological pressure 
and flow waveforms. It was observed that the VIA with maximum compliance 
adjustment reduced the forward flow volume displaced by the pump piston. 
Therefore, peak flow was used as the test condition rather than the stroke volume 
(Jennings et al., 2001). Therefore, VIA with maximum compliance and peak flow were 
considered as test conditions. The precise pulsatile flow conditions for specific heart 
valve root tests have been detailed in the relevant chapters. After setting the heart 
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rate to 72 bpm and adjusting stroke volume or peak flow, a 2 second video clip of 
leaflet motion under pulsatile conditions was recorded using an AOS Technologies S-
PRI high speed camera set to a capture rate of 500 frames.s-1.  
2.4.7.5 Data Processing  
The performance of the heart valve roots was characterised by evaluating the 
leaflet dynamics, transvalvular pressure difference (ΔP) during forward flow, the 
heart valve root mean square (RMS) forward flow (QRMS), and effective orifice area 
(EOA). The EOA was calculated using the formula that was derived by Gabbay et al. 
(1978), EOA = QRMS (mL/s)/51.6√ΔP(mmHg). Typical pressure and flow waveforms 
obtained by ViVitro software for the BSM mechanical control valve are shown in 
Figure 2.17. All the flow and pressure crossover positioning, data acquisition, and 
analysis were in accordance with ISO 5840 (2015). During the test, the software 
captured data for 10 cycles. Once all pressure and flow crossover adjustment of 10 
cycles was completed, means and standard deviations for the 10 cycles were saved 
as a .csv file (excel file) for further analysis. It was possible to obtain regurgitant 
volumes from pulsatile flow testing, but the data was not reliable due to artifacts in 
flow oscillations in the heart valve root during diastole (Jennings, 2001). Hence this 
data was not included in the results. However, closed regurgitant flow rates were 
determined in the competency testing to give an indication of performance during 
the closed phase. 
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Figure 2.17 Example of Acquired Pressure and Flow Curve (a) Minimum (b) Maximum Compliance 
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The flow and pressure crossover points detailed in Figure 2.17 are defined as 
follows: 
Flowrate 
f1 forward flow at the beginning of systole 
f2 forward flow at the end of systole 
f3 flow when the valve leakage begins or mitral valve starts to 
close 
f4 flow at end of the cycle 
Pressure 
Aortic (positive) pressure difference between the beginning and the end of 
systole positive pressure drop 
Mitral (positive) pressure difference between the beginning and the end of 
diastole positive pressure drop 
 
All the tests were performed using physiological 0.9% (w/v) saline to maintain 
compatibility with the flow probe which measures the voltage of a conductive 
solution flowing through a magnetic field.  The hydrodynamic performance of the 
heart valve roots were expressed as transvalvular pressure gradient versus RMS 
forward flow (QRMS) and EOA. The RMS Forward Flow and transvalvular pressure was 
automatically calculated in the software with below formula:  
RMS forward flow (QRMS mL.s-1) = RMS Flowrate (f1 to f2) *1000)/60 (s.min-1)  
Transvalvular pressure difference (ΔP mmHg) = Mean of pressure difference 
between outflow and inflow of points between f1 to f2.  
The valve leaflet dynamics were assessed using an AOS Technologies S-PRI high 
speed camera recording at a rate of 500 frames per second during a complete cardiac 
cycle under pulsatile condition, when the heart rate was 72 bpm.  
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2.4.7.5.1 Statistical Analysis 
Regression analysis was performed to assess the trend and the difference 
between transvalvular pressure of the heart valve roots (cellular and decellularised 
human pulmonary and aortic) for different RMS flow conditions. A second order 
polynomial trend line was fitted with R-squared value close to 1 in Microsoft Excel 
2013. The mean EOA is presented as the mean ± 95 % confidence intervals. Statistical 
significance between the cellular and decellularised aortic heart valve roots (porcine 
and human), and between the cellular and decellularised human pulmonary heart 
valve roots, was determined using Student’s t test using SPSS for Windows (version 
21.0; SPSS, Inc., USA). P<0.05 was considered statistically significant. 
2.4.7.5.2 Validation of Pulsatile Flow Simulator  
The performance of the simulator was verified using a 23 mm Björk-Shiley mono 
leaflet (Shiley Corporation Incorporated, USA) mechanical control valve before each 
test. This valve was tested at heart rates of 60, 72, 80, 100 and 120 bpm with 
corresponding stroke volumes 60, 70, 70, 80 and 80 mL. A 50% input sine wave was 
used for all iterations. The systemic pressure was adjusted between 120 and 80 
mmHg. The VIA was set for minimum compliance. The function of the valve was 
assessed using the mean Δp, QRMS, and EOA. All data were processed and analysed 
using Microsoft Excel and compared with the historical data and test data for the 
same valve obtained during previous testing using a previous version of this pulsatile 
flow simulator by Jennings (2001). The recorded data was within a range of ± 5 % of 
the mean of the historical data. 
  Biomechanical Performance 
2.4.8.1 Biomechanical Performance I: Expansion Characteristics (Dilation 
Testing)……………………………………………………………………………………………. 
The circumferential expansion of each heart valve roots (cellular porcine aortic 
and pulmonary, human cellular and decellularised aortic, human cellular and 
decellularised pulmonary) was determined in terms of percentage dilation using a 
dilation test procedure adapted from previous studies (Wilcox et al., 2005, Jennings 
et al., 2002). Circumferential expansion is influenced by material properties of wall 
82 
Chapter 2 
layers (Roach and Burton, 1957), but it is not indicative of wall stiffness because the 
expansion is also affected by heart valve root size and wall thickness. Jennings (2001) 
used different sizes of syringe to mount porcine heart valve roots. However, due to 
limitations in syringe size availability it was limited to test different sizes of the heart 
valve roots. Also there were a few other problems with the method such as pressure 
control, valve leakage and repeatability of the method. Therefore, it was essential to 
develop a robust dilation testing method. The design specification for the dilation 
tester is described in the Table 2.5. 
Table 2.5 Design Specification for Dilation Tester 
Feature Requirement/ Specification 
Dimensions Able to fit various sizes of the heart valve roots (⌀ 20-32 mm) 
Material Durable enough to withstand repeated use  
Able to clean thoroughly with disinfectant  
Able to see test fluid level 
Operation Easy mounting and removal of the specimen without causing damage 
Able to apply maximum pressure of 120 mmHg and easy to control 
 
2.4.8.1.1 Dilation Tester 
Cylindrical Perspex tubes of different sizes were designed to accommodate 
heart valve root sizes with diameters ranging from 20 to 32 mm. The narrow end of 
the Perspex tube was connected to a stainless steel luer lock 1/4-28 UNF threaded 
fitting for easy and leak free connection of tubing with air pressure supply (Figure 
2.18). 
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Figure 2.18 Perspex Tube for Dilation Test Setup 
 
Figure 2.19 Schematic Diagram of Dilation Test Setup 
The schematic diagram of dilation test set up is shown in Figure 2.19. A Canon 
digital SLR 550 D camera was mounted perpendicular to the Perspex column (or heart 
valve root) to take images of the heart valve root. A reference scale and a digital 
pressure transducer (S/N: 63204/3, Comark Instruments, Inc.) were mounted on a 
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retort stand in the same plane as the Perspex column (or a heart valve root) for 
calibration.  
2.4.8.1.2 Test Procedure 
The heart valve root outflow was mounted onto the wide end of the tube and 
secured with a cable tie. The myocardial end of the heart valve root was free to move 
longitudinally, allowing the heart valve root to expand freely in the axial direction. 
For the pulmonary heart valve roots, an appropriately sized annulus ring (Figure 2.20) 
was used due to the fact that when removed from the heart the pulmonary heart 
valve root is hardly supported by the thin right ventricle myocardium, whereas aortic 
heart valve root is supported by the thick left ventricle myocardium. 
 
Figure 2.20 Dilation Testing Setup for Pulmonary Heart Valve Root with 
Annulus Ring 
One end of the 3 way connector was connected to a digital pressure transducer 
and another to a pneumatic air regulator. The Perspex tube was filled with PBS 
solution through the three-way connector and gradually pressurized using a 
pneumatic air regulator. The root was marked with reference points at least 5 mm 
above the sinotubular junction to help identify relative deformation using a tissue 
marking dye. Pressure was increased in increments of at least 5 mmHg and the heart 
valve root was photographed at each increment. The images were taken such that 
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the digital display of the pressure meter and the reference scale were in the field of 
view. The process stopped when the maximum pressure was reached or until the 
heart valve root “failed”, whichever occurred first. The maximum applied pressure 
for aortic and pulmonary heart valve roots was 120 and 35 mmHg respectively.  
Failure was considered when the PBS solution leaked out of the heart valve root 
faster than the pressure could be applied.  
 
Figure 2.21 Static Pressure Calculation during Dilation Testing 
A preliminary image, without application of any external pressure, was also 
captured to help calculate the static pressure experienced by the heart valve root due 
to PBS solution level in the Perspex tube (Figure 2.21). First the scale was calibrated 
using the reference scale (10 mm) as the reference to convert pixels to millimeters. 
Then the measured height (h) of the column of PBS solution divided by 13.6 (mercury 
is approximately 13.6 times denser than the PBS solution) to measure the static 
pressure (Po) in millimetres of mercury. This static pressure value, Po, was added to 
all the other applied pressure values (Pa). The height (h) of PBS at the start of the test 
was different for each heart valve root, resulting in different final pressure values Pf 
(Pf =Pa + Po) for all the heart valve roots.  
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2.4.8.1.3 Data Analysis 
 
Figure 2.22 Representative images taken during dilation test at (a) 0 mmHg 
and (b) 35 mmHg 
All the images were uploaded into ImageJ, a Java-based open source image 
processing software ImageJ (NIH, Bethesda, MD), for analysis.  
Image stacks of pressure measurements for each heart valve root were 
collected and aligned on a single canvas using the ImageJ plug-in called Montage. An 
edge detection plug-in in ImageJ was used to find the edges of the reference marks 
and the heart valve root (Figure 2.22).  
The distance Da between two reference marks were measured for each 
pressure Pa. Similarly, the distance Do was measured at pressure Po. The formula 
shown below was used to measure percentage dilation for each pressure 
measurement: 
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𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝐷𝑖𝑙𝑎𝑡𝑖𝑜𝑛 =  
Da − Do 
Do 
 × 100 
The results for each heart valve root are presented in terms of percentage 
dilation as a function of internal pressure. The mean percentage dilation is presented 
at 20 mmHg for pulmonary and 40 mmHg for aortic heart valve roots.   
2.4.8.1.4 Statistical Analysis 
Statistical significance between two groups was determined by applying 
Student’s t-test using SPSS for Windows (version 21.0; SPSS, Inc., USA). The 
significance level was set at 0.05. 
2.4.8.2 Biomechanical Performance II: Uniaxial Tensile Test and Suture Pull-Out 
Test ……… 
The mechanical testing of soft biological heart valve roots is often confounded 
by local complexities introduced at sample-grip interfaces (i.e., bending, preloading, 
cross-section area measurement, stress concentrations, tearing). This requires 
additional diligence in ensuring the accuracy of measurements of all parameters. 
Also, it was important to develop an accurate, reliable, and repeatable test method 
to test this tissue under uniaxial tension. 
2.4.8.2.1 Uniaxial Tensile Tester: Instron 3365 (Instron® Corporation) 
Tensile material properties of the heart valve root (cellular porcine aortic and 
pulmonary, human cellular and decellularised aortic, human cellular and 
decellularised pulmonary, cellular ovine pulmonary, explanted decellularised porcine 
pulmonary, decellularised porcine pulmonary, cryopreserved cellular porcine 
pulmonary) wall and leaflets were determined using uniaxial tensile tests. Suture 
pull- out properties of the wall and myocardium of the heart valve root (cellular 
porcine aortic and pulmonary, human cellular and decellularised aortic, human 
cellular and decellularised pulmonary) were determined using suture pull-out tests. 
These tests were performed with an Instron 3365 materials testing machine 
(3365K5747, Instron® Corporation). 
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Figure 2.23 Uniaxial Tensile Tester 3365 with Biobath 
The machine was equipped with a 50 N load cell (UKAS traceable calibrated), a 
biobath containing PBS, and a temperature control system (Figure 2.23). The Instron 
3365 is a dual column table-top testing system, ideal for tension and/or compression 
applications. It has a capacity of 5 kN, maximum speed 1000 mm/min, and 1193 mm 
vertical test space.  
2.4.8.2.2 Thickness Measurement 
The thicknesses of the heart valve root wall and leaflet specimens were 
measured at six locations in gauge length area using two different tissue thickness 
gauges (Mitutoyo 700-122, James H. Heal J-40-V). Heart valve root wall and leaflet 
specimens are compressible. This means that they change their thickness depending 
on the vertical force applied on them. Therefore, great care was taken during 
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thickness measurements and thickness gauge with minimum specimen compression 
during thickness measurement was chosen.  
 
Figure 2.24 Mitutoyo Digital Thickness Gauge 700-122 
The porcine heart valve root specimens thickness were measured with a 
lightly spring loaded Mitutoyo (Model No: 700-122) quick mini digital thickness 
gauge (Figure 2.24). The thickness gauge was used in previous other studies to 
measure pulmonary valve wall (2011) and patellar tendon (Herbert et al., 2016). It 
had a 0-25.4 mm range and 0.01 mm resolution. The applied force on the tissue 
specimen was variable as it was hand held. The limitations of the thickness gauge 
were identified during the method evaluation study. As the heart valve root 
specimens were wet and the loading spring of the thickness gauge was exposed and 
resulted in frequent replacement of the spring due to stiction and corrosion. Also, it 
was difficult to hold the gauge length region of the tissue specimens (wall and 
leaflets) between the two anvils of the thickness gauge whilst holding the thickness 
gauge at the same time. 
To eliminate limitations with the Mitutoyo thickness gauge a low load (0.05 
N/cm2) digital thickness gauge J-40-V (James H. Heal and Company Limited) (Figure 
2.25) with an accuracy of ± 0.01 mm was used. The J-40 V thickness gauge consisted 
of a fixed bottom anvil and a moving upper anvil with a diameter of 50 mm. The large 
upper anvils of the thickness gauge made it difficult to mount small specimen in the 
middle of the anvils for the thickness measurement. This issue was mitigated by 
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reducing the diameter of the top anvil to 10 mm which allowed for precise positioning 
of the specimen between the anvils. The modified size of the top anvil relative to the 
bottom anvil is shown in Figure 2.25. 
 
Figure 2.25 Digital Thickness Gauge J-40 V (James H. Heal and Company 
Limited) 
During measurement, the specimen was carefully placed on the middle of the 
bottom anvil and the top anvil was moved downward until it touched an area of the 
specimen. The resulting height was recorded. To prevent the specimens from drying 
out, PBS was regularly applied with a syringe during measurement, as dehydration 
may have led to underestimation of the specimen thickness due to shrinkage. This 
method gave an accurate measure of the thickness and was free of any error due to 
change in load associated with spring loaded thickness gauge.  
2.4.8.2.3 Uniaxial Tensile Test 
Uniaxial tensile testing of heart valve tissue specimens has always raised the 
question of test reliability. Because of their viscoelastic characteristics and low 
friction between the holder material and wet soft biological tissue specimen, it is 
difficult to hold them rigidly at in vitro strain and tensile load. Excessive compression 
on the soft tissue will elevate stress around the contact area, which leads to rupture 
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before target loads are achieved, too little compression will result in slippage. 
Therefore, it was deemed important to develop a holder for tensile testing of heart 
valve tissue specimens. To achieve to the best holder design to allow effective 
characterisation of the tensile properties of the heart valve tissue specimen. Design 
specification for the holder is described in Table 2.6. 
Table 2.6 Design Specification for the Holder to Test Heart Valve Specimens 
under Uniaxial Tensile Testing 
Feature Requirement/ Specification 
Dimensions Must be able to fit in the uniaxial tensile tester 3365 and able to 
connect with 50 N Load cell and Bio bath 
Material Durable enough to withstand repeated use  
Able to clean thoroughly with disinfectant /Autoclavable 
Operation Easy mounting and removal of the specimen without causing damage 
Able to hold specimen rigidly at maximum load 30 N 
Able to hold specimen with different thickness and texture (aortic and 
pulmonary walls and leaflets) 
 
2.4.8.2.3.1.1 Holder Design and Specimen Clamping 
Securing the wall and leaflet specimens to the grips for uniaxial tensile testing 
for accurate tensile testing posed many challenges and required some innovative 
solutions. In order to measure accurate stress strain characteristics of the specimens, 
it was imperative to ensure a firm grip between the specimen and the grips without 
damaging the specimen. Designing a holder with gripping surfaces that could hold 
the specimens tightly without damaging them was one of the important criteria as 
described in Table 2.6. For this purpose, a holder was redesigned. The new design 
(Figure 2.26) was simple, light weight, and easy to mount in the Instron machine.  
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Figure 2.26 Tissue Specimen Holder for the Uniaxial Tensile Tester 
The holder was made of titanium and had two different gripping surfaces for 
testing different types of tissues such as leaflet and wall of the heart valve root. It 
was required that holder should fit with the Bio bath and 50 N load cell. Therefore, 
two adapters (bottom adaptor – connect to Bio bath Figure 2.27 (a), Top adaptor – 
connect to 50 N load cell Figure 2.27 (C)) were designed. Both the adapters were T- 
slotted as shown in Figure 2.27, so the holder could be easily mounted and removed 
from the Instron. The plunger assembly was inserted in the hole of the bottom 
adapter (connected to the Bio bath) as shown in Figure 2.27 (a). As the plunger 
assembly was spring loaded, it allowed automatic adjustment of the slack between 
the holder and adaptor as shown in Figure 2.27 (b).  
One challenge in the tensile testing of the heart valve tissues was defining the 
gauge length and mounting the tissue in its fully relaxed state, therefore not pre-
tensioning the tissue. The gauge length refers to reference length of a test specimen 
at which it begins to resist load. The holder design allowed adjustment of the 
specimen gauge length before it was mounted in the Instron. Base plates with 
different gauge blocks were used to set up different gauge lengths (Figure 2.26). 
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Figure 2.27 (a) Bottom Adaptor with Plunger Assembly – Connect to Bio Bath 
(b) Spring Loaded Plunger Assembly Automatically Adjusts Holder Slack (c) Top 
Adaptor –Connect to 50 N Load Cell 
As described in Table 2.6, the other requirement of the holder design was the 
capability to hold specimens without damage. The tissue wall specimens were thick 
and slippery, whereas the leaflet tissue specimens were very thin and fragile. All the 
preliminary prototypes which were used in previous studies were tried to prevent the 
grip-specimen slippage during testing including serrated jaws (Jennings, 2001), 
sandpaper (Warnock et al., 2010, Sokolis et al., 2002), tissue paper (Seebacher et al., 
2008), etc. None of the gripping techniques were capable of holding the specimen 
without damaging it. It was observed that wall tissue specimens were much more 
‘slippery’ compared to leaflet tissue specimens. The answer to this challenge 
consisted of two parts: redesigned grips and sutures to hold the tissue. The gripping 
surfaces for wall and leaflet tissues were redesigned to minimise damage to 
specimens during the mounting and to avoid premature failure at grip edges during 
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the testing. A holder with gripping surfaces consisting of 1 mm deep grooves at a 1.8 
mm pitch was used for wall tissue specimens. A holder with finer gripping surfaces, 
0.5 mm deep grooves at 0.8 mm pitch, was used for leaflet tissue specimens. Slipping 
or failing at the grips during specimen mounting was prevented by using a 2-0 gauge 
(PROLENE™) non-absorbable polypropylene suture to hold the wall tissue specimen 
in the middle of the grips. Both ends of the tissue specimens were tied with suture to 
the lower face of the grips as shown in the Figure 2.28 (a) and (b). 
 
Figure 2.28 Clamping of the Wall Tissue Specimen (a) with Polypropylene 
Suture to hold the wall specimen in the middle of the grips (b) Top View (C) Side 
View 
One M4 cap head screw was used to fix the clamps together. Also a M3 grub 
screw was used to keep the two gripping surfaces parallel as shown in Figure 2.28 (c). 
The specimen was mounted in its fully relaxed state and care was taken to prevent 
specimen bending or stretching. This technique reduced the stress concentration at 
the grip specimen interface. It was predicated that the suture, which helped to keep 
the specimen in the middle of the grips during the mounting and act as a dissipater 
to reduce stress at grip-specimen interface. 
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The tissue specimen holder and adapters (Appendix B) were drawn in 
SolidWorks by technician Rhys Moore, Faculty of Engineering, University Of Leeds. 
2.4.8.2.3.1.2 Specimen Preparation and Cross Sectional Area Measurement…………. 
Accurate measurement of cross-sectional area of wall and leaflet tissue 
specimens is critical for calculation of their material properties. In this study, the 
specimen width was controlled using a custom made cutter shown in Figure 2.29. The 
cutter consisted of two single bevel cutting blades with two stainless steel spacer 
blocks. The spacer block (5 mm or 3 mm) between the two blades defined the gauge 
width of the tissue specimen.  
 
Figure 2.29 Specimen Cutter 
Specimens with an approximate length of 20 mm and width of 5 mm were taken 
from each heart valve root wall in the axial and circumferential directions. These 
strips were cut at least 2-3 mm above the sinotubular junction (Figure 2.30). Sections 
of the leaflet were cut from the same heart valve root in the radial and 
circumferential directions. Due to sample size limitations, valve leaflets were cut into 
width of 5 mm in circumferential and 3 mm in radial direction with maximum possible 
lengths from each valve. 
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Figure 2.30 Specimen Preparation 
The gauge length was 10 mm for the wall tissue specimens in both the axial and 
circumferential directions and leaflet specimens in the circumferential direction. 
Whereas, the gauge length was 6 mm for all the leaflet radial specimens. It was 
notably difficult to cut the leaflet specimens to the correct dimensions. To ease the 
cutting process, the leaflets were placed on a thin transparent plastic sheet over 
coloured paper. The leaflets were kept hydrated with PBS solution during the cutting 
process. The thickness of the specimens was measured as described in Section 
2.4.8.2.2. 
2.4.8.2.3.1.3 Test Procedure 
Consistency in the physiological environment during testing, for factors such as 
hydration and temperature, helps to make procedures repeatable and reliable. A bio 
bath with PBS solution at 37°C was used to achieve a controlled physiological 
environment. First the bio bath and grips with specimens were mounted in the 
Instron. Then the specimen thickness, width, and length were entered in the 
software. Initial extension and load measurement were reset to zero. Test data was 
recorded as the change in length of the tissue and the corresponding force detected 
on the load cell. The data was stored in Microsoft Excel format. A strain rate of 10 
mm.min-1 (0.028 s-1) was used for all the specimens. A similar strain rate had been 
used in previous studies to test similar tissues, such as human thoracic aorta (Duprey 
et al., 2010), mitral valve tissue (Kunzelman and Cochran, 1992) and porcine 
97 
Chapter 2 
pulmonary valve tissue (Bader et al., 1998). No preloading or preconditioning was 
used. The intrinsic properties of the test specimen in the elastin phase may alter due 
to preloading by starting the data collection at an arbitrary value rather than the 
relaxed state of the specimen.  
2.4.8.2.3.1.4 Data Processing 
The load (N) and corresponding displacement (mm) was recorded for each test 
by the Bluehill 2 software (Version 2.35.917). This data was stored in Microsoft Excel 
files for further analysis. The data (load and displacement) were converted to stress 
(MPa) and strain as follows:  
𝐸𝑛𝑔𝑖𝑛𝑒𝑒𝑟𝑖𝑛𝑔 𝑆𝑡𝑟𝑒𝑠𝑠 (σ) =  
𝐹
𝐴𝑜
  
Where Ao is the initial cross-sectional area = specimen width x specimen 
thickness, and F is the load in Newtons registered by the Instron machine.  
𝐸𝑛𝑔𝑖𝑛𝑒𝑒𝑟𝑖𝑛𝑔 𝑆𝑡𝑟𝑎𝑖𝑛 (ε) =  
𝐿
𝐿𝑜
 
Where Lo is the original gauge length during tensile testing, and L is the 
extension from the original gauge length. 
The engineering stress–engineering strain data must be interpreted with 
caution because during uniaxial tensile testing the specimens experience significant 
change from their original dimensions during testing. Conversely, the true stress–true 
strain can gives a more direct measure of the material's response instantaneously. 
Hence, for testing associated with large strain and significant reduction in cross-
sectional area, the true stress (force divided by instantaneous area) and a higher 
order strain may be preferable. However, to determine true stress-strain, it requires 
the right equipment in order to measure the instantaneous changing values of width 
and length of specimen during testing.  
Therefore, the data was analysed using engineering stress versus engineering 
strain graphs, considering uniform cross-sectional during testing; this made the 
measurement easier to perform, but the results can be only comparative, not 
absolute. 
98 
Chapter 2 
 
Figure 2.31 Typical Stress-Strain Graph of Heart Valve Tissue Specimen 
Subjected to Uniaxial Tensile Loading to Failure. 
For each specimen, a stress-strain graph was created. Two linear regions 
(elastin and collagen) of the stress-strain graphs were approximated. Elastin phase 
slope and collagen phase were created through linear regression of the linear 
portions of the stress-strain graph performed in Microsoft Excel. In order for a test to 
be valid the trend line was required to have an R2 > 0.85. The maximum failure stress 
value was referred to as the ultimate tensile strength (UTS). 
2.4.8.2.4 Suture Pull-out Test  
The suture retention properties of heart valve root tissues were investigated in 
this study because the decellularised heart valve roots must have adequate suture 
retention strength, and hence, be capable of resisting sutures from pulling through.  
The suture pull out method was adopted from the method described by ISO 
7198 (2016) for Cardiovascular implants - Tubular vascular prostheses. 
2.4.8.2.4.1.1 Specimen Preparation 
The specimens were taken from the wall and myocardium of each heart valve 
root. All specimens were cut axially into a 20 mm x 15 mm strip as shown in Figure 
2.32. 
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Figure 2.32 Specimen Preparation for Suture Pull-Out Testing 
A holder with wider custom made grips (Figure 2.33 ) was designed on the 
basis of the holder used for tensile testing (Section 2.4.8.2.3.1.1) to secure the wider 
tissue specimen. 
 
Figure 2.33 Tissue Specimen Holder for the Suture Pull-Out Testing  
One end of the specimen was clamped. A 5 mm suture loop (4-0 non-absorbable 
monofilament suture with taper needle, Premilene®) (Karck and Haverich, 2005, Park 
et al., 2012) was created at the centre of the other end of the specimen, 4 mm from 
the free edge (Figure 2.34).  
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Figure 2.34 A Sample Specimen Showing the Position of Suture through 
Material 
The suture was clamped on the upper gripping surface. The full specimen 
clamping arrangement was mounted in the Instron 3365 (Instron, Bucks, UK), uniaxial 
tensile tester. A 50 N load cell was used and strain was applied at a rate of 10 
mm/min. The thickness of the specimens were measured at the suture insertion point 
using a thickness gauge J- 40 V as described in Section 2.4.8.2.2. The tests were 
continued until the suture was completely pulled out from the specimens.  
2.4.8.2.4.1.2 Data Processing 
The peak load was recorded as the maximum suture pull-out force and the type 
of failure was recorded. The peak load recorded was reported as the suture pull-out 
force. Also resistance to tearing was calculated by using the formula below. 
           T= F max / t 
Where T= Resistance to tearing (N/mm) 
      F max= Maximum suture pull-out load measured in Newton 
            t= Thickness measured in mm 
 Tissue Behavior 
Images were taken during the uniaxial tensile testing of the wall and leaflet 
specimens and suture pull-out testing of the wall specimens. It was observed that the 
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majority of the wall and leaflet tissue specimens (aortic and pulmonary) failed in the 
gauge length during uniaxial tensile testing (Figure 2.35). 
 
Figure 2.35 Representative Images of Tissue Specimens Undergoing Uniaxial 
Tensile Testing 
During suture pull-out testing of the wall specimens (aortic and pulmonary) the 
first sign of failure was the appearance of a small hole behind the suture. This was 
followed by a wedge shaped cut spreading from the suture in the circumferential 
direction perpendicular to the axial axis (direction of pulling) (Figure 2.36).  
 
Figure 2.36 Circumferential Wedge Propagation in the Wall Specimen due to 
a Suture Pull-Out Load in the Axial Axis. 
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 Statistical Analysis for Uniaxial Tensile Test and Suture Pull-Out 
Test…………… 
Analysis was carried out in Microsoft Excel 2013 and numerical data presented 
as the mean ± 95 % confidence intervals. The 95 % confidence intervals were 
calculated using Microsoft Excel. Differences between two means were assessed 
using a Student’s t-test. For all analyses, the significance value was set to p ≤ 0.05. All 
analyses were performed using the SPSS for Windows (version 21.0; SPSS, Inc., USA). 
2.5 Summary  
The use of experimental methods for in vitro pre-clinical analysis is a well-
established practice. However, the complex collagenous structure inherent in human 
heart valve roots warrants a truly complete picture of performance of heart valve 
roots. This requires accurate and robust in vitro analysis of functional performance of 
heart valve root. Keeping this objective in mind, the preceding sections in this chapter 
described robust, repetitive, and accurate biomechanical and hydrodynamic test 
methods to test biological heart valve roots. 
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 In vitro Hydrodynamic and Biomechanical Performance of Cellular 
Porcine Aortic and Pulmonary Heart Valve Roots 
3.1 Introduction 
This study addressed the practical aspects of implementing and evaluating the 
research methods described in Chapter 2 to assess hydrodynamic (competency and 
pulsatile flow) and biomechanical (dilation, uniaxial tensile and suture pull-out) 
performance of heart valve roots before applying the methods to decellularised 
human (aortic and pulmonary) and decellularised porcine pulmonary heart valve 
roots. This method evaluation process was designed to ensure that the methods 
produced results that were consistent with existing data in the literature. In this 
method evaluation study porcine heart valve roots were used because they are 
"healthy" and more consistent in properties compared to human roots which are 
highly variable due to age and lifestyle of the donors. Cellular porcine samples are 
widely used in cardiovascular research due to the circulatory system being 
comparable to that of humans (Schuster et al., 2010). In addition, low infection risk, 
ease of availability, and low cost have led to the extensive use of porcine samples in 
biomedical research. The hydrodynamic (Syedain et al., 2013, Fisher et al., 1986, 
Reimer et al., 2015, Jennings et al., 2002) and biomechanical (Korossis et al., 2002, 
2014, Anssari-Benam et al., 2011) performance of porcine heart valve roots has been 
accepted as a near equivalent measure of human heart valve roots. In addition, 
robust hydrodynamic and biomechanical performance data for porcine aortic and 
pulmonary heart valve roots provided confidence in test methods as well as a 
benchmark control for comparison with decellularised heart valve roots.  
3.2 Aim and Objectives 
The aim of this study was to derive hydrodynamic and biomechanical 
performance of cellular porcine aortic and pulmonary heart valve roots and compare 
the performance with data published in the literature. 
Specifically, the objectives of this study were: 
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1. To determine the hydrodynamic performance of cellular porcine aortic and 
pulmonary heart valve roots and compare to published data. 
2. To determine the biomechanical performance of cellular porcine aortic and 
pulmonary heart valve roots and compare to published data. 
3.3 Materials  
Six pulmonary (assigned identification PP1 to PP6) and six aortic (assigned 
identification PA1 to PA6) heart valve roots were dissected from porcine hearts, 
obtained from M & C Meats, Crossgates, Leeds and John Penny & Sons, Rawdon, 
Leeds, UK. For each performance assessment, six independent cellular porcine 
pulmonary and six independent cellular porcine aortic heart valve roots were used. 
The cellular porcine pulmonary and aortic heart valve roots were sized between 19 
and 24 mm. The details of the heart valve root storage and defrosting procedure was 
described in Chapter 2 Section 2.4.4. 
3.4 Methods 
  Hydrodynamic Performance of Cellular Porcine Aortic and Pulmonary Heart 
Valve Roots 
3.4.1.1 Hydrodynamic Performance I: Competency  
The competency of each cellular porcine aortic and pulmonary heart valve root 
was measured in terms of leakage flow rate by applying a maximum static back 
pressure of 120 and 60 mmHg respectively. The time taken for this test fluid to drop 
to 80 mmHg (aortic) and 20 mmHg (pulmonary) were recorded. The root was 
considered to be competent if the pressure head had not dropped to 80 mmHg (for 
aortic) or 20 mmHg (for pulmonary) within a cut-off period of 30 minutes for aortic 
and 20 minutes for pulmonary heart valve roots. The detailed test procedure and test 
conditions for the competency testing of porcine pulmonary and aortic heart valve 
roots were described in Chapter 2 Section 2.4.6.1.3. 
It was not considered necessary to measure the arterial diameter of the heart 
valve root during the competency assessment since this would not have given any 
further information to support the method evaluation. 
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3.4.1.2 Hydrodynamic Performance II: Pulsatile Flow  
The hydrodynamic performance of the cellular porcine aortic and pulmonary 
heart valve roots was measured in terms of root mean square flow, transvalvular 
pressure difference and effective orifice area (EOA) using a pulsatile flow simulator. 
The EOA is presented as the mean ± 95% confidence intervals. The leaflet dynamics 
of the roots were measured with a high speed camera at 500 frames. s-1 at a heart 
rate 72 bpm.  
Table 3.1 Test Conditions Used in the Pulsatile Flow Performance of Cellular 
Porcine Aortic and Pulmonary Heart Valve Roots (Maximum Compliance Condition) 
 Aortic Heart Valve Root Pulmonary Heart Valve Root 
Heart Rate (bpm) Mean Peak Flow (mL .s-1) 
60 249 239 
72 352 348 
80 383 388 
100 546 537 
 
The heart valve roots were mounted on the appropriate size of spigots as 
described in Chapter 2 Section 2.4.7.3 and tested as described in Chapter 2 Section 
2.4.7.4. The heart valve roots were initially tested in the pulsatile flow simulator at 
minimum compliance with heart rates 60, 72, 80 and 100 bpm with corresponding 
stroke volumes 60, 70, 80 and 80 ml to determine the peak flow conditions required 
for the testing at maximum compliance, which are detailed in Table 3.1. The systemic 
pressure was held between 120 to 80 mmHg for aortic heart valve roots and between 
45 to 15 mmHg for pulmonary heart valve roots to represent in vivo conditions. 
  Biomechanical Performance of Cellular Porcine Aortic and Pulmonary Heart 
Valve Roots 
3.4.2.1 Biomechanical Performance I: Dilation (Expansion Characteristics)……. 
The circumferential expansion characteristics of each cellular aortic and 
pulmonary heart valve root wall was derived in terms of percentage dilation. As 
described in Chapter 2 Section 2.4.8.1.2, the test involved attaching the heart valve 
root (aortic and pulmonary) outflow to the end of a Perspex cylindrical tube with a 
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cable tie. The maximum applied pressures were 120 (aortic) and 35 mmHg 
(pulmonary) or until the valve “failed“. The percentage dilation was calculated for 
each pressure measurement. The results are presented as percentage dilation as a 
function of increasing pressure. The mean percentage dilation was recorded at 20 
mmHg for the pulmonary and 40 mmHg for aortic heart valve roots. All data are 
presented as the mean ± 95% confidence intervals.  
3.4.2.2 Biomechanical Performance II: Uniaxial Tensile and Suture Pull-
Out…………... 
The tensile material properties of the wall and leaflets from each cellular aortic 
and pulmonary heart valve root were characterised using the uniaxial tensile testing 
method. Two walls (axial and circumferential) and two arbitrary leaflets (radial and 
circumferential) specimens from each heart valve root were tested. The specimen 
sizes and test method were described in Chapter 2 Section 2.4.8.2.3.1.3. The ultimate 
tensile stress (UTS), failure strain and slopes for the elastin and collagen phases were 
determined for each specimen tested.  
The maximum suture pull-out force was determined for additional wall 
specimens from each pulmonary and aortic heart valve root. The specimen sizes and 
test methods were described in the Chapter 2 Section 2.4.8.2.4. The peak load for 
each tested specimen was recorded as the maximum suture pull-out force. It was not 
considered necessary to determine the suture pull-out force of the myocardial 
specimen from the heart valve root since this would not have given any further 
information to support the method evaluation procedure. 
The specimen thickness was measured with a Mitutoyo digital thickness gauge. 
All data are presented as the mean ± 95% confidence intervals.  
3.5 Results 
 Hydrodynamic Performance of Cellular Porcine Aortic and Pulmonary Heart 
Valve Roots 
3.5.1.1 Hydrodynamic Performance I: Competency  
The valve competency in terms of mean leakage flow times and rates for the 
cellular porcine aortic and pulmonary heart valve roots is shown in Table 3.2. 
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Table 3.2 Mean Leakage Flow Times (TL) and Mean Leakage Flow Rates (FL) for 
the Cellular Aortic and Pulmonary Heart Valve Roots 
 Cellular Porcine Aortic  
Heart Valve Roots 
Cellular Porcine Pulmonary 
 Heart Valve Roots 
Valve 
TL  
second 
F L  
mL.s-1 
Competent 
Yes+ 
Or 
No++ 
Valve 
TL  
second 
F L  
 mL.s-1 
Competent 
Yes* 
Or 
No** 
PA1 832 1.86 No++ PP1 577 2.66 No** 
PA2 >1800 <0.85 Yes+ PP2 684 2.97 No** 
PA3 >1800 <0.85 Yes+ PP3 414 3.71 No** 
PA4 >1800 <0.85 Yes+ PP4 262.5 5.85 No** 
PA5 >1800 <0.85 Yes+ PP5 118 13.01 No** 
PA6 >1800 <0.85 Yes+ PP6 421 3.65 No** 
Yes+ - leakage flow rate ≤ 0.85 mL.s-1, No++ leakage flow rate > 0.85 mL.s-1 
Yes* - leakage flow rate ≤ 1.28 mL.s-1, No ** leakage flow rate > 1.28 mL.s-1 
  
The majority of the cellular porcine aortic heart valve roots were competent 
with leakage flow rates lower than 0.85 mL.s-1, except heart valve root PA1 which had 
a mean leakage flow rate of 1.86 mL.s-1.  
All six cellular porcine pulmonary heart valve roots were regurgitant and had a 
central regurgitant jet, taking on average 413 seconds to drop from 80 to 20 mmHg, 
giving a mean leakage flow rate of 5.31 mL.s-1. 
3.5.1.2 Hydrodynamic Performance II: Pulsatile Flow  
The mean transvalvular pressure difference and mean RMS forward flow for the 
six cellular porcine aortic and pulmonary heart valve roots is shown in Figure 3.1 (a) 
and (b) respectively. At a heart rate 72 bpm, the mean transvalvular pressure 
difference and the mean RMS flow for the porcine aortic heart valve roots was 2.01 
± 0.46 mmHg and 215.42 ± 8.66 mL.s-1 respectively; and mean transvalvular pressure 
was 2.57 ± 0.99 mmHg and RMS flow was 220.73 ± 18.31 66 mL.s-1 for the pulmonary 
heart valve roots. 
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(a) 
 
(b) 
Figure 3.1 Mean Transvalvular Pressure Difference versus RMS Flow for 
Cellular Porcine (a) Aortic (b) Pulmonary Heart Valve Roots – Data fitted with 
second order polynomial trend line - The error bars indicate 95 % confidence limits 
The effective orifice area (EOA) for each aortic and pulmonary heart valve root 
was averaged over all tested conditions as shown in Table 3.3. The mean EOA with ± 
95 % confidence limits for cellular porcine aortic and pulmonary heart valve roots was 
3.03 ± 0.34 cm2 and 2.84 ± 0.56 cm2 respectively. 
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Table 3.3 Mean Effective Orifice Areas for Cellular Porcine Pulmonary and 
Aortic Heart Valve Root  
Aortic  
Heart Valve Root 
EOA (cm2) 
 PA1 PA2 PA3 PA4 PA5 PA6 
2.88 3.48 3.24 3.26 2.91 3.43 
Pulmonary  
Heart Valve Root 
EOA (cm2) 
 PP1 PP2 PP3 PP4 PP5 PP6 
3.75 2.60 3.24 2.45 2.39 2.64 
 
The leaflet kinematics were assessed during the opening, fully opened, closing 
and fully closed phases and representative images of these phases are shown in 
Figure 3.2 for the cellular porcine (a) aortic and (b) pulmonary heart valve roots 
respectively.  
Aortic Heart Valve Root  Pulmonary Heart Valve Roots 
  
 
  
Valve Opening 
Valve Fully 
Opened 
 Valve Opening 
Valve Fully 
Opened 
  
 
  
Valve Closing Valve Fully Closed  Valve Closing Valve Fully Closed 
(a)  (b) 
Figure 3.2  Valve Opening, Valve Fully Opened, Valve Closing and Valve Fully 
Closed Images of a Typical Cellular Porcine (a) Aortic and (b) Pulmonary Heart Valve 
Root at Heart Rate 72 bpm, Captured from the Front View by a High-Speed Camera 
All the cellular porcine aortic heart valves roots showed a triangular orifice 
during the opening phase and circular orifice in the fully opened phase. There was no 
leaflet folding observed. During the closing phase, all the aortic valves were observed 
to fully close, with no visible leakage orifice during the fully closed phase. 
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For all the cellular porcine pulmonary heart valve roots, synchronous opening 
was observed. During the closed phase, a small central leakage orifice at lower heart 
rates and redundant leaflet material was observed.  
 Biomechanical Performance of the Cellular Porcine Aortic and Pulmonary 
Heart Valve Roots 
3.5.2.1 Dilation (Expansion Characteristics)  
The percentage dilation as a function of the internal pressure for all the cellular 
porcine aortic and pulmonary heart valve roots is shown in Figure 3.3 (a) and (b) 
respectively.  
  
(a) (b) 
Figure 3.3 Percentage Dilation as a Function of Applied Pressure of all Cellular 
Porcine (a) Aortic and (b) Pulmonary Heart Valve Roots - Data fitted with a second 
order polynomial trend line 
The figures showed that percentage dilation with respect to pressure 
relationship seemed to be linear for both the cellular aortic and pulmonary heart 
valve roots. 
The mean percentage dilation was 11.58 ± 5.56 % at 40 mmHg internal pressure 
for aortic heart valve roots and it was 20.54 ± 18.44 % at 20 mmHg pressure for 
pulmonay heart valve roots.  
3.5.2.2 Uniaxial Tensile and Suture Pull – Out Characteristics 
The mean wall and leaflet specimen thicknesses ± 95 % confidence limits of the 
porcine pulmonary and aortic heart valve roots are shown in Table 3.4. 
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Table 3.4 Mean Thickness ± 95 % Confidence Limits for the Cellular Porcine 
Aortic and Pulmonary Heart Valve Root Specimens (Wall and Leaflet) 
 
Mean Thickness ± 95 % confidence limits 
(mm) 
Specimen Type 
Aortic  
Heart Valve Root 
Pulmonary  
 Heart Valve Root 
Root wall axial 3.02 ± 0.29 2.22 ± 0.28 
Root wall circumferential 2.62 ± 0.24 1.88 ± 0.28 
Leaflet radial 0.52 ± 0.11 0.39 ± 0.09 
Leaflet circumferential 0.63 ± 0.13 0.38 ± 0.09 
 
The stress-strain graphs of six specimens of the cellular porcine pulmonary and 
aortic heart valve root wall in the axial and circumferential and leaflet in radial and 
circumferential directions are shown in Figure 3.4. 
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Cellular Porcine Aortic Heart Valve Roots 
  
(a) Wall (b) Leaflets 
Cellular Porcine Pulmonary Heart Valve Roots 
  
(c) Wall (d) Leaflet  
Figure 3.4 Stress-Strain Graphs for the Cellular Porcine (a) Aortic Wall, (b) 
Aortic Leaflets, (c) Pulmonary Wall and (d) Pulmonary Leaflets Specimens [Wall 
Specimens: Axial (Solid Lines) and Circumferential (Dotted lines)] and Leaflet 
Specimens [Radial (Solid Lines) and Circumferential (Dotted lines)] 
The leaflet specimens demonstrated a noticeable anisotropy between the 
radial and circumferential directions for both pulmonary and aortic heart valve roots. 
The stress-strain characteristics of the aortic and pulmonary heart valve root walls 
had a similar three-phased behaviour to the leaflet tissue, with a low modulus region 
during the elastin phase and a high modulus region during the collagen phase but no 
clear anisotropy between the axial and circumferential directions.  
The mean biomechanical parameters with 95 % confidence limits for the 
porcine aortic and pulmonary specimens (wall and leaflet) are shown in Table 3.5.  
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Table 3.5 Mean Collagen Phase Slope (Ec), Mean Elastin Phase Slope (Ee), 
Mean Ultimate Tensile Stress (UTS) and Mean Failure Strain (ɛf) (± 95 % Confidence 
Limits) for the Cellular Porcine Aortic and Pulmonary Wall and Leaflet Specimens 
 Ec Ee UTS ɛf 
 MPa MPa MPa  
Aortic Wall 
Axial 0.86 ± 0.22 0.15 ± 0.02 0.70 ± 0.09 1.56 ± 0.13 
Circumferential 1.55 ± 0.18 0.23 ± 0.02 1.38 ± 0.12 1.69 ± 0.20 
Aortic Leaflet 
Radial 1.42 ± 0.52 0.03 ± 0.01 0.70 ± 0.26 1.01 ± 0.17 
Circumferential 22.07 ± 6.44 0.81 ± 0.82 4.17 ± 0.85 0.38 ± 0.05 
Pulmonary Wall 
Axial  0.76 ± 0.26 0.04 ± 0.01 0.55 ± 0.07 1.65 ± 0.30 
 Circumferential 1.52 ± 0.45 0.10 ± 0.03 1.19 ± 0.29 1.83 ± 0.22 
Pulmonary Leaflet 
Radial 0.92 ± 0.51 0.03 ± 0.01 0.51 ± 0.19 1.05 ± 0.27 
Circumferential 18.22 ± 9.55 0.44 ± 0.31 3.84 ± 1.96 0.40 ± 0.04 
  
The mean maximum suture pull-out force for the aortic and pulmonary wall 
specimens was 4.14 ± 1.43 N and 8.07 ± 5.19 N respectively. 
3.6 Discussion 
This study assessed the hydrodynamic and biomechanical performance of 
cellular porcine aortic and pulmonary heart valve roots. The majority of the cellular 
porcine aortic heart valve roots were shown to be competent, whereas all the cellular 
porcine pulmonary heart valve roots were regurgitant. This was possibly due to the 
anatomy of the pulmonary heart valve root combined with a test artefact. 
Physiologically the pulmonary heart valve root is supported by thin and delicate 
myocardium, in comparison with the aortic heart valve root, which is strongly 
supported by its thick myocardium and in a position wedged between the left and 
right atrioventricular annuli and bulging thick left ventricular wall (Misfeld and 
Sievers, 2007). It was hypothesised that the pulmonary valve regurgitation was due 
to the lack of annulus support, resulting in a lack of coaptation of the leaflets of the 
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valves. Modification in the competency assessment method by adding annulus 
support was a possible way to solve this issue and this hypothesis and solution is 
investigated further in Chapter 5. 
An in vitro assessment of EOA gives information about valve performance and 
this provides clinicians and engineers of a way to compare different types of heart 
valves. The porcine aortic heart valve roots showed excellent performance in terms 
of valve opening and closing characteristics under pulsatile flow conditions. The EOA 
derived in this study (3.03 ± 0.34 cm2) for the aortic heart valve roots was similar to 
the EOA derived by Nagy et al. (2000) and Jennings (2001). Both Nagy et al. (2000) 
and Jennings (2001) investigated the hydrodynamic performance of cellular porcine 
aortic heart valve roots in a similar experimental set up. Nagy used varying sizes of 
aortic heart valve roots and found the mean EOA to be 2.73 ± 0.47 cm 2 at a heart 
rate 72 bpm. Jennings (2001) used 23 mm size of porcine aortic heart valve root and 
the mean EOA was determined to be 2.59 ± 1.53 cm2.   
Under pulsatile flow conditions, all the cellular porcine pulmonary heart valve 
roots showed synchronous leaflet opening, the fully open leaflet configuration and 
leaflet fluttering characteristics. A small central leakage orifice was observed for 
lower heart rates during the fully closed phase. It was observed that porcine 
pulmonary heart valve roots had some redundant leaflet above the coaptation 
surface. These findings were also reported in previous studies (Jennings, 2001, 2014). 
The mean EOA for the pulmonary heart valve roots was 2.84 ± 0.56 cm2, which agreed 
well with the values 2.85 ± 0.61 cm2 and 2.74 ± 0.39 cm2  derived by Nagy et al. (2000) 
and Jennings (2001) respectively. The hydrodynamic parameters (EOA, transvalvular 
pressure) for porcine pulmonary heart valve roots derived in this study showed good 
agreement with previous studies (Jennings, 2001, Nagy et al., 2000). Overall the 
repeatability of the pulsatile flow tests was comparable with literature. 
The mean percentage dilation was 11.58 ± 5.56 % at 40 mmHg pressure for the 
aortic heart valve roots. However, the pulmonary heart valve root was much more 
expansible in the circumferential direction with a mean percentage dilation of 20.54 
± 18.44 % at 20 mmHg. The dilation characteristics of the cellular porcine aortic heart 
valve roots at 40 mmHg agreed well with those reported (mean percentage dilation 
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12.22 ± 5.04 %) by Jennings (2001). Jennings (2001) however reported higher mean 
percentage dilation at 20 mmHg of cellular porcine pulmonary heart valve roots to 
be 33.93 ± 14.75 %. This could have been due to different test set up used for heart 
valve root dilation measurements. In this study, the annulus of pulmonary heart valve 
root was supported with an appropriately sized annulus ring during dilation 
measurement, whereas Jennings (2001) did not use annulus support during dilation 
measurement of pulmonary heart valve root. The circumferential expansion of the 
aortic and pulmonary root artery has been shown to be an important element of the 
leaflets opening (Nagy et al., 2000). Circumferential expansion was chosen as the 
indicator of arterial stiffness due to its direct representation of the overall arterial 
compliance and close correlation with the volume of blood flow through the artery 
of the heart valve root. Also maintaining the heart valve root as a whole structure as 
opposed to manipulating tissue into flat strips provided more informed analysis of 
the heart valve biomechanical function under physiological conditions. Dilation 
testing has the ability to preserve the physiological structure of the heart valve root 
and thus provides characteristics that more closely mimic those of a clinical setting. 
The extensibility of the heart valve root in the circumferential and axial directions 
was studied using pressure inflation tests with radiopaque markers, sonomicrometric 
crystals or syringe test set up either in vitro or in vivo animal models by several 
research groups (Dagum et al., 1999, Hansen et al., 1995, Vesely et al., 1991). 
Jennings (2001) has used different sizes of syringes to mount the heart valve roots 
which limited the ability to test different sizes of the heart valve roots. In this study, 
the purposely designed Perspex tubes in various sizes allowed the measurement of 
dilation of various sizes of the heart valve roots with diameters ranging from 20 to 32 
mm. Furthermore, during the dilation measurement it was important to mark the 
heart valve root wall with reference points, so the percentage dilation could be 
measured accurately between the reference points for small incremental pressure 
intervals from the captured images. A tissue marking dye was used to mark the 
reference points on the heart valve root wall which were clearly visible in the 
captured images and hence dilation was able to be accurately measured. 
It was important to develop a robust method for the determination of material 
properties so that the effects of decellularisation on cellular porcine and human heart 
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valve roots could be assessed. The clamping of fragile biological specimens and 
preventative slippage or premature failure is problematical during tensile testing. 
Many authors have designed or adapted clamping holders or techniques specifically 
for the tissue they were investigating (Gallagher et al., 2012, Lei et al., 2018, Marei et 
al., 2015, Guedes et al., 2018). In this study, the majority of the wall specimens failed 
in the middle of the gauge length during uniaxial tensile testing, this indicated that 
the utilisation of the new holder design combined with a new suture technique 
substantially reduced the stress concentration at the grip-specimen interface. The 
new valve holder design and clamping technique for uniaxial tensile testing (Chapter 
2 Section 2.4.8.2.3.1.1) was able to facilitate the accurate measurement of the 
material properties of porcine aortic and pulmonary heart valve root wall and leaflet 
specimens. This was one of the vital steps in the accurate measurement of the 
material properties of the biological heart valve root specimens with the tensile test 
method to ensure that the specimen did not slip from the grip edge during the 
testing.  
It was also important to measure the thickness of the specimens accurately 
during uniaxial tensile testing of the heart valve root specimens, since the thickness 
directly affected the stress calculation. The aortic wall was thicker than the 
pulmonary wall in both the axial and circumferential directions. The mean thickness 
of the cellular porcine pulmonary wall (axial: 2.22 ± 0.28 mm, circumferential: 1.88 ± 
0.28 mm) and leaflet (radial: 0.39 ± 0.09 mm, circumferential: 0.52 ± 0.11 mm) 
specimens was higher than the wall (axial: 1.74 mm, circumferential: 1.66 mm) and 
leaflet (radial and circumferential: 0.16 mm) thickness, reported by , 2011). The mean 
thickness of the aortic leaflets measured in this study was 0.58 ± 0.07 which was 
similar in thickness (0.5 mm) measured by Sauren et al. (1983). In this study, the aortic 
wall specimen mean thicknesses were 3.02 ± 0.29 mm (axial) and 2.62 ± 0.24 
(circumferential) which were higher than the thicknesses (2.40 ± 0.09 mm) measured 
by Jennings (2001). It was likely that variation in thickness measurements in porcine 
pulmonary and aortic heart valve leaflet specimens between different studies was 
due to user accuracy during the thickness measurement procedure, the choice of 
measuring equipment and arbitrarily selection of leaflets for tensile testing. The 
posterior leaflets tend to be thicker, have a larger surface area, and weigh more than 
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the right or left leaflet in the pulmonary heart valve roots; and the average width of 
the right coronary leaflet is greater than that of the other two leaflets in the aortic 
heart valve roots (Chandran et al., 2012). This study used a lightly loaded Mitutoyo 
(Model No: 700-122) digital thickness gauge, which when exerting a small 
compressive force on the tissue specimen would have given more consistent result. 
However, the thickness gauge had the following limitations: 1) failure due to spring 
corrosion and stiction and 2) difficult to hold the tissue specimens between the two 
anvils of the thickness gauge whilst holding the thickness gauge at the same time. In 
addition, the high water content of the specimens made it difficult to measure 
thickness accurately. To reduce experimental error and variation, thickness was 
measured six times and an average was taken. To address the limitations of the 
Mitutoyo thickness gauge a low load (0.05 N/cm2) digital thickness gauge J-40-V 
(James H. Heal and Company Limited) was used to measure wall and leaflet thickness 
of the heart valve root (Chapter 4, 5, 6 and 8). 
For the aortic leaflet specimens, the average collagen phase slopes 
(circumferential: 22.07 ± 6.44 MPa and radial: 1.42 ± 0.52 MPa) obtained in this study 
were lower than the collagen phase slopes of 54.6 ± 7.4 MPa and 7.82 ± 0.58 MPa for 
the circumferential and radial directions respectively, reported by Lee et al. (1984) 
and 28 ± 10 MPa in the circumferential direction reported by Sauren et al. (1983). 
Similar discrepancies were obtained in the wall tensile parameters. The elastic phase 
slope for circumferential aortic wall specimen was 0.23 ± 0.02 MPa, which was larger 
than the 0.12 ± 0.02 MPa reported by Korossis et al. (2002) and 0.113 ± 0.036 MPa 
reported by Zhou et al. (1997). Similarly in the axial direction, the elastic phase slope 
for the aortic wall specimen derived in this study was 0.15 ± 0.02 MPa, which was 
larger than 0.087 ± 0.021 MPa reported by Korossis et al. (2002). It was clear that the 
elastic moduli for the leaflets were highly dependent upon test specimen orientation. 
The leaflet circumferential specimens had significantly higher elastic modulus than 
the radial specimens. This anisotropy was expected since the load bearing collagen 
fibers are preferentially aligned in the circumferential direction. 
The mean elastic phase slopes obtained in this study were considerably lower 
than the elastic phase of 0.76 and 0.34 MPa in the circumferential and radial 
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directions respectively for the pulmonary leaflet specimens, reported by , 2011). 
Whereas, the mean collagen phase for the pulmonary leaflet specimens reported in 
this study were higher than the collagen phase of 0.15 and 0.12 MPa in the 
circumferential and radial directions respectively, reported by , 2011). The mean 
collagen phase slope for pulmonary wall specimens derived here was 0.76 ± 0.26 MPa 
and 1.52 ± 0.45 MPa in the axial and circumferential directions respectively which 
were larger than the values obtained by , 2011).  
There was a high variability in the tensile wall and leaflets parameters for the 
porcine aortic and pulmonary heart valve roots, obtained in various studies (Sauren 
et al., 1983, 2011, Korossis et al., 2002, Lee et al., 1984). This could have been due to 
the fact that a few studies (2011, Korossis et al., 2002) used preconditioning and 
preloading. , 2011) preloaded pulmonary heart valve specimens with 0.02 N to obtain 
an accurate measure of the tissue gauge length and hence, zero extension was taken 
at the point where a 0.02 N was measured. Korossis et al. (2002) preconditioned 
aortic leaflet specimens for 50 cycles to produce a steady-state load-elongation 
response. However, the intrinsic properties of the test specimen in the elastin phase 
may alter due to preloading by starting the data collection at an arbitrary value rather 
than the relaxed state of the specimen. It has been reported that tissue 
preconditioning does not contribute to the generation of repeatable stress-strain 
curves for heart valve tissue (Carew et al., 2004). A need for preconditioning in the 
determination of heart valve tissue material properties will be dependent upon the 
purpose of the study. For example, for comparative studies, preconditioning can be 
omitted as long as the test conditions for each test groups are kept same. Also the 
tensile properties of the heart valve root specimen depend on specimen hydration 
and test conditions such as strain rate and test temperature.  
3.7 Conclusion 
The hydrodynamic and biomechanical performance of cellular porcine 
pulmonary and aortic heart valve roots suggested that the methods developed have 
the ability to generate accurate and repeatable hydrodynamic and biomechanical 
performance of any type of biological heart valve roots.  
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These in vitro methods will be used for human cellular and decellularised aortic 
(Chapter 4) and pulmonary (Chapter 5) heart valve roots to derive the effect of 
decellularisation and the uniaxial tensile test method will be used for different types 
of xenogenic pulmonary heart valve roots (Chapter 6) to derive the effect of 12 
months implantation in sheep on decellularised porcine pulmonary heart valve roots 
before they can be utilised in clinical studies.  
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 Effect of Decellularisation on Hydrodynamic and Biomechanical 
Performance of Human Aortic Heart Valve Roots 
4.1 Introduction 
The characteristics of low concentration sodium dodecyl sulphate (SDS)  
decellularised human aortic heart valve roots (Vafaee et al., 2016) were investigated 
in this study to determine whether the hydrodynamic and biomechanical 
performance has been affected as a result of the decellularisation treatment. 
Cryopreserved cellular aortic human heart valve roots were included as the control, 
against which all the decellularised heart valve roots were compared, since 
cryopreserved cellular human aortic heart valve roots are the existing clinical 
product. This study was carried out in collaboration with NHS BT TES, Speke, Liverpool 
with a view to manufacturing decellularised aortic heart valve roots and supplying 
them for clinical use for the replacement of severely damaged aortic heart valves. 
4.2 Aim and Objectives 
The aim of this chapter was to fully assess the effects of low concentration SDS 
decellularisation on the hydrodynamic and biomechanical performance of human 
aortic heart valve roots. 
The specific objectives were: 
1. To determine and compare the hydrodynamic (competency, pulsatile flow) and 
biomechanical (dilation, tensile, suture pull-out) performance of cellular and 
decellularised human aortic heart valve roots. 
2. To determine and compare the biomechanical (dilation, tensile, suture pull-out) 
performance of cellular and decellularised human aortic heart valve roots. 
4.3 Study Experimental Design  
This study was designed to assess the effect of decellularisation on the 
hydrodynamic (competency, pulsatile) and biomechanical (dilation, tensile, suture 
pull-out) performance of human aortic heart valve roots (un-paired comparison). The 
hydrodynamic and biomechanical performance of each aortic heart valve root 
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(cellular and decellularised) was evaluated in the sequence shown in Figure 4.1 within 
two consecutive days.  
 
Figure 4.1 Flow Chart Indicating Cellular and Decellularised Aortic Heart Valve 
Root Hydrodynamic and Biomechanical Performance Assessment Sequence  
4.4 Materials 
The cryopreserved human donor aortic heart valve roots were supplied by NHS 
BT TES, Speke, Liverpool. The valves were found to be unsuitable for therapeutic use 
but had full research and development consent. The study was conducted under UK 
NHS Health Research Authority approval (REC 09/H1307/02). The decellularised 
human aortic heart valve roots were prepared by Dr Tayyebeh Vafaee in the Faculty 
of Biological Sciences (University Of Leeds). The protocol used to decellularise human 
aortic heart valve roots has been described in detail by Vafaee et al. (2016). Following 
decellularisation the heart valve roots were cryopreserved using the standard NHS 
BT TES process and stored at -80oC. All cryopreserved cellular and decellularised 
human aortic heart valve roots detailed in Table 5.1 and Table 4.2 were thawed on 
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the day before testing and stored in 100 ml Cambridge antibiotic solution at 4 °C to 
inhibit antibacterial growth. The heart valve root defrosting procedure is described 
in detail in Chapter 2 Section 2.4.4. A representative image of a thawed human aortic 
heart valve root is shown in Figure 5.2. Immediately before testing, the heart valve 
roots were rinsed with PBS. In between the tests the heart valve roots were stored in 
Cambridge antibiotic solution at 4 °C.  
 
Figure 4.2 Representative Image of Human Aortic Heart Valve Root  
As received, the sizes (internal diameter) of all the valves were measured with 
obturators.  
Table 4.1 Details of Cellular and Decellularised Aortic Heart Valve Roots 
Including Patient Age, Patient Sex and Valve Size Used for Hydrodynamic and 
Biomechanical Performance Testing 
Cellular Aortic Heart Valve Roots 
 
Decellularised Aortic Heart Valve Roots 
 ID 
Number 
Patient 
Age 
(Year) 
Patient 
Sex 
Valve 
Size 
(mm) 
 
ID 
Number 
Patient 
Age 
(Year) 
Patient 
Sex 
Valve 
Size 
(mm) 
        
HA045 56 M 22 HA048 71 M 25 
HA044 76 F 21 HA046 57 M 23 
HA049 50 M 23 HA047 47 M 24 
HA057 27 M 19 HA050 75 F 21 
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Due to the quality and variability in cellular human aortic valve roots, it was 
difficult to prepare enough samples to test, especially from the leaflets. Therefore, 
four additional cellular aortic heart valve roots (Table 4.2) were obtained from NHS 
BT TES, Speke, Liverpool for uniaxial tensile and suture pull-out testing; giving a total 
of eight cellular aortic and four decellularised aortic heart valve roots. 
Table 4.2 Details of the Four Additional Cellular Aortic Heart Valve Roots 
including Patient Age and Patient Sex Used for Uniaxial and Suture Pull-Out Testing 
Cellular Aortic Heart Valve Roots 
ID 
Number 
Patient Age 
(Years) 
Patient Sex 
   
HA056 50 F 
HA059 60 F 
HA060 46 M 
HA061 61 M 
4.5 Methods  
  Hydrodynamic Performance I: Competency  
In order to assess valve competency, the leakage flow rate of each valve was 
measured by applying static back pressure. The maximum static back pressure for 
aortic heart valve roots was 120 mmHg and the time (TL) taken for the pressure of 
the test fluid to drop to 80 mmHg was recorded. The leakage flow rate (FL) for each 
heart valve was calculated. The aortic heart valve root was classified as competent if 
the pressure head had not dropped to 80 mmHg pressure within a cut-off period of 
30 minutes (or leakage rate ≤ 0.85 mL. s-1). The detailed test procedure for 
competency testing is described in Chapter 2 Section 2.4.6.1.3. When the maximum 
static back pressure was applied, the diameter of the root was measured at 4 to 5 
mm above the sinotubluar junction using a digital Vernier Calliper. 
  Hydrodynamic Performance II: Pulsatile Flow  
To evaluate hydrodynamic performance, each aortic heart valve root was 
function tested in the pulsatile flow simulator. A 23 mm Björk-Shiley mono leaflet 
mechanical control valve (BSM; Shiley Corporation Incorporated, USA) was also 
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tested and compared with previous results to verify the performance of the pulsatile 
flow rig prior to testing of the aortic heart valve roots.  
Table 4.3 Test Conditions Used in the Pulsatile Flow Performance of Cellular 
and Decellularised Aortic Heart Valve Roots 
Heart Rate (bpm) Peak Flow (mL .s-1) 
60 225 
72 325 
80 409 
The aortic heart valve roots were initially tested in the pulsatile flow simulator 
at minimum compliance with heart rates 60, 72 and 80 bpm with corresponding 
stroke volumes 60, 70 and 80 ml to determine the peak flow conditions required for 
the testing at maximum compliance, which are detailed in Table 4.3. 
The aortic heart valve roots were subsequently tested at maximum compliance 
using the three pulsatile flow conditions detailed in Table 4.3 following the procedure 
detailed in Chapter 2 Section 2.4.7.4. The systemic pressure was held between 120 
to 80 mmHg to mimic in vivo conditions. The pump input profile was a 50 % systolic 
duration sine waveform in both cases to replicate physiological cardiac waveforms 
benchmarked in previous studies (Jennings, 2001, 2011) .  
As previously discussed the pulsatile flow testing allowed the evaluation of 
hydrodynamic performance of the aortic heart valve roots by producing 
measurements of transvalvular pressure across the valve, root mean square (RMS) 
flow and Effective Orifice Area (EOA). High speed video imaging at 500 frames. s-1 
allowed the leaflet dynamics to be assessed.  
  Biomechanical Performance I: Dilation (Expansion Characteristics)  
The circumferential expansion of each heart valve root was determined in terms 
of percentage dilation using the dilation test procedure described in Chapter 2 
Section 2.4.8.1.2. The test procedure involved attaching the heart valve root outflow 
to the end of a Perspex cylindrical tube, filling with PBS solution, and subjecting to 
various incremental internal static pressures. The maximum applied pressure for 
aortic heart valve roots (cellular and decellularised) was 120 mmHg or until the valve 
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failed. The mean percentage dilation is presented at 40 mmHg for aortic heart valve 
roots.  
  Biomechanical Performance II: Uniaxial Tensile and Suture Pull-Out  
Tensile material properties of the wall (axial and circumferential) and leaflets 
(radial and circumferential) from each aortic heart valve root were characterised 
using the uniaxial tensile testing method described in Chapter 2 Section 2.4.8.2.3.1.3. 
The specimen thickness was measured with a digital thickness gauge J-40-V (James 
H. Heal and Company Limited). The tensile material parameters: elastin phase slope, 
collagen phase slope, ultimate tensile stress (UTS) and failure strain were calculated 
from the stress-strain graphs.  
To determine the resistance to tearing of the wall and myocardial from each 
heart valve root, the suture pull - out test was performed on the wall and 
myocardium. The peak load was recorded as the maximum suture pull-out force and 
the resistance to tearing for all the samples was determined. The detailed test 
procedure and resistance to tearing calculation is described in Chapter 2 Section 
2.9.6.4.  
  Statistics 
All the hydrodynamic and biomechanical performance data for the cellular and 
decellularised aortic heart valve roots are presented as the mean ± 95% confidence 
limits and statistical significance between the cellular and decellularised aortic heart 
valve roots performance was determined using Student’s t-test. A significance level 
of p < 0.05 was applied. Statistical analyses were performed using SPSS for Windows 
(version 21.0; SPSS, Inc., USA). 
4.6 Results 
  Hydrodynamic Performance of Human Cellular and Decellularised Aortic 
Heart Valve Roots 
4.6.1.1 Competency  
Three out of four of the cellular aortic heart valve roots were judged to be fully 
competent (Table 4.4).  
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Table 4.4 Mean Leakage Flow Times (TL), Mean Leakage Flow Rates (FL), 
Competency and  Arterial Diameters at 120 mmHg Pressure of Tested Human 
Cellular and Decellularised Aortic Heart Valve Roots 
ID 
Number 
TL  
(Second) 
F L  
(mL.s-1) 
Competent 
Yes 
or 
No 
Arterial  
Diameter 
(D1) 
mm 
Cellular Aortic Heart Valve Roots 
HA045 >1800 <0.85 Yes 31 
HA044 >1800 <0.85 Yes 32 
HA049 >1800 <0.85 Yes 34 
HA057 857.2 1.78 No 28 
Decellularised Aortic Heart Valve Roots 
HA048 83 18.48 No 42 
HA046 162.5 9.44 No 32 
HA047 1145 1.34 No 35 
HA050 539 2.84 No 28 
     
Competent- Yes: Leakage flow rate ≤ 0.85 mL.s-1, No: Leakage flow rate> 0.85 mL.s-1 
However, all the decellularised aortic heart valve roots were regurgitant with 
leakage flow rate greater than 0.85 mL.s-1. An image of a decellularised aortic 
regurgitant valve during competency assessment is shown in Figure 4.3.  
 
 Figure 4.3 Decellularised Aortic Heart Valve HA050 Showing Central 
Regurgitant Jet 
The arterial diameters for all the aortic heart valve roots (cellular & 
decellularised) at 120 mmHg pressure are shown in Table 4.4. At 120 mmHg, the 
127 
Chapter 4 
arterial diameters of the cellular aortic heart valve roots ranged between 28 to 34 
mm and for the decellularised heart valve roots, the arterial diameters ranged 
between 28 to 42 mm. 
4.6.1.2 Pulsatile Flow  
The mean transvalvular pressure versus mean RMS forward flow for the cellular 
and decellularised aortic heart valve roots is shown in Figure 4.4.  
The cellular aortic heart valve roots had similar pressure flow characteristics to 
the decellularised aortic heart valve roots. 
The mean transvalvular pressure with 95% confidence limits for the cellular 
aortic heart valve roots at 72 bpm was 11.6 ± 3.8 mmHg and for the decellularised 
aortic heart valve roots the transvalvular pressure was 9.3 ± 3.2 mmHg. 
 
Figure 4.4 Mean Transvalvular Pressure versus Mean RMS Flow for Human 
Cellular and Decellularised Aortic Heart Valve Roots - Data fitted with a second 
order polynomial trend line - The error bars indicate 95 % confidence limits 
The EOA averaged over three heart rate conditions for all the cellular and 
decellularised aortic heart valve roots is shown in Table 4.5. 
 
 
128 
Chapter 4 
Table 4.5 Effective Orifice Area for Each Human Cellular and Decellularised 
Aortic Heart Valve Root Averaged over 3 Heart Rate conditions 
Cellular Aortic Heart Valve Roots Decellularised Aortic Heart Valve Roots 
ID Number 
Effective Orifice Area 
(EOA) 
cm2  
Valve  
ID Number 
Effective Orifice 
Area (EOA) 
cm2  
HA044 1.16 HA046 1.55 
HA045 1.22 HA047 1.52 
HA057 1.14 HA048 1.99 
HA049 1.66 HA050 1.16 
 The mean EOA for decellularised aortic valve heart valve roots (1.55 ± 0.33 
cm2) was not significantly different than the cellular aortic heart valve roots (1.29 ± 
0.39 cm2 ; P=0.26, Student’s t-test) 
Images of all tested cellular and decellularised heart valve roots in opening, fully 
opened, closing and fully closed phases are shown in Figure 4.5 and Figure 4.6 
respectively. 
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Figure 4.5 (a) Valve Opening, (b) Valve Fully Opened, (c) Valve closing and (d) 
Valve Fully Closed Images of Human Cellular Aortic Heart Valve Roots at Heart Rate 
72 bpm, captured from the Front View by a High-Speed Camera 
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Figure 4.6 (a) Valve Opening, (b) Valve Fully Opened, (c) Valve closing and (d) 
Valve Fully Closed Images of Human Decellularised Aortic Heart Valve Roots at 
Heart Rate 72 bpm, captured from the Front View by a High-Speed Camera 
The Cellular heart valve root HA044, HA049 and decellularised heart valve root 
HA047 showed excellent closed leaflet configuration, with perfect coaption at the 
free edge of the leaflets. However, the cellular heart valve root HA045, HA057 and 
decellularised heart valve root HA046, HA048 and HA050 had a small central leakage 
orifice. The cellular heart valve roots HA044, HA057 and decellularised heart valve 
root HA050 did not fully open resulting in a restricted triangular orifice, whereas the 
other heart valves had a fully opened leaflet configuration. The cellular heart valve 
root HA049 and decellularised heart valve roots HA047, HA048 had a fully open 
configuration.  
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  Biomechanical Performance of Human Cellular and Decellularised Aortic 
Heart Valve Roots 
4.6.2.1 Dilation 
The percentage dilations for all the tested aortic heart valve roots (cellular and 
decellularised) are shown as a function of applied internal pressure in Figure 4.7. The 
data showed that there was a variation within the cellular heart valve root group in 
dilation properties after 60 mmHg pressure. The dilation of the decellularised heart 
valve root HA048 could not be determined as it was leaking faster than the pressure 
applied.  
 
Figure 4.7 Percentage Dilation as a Function of Applied Pressure of all Cellular 
(Solid line, n=4) and Decellularised (Dotted line, n=3) Aortic Heart Valve Roots - 
Data fitted with a third order polynomial trend line 
The expansion characteristics of decellularised aortic heart valve roots were 
similar to cellular heart valve roots at an internal pressure of 40 mmHg. The external 
wall diameters of the decellularised and cellular aortic heart valve roots, at 40 mmHg 
pressure, dilated by 12.6 ± 2.6 % and 15.4 ± 5.4 % respectively, which were not 
significantly different (p=0.23, Student’s t test).  
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4.6.2.2 Tensile Properties  
Images were captured during the uniaxial and suture pull-out testing of cellular 
and decellularised tissue. It was observed that all the cellular and decellularised wall 
and leaflet tissue failed in the gauge length during uniaxial tensile testing as explained 
in Chapter 2 Section 2.4.9. 
During the uniaxial tensile testing, two decellularised circumferential, two 
decellularised radial, two cellular circumferential and four cellular radial leaflet 
specimens tended to fail first at one point and then failure propagated across the 
leaflet and showed primary and secondary peak loads (Figure 4.8). For the UTS 
calculation, the primary peak load was considered. 
 
Figure 4.8 Load versus Extension Graph with Two Peaks for the Leaflet 
Specimen Undergoing Uniaxial Tensile Testing  
The stress-strain graphs for all the cellular and decellularised aortic wall and 
leaflet specimens are shown in Figure 4.9. The graphs demonstrated the typical tri -
phasic characteristics. The decellularised wall stress-strain characteristics were 
similar to that of the cellular wall in the circumferential and axial directions. However, 
stress-strain leaflet characteristics in radial and circumferential directions 
demonstrated a rise in the ultimate tensile stress after decellularisation [Figure 4.9 
(c) and (d)]. 
133 
Chapter 4 
  
(a) (b) 
  
(C) (d) 
Figure 4.9 Stress-Strain Graphs for the Cellular (solid line, n=8) and 
Decellularised (dotted line, n=4) (a) Circumferential Aortic Wall (b) Axial  Aortic Wall 
(c) Circumferential Aortic Leaflet (d) Radial Aortic Leaflet Specimens 
Table 4.6 shows mean thickness with 95 % confidence limits and Table 4.7 
shows tensile parameters with 95 % confidence limits for the cellular and 
decellularised aortic heart valve root wall (axial and circumferential) and leaflet 
(radial and circumferential) specimens. 
The initial linear region of the stress-strain curve was used to derive the elastin 
phase modulus and it was not distinct for one decellularised and two cellular 
circumferential leaflet specimens. Hence these samples were omitted and only six 
cellular and three decellularised samples were used for the mean elastin phase slope 
calculation. 
There was no significant difference between the mean cellular and 
decellularised aortic wall and leaflet specimen thickness in both the axial and 
circumferential directions (p>0.05, Student’s t-test). 
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Table 4.6 Mean Thickness for the Cellular and Decellularised Aortic Heart 
Valve Root Wall and Leaflet specimens – p values:  statistical probability in the 
comparison between cellular and decellularised aortic heart valve roots 
 
Specimen Direction 
Mean Thickness (mm) p 
Value Cellular Decellularised 
Aortic Heart valve 
root wall 
Number of 
Specimens 
8 4  
Axial 1.99 ± 0.32 2.03 ± 0.11 0.89 
Circumferential 2.11 ± 0.18 2.23 ± 0.27 0.33 
Aortic Heart valve 
root Leaflet 
Number of 
Specimens 
8 4  
Radial 0.58 ± 0.14 0.49 ± 0.12 0.37 
Circumferential 1.11 ± 0.94 0.72 ± 0.20 0.23 
 
Table 4.7 Tensile Parameters (Collagen Phase Slope Ec, Elastin Phase Slope E e, 
Ultimate Tensile Stress σ UTS, Failure Strain ɛ failure) for Cellular and Decellularised 
Aortic Wall in the Axial (A) and Circumferential (C) Directions and Leaflet Specimens 
in the Radial (R) And Circumferential (C) Directions, Number of Specimens (n). *-
Statistical significant difference (p<0.05; Student`s t-test) for decellularised versus 
cellular heart valve roots.   
Aortic Heart n Ec E e σ UTS ɛ failure 
Valve Roots MPa MPa MPa  
 
 Wall (A) 
Cellular  8 1.72 ± 1.09 0.14 ± 0.10 0.72 ± 0.27 0.86 ± 0.15 
Decellularised  4 1.98 ± 1.07 0.16 ± 0.17 0.82 ± 0.44 0.78 ± 0.45 
P Value  0.72 0.79 0.62 0.57 
 Wall (C) 
Cellular  8 3.23 ± 0.74 0.19 ± 0.07 1.47 ± 0.68 0.89 ± 0.37 
Decellularised  4 4.24 ± 2.64 0.21 ± 0.09 1.44 ± 0.42 0.74 ± 0.52 
P Value  0.19 0.70 0.95 0.55 
 Leaflet (R) 
Cellular  8 1.30 ± 0.56 0.04 ± 0.04 0.19 ± 0.07 0.32 ± 0.82 
Decellularised   4 4.06 ± 2.56* 0.15 ± 0.18 0.59 ± 0.21* 0.30 ± 0.10 
P Value  0.002 0.05 0.00009 0.67 
 Leaflet (C) 
Cellular  8X 11.91 ± 7.18 0.36 ± 0.25 1.40 ± 0.56 0.21 ± 0.69 
Decellularised   4xx 20.62 ± 9.08 1.76 ± 0.92* 2.41 ± 1.02* 0.16 ± 0.22 
P Value  0.1 0.0004 0.03 0.28 
x n=8 for all cellular leaflet parameters except n=6 for mean elastin phase slope, xx n=4 for all 
decellularised leaflet parameters except n=3 for mean elastin phase slope  
 
135 
Chapter 4 
The tensile wall parameters for the decellularised aortic heart valve roots were 
similar to the cellular aortic heart valve roots (Student’s t-test, p>0.05). There was no 
significant difference among the cellular and decellularised leaflet for the following 
parameters: the collagen phase slope in the circumferential direction, elastin phase 
slope in the radial direction, failure strain in the radial and circumferential direction 
(p>0.05, Student’s t-test). The mean collagen phase slope for decellularised radial 
leaflet specimens was significantly higher than for cellular specimens (p=0.002, 
Student’s t-test). There was also a significant increase in elastin phase slope for 
decellularised specimens compared to cellular specimens in the circumferential 
direction (p=0.0004, Student’s t-test). The mean ultimate tensile stress was 
significantly increased for decellularised specimens compared to the cellular 
specimens in radial and circumferential directions (p<0.05, Student’s t-test). 
 
4.6.2.3 Suture Pull – Out Properties 
During suture pull-out testing of wall and myocardial specimens, failure was 
seen as a wedge shaped cut spreading from the suture in the circumferential 
direction perpendicular to the axial axis as explained in Chapter 2 Section 2.4.9. 
The mean suture pull-out force and mean resistance to tearing for 
decellularised aortic heart valve root wall and myocardial specimen was not 
significantly different than the cellular aortic heart valve root wall and myocardium 
specimen (Table 4.7; p>0.05, Student’s t-test). 
Table 4.8 Mean Maximum Suture Pull-Out Force and Mean Resistance to 
Tearing for the Cellular and Decellularised Aortic Heart Valve Root Wall and 
Myocardial specimens (Where n- Number Specimens) - p values: statistical 
probability in the comparison between cellular and decellularised aortic heart valve 
roots 
Specimen 
Type 
n Maximum Suture Pull-Out 
Force (N) 
Resistance to Tearing 
(N/mm) 
  Wall Myocardial Wall Myocardial 
Cellular  8 6.87 ± 3.26 5.71 ± 1.07 0.91 ± 0.21 2.63 ± 1.00 
Decellularised 4 6.63 ± 1.90 6.12 ± 7.83 0.27 ± 1.74 2.75 ± 1.21 
P value  0.91 0.83 0.86 0.45 
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4.7 Discussion 
 Effect of Decellularisation on Hydrodynamic Performance of Human Cellular 
Aortic Heart Valve Roots 
The in vitro hydrodynamic performance of decellularised aortic heart valve 
roots was shown to be improved compared to cellular aortic heart valve roots with 
lower transvalvular pressure gradients for all the tested conditions, indicating a 
reduced resistance against forward flow. Indeed, the mean pressure - flow 
characteristics for the decellularised group were slightly superior. This superiority 
was also observed with a larger mean EOA for decellularised aortic valve heart valve 
roots of 1.55 ± 0.33 cm2 compared to 1.29 ± 0.39 cm2 for the cellular aortic valve 
heart valve roots. However, the EOA values were not significantly higher for 
decellularised aortic heart valve roots (p=0.29).  
Analysis of high speed videos demonstrated that fully closed leaflet 
configuration was excellent for two of the cellular aortic heart valve roots with no 
visible central leakage orifice and a minor central leakage orifice was observed in the 
two remaining cellular heart valve roots. The images of closed leaflet configuration 
for cellular aortic heart valve roots correlated well with measured leakage flow rate 
under static back pressure.  
For most of the decellularised aortic heart valve roots, the leaflets opened fully 
or near-fully, producing circular or near-circular orifices. However, for one of the 
decellularised aortic heart valve roots, the leaflets did not fully open resulting in a 
restricted triangular orifice. All the decellularised aortic heart valve roots appeared 
competent since a central leakage orifice was negligible or not observed during 
closed phase. Nevertheless, the valve competency assessment under static back 
pressure showed that all the decellularised aortic heart valve roots appeared to be 
regurgitant (having a leakage rate of > 0.85 mL.s-1). Although two out of four 
decellularised heart valve roots had a mean leakage flow rate of 2.09 mL.s-1, this was 
lower than the baseline value of 4.95 ± 1.78 mL.s-1 derived for a clinical heart valve 
(23 mm Björk-Shiley mono leaflet valve; Chapter 2 Section 2.4.6.1.2). The 
decellularised aortic heart valve root HA048 had the highest leakage flow rate along 
with the highest arterial diameter (42 mm at 120 mmHg). Conversely, heart valve 
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root HA048 showed good closed leaflet configuration under pulsatile flow. This may 
have been related to the lack of annulus support during competency testing. Also, 
the arterial diameters of these heart valve roots were not measured before the 
decellularisation treatment so it could not be ascertained whether this was a result 
of decellularisation processing. These pulsatile flow results must be interpreted with 
care due to the complex dynamic movement of the heart valve root during the 
pulsatile flow testing.  
 Effect of Decellularisation on Biomechanical Performance of Human Cellular 
Aortic Heart Valve Roots 
The biomechanical performance of the decellularised human aortic heart valve 
roots was evaluated and compared with human cellular aortic heart valve roots. The 
decellularised aortic heart valve root walls had similar expansion characteristics to 
the cellular heart valve roots. The mean dilation for decellularised and cellular aortic 
heart valve root wall was 12.6 ± 2.6 % and 15.4 ± 5.4 % respectively at 40 mmHg. In 
addition, the maximum suture pull - out force and resistance to tearing were similar 
for the decellularised and cellular aortic specimens (wall and myocardial).   
The tensile properties of decellularised aortic wall specimens were not 
significantly changed in terms of stiffness, elasticity and strength compared to the 
cellular specimens when tested in the axial and circumferential directions. There 
were however significant differences between the tensile properties of the cellular 
and decellularised leaflet specimens. The decellularised circumferential leaflet 
specimens were significantly stronger with mean ultimate tensile stress 2.41 ± 1.02 
MPa compared to 1.40 ± 0.56 MPa for cellular circumferential specimens. Also 
decellularised circumferential leaflet specimens were stiffer with a collagen phase 
slope 20.62 ± 9.08 MPa compared to 11.91 ± 7.18 MPa for cellular specimens, this 
difference was not statistically significant (p=0.1). The reason behind decellularised 
leaflets being stiffer and significantly stronger than cellular leaflets in the 
circumferential direction was possibly due to loosening and un-crimping of the 
collagen fibre network (Freed and Doehring, 2005) which leads to an increased in 
stiffness of the tissue. Also, results from this study showed that the extensibility of 
the decellularised circumferential aortic leaflet specimens was higher than the 
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cellular specimens. The radial elasticity of the aortic leaflet remained unaffected by 
the decellularisation procedure. The ultimate tensile stress and collagen phase slope 
was higher for decellularised leaflet specimens compared to cellular leaflet 
specimens in the radial direction. The findings from this study correlated well with a 
previous study which tested porcine aortic leaflets and found that after 
decellularisation treatment, their extensibility and failure strain significantly 
increased in the circumferential direction, while in the radial direction, the increase 
in strength was not significant (Korossis et al., 2002). Nonetheless, consideration 
must be taken to allow for species-related differences when interpreting these 
results. Although, the strength and stiffness of the aortic leaflets was affected by the 
decellularisation procedure, it did not appear to negatively affect valve function. 
Moreover, the expansion characteristics of the decellularised aortic wall were similar 
to the cellular aortic wall in the physiological pressure range, contributing to its 
positive performance.  
In this study, human aortic heart valve roots were decellularised using 
hypotonic buffer, 0.1 % (w/v)  sodium dodecyl sulphate (SDS) and nuclease digestion 
to remove cells from all regions (wall, leaflet and myocardium) (Vafaee et al., 2016). 
Decellularised heart valve roots for heart valve replacement may be used either pre-
seeded with the patient’s own autologous cells before implantation (Steinhoff et al., 
2000, Lichtenberg et al., 2006) or implanted directly with a view to the patient’s own 
endogenous cells repopulating and regenerating the decellularised scaffolds in vivo 
(da Costa et al., 2010). Nevertheless, harvesting of cells from patients and pre-
seeding of decellularised scaffolds would be a time consuming, costly and potentially 
risky procedure. When this project commenced, it was decided to consider a strategy 
whereby decellularised human heart valve roots would be directly implanted, 
remodelled and regenerated in vivo. The aim of this study was to characterise human 
aortic heart valve roots decellularised using a proprietary process developed at the 
University of Leeds (Booth et al., 2002) before using them in clinic as a replacement 
valve. Aortic allograft valves that have been decellularised using different processes 
are already delivering promising in vivo results. Zehr and colleagues reported 
favourable clinical results on the use of SynerGraft® decellularised aortic valve 
allografts for aortic valve replacement (Zehr et al., 2005). These valves had been 
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implanted in patients with a mean age of 53 ± 14 years. Although the small number 
of patients (n=22) and short term mean follow up (30.3 months) limits the results. 
Zehr et al. (2005) demonstrated no calcification in the wall or leaflets with stable 
hemodynamic function without major complications during echocardiography. 
Calcification of cellular aortic valve allografts rarely occurs immediately after 
implantation (Doty et al., 1998), hence long term results are required. da Costa et al. 
(2010) implanted decellularised aortic allografts in 41 patients with a mean age of 34 
years. da Costa et al. (2010) used a similar decellularisation protocol to the one used 
in this study. The post-operative results showed stable structural integrity, low rate 
of calcification, and adequate hemodynamics in the short term follow–up (maximum 
19 months); however, one patient underwent reoperation due to mitral valve 
stenosis (da Costa et al., 2010). Tudorache et al. (2016) analysed results of 69 
decellularised aortic allograft implants in children and young patients. Hemodynamic 
performance of these decellularised allografts was excellent up to 7.6 years of follow 
up. Most importantly, this study showed clinical data of decellularised aortic allograft 
implanted in 16 patients younger than 10 years (Tudorache et al., 2016). The data 
from this younger group of patients raised concerns about supravalvular stenosis and 
valvular regurgitation. However, the mean short term follow up, the small number of 
patients and complex surgical procedure in these young patients, limit the discussion 
of the results. Overall the results from these studies (da Costa et al., 2010, Zehr et al., 
2005, Tudorache et al., 2016) are promising; even though the decellularisation 
protocols were different to the decellularisation protocol used in this study, this can 
nevertheless be seen as another sign of the excellent preliminary results achieved 
using decellularised allografts. 
 Limitations  
There are several limitations to this study. First, the in vitro nature of this study 
meant the test methodologies used were a simplification of the environmental 
conditions under which the decellularised aortic heart valve roots will be placed in 
vivo; there was also no consideration of the effects of inflammation, cell repopulation 
or tissue remodelling, all of which may influence the mechanical properties and flow 
characteristics of the valves. Second, the relatively small sample size meant a lack of 
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statistical power to discriminate/provide significant differences between 
biomechanical properties of the cellular and decellularised aortic heart valve roots. 
The statistical power was also influenced by inherent biological variation and quality 
of the tissue.  
4.8 Conclusion 
In conclusion, an extensive in vitro hydrodynamic and biomechanical 
comparison of decellularised and cellular human aortic heart valve roots has been 
performed. Neither pulsatile flow parameters nor expansion properties of human 
aortic heart valve roots were significantly affected by the low concentration SDS 
decellularisation treatment. However, decellularisation significantly altered 
hydrodynamic performance under static back pressure and some of the directional 
material properties of aortic heart valve leaflets. This work has been published in the 
The Journal of the Mechanical Behavior of Biomedical Materials, and publication 
details can be found in Appendix A. 
141 
Chapter 5 
 Effect of Decellularisation on Hydrodynamic and Biomechanical 
Performance of Human Pulmonary Heart Valve Roots 
5.1 Introduction 
In addition to developing a process for decellularisation of human aortic heart 
valve roots, the study by Vafaee et al. (2016) also developed a process for 
decellularisation of human pulmonary heart valve roots, in collaboration with NHS BT 
TES, with a view to supplying them for clinical use in the pulmonary valve switch 
operation (Ross procedure). The decellularised pulmonary heart valve roots were 
developed on the basis of hypothesis that removal of the major cellular immunogenic 
components had been achieved without adverse effects on the extracellular matrix 
(ECM). To determine whether the ECM had been affected as a result of the low 
concentration sodium dodecyl sulphate (SDS) decellularisation (Vafaee et al., 2016) 
treatment, the hydrodynamic and biomechanical performance of human cellular and 
decellularised pulmonary heart valve roots was evaluated. Cryopreserved cellular 
human pulmonary heart valve roots were included as the control to which all the 
decellularised pulmonary heart valve roots were compared, since cryopreserved 
cellular human pulmonary heart valve roots are the existing clinical product. The 
importance of physiological boundary conditions during the assessment of valve 
competency was also explored in this study. 
5.2 Aim and Objectives 
The aim was to fully assess the effects of low concentration SDS 
decellularisation on the hydrodynamic and biomechanical performance of human 
pulmonary heart valve roots. 
The specific objectives were: 
1. To determine and compare the hydrodynamic (competency, pulsatile flow) and 
biomechanical (dilation, tensile, suture pull-out) performance of cellular and 
decellularised human pulmonary heart valve roots (in an un-paired comparison). 
2. To determine the influence of a specific processing step (scraping) on the 
functional biomechanical performance (competency, dilation) of cellular and 
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decellularised (scraped and un-scraped) pulmonary heart valve roots (in a paired 
comparison). 
5.3 Study Experimental Design  
This study was conducted in two phases. Study I was designed to assess the 
effect of decellularisation on the hydrodynamic (competency, pulsatile) and 
biomechanical (dilation, tensile, suture pull-out) performance of human pulmonary 
heart valve roots in an un-paired comparison (Objective 1). The hydrodynamic and 
biomechanical performance of each pulmonary heart valve root (cellular and 
decellularised) was evaluated in the sequence shown in Figure 5.1(a) within two 
consecutive days. The decellularised heart valve roots were processed as reported by 
(Vafaee et al., 2016), which included the removal of excess fat, connective tissue and 
the adventitial layer of the pulmonary heart valve root wall by scraping using a scalpel 
blade (referred to throughout as ‘scraping’), to allow diffusion of decellularisation 
solutions. It was not known whether this scraping process disrupted the structure of 
the valve in any way and altered the mechanical properties of the tissue. Therefore, 
a further study (Study II) was introduced to investigate the influence of this scraping 
step on the functional biomechanical properties of the pulmonary heart valve roots 
(Objective 2). 
Study II used a repeated measure design approach, in which functional 
biomechanical performance (competency and dilation) of the cellular and 
decellularised pulmonary heart valve roots was evaluated [Figure 5.1 (b)] and 
compared in a paired comparison. Here functional mechanical performance of all the 
cellular pulmonary heart valve roots was evaluated and then the heart valve roots 
were divided into two groups with each group assigned a different decellularisation 
processing protocol either with or without the scraping step [Figure 5.1(b)]. Following 
the decellularisation treatment, the functional biomechanical performance of the 
pulmonary heart valve roots was again evaluated. The dimensional quantification of 
heart valve roots before and after decellularisation (with and without scraping) could 
be an indication of whether the internal tissue structure was altered. Therefore, the 
functional assessments, the dimensions of each pulmonary heart valve root were 
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measured throughout. This approach helped to reduce variability and hence sample 
size.  
 
(a)                                                                 (b) 
Figure 5.1 Flow Chart Indicating Pulmonary Heart Valve Roots Performance 
Assessment Sequence used in (a) Study I and (b) Study II 
  Materials (Study I and Study II) 
In Study I, four cellular and four decellularised human pulmonary heart valve 
roots were used as detailed in Table 5.1.  
In Study II, eight human cellular pulmonary heart valve roots were used as 
detailed in Table 5.1.  
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Table 5.1 Details of Pulmonary Heart Valve Roots Assessed in Study I, 
Including Patient Age, Sex and Valve Size.  
Pulmonary Heart Valve Roots 
 
 Study I   Study II 
ID  
Number 
Age 
(Years) 
Sex 
Valve 
Size 
(mm) 
ID  
Number 
Age 
(Year) 
Sex 
Valve 
Size 
(mm) 
Cellular  
HP041 44 F 26 HP056 56 M 23 
HP045 75 M 23 HP058 59 F 23 
HP044 69 M 25 HP063 72 M 22 
HP055 66 M 23 HP062 70 F 22 
Decellularised HP060 64 M 21 
HP042 75 M 22 HP061 18 F 20 
HP046 59 M 26 HP057 57 F 25 
HP043 72 M 26 HP059 68 M 24 
HP040 84 F 25     
 
The cryopreserved human donor pulmonary heart valve roots used in this study 
were supplied by NHS BT TES, Speke, Liverpool. The study was conducted under UK 
NHS Health Research Authority approval (REC 09/H1307/02). The decellularised 
human pulmonary heart valve roots were prepared by Dr Tayyebeh Vafaee in the 
Faculty of Biological Sciences (University Of Leeds). A detail decellularisation protocol 
used to decellularise heart valve roots is described by Vafaee et al. (2016). Following 
decellularisation the pulmonary heart valve roots were cryopreserved using the 
standard NHS BT TES process and stored at -80oC. All cryopreserved cellular and 
decellularised human pulmonary heart valve roots were thawed on the day before 
testing and stored in 100 ml Cambridge antibiotic solution at 4 °C. The heart valve 
root defrosting procedure is described in detail in Chapter 2 Section 2.5. Immediately, 
before testing, the heart valve roots were rinsed with PBS. In between the tests the 
heart valve roots were stored in Cambridge antibiotic solution at 4 °C. A 
representative image of a thawed cellular human pulmonary heart valve root is 
shown in Figure 5.2. 
As received, the sizes (internal diameter) of all the valves were measured with 
obturators. 
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Figure 5.2 Representative Image of Cellular Human Pulmonary Heart Valve 
Root 
5.4 Methods   
 Methods Used in Study I 
5.4.1.1 Hydrodynamic Performance 
5.4.1.1.1 Competency  
In order to assess valve competency under static back pressure the leakage flow 
rate (FL) of each heart valve root was measured as described in Chapter 2 Section 
2.4.6.1.3. The heart valve roots were deemed to be competent if the pressure head 
had not dropped from 60 to 20 mmHg within the cut-off period of 20 minutes (or 
leakage rate ≤ 1.28 mL.s-1). The time (TL) taken for the test fluid to drop from 60 to 20 
mmHg was recorded. The diameter of the heart valve root was measured at 4 to 5 
mm above the sinotubluar junction using a Vernier Calliper. 
5.4.1.1.2 Pulsatile Flow  
To evaluate hydrodynamic performance, each human pulmonary heart valve 
root was function tested in the pulsatile flow simulator. The heart valve root was 
initially tested in the pulsatile flow simulator at minimum compliance following the 
procedure detailed in Chapter 2 Section 2.4.7.4 to determine the peak flow 
conditions required for testing at maximum compliance, which are detailed in Table 
5.2. The systemic pressure was held between 45 mmHg to 15 mmHg to mimic in vivo 
conditions. The test was repeated with the viscoelastic impendence adapter (VIA) 
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adjusted to its maximum compliance setting to produce relevant physiological 
pressure and flow characteristics.  
Table 5.2 Test Conditions Used in the Pulsatile Flow Performance of Cellular 
and Decellularised Pulmonary Heart Valve Roots 
Heart Rate (bpm) Peak Flow (mL .s-1) 
60 241 
72 342 
80 405 
  
The evaluation of hydrodynamic performance of the pulmonary heart valve 
roots was achieved by producing measurements of transvalvular pressure across the 
valve and root mean square (RMS) flow and the Effective Orifice Area (EOA). The 
opening and closing of the valve was recorded with a high speed digital camera at 
500 frames.s-1.  
5.4.1.2 Biomechanical Performance 
5.4.1.2.1 Dilation (Expansion Characteristics)  
The circumferential expansion of each heart valve root was determined in terms 
of percentage dilation using the dilation test procedure described in Chapter 2 
Section 2.4.8.1.2. The maximum applied internal pressure was 35 mmHg or until the 
valve failed. The mean percentage dilation was calculated at 20 mmHg. 
5.4.1.2.2 Uniaxial Tensile and Suture Pull-Out  
The tensile material properties of the wall (axial and circumferential) and 
leaflets (radial and circumferential) from each heart valve root were characterised 
using the uniaxial tensile testing method. The sample sizes and test method were 
described in Chapter 2 Section 2.4.8.2.3.1.3. The specimen thickness was measured 
with a digital thickness gauge J-40-V (James H. Heal and Company Limited). The 
tensile material parameters (elastin phase slope, collagen phase slope, ultimate 
tensile stress (UTS) and failure strain) were calculated from the stress strain graphs. 
To determine the suture pull-out force and resistance to tearing of the wall and 
myocardial from each heart valve root, the suture pull - out test was performed on 
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the wall and myocardium as described in Chapter 2 Section 2.4.8.2.4. The peak load 
was recorded as the maximum suture pull-out force and the resistance to tearing for 
all the samples was determined.   
  Statistics 
All the hydrodynamic and biomechanical performance data for the cellular and 
decellularised pulmonary heart valve roots are presented as the mean ± 95 % 
confidence limits and statistical significance between the cellular and decellularised 
pulmonary heart valve roots performance was determined using Student’s t-test. A 
significance level of p < 0.05 was applied. Statistical analyses were performed using 
SPSS for Windows (version 21.0; SPSS, Inc., USA). 
  Methods Used in Study II 
5.4.3.1 Dimensional Measurements 
To derive the effect of decellularisation treatments with and without scraping 
on the heart valve root external morphology, the dimensions of each root, whilst laid 
flat were measured before and after each treatment as described in Chapter 2 
Section 2.4.5. The scraping procedure and treatment resulted in four groups of heart 
valves [cellular un- scraped (Group 1), cellular scraped (Group 2), decellularised un-
scraped (Group 3) and decellularised scraped (Group 4)]. The annulus width W1 and 
width W2 (Chapter 2, Figure 2.4) in the wall region were measured for each root 
before and after each treatment (scraping and decellularisation). The percentage 
change in the widths for W1 (△W13 and △W14) and W2 (△W23 and △W24) for Group 
3 (un- scraped decellularised) relative to Group 1 (un- scraped cellular) and Group 4 
(scraped decellularised) relative to Group 2 (cellular scraped) were compared.  
As explained in Chapter 2  Section 2.4.5.2, the accuracy of the valve dimensional 
measurements using imageJ was ± 5 %, all the changes in widths less or equal to ± 5 
% were considered as no change. 
5.4.3.2 Functional Biomechanical Performance 
5.4.3.2.1 Competency with Annulus Support 
In order to assess valve closure after each treatment (scraping and 
decellularisation), competency tests were performed under a physiological static 
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back pressure range for each human pulmonary heart valve root [cellular un- scraped 
(Group 1), cellular scraped (Group 2), decellularised un-scraped (Group 3)  and 
decellularised scraped (Group 4)]. The test set up used in Study II was modified 
compared to Study I (Section 5.4.1.1). In this phase, the annulus of each heart valve 
root was supported with an appropriately sized annulus ring as shown in Figure 5.3. 
This annulus ring helped to restore the shape and size of the valve annulus to its 
physiological dimensions and provided support that would physiologically be 
provided by the heart. 
 
Figure 5.3 Pulmonary Heart valve root with Annulus Ring Mounted in Static 
Leakage Tester  
The competency test was performed with and without annulus support for each 
pulmonary heart valve root as described in Chapter 2 Section 2.4.6.1.3. The time 
taken (TL) for the test fluid to drop from 60 mmHg to 20 mmHg was recorded. The 
mean leakage flow rate (FL) was calculated for each heart valve root. The heart valve 
root was considered to be competent if the pressure head had dropped to 20 mmHg 
within a cut-off of period of 20 minutes (or leakage rate ≤ 1.28 mL.s-1). 
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The change in arterial diameter D1 of each heart valve root for group 3 (un- 
scraped decellularised) relative to group 1 (un- scraped cellular) and group 4 (scraped 
decellularised) relative to group 2 (cellular scraped) was calculated.   
5.4.3.2.2 Dilation (Expansion Characteristics) 
Following the dimensional measurement of each pulmonary heart valve root, 
the circumferential wall expansion characteristics were determined in terms of 
percentage dilation using the dilation test procedure which was identical to Study I 
(Section 5.4.1.2). Before converting dilation data to percentage, data distribution was 
tested using the Shapiro–Wilk test, and the data were considered normal if the 
probability value was P > 0.05. The data obtained were homogeneous (p=0.2) and 
hence analysis was continued using the one-way analysis of variance (ANOVA) test. 
To evaluate the difference in the mean dilation between the four pulmonary heart 
valve root groups (cellular, cellular scraped, un-scraped decellularised and scraped 
decellularised), one-way ANOVA was performed, followed by Gabriel post-hoc test. 
Analysis was performed using the SPSS statistics program, and p-value of ≤ 0.05 was 
considered to be statistically significant. 
5.5 Results  
  Study I 
5.5.1.1 Hydrodynamic Performance of Human Cellular and Decellularised 
Pulmonary Heart Valve Roots 
5.5.1.1.1 Competency  
The valve competency, mean leakage flow times, mean leakage flow rates and 
arterial diameter for the cellular and decellularised pulmonary heart valve roots are 
shown in Table 5.3. 
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Table 5.3 Mean Leakage Flow Times (TL), Mean Leakage Flow Rates (FL), 
Competency and Arterial Diameters of Human Cellular and Decellularised 
Pulmonary Heart Valve Roots, assessed in Study I 
Valve ID 
Number 
TL  
(second) 
F L  
(mL.s-1) 
Competent 
Yes 
Or 
No 
Arterial  
Diameter 
(D1) 
(mm) 
 Cellular Pulmonary Heart Valve Roots 
HP041 449.5 3.41 No 30 
HP045 389 3.95 No 29.8 
HP044 >1200 <0.85 Yes 31.5 
HP055 >1200 <0.85 Yes 31 
Decellularised Pulmonary Heart Valve Roots 
HP042 634 2.42 No 28 
HP046 303.5 5.05 No 33.5 
HP043 241.5 6.37 No 32.5 
HP040 90 17.25 No 37 
 Competent: Yes: Leakage flow rate ≤ 1.28 mL.s-1; No: Leakage flow rate > 1.28 mL.s-1 
  
The majority of cellular and decellularised pulmonary heart valve roots were 
regurgitant. Two of the cellular heart valve roots (HP044 and HP055) were competent 
with mean leakage flow rates less than 0.85 ml. s-1. The decellularised heart valve 
root, HP040, had the highest mean leakage flow rate of 17.25 mL.s-1. The other three 
decellularised pulmonary heart valve roots had mean leakage flow rates below 7 
mL.s-1. 
At 60 mmHg, the measured arterial diameters of the cellular pulmonary heart 
valve roots ranged between 29.8 mm and 31 mm. The arterial diameters of the 
decellularised pulmonary heart valve roots ranged between 28 mm and 37 mm (Table 
5.3).  
5.5.1.1.2 Pulsatile Flow  
The mean transvalvular pressures versus mean RMS flows for human cellular 
and decellularised pulmonary heart valve roots for tested heart rates is shown in 
Figure 5.4.  
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Figure 5.4 Mean Transvalvular Pressure versus Mean RMS Flow for Human 
Cellular and Decellularised Pulmonary Heart Valve Roots - Data fitted with second 
order polynomial trend line - The error bars indicate 95 % confidence limits 
At a heart rate of 72 bpm, the mean transvalvular pressure with 95 % 
confidence limits across the decellularised pulmonary heart valve roots was 6.1 ± 2.8 
mmHg and for the cellular pulmonary heart valve roots was 8.1 ± 2.6 mmHg. When 
comparing between the cellular and decellularised heart valve roots the mean 
transvalvular pressure across the decellularised heart valve roots was similar to the 
cellular heart valve roots for all three tested conditions (p>0.05).  
Table 5.4 Effective Orifice Area (EOA)for each Human Cellular and 
Decellularised Pulmonary Heart Valve Root averaged over the three Cycle Rates 
Cellular Pulmonary Heart Valve Root Decellularised Pulmonary Heart Valve 
Root 
 
ID 
Number 
Effective Orifice Area 
(EOA) cm2 (PF) 
ID 
Number 
Effective Orifice Area 
(EOA) cm2 (PF) 
HP044 2.09 HP042 2.37 
HP041 2.12 HP046 2.07 
HP045 2.44 HP043 2.12 
HP055 2.59 HP040 1.82 
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The EOA of each cellular and decellularised heart valve root, averaged over 
three cycle rates tested is shown in Table 5.4. The mean EOA with 95 % confidence 
limits was 2.31 ± 0.39 cm2 and 2.10 ± 0.36 cm2 for the cellular and decellularised 
pulmonary heart valve roots respectively which were similar (Student’s t-test, p=0.2). 
Images of all the tested cellular and decellularised pulmonary heart valve roots 
in their closing, fully closed, opening and fully opened configuration are shown in 
Figure 5.5 and Figure 5.6 respectively. 
 
Figure 5.5 (a) Valve Opening, (b) Valve Fully Opened, (c) Valve closing and (d) 
Valve Fully Closed Images of Human Cellular Pulmonary Heart Valve Roots at Heart 
Rate 72 bpm, captured from the Front View by a High-Speed Camera 
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Figure 5.6  (a) Valve Opening, (b) Valve Fully Opened, (c) Valve closing and (d) 
Valve Fully Closed Images of Human Decellularised Pulmonary Heart Valve Roots at 
Heart Rate 72 bpm, captured from the Front View by a High-Speed Camera 
It was observed that most of the cellular and decellularised heart valve roots 
demonstrated synchronous and triangular leaflet opening with leaflet fluttering 
during systole. In the decellularised heart valve roots HP040 and HP043, a large 
central leakage orifice was clearly visible. The decellularised heart valve roots HP040 
and HP043 showed incomplete leaflet coaptation where the leaflet edges appeared 
to be taut, resulting in large central and commissural regurgitant orifices (Figure 5.6). 
Also the cellular heart valve roots HP044, HP041 and decellularised valve HP046 had 
minor central leakage orifices. The fully closed leaflet configuration for the cellular 
heart valve root HP055 and decellularised heart valve root HP042 showed full 
coaptation of the leaflets. The fully closed configuration of the cellular heart valve 
root HP045 exhibited an excess redundant free edge material. Also there were a few 
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small holes (fenestrations) observed in the tips of the leaflets for the cellular valve 
HP044 and decellularised valve HP042 as shown in Figure 5.7. Fenestration of valve 
leaflets is commonly noted at medical examination and surgery.  
 
Figure 5.7 Human Decellularised Pulmonary Heart Valve HP042 with 
Fenestrations Visible 
5.5.1.2 Biomechanical Performance of Human Cellular and Decellularised 
Pulmonary Heart Valve Roots 
5.5.1.2.1 Dilation (Expansion Characteristics)  
The expansion characteristics in terms of percentage dilation as a function of 
applied internal pressure for the cellular and decellularised pulmonary heart valve 
roots are shown in Figure 5.8.  
The expansion characteristics of the decellularised heart valve root HP040 could 
not be determined as it was leaking faster than the pressure applied. The expansion 
characteristics show that decellularised pulmonary heart valve roots (dotted lines) 
were more compliant than the cellular heart valve roots (solid lines). 
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Figure 5.8 Percentage Dilation as a Function of Applied Pressure of Cellular 
(Solid Line, n=4) and Decellularised (Dotted Line, n=3) Porcine Heart Valve Roots- 
Data fitted with a third order polynomial trend line 
During the dilation testing, the starting pressure due to the height of saline was 
different for all the pulmonary heart valve roots. Although subsequent pressure was 
applied in similar regular intervals, it resulted in discrete final pressure values for all 
the heart valve roots. Therefore percentage dilation at the measurement point 
closest to 20 mmHg was used in the calculation of the mean percentage dilation.  
These mean percentage dilation for cellular and decellularised was 6.23 ± 2.02 
and 12.90 ± 4.27 mmHg respectively at 20 mmHg pressure. The decellularised 
pulmonary heart valve roots were significantly more compliant than the cellular 
pulmonary heart valve roots (P=0.002, Student’s t-test). 
5.5.1.2.2 Tensile Properties 
The majority of the cellular and decellularised wall and leaflet tissue specimens 
failed in the gauge length during uniaxial tensile testing. 
The stress-strain graphs for all cellular and decellularised pulmonary wall and 
leaflet tissue specimens are illustrated in Figure 5.9.  
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(a) (b) 
  
(c) (d) 
Figure 5.9 Stress-Strain Graphs for the Cellular (solid line, n=4) and 
Decellularised (dotted line, n=4) (a) Circumferential Pulmonary Wall (b) Axial 
Pulmonary Wall (c) Circumferential Pulmonary Leaflet (d) Radial Pulmonary Leaflet 
Specimens 
The graphs demonstrated the typical tri phasic characteristics. Figure 5.9 (a) and 
(b) clearly showed clearly showed no obvious differences between the tensile wall 
characteristics (axial and circumferential) of the decellularised and cellular heart 
valve roots. However, tensile leaflet characteristics in circumferential directions 
demonstrated a rise in ultimate tensile stress after decellularisation. [Figure 5.9 (c)]. 
The mean thickness with 95 % confidence limits and tensile parameters with 95 
% confidence limits for the cellular and decellularised pulmonary heart valve root wall 
(axial and circumferential) and leaflet (radial and circumferential) specimens are 
presented in Table 5.5 and Table 5.6 respectively.  
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Table 5.5 Mean Thickness for the Cellular and Decellularised Pulmonary Heart 
Valve Root Wall and Leaflet Specimens - p values:  statistical probability in the 
comparison between cellular and decellularised pulmonary heart valve roots 
 
Specimen 
Direction 
Mean Thickness (mm) p 
Value 
Cellular Decellularised 
Pulmonary Heart 
valve root wall 
Axial 1.27 ± 0.28 1.11 ± 0.20 0.18 
Circumferential 1.20 ± 0.22 1.09 ± 0.15 0.23 
Pulmonary Heart 
valve root Leaflet 
Radial 0.26 ± 0.20 0.22 ± 0.07 0.57 
Circumferential 0.33 ± 0.28 0.22 ± 0.07 0.33 
 
There was no significant difference among the mean cellular and decellularised 
pulmonary wall and leaflet specimen thickness in both tested directions (p>0.05, 
Student’s t-test). 
Table 5.6 Tensile Parameters (collagen phase slope Ec, elastin phase slope Ee, 
ultimate tensile stress σUTS, failure strain ɛfailure) based on the Engineering Stress 
versus Engineering Strain behaviour of the Cellular and Decellularised Pulmonary 
Heart Valve Root Wall Specimens [Axial (A) and Circumferential (C) Directions] and 
Leaflet Specimens [Radial (R) and Circumferential (C) Directions] *-Statistical 
significant difference (p<0.05) for decellularised versus cellular heart valve roots 
Pulmonary 
Heart Valve 
Root Specimen 
Ec 
MPa 
E e 
MPa 
σ UTS 
MPa 
ɛ failure 
Wall (A) 
Cellular 2.14 ± 0.70 0.15 ± 0.18 0.83 ± 0.28 0.86 ± 0.28 
Decellularised 1.59 ± 0.55 0.10 ± 0.02 0.59 ± 0.20 0.84 ± 0.38 
p Value 0.10 0.42 0.08 0.91 
Wall (C) 
Cellular 3.20 ± 3.95 0.10 ± 0.02 1.35 ± 1.28 0.93 ± 0.23 
Decellularised 4.23 ± 2.71 0.15 ± 0.14 1.42 ± 0.79 0.70 ± 0.30 
p Value 0.52 0.27 0.87 0.10 
Leaflet (R) 
Cellular 3.81 ± 3.73 0.33 ± 0.75 0.53 ± 0.30 0.33 ± 0.14 
Decellularised 1.76 ± 1.33 0.33 ± 0.43 0.20 ± 0.13* 0.24 ± 0.18 
p Value 0.15 0.99 0.02 0.25 
Leaflet (C) 
Cellular 15.44 ± 9.72 1.07 ± 1.72 1.54 ± 0.84 0.17 ± 0.53 
Decellularised 29.50 ± 6.31* 1.80 ± 2.18 3.28 ± 0.73* 0.18 ± 0.58 
p Value 0.008 0.43 0.003 0.79 
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There was no significant difference between cellular and decellularised 
pulmonary heart valve root wall tensile parameters in the axial and circumferential 
directions (p>0.05, Student’s t-test) 
The collagen phase slope and UTS of the decellularised pulmonary leaflet was 
significantly higher in the circumferential direction compared to cellular leaflet 
(p<0.05, Student’s t-test). However, in the radial direction the ultimate tensile stress 
for decellularised pulmonary leaflet specimens was significantly lower than 
decellularised specimens (p=0.02, Student’s t-test). 
5.5.1.2.3 Suture Pull-Out Properties 
During suture pull-out testing of wall and myocardial specimens, failure was 
seen as a wedge shaped cut spreading from the suture in the circumferential 
direction perpendicular to the axial axis. 
The mean suture pull-out force and mean resistance to tearing for 
decellularised pulmonary heart valve root wall and myocardial specimen was not 
significantly different than the cellular pulmonary wall and myocardium specimen 
(Table 5.7; p>0.05, Student’s t-test). 
There was no significant difference between the cellular and decellularised 
groups for the following factors: mean maximum suture pull out force for wall and 
myocardial specimens and resistance to tearing for the wall and myocardium 
specimens (p>0.05). 
Table 5.7 Mean Maximum Suture Pull-Out Force and Mean Resistance to 
Tearing for the Cellular and Decellularised Pulmonary Heart Valve Root Wall and 
Myocardial specimens - p values:  statistical probability in the comparison between 
cellular and decellularised pulmonary heart valve roots 
Specimen 
Type 
Mean Maximum force  ± 95 
% confidence limits (N) 
Resistance to Tearing 
(N.mm-1) 
 Wall Myocardium Wall Myocardium 
Cellular  3.97 ± 1.98 1.74 ± 1.00 2.58 ± 1.57 0.60 ± 0.42 
Decellularised 3.18 ± 1.04 2.14 ± 0.56 2.47 ± 1.10 1.05 ± 0.43 
p Value 0.30 0.31 0.85 0.05 
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  Study II 
5.5.2.1 Dimensions of Human Pulmonary Heart Valve Roots (Cellular Un scraped, 
Cellular Scraped, Decellularised Un-Scraped and Decellularised Scraped 
Heart Valve Roots) 
The dimensions of each pulmonary heart valve root when laid flat for all the 
groups are detailed in Table 5.8.  
As shown in Table 5.8, a paired width comparison (△W13, △W14, △W23 △W24) 
was made between the appropriate pair of groups i.e., Group 3 (decellularised un-
scraped) was compared with Group 1 (cellular) and Group 4 (decellularised scraped) 
was compared with Group 2 (cellular scraped). As the sensitivity of measurement 
technique was ± 5 %, all the changes in width less than or equal to ± 5 % were 
considered as no change. The results in Table 5.8 showed that the measurements for 
cellular and decellularised heart valve roots did not exhibit any trend. These results 
were highly dependent on the quality and consistency of the captured images and 
sensitivity of the diameter measurement technique in imageJ. 
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Table 5.8 Wall Widths (W1 and W2) of each Human Pulmonary Heart Valve Root for all the Groups [Cellular Un- Scraped (Group 1), 
Cellular Scraped (Group 2), Decellularised Un-Scraped (Group 3), Decellularised Scraped (Group 4)] and Percentage Change in Widths W1 
(△W13 and △W14) and W2 (△W23 and △W24) for Decellularised Un-Scraped (Group 3) and Decellularised Scraped (Group 4) Human 
Pulmonary Heart Valve Roots 
 
 
 
 
 
 
 
 
↑:Increase, ↓:Decrease , −: No change 
                                                                                                                                                                                                                                                    
ID 
 
Heart Valve Root Width Change in 
Width 
Heart Valve Root Width Change in 
Width W1 (mm) W2 (mm) 
Group  Group  
1 2 3 4 △W13 △W14 1 2 3 4 △W23 △W24 
HP056 41.1 42.8  47.9  ↑ 32.6 34.4  36.8  ↑ 
HP058 47.8 60.3  51.1  ↓ 35.3 42.1  42.2  − 
HP063 41.8  41.9  −  36.8  39.5  ↑  
HP062 49.4  47.9  −  45.4  40.7  ↓  
HP060 37.3 39.2  42.0  ↑ 34.2 33.4  34.8  − 
HP061 33.6 35.9  33.3  ↓ 32.1 32.9  36.8  ↑ 
HP057 51.4  52.7  −  42.9  42.7  −  
HP059 44.4  46.8  ↑  33.1  33.2  −  
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5.5.2.2 Functional Biomechanical Performance of Human Pulmonary Heart valve 
roots (Cellular Un scraped, Cellular Scraped, Decellularised Un-Scraped 
and Decellularised Scraped Heart Valve Roots) 
5.5.2.2.1 Competency with and without Annulus Support  
The valve competency (Cp) and mean leakage flow rates (F L) for all the heart 
valve roots of all the groups [cellular un- scraped (Group 1), cellular scraped (Group 
2), decellularised un-scraped (Group 3) and decellularised scraped (Group 4)] are 
shown in Table 5.9. 
As shown in Table 5.9, the heart valve root competency assessment revealed 
that without annulus support the majority of cellular un-scraped, cellular scraped, 
decellularised un-scraped and decellularised scraped pulmonary heart valve roots 
were regurgitant.  
The mean leakage flow rate for the cellular group (un-scraped and scraped) of 
heart valve roots was under 2.5 mL.s-1 with annulus support, with the majority being 
competent. After decellularisation treatment the mean leakage flow rate for these 
heart valve roots were also under 2.5 mL.s-1 with annulus support with the exception 
of the decellularised un-scraped heart valve root HP059 (4.4 mL.s-1). The competency 
of the cellular un-scraped heart valve roots HP057 could not be measured without 
the annulus ring as the valve was leaking faster than the static pressure applied and 
when the competency was assessed again with annulus ring it was still an 
incompetent valve with the highest mean leakage flow rate of 26.0 mL.s-1. However, 
after decellularisation, the valve appeared more competent and the mean flow rate 
was reduced to 1.01 mL.s-1. The reason for this was not clear. The mean leakage rates 
for the valves HP056, HP058, HP060 and HP061 before (Group 1) and after scraping 
(Group 2) were similar. The arterial diameters for each heart valve root for all the 
groups at 60 mmHg pressure are shown in Table 5.10. The dimension of heart valve 
root HP057 could not be measured before and after the treatments (scraping and 
decellularisation), as the valve leakage was too fast and it was difficult to control 
pressure at 60 mmHg. The data did not show any trend in arterial diameters of the 
pulmonary heart valve roots groups. 
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Table 5.9 Mean Leakage Flow Rates (FL mL.s-1) and Competency (Cp) for each Human Pulmonary Heart Valve Root for all the Groups 
[Cellular Un- Scraped (Group 1), Cellular Scraped (Group 2), Decellularised Un-Scraped (Group 3), Decellularised Scraped (Group 4)] 
 
Group 1 
 
Group 2 
 
Group 3 Group 4 
Without With Without With Without With Without With 
Support Support Support Support 
FL Cp F L Cp FL Cp FL Cp FL Cp FL Cp FL Cp FL Cp 
HP056 3.41 No 1.28 Yes 3.05 No 1.28 Yes     3.40 No 2.13 No 
HP058 1.26 Yes 1.28 Yes 1.30 No 1.28 Yes     2.16 No 1.28 Yes 
HP063 2.26 No 0.99 Yes     6.39 No 2.49 No     
HP062 3.63 No 1.28 Yes     6.64 No 1.44 No     
HP060 1.55 No 1.28 Yes 2.51 No 1.28 Yes     3.18 No 1.94 No 
HP061 3.97 No 1.47 No 1.47 No 1.28 Yes     4.79 No 2.35 No 
HP057 ~~ ~~ 26.0 No     1.01 Yes 1.28 Yes     
HP059 3.55 No 2.39 No     4.93 No 4.40 No     
 ~~ - Leakage rate not measured. Cp - Competency (Yes- leakage rate ≤ 1.28 mL.s-1, No -leakage rate ≥ 1.28 mL.s-1
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Table 5.10 Diameters D1 of each Human Pulmonary Heart Valve Root for all 
the Groups [Cellular Un- Scraped (Group 1), Cellular Scraped (Group 2), 
Decellularised Un-Scraped (Group 3), Decellularised Scraped (Group 4)] at 60 mmHg 
Static Pressure and Change in Diameter △D1 
 
ID 
 
Heart Valve Root 
Diameter D1 (mm) 
△D1 
mm 
Group 
1 2 3 4 3 4 
HP056 35.4 36.5  34.9  − 
HP058 40.1 32.4  34.8  ↑ 
HP063 35.9  30.9  ↓  
HP062 30.3  30.4  −  
HP060 33.9 31.9  31.6  − 
HP061 37.0 38.0  36.0
1 
 ↑ 
HP057 ~~  ~~  ~~  
HP059 36.8  34.2  ↑  
↑: Increase, ↓: Decrease , −: No change, ~~ : Diameter not measured 
5.5.2.2.2 Dilation (Expansion Characteristics)  
The percentage dilations for the pulmonary heart valve roots (cellular, cellular 
scraped, decellularised un-scraped and decellularised scraped) are shown as a 
function of applied pressure in Figure 5.10.  
 
Figure 5.10 Percentage Dilation as a Function of Applied Pressure of Cellular 
Un-scraped (Group 1, n=7) and Cellular Scraped (Group 2, n=4), Decellularised Un- 
Scraped (Group 3, n=3) and Decellularised Scraped (Group 4, n=4) Heart valve roots 
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The percentage dilation for the heart valve root HPO57 could not be 
determined as it was leaking faster than the pressure applied. The donor age for the 
valve HP061 (18 years) was not in the same range as the other valves and also the 
dilation results for the valve before and after decellularisation were not in range with 
the other heart valve roots. Hence the dilation data for valve HP061 was omitted from 
the analysis. 
The mean percentage dilation for all the groups of heart valve roots at 20 mmHg 
pressure was similar (p> 0.05, one way Anova).   
As shown in Figure 5.11, the mean dilation for the decellularised scraped 
pulmonary heart valve roots (Group 4) was higher than that of all the other groups, 
but not significantly (p>0.05).   
 
Figure 5.11 Mean Percentage Dilation at Approximately 20 mmHg For All the 
Pulmonary Cellular (Group 1, n=6), Cellular Scraped (Group 2, n=3), Decellularised 
Un-Scraped (Group 3, n=3) and Decellularised Scraped (Group 4, n=3) Heart Valve 
Roots. - The error bars indicate 95 % confidence limits. 
5.6 Discussion 
 Effect of Decellularisation on Hydrodynamic Performance of Human Cellular 
Pulmonary Heart Valve Roots 
The decellularised pulmonary heart valve roots demonstrated similar 
hydrodynamic characteristics to cellular pulmonary heart valve roots. The mean EOA 
for the decellularised pulmonary heart valve roots was also very similar to that of 
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cellular pulmonary heart valve roots (2.10 ± 0.36 cm2 vs 2.31 ± 0.39 cm2 respectively, 
p=0.5). The high speed video analysis showed that one cellular and one decellularised 
pulmonary heart valve root showed good closed leaflet configuration, and a further 
two cellular and one decellularised heart valve root showed minor central leakage 
orifices under pulsatile flow conditions. It was observed however that two 
decellularised heart valve roots HP043 and HP040 had poor closed leaflet 
configuration with visible large leakage orifices. The images of closed leaflet 
configuration correlated well with measured reverse flow rates. The decellularised 
heart valve root HPO40, showed poor closed leaflet configuration during pulsatile 
flow assessment and the highest leakage flow rate of 17.25 mL.s-1 with the largest 
arterial diameter of 37 mm during the valve competency assessment. Overall the 
decellularised heart valve root HPO40 did not perform well under the pulsatile flow 
and static back pressures. In contrast, two of the four cellular pulmonary heart valve 
roots were classified as competent as they had leakage rates less than 1.28 mL.s-1. 
Two of the cellular and majority of the decellularised pulmonary heart valve roots 
were regurgitant with large variation in the leakage flow rates and heart valve root 
diameters, noticeably in decellularised group. Also the decellularised pulmonary 
human heart valve roots were more expansible in the circumferential direction 
(Section 5.5.1.2.1) than cellular human pulmonary heart valve roots. During this 
phase, there was a concern that before application of the decellularisation treatment 
excess fat, connective tissue and the adventitial layer from the pulmonary heart valve 
roots were removed (scraping process) which may have disrupted the outer layer of 
the adventitia. This layer has an important role in the structural support of the vessel 
wall in preventing overstretching (2011, Laflamme et al., 2006). Damage to the 
adventitial layer may adversely affect the biomechanical properties of the artery and 
hence function of the heart valve root.  
It was also apparent that the study was based on a small sample size, and was 
therefore of low statistical power and there was a large variation between samples 
within a group, limiting the interpretation of the results. It was also apparent that it 
was not known whether the human decellularised heart valve roots that had been 
decellularised had a large diameter prior to decellularisation or whether the heart 
valve roots had increased in diameter as a result of the decellularisation process. 
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After data analysis, it was recognised that the method for competency assessment 
was unsuitable for pulmonary heart valve roots due to the thin right myocardium of 
the pulmonary heart valve root which was not supported during competency 
assessment and this is not the case in vivo. This meant that the annulus of the 
pulmonary heart valve root was not being fully supported and therefore, the leaflets 
were not coapting fully. In addition, the competency assessment protocol was 
adopted from the previous study (Jennings, 2001), in which the annulus of the heart 
valve root was not supported, because the majority of the tested heart valve roots 
were fixed with glutaraldehyde and hence they had fixed geometry. Therefore it was 
necessary to improve the method for competency assessment by incorporating a 
more physiological condition. To clarify all these findings, Study II was conducted.  
In Study II, the setup for valve competency assessment was modified to 
incorporate an annulus ring in order to mimic the annulus support provided from the 
heart. The annulus supported competency assessment of the eight cellular 
pulmonary heart valve roots showed that five out of eight heart valve roots had low 
regurgitant flow rates below 2.4 mL.s-1 under physiological static back pressure. 
Maintaining valve competency of biological heart valve roots is dependent on the 
coordinated actions of the annulus, leaflets and associated wall collectively. 
Therefore, stiffening or dilation of the wall or stiffening of the leaflets can impede 
proper coaptation of the valve leaflets during closure and thereby promote 
regurgitation (Sabbah et al., 1986). After the application of the decellularisation 
treatment to these valves, the leakage flow rates remained under 2.5 mL.s-1 with the 
exception of one heart valve root (4.4 mL.s-1). The competency assessment was 
performed with and without annulus support and from those results it was clear that 
the use of an annulus support ring reduced the leakage flow rate, as this ring provided 
structural support to restore the shape and size of the valve annulus to its 
physiological geometrical dimensions. In addition to leakage flow rate, the arterial 
diameter of each heart valve root was measured at 60 mmHg during competency 
testing. The data did not show any trend in annulus or arterial diameters between 
cellular and decellularised heart valve roots. These results should, however be 
considered cautiously, as physiologically the heart valve roots were delicate and 
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covered with fatty tissue, so it was difficult to mount heart valve roots in exactly the 
same orientation each time for an exact comparison.  
The aim of this study was to characterise human pulmonary heart valve roots 
that had been decellularised using low concentration SDS before using them in the 
clinic as a replacement valve, in particular in the Ross procedure to reconstruct the 
right ventricular outflow tract. Several studies (Bechtel et al., 2008, Konuma et al., 
2009, Burch et al., 2010, Brown et al., 2011) have reported short-term and medium-
term in vivo performance of pulmonary human heart valves that have been 
decellularised using different processes (CryoValve SynerGraft®, CryoLife Inc, 
Kennesaw, GA) in comparison to standard cryopreserved allografts. Overall, 399 
CryoValve SynerGraft® pulmonary human heart valves were implanted in several 
centres for pulmonary valve replacement between 2000 and 2005 and results were 
favourable with respect to structural deterioration and endocarditis. Da Costa et al. 
have demonstrated that decellularised pulmonary allografts showed excellent 
hemodynamic behaviour and reduction in immunogenic response compared to 
standard allografts in the right ventricular outflow tract (RVOT) (da Costa et al., 2005). 
Another recent study by Da Costa reported higher reoperation-free survival with 
decellularised pulmonary allografts compared to conventional cryopreserved 
allografts for RVOT reconstruction up to 6 years of follow-up, and, in addition, 
pressure gradients were lower in the decellularised pulmonary allografts (da Costa et 
al., 2014). 
 Effect of Decellularisation on Biomechanical Performance of Human Cellular 
Pulmonary Heart Valve Roots 
The biomechanical performance of the decellularised pulmonary heart valve 
roots was evaluated and compared with cellular pulmonary heart valve roots through 
assessment of wall circumferential expansion characteristics, uniaxial tensile testing 
to failure and suture pull out.  
The decellularised pulmonary heart valve root walls were more extensible in 
the circumferential direction than the cellular pulmonary heart valve root walls. The 
dilation of decellularised pulmonary heart valve root walls increased to 12.9 ± 4.3 %, 
compared to 6.2 ± 2.0 % for cellular heart valve root walls at approximately 20 mmHg 
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internal pressure. However, this was an unpaired comparison. It was believed that 
this increase in dilation could be due to several reasons such as the wall of the 
decellularised heart valve roots being thinner than the cellular heart valve roots 
(although this was not significant); the variability and accuracy in the measurement 
technique; or could have simply been due to inherent biological variation. Also, as 
discussed in Section 5.6.1, the scraping procedure may have induced disruption in 
the wall mechanical properties. Therefore Study II was introduced to investigate the 
influence of the scraping step in the decellularisation protocol on the functional 
biomechanical performance of the heart valve roots. Study II made a paired 
comparison and showed that scraping of the adventitia layer of the wall or 
decellularisation treatment had no significant effect on the circumferential 
characteristics of the pulmonary heart valve root wall. The circumferential expansion 
characteristics of the pulmonary heart valve root walls showed that the processing 
step (scraping) and decellularisation treatment had no significant effect on the 
dilation properties of the pulmonary heart valve roots. Although, 95 % confidence 
limits were high in the dilation test results (Study II), particularly within the cellular 
scraped and decellularised scraped compared to cellular un-scraped and 
decellularised un-scraped pulmonary heart valve roots. These large confidence limits 
may be attributed to the small number of sample sizes (n=3) used in the calculation 
of the mean value.  
To determine effect of heart valve root wall scraping and decellularisation 
treatment on the dimensions of human pulmonary heart valve roots, dimensions of 
the same roots were measured before and after wall scraping and after 
decellularisation. The dimensional measurement data of the pulmonary heart valve 
root groups (cellular un-scraped, cellular scraped, decellularised un-scraped and 
decellularised scraped) did not exhibit any trend. These results were highly 
dependent on the quality and consistency of the captured images and sensitivity of 
measurement analysis in imageJ.  
The decellularised heart valve root wall specimen had similar stress-strain 
characteristics (extensibility and stiffness) in the axial and circumferential directions 
to that of the cellular heart valve root wall specimen. This leads to the conclusion that 
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the heart valve root wall maintains its natural material tensile properties following 
decellularisation due to the preservation of the elastin and collagen content of the 
wall. However, the stress-strain characteristics of decellularised pulmonary leaflets 
differed compared to the cellular leaflets. The decellularised pulmonary leaflets were 
stronger in the circumferential direction with a significant increase in mean collagen 
phase slope and ultimate tensile stress (UTS), compared to cellular leaflets. Such 
changes may be due to the significant reduction of glycosaminoglycan (GAGs) and 
removal of cells reported by Vafaee et al. (2016). The loss of GAGs in the 
decellularised leaflets, may have led to loosening of the fibrous structure and 
uncrimping of the circumferentially aligned collagen fibers. This could potentially 
cause an earlier than normal recruitment and reorientation of the collagen fibers in 
the direction of applied strain during tensile testing (Williams et al., 2009). Previous 
work on decellularised tissues has shown similar findings in bone tissue (Banse et al., 
2002), ligaments (Frank et al., 1995, Herbert et al., 2016) and soft tissue (Freed and 
Doehring, 2005). It is hypothesised that the leaflets of the decellularised heart valve 
roots will recellularise in vivo and regain their physiological tensile properties. 
Conversely, the extensibility of decellularised pulmonary leaflets was comparable to 
the cellular leaflets in both the radial and circumferential directions, while UTS for 
decellularised specimens was significantly reduced in the radial direction. However, 
it is important to note that the biomechanical performance of decellularised and 
cellular heart valve roots was not a paired comparison. Previous results on porcine 
pulmonary heart valve roots decellularised with a similar protocol did not show 
leaflet stiffening but showed wall stiffening in both the axial and circumferential 
directions in the initial elastin phase (2014). These findings related to material 
properties of the decellularised pulmonary heart valve roots, showed that the 
resultant changes due to decellularisation treatment can be highly dependent on 
species, tissue type and method (Gilbert et al., 2006), this highlights the need to carry 
out robust pre-clinical testing of all types of decellularised tissues prior to their 
implantation.  
The decellularised human pulmonary heart valve root wall and myocardial 
specimens had similar suture pull-out forces to cellular human pulmonary heart valve 
root wall and myocardial specimens respectively. However, the resistance to tearing 
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for the decellularised myocardial specimens was significantly higher than the cellular 
specimens. This increase might have been due to the large variation in specimen 
thickness and also quality of the myocardial specimens. A few of the myocardial 
specimens may have become damaged during prior test procedures, which required 
the clamping of the myocardial with cable ties. 
The limitations of this study include the small number of samples giving low 
statistical power, simplification of the in vivo environmental conditions and the 
biological variation within the pulmonary heart valve root groups. 
5.7 Conclusion 
In conclusion, an extensive in vitro hydrodynamic and biomechanical 
comparison of decellularised and cellular human pulmonary heart valve roots has 
been performed. Neither hydrodynamic nor expansion properties of human 
pulmonary heart valve roots were significantly affected by the low concentration SDS 
decellularisation treatment. Also, the processing step (scraping) during 
decellularisation treatment did not alter functional biomechanical properties of 
human pulmonary heart valve roots. However, decellularisation significantly altered 
some of the directional material properties of pulmonary heart valve leaflets. Also, 
there was a trend for increased leakage flow rate following decellularisation although 
after decellularisation treatment the mean static leakage rate for the pulmonary 
valves were also under 2.5 mL.s-1 with annulus support with the exception of one 
heart valve root (4.4 mL.s-1). This work has been published in the Journal of the 
Mechanical Behavior of Biomedical Materials and publication details can be found in 
Appendix A.
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 In vitro Material Properties of Non- and Post-Implanted 
Decellularised Porcine Pulmonary Heart Valve Roots 
In this chapter, material properties of the non-implanted and post-implantation 
decellularised porcine pulmonary heart valve roots were evaluated to assess the 
material properties of decellularised porcine pulmonary heart valve roots after 12 
months implantation in sheep. Comparison of the material properties of the non - 
implanted and implanted decellularised porcine pulmonary heart valve roots 
provided understanding of any biomechanical changes that occurred as a result of 
cellular population in vivo. The material properties assessment of 12 months 
implanted decellularised porcine pulmonary heart valve roots was part of a larger 
collaborative study with Professor Francisco Da Costa, Pontificia Universidade 
Catolica do Parana, Curitiba, Brazil. 
6.1 Introduction 
Decellularised porcine pulmonary heart valve roots, in various sizes, have been 
developed with a view to their clinical use in the Ross procedure (2014). An in vivo 
proof of concept study of these decellularised porcine pulmonary heart valve roots 
was conducted in collaboration with Professor Francisco Da Costa, Pontificia 
Universidade Catolica do Parana, Curitiba, Brazil. The decellularised porcine heart 
valve roots were implanted in the orthotopic position (right ventricular outflow tract; 
pulmonary position) of juvenile sheep (120 days) and explanted at 1 (n=4), 3 (n=4), 6 
(n=4) and 12 (n=8) months. The in vivo functional performance was monitored by 
weight gain and Doppler echocardiography. Roots explanted at 1, 3, 6 and 12 months 
(n=4 per group) were assessed by gross analysis, histology, immunohistochemistry 
and quantitative calcium analysis to assess the regenerative process over time. The 
in vivo and biological data is not described here as it was out with the scope of this 
study (manuscript in preparation). In summary, the functional performance of 
decellularised porcine pulmonary roots over a 12 month period was excellent, with 
evidence of cellular population. However, the levels of calcium in the pulmonary wall 
and leaflets of the 12 month explanted decellularised porcine pulmonary heart valve 
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roots, although low (278-401 ppm) were significantly greater than in the non-
implanted decellularised porcine and cellular ovine pulmonary heart valve roots  
(Berry et al., 2017). 
The aim of this part of the study was to characterise the material of the 
decellularised porcine pulmonary heart valve roots (n=4) following 12 months 
implantation in sheep. Cryopreservation was used to preserve the decellularised 
porcine pulmonary heart valve roots before they were implanted in the sheep. In this 
context, this study was designed to test the following hypotheses: 
 1) The pre-implantation treatments (decellularisation and cryopreservation) 
alter the material properties of the porcine pulmonary heart valve roots. 
2) The material properties of decellularised porcine pulmonary heart valve 
roots changes as a result of post-implantation structural changes, inflammatory 
response and graft incorporation. 
There are many methods to evaluate the material properties of heart valve 
roots, however uniaxial tensile testing is the most practical method and allows 
measurement of stress-strain behavioural properties of the wall and leaflets.  
6.2 Aim 
The aim of the study was to assess the effects of low concentration 
sodium dodecyl sulphate (SDS) decellularisation and cryopreservation on the 
material properties of porcine pulmonary heart valve roots and determine the 
material properties of decellularised porcine pulmonary heart valve roots following 
12 months implantation in three months old sheep.  
The objectives of this study (Figure 6.1) were:  
1. To determine and compare the material properties of the pulmonary artery wall 
and leaflets of cryopreserved cellular porcine non-implanted and non-
cryopreserved cellular porcine non-implanted pulmonary heart valve roots in 
order to investigate the effect of cryopreservation. 
2. To determine and compare the material properties of the pulmonary artery wall 
and leaflets of cryopreserved decellularised porcine non-implanted and 
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cryopreserved cellular porcine non-implanted pulmonary heart valve roots in 
order to investigate the effect of decellularisation. 
3. To determine and compare the material properties of cryopreserved 12 months 
explanted decellularised porcine, cryopreserved decellularised porcine non-
implanted and cryopreserved cellular ovine non-implanted pulmonary heart 
valve roots to determine the effects of 12 months implantation in juvenile sheep. 
 
Figure 6.1 Pulmonary Heart Valve Root Experimental Groups  
6.3 Materials  
Five pulmonary heart valve root groups were studied and each group had n=6 
with the exception of 12 month explanted cryopreserved decellularised porcine 
pulmonary heart valve root group (n=4) as described in Table 6.1. 
The cellular porcine and cellular ovine pulmonary heart valve roots were 
dissected from hearts which were obtained from M & C Meats, Crossgates, Leeds or 
John Penny & Sons, Rawdon, Leeds, UK. within 4 hours of slaughter.  
The decellularised porcine pulmonary heart valve roots were prepared in the 
Faculty of Biological Sciences (University of Leeds, Leeds) using established 
decellularisation procedures (2014). The heart valve roots were cryopreserved using 
the protocol utilised by NHS Blood Transplant Tissue & Eye Services (Speke; Liverpool, 
UK) and stored at -80 °C until use. 
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Four decellularised porcine pulmonary heart valve roots were explanted from 
sheep after 12 months in vivo at the Pontificia Universidade Catolica do Parana, 
Curitiba, Brazil and shipped to Leeds for material properties assessment.  
Phosphate buffered saline (PBS) was used to keep the roots hydrated during 
the test procedure. 
Table 6.1 Details of Pulmonary Heart Valve Roots Groups Assessed Including 
Abbreviation, Age of the Animal and Number of Specimens in Each Group 
Pulmonary Heart Valve 
Root Group 
Abbreviation 
Age of the 
Animal 
(Months) 
Number of  
Specimens (n) 
Cellular cryopreserved 
ovine non-implanted 
CellCP Ovine 15 6* 
12 month explanted 
cryopreserved 
decellularised porcine 
ExpDCP Porcine 15 4 
Decellularised 
cryopreserved porcine 
non-implanted 
DecellCP Porcine 6 - 8 6 
Cellular cryopreserved 
porcine non-implanted 
CellCP Porcine 6 - 8 6 
Cellular unpreserved 
porcine non-implanted 
Cell Porcine 6 - 8 6 
*n=4 for leaflets tested in the radial direction 
6.4 Methods 
 Preparation, Shipment and Storage of Heart Valve Roots for Material 
properties Assessment 
The cryopreserved decellularised porcine pulmonary heart valve roots were 
shipped on dry ice to Brazil through a courier with an import licence (authorisation 
No MP.000.1/13PR). The heart valve roots were stored at -80 °C at the University 
Veterinary Hospital (Hospital Veterinário Para Animais De Companhia) Brazil until 
implantation. The decellularised porcine pulmonary heart valve roots were 
implanted in the right ventricle outflow tract (RVOT) of juvenile sheep (3 months old) 
at the Hospital Veterinário Para Animais De Companhia, Brazil, in accordance with 
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the institutional guidelines for animal care. The Ethics Research Committee on Animal 
Research of Pontifícia Universidade Católica in Paraná (PUC-PR) approved this 
experiment. The cryopreserved roots were gently thawed at 37 °C, washed 
aseptically in 0.9% (w/v) saline solution, myocardial and artery trimmed to 
appropriate length and kept moist until implantation. The details of the heart valve 
roots implantation in sheep are not described here as it was not required for the 
purpose of this study. The implanted pulmonary heart valve roots were retrieved 
from the sheep after 12 months under terminal anaesthesia for in vitro material 
properties assessment. The pulmonary heart valve root explants were cryopreserved 
and stored at - 80 °C. The roots were shipped to the University of Leeds, Leeds, UK 
on dry ice by a courier with appropriate export and import licences. The explanted 
heart valve roots were stored at -80 °C at the University of Leeds until testing. The 
cryopreserved explanted heart valve roots were gently thawed at 37 °C, washed 
aseptically in 0.9% (w/v) saline solution and stored in 200 ml PBS solution on the day 
of testing. 
 Material properties Assessment of Heart Valve Roots 
In order to determine the material properties of the heart valve roots, a uniaxial 
tensile test to failure was performed on the wall (axial and circumferential) and 
leaflets (radial and circumferential). Before tensile testing the sizes (internal 
diameter) of the heart valve roots were measured with obturators. The specimen 
sizes, method of specimen preparation and test procedures are described in Chapter 
2 Section 2.4.8.2. The following material parameters were derived from the stress-
strain graphs: collagen phase slope, elastin phase slope and ultimate tensile stress 
(UTS). 
Results are presented as mean ± 95 % confidence limits. One-way analysis of 
variance (ANOVA) was employed for evaluating the existence of difference among 
the valve groups. If significant variation in the data was detected, Gabriel post hoc 
analysis was used to determine the significance between the two relevant groups to 
investigate the effect of decellularisation (DecellCP Porcine/CellCP Porcine), 
cryopreservation (CellCP Porcine/Cell Porcine) and post-implantation (ExpDCP 
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Porcine/DecellCP Porcine and ExpDCP Porcine/CellCP Ovine). A p-value of <0.05 was 
considered to be statistically significant. 
6.5 Results 
The mean valve size for all the tested pulmonary heart valve root groups is 
shown in Figure 6.2. The ExpDCP Porcine valves were significantly larger than CellCP 
Ovine and DecellCP Porcine valves (p<0.05, one-way ANOVA).  
 
Figure 6.2 Mean Valve Size (Internal Diameter) for Pulmonary Heart Valve 
Root Groups - The error bars indicate 95 % confidence limits. * - Denotes significant 
difference (p<0.05)  
The mean wall thickness in the axial and circumferential directions for all the 
tested pulmonary heart valve root groups is shown in Figure 6.3.  
 
Figure 6.3 Mean Pulmonary Heart Valve Root Wall Groups Thickness in the 
Axial and Circumferential Directions - The error bars indicated 95 % confidence 
limits. * - Denotes significant difference (p<0.05)  
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In the axial direction, the mean wall specimens thickness for all the tested 
pulmonary heart valve root groups were similar. The mean wall thicknesses for CellCP 
Porcine and Cell Porcine heart valve roots were similar in the radial and 
circumferential directions. However, in the circumferential direction, the mean wall 
thickness for ExpDCP Porcine heart valve roots (1.42 ± 0.46 mm) was significantly 
lower than the CellCP Ovine heart valve roots (1.99 ± 0.2 mm) (p=0.04; Gabriel post-
hoc test).  
The mean biomechanical parameters for all pulmonary heart valve root wall 
groups are shown in Figure 6.4, Figure 6.5 and Figure 6.6. 
 
Figure 6.4 Mean Collagen Phase Slope for the Pulmonary Heart Valve Root 
Wall Groups in the Axial and Circumferential Directions - The error bars indicate 95 
% confidence limits. * - Denotes significant difference (p<0.05) 
 
Figure 6.5 Mean Elastin Phase Slope for the Pulmonary Heart Valve Root Wall 
Groups in the Axial and Circumferential Directions - The error bars indicate 95 % 
confidence limits. *- Denotes significant difference (p<0.05) 
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Figure 6.6 Mean Ultimate Tensile Stress (UTS) for the Pulmonary Heart Valve 
Root Wall Groups in the Axial and Circumferential Directions. The error bars 
indicate 95 % confidence limits. * - Denotes significant difference (p<0.05) 
There was no significant difference between the ExpDCP Porcine and DecellCP 
Porcine pulmonary heart valve root wall specimens for the following parameters: the 
mean collagen phase slope (Figure 6.4), the mean elastin phase slope (Figure 6.5) and 
the mean UTS (Figure 6.6) in the axial directions (p>0.05). However, ExpDCP Porcine 
pulmonary heart valve root wall specimens had significantly higher mean collagen 
phase slope (Figure 6.4) and mean UTS (Figure 6.6), when compared to the CellCP 
Ovine pulmonary heart valve root wall specimens in the circumferential direction 
(p<0.05). In addition, DecellCP Porcine pulmonary heart valve root wall specimens 
had a mean elastin phase slope of 0.09 ± 0.04 MPa, significantly higher than the 
CellCP Porcine pulmonary heart valve root wall (0.05 ± 0.01 MPa) in the 
circumferential direction (Figure 6.5) (p=0.01; Gabriel post-hoc test). 
For the heart valve root leaflets, the initial linear region of the stress-strain 
graph was used to derive elastin phase modulus and it was not distinct for two CellCP 
Ovine leaflet radial specimens. Hence these samples were omitted and only four 
CellCP Ovine samples were used in the calculation of mean thickness, elastin phase 
slope, collagen phase slope and UTS. 
The mean leaflet thicknesses (Figure 6.7) for CellCP Porcine and Cell Porcine 
heart valve roots were similar in the radial and circumferential directions. However, 
the DecellCP Porcine pulmonary heart valve root leaflet specimens were significantly 
thinner than CellCP Porcine in the radial (p=0.01; Gabriel post-hoc test) and 
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circumferential (p=0.005; Gabriel post-hoc test) directions. In addition, ExpDCP 
Porcine pulmonary heart valve root leaflet radial specimens (0.17 ± 0.04 mm) were 
significantly thinner than the CellCP Ovine (0.31 ± 0.14 mm) (p=0.02; Gabriel post-
hoc test). 
 
Figure 6.7 Mean Thickness for the Pulmonary Heart Valve Root Leaflets in the 
Radial and Circumferential Directions - The error bars indicate 95 % confidence 
limits. * - Denotes significant difference (p<0.05)   
 
Figure 6.8 Mean Collagen Phase Slope for the Pulmonary Heart Valve Root 
Leaflets in the Radial and Circumferential Directions- The error bars indicate 95 % 
confidence limits. 
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Figure 6.9 Mean Elastin Phase Slope for the Pulmonary Heart Valve Root 
Leaflets in the Radial and Circumferential Directions - The error bars indicate 95 % 
confidence Limits. * - Denotes significant difference (p<0.05) 
 
Figure 6.10 Mean Ultimate Tensile Stress (UTS) for the Pulmonary Heart Valve 
Root Leaflets in the Radial and Circumferential Directions - The error bars indicate 
95 % confidence limits. * - Denotes significant difference (p<0.05)  
The mean collagen phase slopes in the radial and circumferential direction for 
Cell Porcine pulmonary heart valve root leaflet specimens were not significantly 
altered after decellularisation or the cryopreservation process (Figure 6.8). However, 
the mean elastin phase slope was significantly increased for ExpDCP Porcine 
pulmonary radial leaflet specimens (0.05 ± 0.03 MPa) compared to the non-
implanted DecellCP Porcine specimens (0.02 ± 0.01 MPa) (p=0.02; Gabriel post-hoc 
test; Figure 6.9). There was also a significant reduction in UTS for ExpDCP Porcine 
pulmonary leaflet specimens (3.59 ± 2.45 MPa) compared to non-implanted DecellCP 
Porcine pulmonary heart valve root leaflet specimens (6.53 ± 2.40 MPa) in the 
circumferential direction (p=0.03; Gabriel post-hoc test; Figure 6.10).  
181 
Chapter 6 
The mean elastin phase slope for ExpDCP Porcine radial leaflet specimens (0.05 
± 0.03 MPa) was significantly higher when compared to the CellCP Ovine specimens 
(0.01 ± 0.01 MPa) (p=0.001; Gabriel post-hoc test; Figure 6.9).  
Failure of both the wall and leaflet tissue occurred at or near to the centre of 
the gauge length.  
6.6 Discussion 
  Effect of Cryopreservation on Material Properties of the Porcine Pulmonary 
Heart Valve Roots 
The cryopreservation process did not appear to alter the tensile material 
properties of the wall and leaflets of the pulmonary heart valve roots. For example, 
the tensile material parameters (elastin and collagen phase slopes, UTS) of the CellCP 
Porcine wall and leaflet specimens tested in both directions were very similar to these 
of the Cell Porcine specimens. These results agreed with other published studies 
(Langerak et al., 2001, Theodoridis et al., 2016).  
  Effect of Decellularisation on Material Properties of the Porcine Pulmonary 
Heart Valve Roots 
The effects of decellularisation on the biomechanical function of porcine 
pulmonary heart valve roots were evaluated by comparing material properties of 
DecellCP Porcine with CellCP Porcine pulmonary heart valve roots. The majority of 
the tensile material properties of pulmonary heart valve roots were preserved after 
decellularisation. For example, the wall and leaflet material parameters (collagen 
phase slope, elastin phase slope and UTS) for the DecellCP Porcine specimens in axial 
and circumferential directions were similar when compared to the CellCP Porcine, 
with the exception of elastin phase slope for wall specimens which was significantly 
higher in the circumferential direction for the DecellCP Porcine group. Conversely,  
(2014) found that the elastin phase slope for decellularised porcine pulmonary heart 
valve roots wall specimens was significantly higher in both axial and circumferential 
directions compared to cellular wall specimens. This was despite (2014) using a 
similar decellularisation protocol. This discrepancy compared to this study was likely 
due to differences in each experimenter’s methodology and repeatability of 
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experiments, especially with respect to determining the fully relaxed state of tissue 
specimens. The fact that no changes in the collagen phase slopes and ultimate tensile 
stresses indicated that the small increase in elastin phase slope in the circumferential 
direction of the arterial wall may not affect function, observed during the Doppler 
echocardiography of the implanted decellularised pulmonary heart valve roots in all 
sheep at 1, 3, 6 and 12 months of implantation (manuscript in preparation).  
The DecellCP Porcine radial and circumferential leaflet specimens were thinner 
than CellCP Porcine specimens. This was likely due to a previously reported reduction 
in glycosaminoglycan (GAG) levels in the decellularised porcine pulmonary leaflets 
and due to absence of cells (2011).  GAGs are, however, very important components 
in the middle layer (spongiosa) of the porcine pulmonary leaflets which can retain 
water and are believed to contribute to the material properties and the viscoelastic 
properties of the valve (Sacks et al., 2009). Nevertheless, the reduction in GAGs did 
not appear to adversely affect the material properties of these leaflets.  
 Effect of 12 Months Implantation in Sheep on Material Properties of the 
Decellularised Porcine Pulmonary Heart Valve Roots 
The material properties of the 12 months explanted decellularised pulmonary 
heart valve roots were derived and compared with non-implanted DecellCP Porcine 
and CellCP Ovine. The tensile parameters for ExpDCP Porcine pulmonary heart valve 
root wall in the axial and circumferential directions were similar to non-implanted 
DecellCP Porcine pulmonary heart valve root wall. However, the tensile leaflet 
material properties of DecellCP pulmonary heart valve roots appeared to alter 
following 12 months of implantation in sheep. The mean elastin phase slope of the 
ExpDCP Porcine heart valve root radial leaflet specimens was significantly higher than 
the non-implanted DecellCP Porcine heart valve root radial leaflet specimens. 
Furthermore, in the circumferential direction the mean UTS for ExpDCP Porcine heart 
valve root leaflet specimens was significantly lower than DecellCP Porcine heart valve 
root leaflet specimens, but similar to CellCP Ovine pulmonary heart valve root leaflet 
specimens. In addition, the UTS in the axial and circumferential directions for ExpDCP 
Porcine heart valve root wall and leaflets were reduced, although not significantly. 
The trend for decreasing stiffness and strength showed the ExpDCP porcine 
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pulmonary root wall and leaflets were becoming more like cellular ovine. Indeed, it 
was observed in the histological and the immunohistochemical analysis that the wall 
and leaflets of the decellularised porcine pulmonary heart valve roots were 
repopulating with ovine cells following 12 months implantation in sheep (Berry et al., 
2017). These findings have shown that studying the decellularised porcine heart valve 
roots material properties after the effect of in vivo physiological forces is useful to 
better understand the remodeling process. 
 Study Limitations 
This study had the following limitations: 
 The study included a small number of explanted heart valve roots giving low 
statistical power. 
 There was biological variation within the experimental porcine and ovine 
pulmonary heart valve groups.  
 Only uniaxial tensile assessment was used to derive material properties of the 
heart valve roots which ignores in vivo multiaxial loading conditions. 
 The study was limited by a lack of an experimental group (pulmonary heart valve 
root homograft from sheep) comparing material properties of the explanted 
decellularised pulmonary heart valve roots to interpret the results. 
6.7 Conclusion 
From this study, the following conclusions can be made: 
 Cryopreservation did not alter material properties of the cellular porcine 
pulmonary heart valve roots. 
 The decellularisation process had minimal effect on the material properties of the 
porcine pulmonary heart valve root wall and leaflets. 
 After 12 months implantation in sheep, the decellularised porcine pulmonary 
heart valve root wall and leaflets did not appear to be getting stiffer. Indeed, the 
trend for decreasing stiffness and strength showed the decellularised porcine 
pulmonary heart valve root wall and leaflets were becoming more like cellular 
ovine, potentially indicating constructive remodelling. 
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Overall, the current study demonstrated that cryopreserved decellularised 
porcine pulmonary heart valve roots maintained tissue integrity in an in vivo 
environment. The current study showed adequate biomechanical function following 
1) trans-species implantation of decellularised porcine pulmonary heart valve roots 
for 12 months 2) a low concentration SDS decellularised treatment on a porcine 
pulmonary heart valve root. Thus, the study provides valuable pre-clinical 
biomechanical data that can support clinical studies.  
To minimise in vivo testing in large animal, in vitro real time fatigue or durability 
testing could be used to predict heart valve root fatigue and durability, which will be 
addressed in the next chapter (chapter 7), discussing newly developed in vitro real 
time fatigue assessment method for biological heart valve roots. However, the in vivo 
regeneration response will still need to be evaluated with animal studies.  
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 Development of a Pre-Clinical Method for Assessment of Real 
Time Fatigue and Durability of Biological Heart Valve Roots 
This chapter describes the development of an in vitro fatigue and durability 
testing method for biological heart valve roots under cyclic physiological conditions. 
It includes the various stages undertaken to characterise and validate the real time 
wear tester (RWT; Section 7.5), development of a method to determine the real time 
fatigue of biological heart valve roots including the design of a heart valve root holder 
(Section 7.8.1) and modification of the RWT (Section 7.8.2). The method will then be 
used to investigate effect of decellularisation on the durability of decellularised 
porcine aortic heart valve roots to be described in Chapter 8. 
7.1 Introduction 
The prediction of long-term performance and investigation and quantification 
of the effects of factors that influence long term performance of prosthetic heart 
valves are vitally important in the development process in order to improve in vivo 
fatigue and durability. The characterisation of the long term performance or 
durability of a prosthetic heart valve is also one of the requirements established by 
the FDA (2010) and specified in the ISO 5840 (2015)  standard.  
With the potential clinical use of decellularised heart valve roots, biomechanical 
performance, hydrodynamic performance and durability are important 
considerations. The biomechanical and hydrodynamic performance of human cellular 
and decellularised aortic and pulmonary heart valve roots have been described in 
Chapters 4 and 5. This chapter describes the development stages of an in vitro test 
method to determine fatigue and durability of biological heart valve roots under real 
time cyclic test conditions. It describes an advancement of methods currently used 
to assess the durability of prosthetic and bioprosthetic heart valves. 
Cyclic testing of heart valve roots under simulated physiological conditions can 
provide evidence of the possible failure modes and lifespan. It can also aid heart valve 
root development and improvement and can guide future designs. Previous studies 
(Iwasaki et al., 2002, D'Souza et al., 2003, Butterfield and Fisher, 2000) on prosthetic 
and bioprosthetic heart valve durability have used accelerated fatigue testers to 
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attain valve leaflet motion (valve leaflet opening and closing) under non physiological 
test conditions. Accelerated fatigue testers were used at significantly higher 
frequencies (15 to 20 Hz) than physiological frequencies, in order to achieve failure 
in a shortened period of time. These accelerated fatigue testers are not appropriate 
for use with biological heart valve roots such as allografts and decellularised heart 
valve roots, because these valves exhibit highly time dependent viscoelastic 
behaviour and accelerated testing produces highly abnormal biomechanics (D'Souza 
et al., 2003). Accelerated fatigue testers were used at significantly higher frequencies 
than physiological frequencies, so the biological valves did not have enough 
relaxation time and additional forces were applied to the leaflets of the test heart 
valve roots which do not exist in the physiological environment (D'Souza et al., 2003, 
Sacks, 2001). Therefore biological heart valve roots require testing under more 
physiological frequencies and pressures. The test frequency has also been shown to 
influence the life time of polymer valves. Iwasaki et al. (2002) demonstrated that a 
polymer valve known as a Jellyfish valve had varied lifetime with cyclic frequency 
even when the maximum transvalvular pressure difference was constant; therefore, 
using appropriate time dependent test conditions is important. In effect, for 
biological and polymer valves, durability is dependent on the number of cycles, the 
peak pressure and the duration that the pressure is applied in a single cycle (the cycle 
frequency) (D'Souza et al., 2003). Hence, it is important to consider viscoelasticity and 
frequency of testing of the biological heart valve roots during fatigue testing in order 
to predict accurate fatigue and durability of the biological heart valve roots. 
To derive in vitro real time fatigue and durability performance of the heart valve 
roots, a testing equipment was required which could replicate physiological 
pressures and flow waveforms in a simplified, yet effective, controllable and cost-
effective way. 
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Figure 7.1 (a)  Left Ventricle and Aortic Pressure Waveforms During a Cardiac 
Cycle at Heart Rate of 60 bpm (b) Transvalvular Pressure across Aortic Valve, Image 
Adapted from (Conti et al., 2010) 
It was considered to use aortic heart valve roots in the fatigue testing method 
development due to their straight tubular shape which is supported with thick 
myocardium and aortic valve roots are larger in size than pulmonary heart valve 
roots. Hence, the method development and the performance requirements were 
based on the human aortic heart valve roots. The aortic heart valve opens during 
systole when the ventricle is contracting and then closes during diastole as the 
ventricle relaxes. The mean aortic pressure of a healthy human is 100 mmHg (Guyton 
and Hall, 2006), whereas diastolic pressure in the aorta is approximately 70 mmHg 
(Malamed, 2007). A physiological, time-dependent aortic pressure waveform inside 
the aortic heart valve root, ventricular pressure waveform experienced by the leaflets 
and a consistent transvalvular pressure drop (ΔP) to the closed leaflet surfaces 
respectively is shown in Figure 7.1 (a) and (b). Therefore, the first criterion of the 
fatigue tester was that it should be able to operate over a transvalvular pressure of 
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100 mmHg at a physiological heart rate range of 60–120 bpm for adult and children 
(Chirakanphaisarn et al., 2018).  
To mimic physiological pressure conditions, the pressures at the entrance 
(inflow) and exit (outflow) of the test valve needed to be able to be tuned to the 
mean transvalvular pressure difference (ΔP) found in humans (Figure 7.2). Also the 
arterial wall has elastic and viscous properties and their difference reflects the time-
dependent response of the stress–strain relationship (arterial pressure–arterial 
diameter changes). Therefore, in addition to ΔP a pressure across the wall (outflow 
pressure) of the heart valve root needed to be able to be tuned to mimic pressure-
diameter function.   
A real time wear tester (RWT) was purchased from Vivitro Systems Inc, Victoria 
BC, Canada to test biological heart valve roots under physiological test conditions. 
The characterisation and validation of the new equipment was required in order to 
verify that it met the requirements of the user and that it was able to function 
reliably. 
 
Figure 7.2 Inflow and Outflow Pressures in the Heart Valve Root 
Developing the method to investigate the fatigue and durability of the biological 
heart valve roots under real time physiological test conditions was one of the most 
novel aspects of this research. An overview of the process used for the method 
development is given in Figure 7.3. The RWT was designed predominantly for frame 
mounted heart valves so required modification to test biological heart valve roots. 
The development involved characterisation and validation of the RWT, and 
developing an in-house protocol for the real time fatigue and durability testing of 
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biological heart valve roots with the simulation of human physiological and systemic 
pressure conditions.  
 
Figure 7.3 Flowchart of the Method Development Process to Investigate the 
Fatigue and Durability of Biological Heart Valve Roots 
7.2 Aim and Objectives 
The aim of this chapter was to develop a test method to predict fatigue and 
durability of biological heart valve roots under cyclic physiological test conditions. 
The specific objectives were: 
1. To characterise and validate the RWT with a tilting disc mechanical heart valve 
2. To design a biological heart valve root holder 
3. To modify the RWT, so that it could be used for testing the biological heart 
valve roots 
4. To establish a method for real fatigue and durability testing of biological heart 
valve roots in the RWT 
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7.3  Materials and Methods 
  Mechanical Valves 
 
Figure 7.4 Tilting Disc Mechanical Heart Valve 
Three 25 mm tilting disc mechanical heart valves (Figure 7.4) were used for 
characterisation and validation of the RWT due to easier and faster 
mounting/dismantling in the RWT; and to get consistent, repeatable and 
reproducible results.  
  Cellular and Glutaraldehyde Fixed Porcine Aortic Heart Valve Roots 
Cellular and glutaraldehyde fixed porcine aortic heart valve roots were used for 
both the initial method development stage and as a control to understand any 
potential confounding mechanical factors in the system  which were likely to affect 
the biological root testing. Also these heart valve roots were included in the study as 
the “control” against which all the other types of heart valve roots were compared. 
It was decided to use aortic heart valve roots because they are well supported with 
thick myocardium, easy to handle and larger in size than pulmonary heart valve roots. 
Also pulmonary heart valve roots have an arch whereas aortic heart valve roots are a 
straighter tubular shape, so it was more practical to use aortic heart valve roots for 
method development. The geometry of the fixed heart valve roots make the roots 
easier to mount and the inert characteristics help to extend handling time and thus, 
the root holder design could be checked more easily. The fixation procedure is 
described in Chapter 2 Section 2.4.2.  
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7.4 Real Time Wear Tester (RWT) 
Fundamentally the RWT is intended for the use of durability assessment of 
prosthetic valves under various types of time dependent waveforms (sinusoidal, non-
sinusoidal, square, triangle etc).  
 
Figure 7.5 Real Time Wear Tester 
The real time wear tester consisted of a positive displacement SuperPump with 
control system (Vivitro Systems Inc, Victoria BC, Canada), a Perspex tank, silicone 
tubing and pressure measurement system (Vivitro Systems Inc, Victoria BC, Canada) 
(Figure 7.5). The RWT was monitored by HiTest software (Vivitro Systems Inc, Victoria 
BC, Canada). The tank was divided into two chambers, the inflow chamber attached 
to the piston with a metal bellow. The outflow chamber was open to the air. The RWT 
allowed the mounting of six test valves between the inflow and outflow chamber.  
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Figure 7.6 Basic Working Principle of the RWT (a) Backward Piston Stroke 
Closes the Test Valve (b) Forward Piston Stroke Opens the Test Valve 
Figure 7.6 (a) and (b) shows the basic principle of the RWT which can be 
explained as follows: The piston motion was designed to control with physiological 
input waveforms. When the piston stroke travels backwards (moves away from the 
test valve), the metal bellow expands, a volume of test solution is drawn into the 
inflow chamber through the test valve and closes the valve leaflets [Figure 7.6 (a)]. 
On the forward piston stroke, the test solution is expelled, the metal bellow 
compresses and opens the test valve [Figure 7.6 (b)]. The RWT comprised of a one-
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way adjustable bypass valve to control the inflow pressure and negative back 
pressure on the test valve. 
The functionality of the bypass valve will be discussed later in the chapter. In 
summary, the RWT was designed on the principle of dynamic pressurisation, where 
valve closure occurs during the closed part of the input waveform and applied 
negative pressure on the test valve as measured by inflow pressure transducer P1 
[Figure 7.6(a)]. During the open part of the input waveform, the piston moved 
forward and opened the test valve Figure 7.6 (b). The pressure measured by outflow 
pressure transducer P2 [Figure 7.6 (b)] was approximately zero. Therefore, the 
pressure across the closed valve (transvalvular pressure difference ΔP) was similar to 
inflow pressure P1 (Figure 7.7). 
 
Figure 7.7 Negative Pressure in the Inflow Chamber Measured by Inflow 
Pressure Transducer P1 at 60 bpm 
One cycle at a heart rate of 60 bpm lasts for one second, during which time 
2000 data points are collected by the inflow pressure transducer in the RWT (Figure 
7.7).  
7.4.1.1 SuperPump and Pump Controller 
The SuperPump (AR Series, Vivitro Systems Inc, Victoria BC, Canada) was a 
digitally controlled microprocessor based piston-in-cylinder pump that creates 
physiological cardiac flows. The complete SuperPump system included a digital 
amplifier with stroke volume and cycle count display, pre-programed waveforms, and 
inter-connecting cables. The amplifier had capacity to store five programmable 
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physiological waveforms at different heart rates ranging from 30 to 200 bpm. The 
stroke volume in terms of percentage gain (amplitude) of the waveforms was 
controllable by an amplitude controller on the amplifier. 
7.4.1.2 Tank Assembly 
There were six equally spaced stations (numbered 1 to 6) for mounting the test 
valves housed in the tank (Figure 7.8).  
 
Figure 7.8 Real Time Wear Tester with (a) Side View (b) Front View with one 
Mechanical Valve in Station 4 and five Stations blanked off (C) Tank Assembly with 
one Mechanical Valve in Station 4 and five Stations blanked off and Bypass Valve 
Adjustment (Front View)  
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The tank was divided into two chambers: the inflow chamber was a closed 
chamber attached to the pump through a metal bellow and a piston; and the outflow 
chamber was open to the air as shown in Figure 7.6. Approximately 31 litres of test 
fluid was required to fill the tank. The tester had a pressure controlled one way 
bypass valve between the two chambers to regulate the fluid flow (a valve that opens 
only with forward or reverse flow) as shown Figure 7.8.  
The bypass valve had flexible rubber diaphragms which moved in the direction 
of the flow and were attached to fluid restriction passageways (Figure 7.9). Flow in 
the reverse direction deflected the diaphragms backwards, allowing free passage of 
the test fluid in the inflow chamber [(Figure 7.10 (a)] and the amount of test fluid 
passing into the inflow chamber was dependent on the opened/closed percentage of 
the fluid restriction passageways. 
 
 Figure 7.9 Bypass Valve Assembly 
To adjust the fluid restriction passageway, the bypass valve consisted of a 
stainless steel shaft, which could be rotated clockwise or anticlockwise with a 
wrench, as shown in Figure 7.8. Conversely, flow in the forward direction closed the 
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diaphragms, therefore closing the fluid restriction passageways completely [Figure 
7.10 (b)].   
 
(a) 
 
(b) 
Figure 7.10 Working Principle of the Bypass Valve showing Movement of 
Rubber Diaphragms with Flow in (a) Reverse and (b) Forward Directions 
7.4.1.3 Valve Holder 
There were six valve holders in total, these were the original holders of the RWT 
which were designed to work with standard mechanical heart valves or frame 
mounted bioprosthetic heart valves (Figure 7.11). Each valve holder had four 
thumbscrews and a retaining ring for test specimen mounting and dismantling. The 
default configuration for the test valve to open was towards the front of the tank as 
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shown in Figure 7.11. The valve holder had a threaded flange, so it was easy to install 
or remove from the valve stations.  
A silicone mounting mould (Figure 7.11) was supplied with the valve holder and 
could be used to seal the appropriate boundaries between the valve specimen and 
the valve holder. 
 
Figure 7.11 Standard Valve Holder (Side View), Image Adapted from Vivitro 
Systems Inc, Victoria BC, Canada Manual  
7.4.1.4 Pressure Measurement Instruments and Data Acquisition 
The RWT had two Vivitro pressure transducers (Vivitro Systems Inc, Victoria BC, 
Canada) to measure the inflow and outflow chamber pressures. The inflow pressure 
can be described as valve closing pressure or back pressure on the valve and the 
outflow pressure can be described as the aorta pressure. Both pressure transducers 
were connected to the amplifier. 
To collect output test data, the RWT was connected with a 16 bit analogue to 
digital Vivitro I/O module. The output data consisted of test set up information (valve 
details, targeted pressure) and raw pressure (inflow and outflow) measurements for 
any of the captured cycles during the test. The recorded data was processed using 
HiTest software (Vivitro Systems Inc, Victoria BC, Canada). The HiTest software 
consisted of various programs allowing; calibration, analysis, individual valve display, 
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data acquisition and results panel (Figure 7.12). The results panel showed live data 
regarding pressure values as follows: 
 Targeted pressure boundary (Targeted or defined transvalvular pressure 
difference ΔP mmHg): this value showed the predefined transvalvular pressure 
value across the closed test valve. For an aortic heart valve root the target 
transvalvular pressure difference was 100 mmHg.  
 Mean peak differential pressure (mean transvalvular pressure): this value 
monitored the mean transvalvular pressure value across the closed valve during 
the test procedure by calculating the difference between inflow and outflow 
pressure.  
During the closed part of the cycle, due to expansion of the metal bellow, 
a large negative inflow pressure was generated and closed the valve leaflets. 
Consequently, the mean transvalvular pressure was negative. 
 % All peak pressure meeting target: this value monitored percentage of test 
cycles achieving the targeted peak transvalvular pressure (ΔP) across the closed 
valve during testing [As per ISO 5840 (2015), the defined transvalvular pressure 
value across the closed valve (ΔP) should be maintained for 95% or more of all 
test cycles and must be maintained for at least 5% of the test cycle duration] 
 Mean % of cycle time meeting target: this value monitored percentage of each 
cycle achieving the minimum peak transvalvular pressure across the closed valve 
during testing [As per ISO 5840 (2015), at least 5% of each cycle, the transvalvular 
pressure value (ΔP) across the closed valve must be at least at the defined 
transvalvular pressure] 
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Figure 7.12 The HiTest Software Process Display 
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7.4.1.5 Data Analysis 
The inflow and outflow data was analysed by HiTest software for 10 
consecutive cycles. The difference between the inflow and outflow pressure was the 
transvalvular pressure, this was automatically calculated by the software and saved 
in Microsoft Excel. Graphs were plotted in Microsoft Excel for inflow, outflow and 
transvalvular pressures. 
7.5 Terminology and Conditions Used During Characterisation, Validation and 
Method Development 
 
Figure 7.13 Constant Amplitude Sine Wave (S50) with 50% Systolic and 50% 
Diastolic Phase  
Amplitude (Gain):  As shown in Figure 7.13 the input sine waveform was 
characterised by the parameters of amplitude and frequency. The peak amplitude 
Samp represented the maximum forward or backward displacement of the piston and 
hence maximum volume of test fluid displaced by the piston during the positive or 
negative part of the input cycle (sine wave). The amplitude of the input waveform 
was adjusted in terms of percentage of Samp with the amplifier controller and the 
value was presented as a percentage of maximum amplitude (Samp). 
Frequency: The frequency (f Hz = heart rate (bpm)/60) of the input waveform 
was adjusted as per the test requirement. 
% Bypass Valve Closing:  The RWT tank had a pressure controlling bypass 
(Figure 7.8). The detailed working principle of the bypass valve is explained in Section 
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7.4.1.1. As shown in Figure 7.14, visually 50 % of the fluid restriction passageways 
could be closed to control test fluid flow and pressure in the RWT. 
 
Figure 7.14 Schematic showing Fluid Restriction Passageways of Bypass Valve 
Visually 50 % Closed Configuration  
 In all tests, in this chapter the test solution was 0.9 % w/v saline and input 
waveform was a sine wave (S50) (Figure 7.13). The RWT was allowed to run for 30 
min for each test to ensure that a steady state had been reached. 
7.6 Approach to Characterisation and Validation of the RWT 
The RWT was purchased specifically for this research. It was manufactured by 
Vivitro Systems Inc, Victoria BC, Canada and therefore little was known about the 
equipment and testing procedure. This led to a need for the tester to be 
characterised, validated and calibrated. A characterisation and validation of the RWT 
was conducted using the assumption that it was designed for frame mounted valves. 
Part of the validation procedure involved controlling closing pressure of the standard 
tilting disc mechanical heart valve and measuring transvalvular pressure across the 
valve.  
 Mounting of Tilting Disc Mechanical Heart Valves in the RWT 
To validate the RWT and ensure the output was accurate, a simplified 
sinusoidal input waveform (Figure 7.13) and tilting disc mechanical valves were used, 
the remaining stations were blanked off. Circular 43 mm diameter blanking plates 
were designed and manufactured to blank off the other five valve stations as shown 
Figure 7.15 (a). The blanking plate had a peripheral o-ring seal [Figure 7.15 (b)]. Upon 
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ensuring the attachment of the mechanical valve to the holder [Figure 7.15 (c) and 
(d)], the whole device was secured into the RWT and inflow and outflow pressure 
transducers were mounted as shown in Figure 7.8 (a) and (b). 
 
Figure 7.15 (a) Blanking Plate Sealed in the Valve Holder (Top View) (b) 
Blanking Plate (c) A Tilting Disc Mechanical Heart Valve Mounted in the Valve 
Holder (Top View) (d) A Tilting Disc Mechanical Heart Valve Mounted in a Delrin 
Fixture (Looking from Inflow Side) 
 Pressure Transducers Calibration 
In order to collect accurate pressure data from the tester, the pressure sensors 
had to be calibrated before any experiment was conducted. Part of the calibration 
and characterisation of the tester had to be carried out simultaneously. 
 Before the start of the test, the pressure transducers were calibrated. Both 
pressure transducers were initially zeroed by keeping them open to the atmosphere 
until the software read zero and then both were assigned with the corresponding 
voltage, approximately 0 volt. A pressure of 200 mmHg was then applied until the 
software assigned the corresponding voltage, approximately 7 Volts. Following this 
procedure, the HiTest software automatically calculated and stored calibration values 
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in mV/mmHg. Once the calibration process was completed, the software prompted 
the user to measure the static head zero offset values for the pressure sensors. 
 Pressure Tuning 
The pump controller was designed with a rotary encoder to determine 
acceleration, and that combined with the precision glass cylinders produced the 
stroke volume. However if there are any constraints present such as narrow tubing 
or a variation in heart valve diameters the pump could slow down due to an internal 
current limit which is part of the pump controller feedback loop. Hence, the 
characterisation and validation of the RWT was performed using the pressure 
measurement across the test valve as opposed to the measurement of piston 
displacement or stroke volume. 
Table 7.1 Test Plan for the Evaluation of Pressure Controlling Mechanism in 
the RWT 
Input 
Conditions 
Variables Case 1 Case 2 Case 3 Case 4 
S50 Sine 
Wave 
 
Heart Rate 
1) 60 bpm 
2) 120 bpm 
3) 200 bpm 
120 bpm  120 bpm  120 bpm  
Amplitude 
50 % gain 75 % gain 1) 25 % gain 
2) 50 % gain 
3) 75 % gain 
25 % gain 
Bypass 
Valve 
50 % gain 1) 25 % 
closed  
2) 50 % 
closed 
50 % Closed 100 % 
(fully) 
closed 
Number of 
Specimens 
(tilting disc 
mechanical 
heart valve) 
One One  One 1) One 
2) Three 
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The FDA (2010)and ISO 5840 (2015) standards require that a minimum peak 
transvalvular pressure of 90 mmHg must be established on the closed aortic valve 
and should be maintained for 95 % or more of all test cycles during durability testing. 
As described in Section 7.4.1.4, the HiTest software had the capability to measure 
peak transvalvular pressure and monitor how much percentage peak transvalvular 
pressure was meeting the target during the operation of the RWT. However, the 
controlling mechanism to adjust desired transvalvular pressure across the closed 
valve needed to be evaluated to establish a method for RWT pressure tuning, as no 
previous data was available with the RWT. Therefore, to understand the pressure 
controlling mechanism in the RWT, a transvalvular pressure difference was recorded 
with different combinations of variables as described in Table 7.1. The transvalvular 
pressure data were acquired using the HiTest software for 10 consecutive cycles and 
saved to Microsoft Excel.  
Case I: Variable Heart Rate, Fixed Bypass Valve, Fixed amplitude and Fixed Number 
of Specimens 
To begin with the heart rate was adjusted to 60 bpm (1 Hz) with the bypass 
valve and the sine wave amplitude (gain) adjusted to 50 % to assess the operational 
performance of the RWT. This procedure was repeated at 120 bpm (2 Hz) and 200 
bpm (3.3 Hz), keeping all other conditions the same.  
Transvalvular pressure waveforms were generated for the different heart 
rates and each of the three generated waveforms corresponded to the piston 
movement (Figure 7.16).  
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Figure 7.16 Transvalvular Pressure across Tilting Disc Mechanical Heart Valve 
at Heart Rate (a) 60, (b)120 and (c)200 bpm 
The outflow pressure was close to zero for all the tested conditions, as the valve 
opened to the outflow chamber, which was opened to the air. Therefore, the 
transvalvular pressure waveforms were similar to the inflow pressure waveforms. 
There was a maximum pressure (negative) spike when the valve was closed and a low 
level of positive spike in pressure when the valve was open producing forward flow. 
The results also showed that the valve was fully closed 1, 2 and 4 times with heart 
rate 60, 120 and 200 bpm respectively in 1 second as shown in Figure 7.16. 
Case 2: Variable Bypass Valve, Fixed Heart Rate, Fixed amplitude and Fixed 
Number of Specimens 
One tilting disc mechanical heart valve was mounted in the RWT as described 
in Section 7.6.1. The sine wave was adjusted for a frequency of 2 Hz (heart rate 120 
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bpm) and amplitude of 75%. Transvalvular pressure waveforms were obtained for 
the flow bypass valve set at 25 % and 50 % closed as shown in Figure 7.17.  
The transvalvular pressure waveforms demonstrated that there was a higher 
negative pressure drop for the 50 % bypass valve closed than the bypass valve 25 % 
closed, whereas positive pressures were same for both conditions. This means that 
the percentage amount of bypass valve closing affected the transvalvular pressure 
across the closed valve (negative pressure) but not across the opened valve (positive 
pressure). 
 
Figure 7.17 Transvalvular Pressure across one Tilting Disc Mechanical Heart 
Valve for Different Bypass Valve Conditions 
Case 3: Variable Amplitude, Fixed Heart Rate, Fixed Bypass Valve and Fixed 
Number of Specimens 
The RWT with one tilting disc mechanical heart valve was set to 120 bpm heart 
rate and 50 % bypass valve closed. The transvalvular pressure waveforms were 
obtained for 25, 50 and 75% amplitude (gain) (Figure 7.18). 
These transvalvular pressure waveforms showed that there was an overall 
higher pressure drop (positive and negative) across the valves for the higher 
amplitude value. Therefore, the pressure across the closed and opened valve was 
increased with increments in the amplitude value of the input sine waveform. 
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Figure 7.18 Transvalvular Pressure Difference across one Tilting Disc 
Mechanical Heart Valve for Different Amplitude Conditions     
Case 4: Variable Number of Specimens, Fixed Heart Rate, Fixed Amplitude and 
Fixed Bypass Valve 
A sensitivity analysis to investigate the impact of varying the number of test 
specimens on the inflow pressure of the test valves was carried out. The RWT had six 
equally spaced stations numbered 1 to 6 (Figure 7.8), these were not independent in 
that they had common inflow and outflow. Therefore, it was important to understand 
the effect of the number of test specimens on the system pressures, especially the 
inflow pressure.  
 
Figure 7.19 Transvalvular Pressures Difference across Tilting Disc Mechanical 
Heart Valve 
To investigate this, a valve holder with a tilting disc mechanical valve was placed 
in station 5 and five valve holders with blank plates were placed in all other stations. 
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The heart rate was adjusted to 120 bpm with the bypass valve fully closed and the 
gain was adjusted to 25 %. Following that the pressure data was captured for ten 
consecutive cycles. This procedure was repeated for three tilting disc mechanical 
valves mounted in stations 1, 3 and 5 and blank plates in stations 2, 4 and 6, by 
keeping all other test conditions the same as before. By inserting the valves in this 
manner even loading of the tester was achieved. The transvalvular pressure 
waveforms were captured for both cases as shown in Figure 7.19. 
The negative part of the inflow pressure represented valve closing and valve 
closed pressures and the positive part of the inflow pressure represented valve open 
pressure. The valve closed pressures were the same in both cases. However, the 
outflow positive pressures were different in both cases but less than 10 mmHg as 
there was nothing to restrict flow on the outflow chamber and the outflow chamber 
was open to the air. Hence the transvalvular pressure across the closed valve was 
approximately the same as inflow pressure. In summary, the increment in the 
number of test specimens did not affect the inflow closed pressure and hence 
transvalvular pressure on the closed valve. All test valves experienced the same 
transvalvular pressure when they were fully closed. 
 Discussion and Conclusions Following Characterisation and Validation of the 
RWT  
The RWT was tested with a tilting disc mechanical heart valve to understand the 
operation of the RWT and to verify consistency and repeatability to control 
physiological test pressure.   
The following observations and conclusions were made during this study: 
 An important aspect of the RWT from this data was verified, that the piston 
moved a shorter distance as the frequency increased. This was most likely due to 
the pump trying to “keep pace” at higher frequencies meaning that if it moves a 
shorter distance, it can move at a faster rate. As the frequency increased, systolic 
duration decreased and as stroke volume increased, volumetric flow rate also 
increased. The tester also naturally increased pressure as the frequency increased 
and this allowed the piston to move a shorter distance while still maintaining the 
correct pressure measurements. 
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 The amplitude dial set the drive level of the piston in terms of percentage gain, 
which increased or decreased the peak to peak movement of the piston, and thus 
the pressures. The amplitude control was used as a tool for setting the 
transvalvular pressure only, and not the piston displacement. The relationship 
between the amplitude control number (percentage gain) and the test pressures 
or the piston displacement was not absolute but dynamic, as it depends on 
several factors, including frequency (heart rate), bypass valve settings, type of the 
valves, and biological variation between the heart valve roots under test.  
 Due to the lack of flow probes in the RWT, cardiac output relied on the metal 
bellow size and piston displacement. The piston waveform (input waveform) was 
scaled by frequency and piston displacement, in order to achieve physiological 
valve opening and closing. The amplitude of the piston waveform was adjusted 
to the length of the displacement of the piston and hence the volume of fluid 
being displaced. During the positive portion of the input waveform, the positive 
upstroke forces compressed the metal bellow, moved the test fluid forward and 
opened the test valve. During the negative or depressurisation portion of the test 
cycle, i.e., that portion of the input waveform having negative percentage 
amplitude values, expanded the metal bellow, the flow was reversed and the test 
valve was closed. As the negative portion of the cycle began, the fluid moved 
through the bypass valve into the inflow chamber. During return flow, the test 
valve remained closed due to the flow reversal and transvalvular pressure present 
between the inflow and outflow chamber. The pump drive system returned to its 
starting position and the process was repeated, cyclic opening and closing of the 
test valve. 
 Transvalvular pressure waveforms were influenced by the heart rate (frequency) 
of the input waveforms. The transvalvular pressure waveforms showed that, 
during the specific amount of time t (Figure 7.16), the tilting disc mechanical heart 
valve was fully closed and opened 5, 3 and 1 times for frequency 3.33, 2 and 1 Hz 
respectively. This explained that the valve stayed closed for a long period of time 
at a specific transvalvular pressure for the lower frequency compared to the 
higher frequency. 
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 The RWT was designed to control the back pressure acting on the test valve as a 
primary variable. The input sine waveform controlled the negative pressure for a 
desired duration while limiting a peak reverse pressure on the valve. The bypass 
valve helped to control the excessive negative pressure on the valve. 
A pressure tuning process across the test valve which involved making 
systematic adjustments to the amplitude of the input waveform and the flow bypass 
valve setting was developed. Figure 7.20 shows representative waveforms obtained 
during the process to achieve full opening and closing of the mechanical test valves 
(n=3) and simultaneously controlling transvalvular pressure across the closed valve 
by adjusting the closing of the bypass valve and amplitude of the input waveforms. 
 
Figure 7.20 Transvalvular Pressure Waveforms Obtained for Different Bypass 
Valve Setting and Amplitude Values 
The following sequence for RWT Pressure tuning was established for start of 
each test:  
1. Initially the flow bypass valve was kept fully opened.  
2. The opening of the test valve was monitored and the amplitude was increased 
until full valve opening was achieved.  
3. The targeted transvalvular pressure was adjusted by closing the bypass valve. 
4. If opening was excessive, amplitude was reduced and the bypass valve was 
readjusted for targeted transvalvular pressure.  
5. If opening was insufficient, amplitude was increased and the bypass valve was 
adjusted for targeted transvalvular pressure.  
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6. The inflow pressure of the RWT was independent of the number of test 
specimens used. 
 Summary 
In summary, the pressure waveforms helped to characterise the RWT and set it 
up to work correctly. It was essential to maintain physiological pressures during the 
testing. To achieve this it was important to understand or establish a pressure tuning 
technique in the RWT, which was discussed in Section 7.6.4. Selecting appropriate 
specimens for the method development was paramount. The method development 
should start with the minimum number of specimens to keep the procedure simple. 
The RWT was designed to test a maximum of six specimens, therefore it was essential 
to determine the impact of varying test specimens, which was discussed in Section 
7.6.3. 
7.7 Method Development Approach for Testing Biological Heart Valve Roots.... 
Before beginning the method development for biological heart valve roots, four 
initial questions were asked and addressed as described in Table 7.2. 
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Table 7.2 Specifications for Initial Method Development 
Question Answer 
What will be the intended outcome of 
the method? 
A robust method to assess fatigue and 
durability of biological heart valve roots 
under physiological test conditions 
What types and sizes of the biological 
heart valve roots will be used for 
method development? 
Cellular and fixed porcine aortic heart 
valve roots with valve size 21 ± 2 mm 
How many test specimens will be used 
for method development? 
Minimum three test specimens  
What will be the intended test 
conditions? 
Frequency: 1, 2, 3.3 Hz 
Transvalvular pressure across the valve: 
100 ± 20 mmHg - should be maintained 
for 95% or more of the test cycles 
Pressure in the aorta: 70 ± 20 mmHg 
Temperature: Ambient temperature 
Valve dynamics: Valve open fully and 
closed completely 
 
7.8 Method Development: Real Time Fatigue Testing of Biological Heart Valve 
Roots……….. 
When received from the manufacturer, the RWT had holders to mount frame 
mounted valves only, but these frame mounted bioprosthetic or mechanical valves 
differ significantly from that of biological heart valve roots. As the main intention was 
to test biological heart valve roots in the RWT, it was essential to design a new holder 
or modify the existing holders. It was decided to use fixed aortic heart valve roots 
during the initial method development stage to understand any potential 
confounding factors that may occur during biological heart valve root testing. The 
fixed heart valve roots were chosen due to longer and easy handling characteristics 
and thus, the valve holder design could be more easily examined.  
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  Design Specification for Heart Valve Root Holder 
In order for the tester to be used with biological heart valve roots, valve holders 
had to be designed and manufactured that would fit into the test space provided and 
that would also accommodate the root wall and myocardial muscles along with the 
leaflets and annulus. Before designing the holders for the heart valve roots, a number 
of important parameters were acquired from the characterisation work, validation 
tests with mechanical valve (Section 7.6) and the literature part of the thesis (Chapter 
1). These parameters, together with additional factors considered necessary to 
design the holder for the heart valve root, have been described in the design 
specification in Table 7.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
214  
Chapter 7 
Table 7.3 Heart Valve Root Holder Design Specification 
Criteria Essential= E 
Desirable=D 
Target 
Design 
Robust E Should work with heart rate 60-200 bpm 
E Should work with maximum 37 °C temperature  
E 
 
Can be used with test solution (0.9 % w/v saline, 0.04 
% sodium azide solution) 
Modular 
 
 
 
D 
 
Easy aortic heart valve root mounting (maximum 
mounting time 5 min, one user able to complete 
without assistance) 
E Simple design 
E Ease of use 
Simplicity  D Maximum number of parts 5 
D Easy to manufacture 
Enable valve 
visualisation 
E 
High speed video will be used to assess leaflet 
dynamics 
Easy to clean 
Attributes 
E Less bacterial growth, sterilisable 
E Light weight and low cost  
Performance 
Pressure  E 
 
Transvalvular pressure: 100 ± 20 mmHg 
Pressure in the aorta: 70 ± 10 mmHg 
size  
E 
22 ± 2  mm  diameter of valve with aorta with 
maximum length 70 mm 
Movement 
D 
Axial and circumferential heart valve root wall 
maximum movement to 10 mm  
Measurement Capability 
Pressure E Inflow and outflow pressure near the test valve 
 
215  
Chapter 7 
7.8.1.1 Conceptual Designs for the Heart Valve Root Holder 
The design of the heart valve root holder began with a conceptual design stage 
in which three conceptual modular designs for the heart valve root holder were 
generated and are presented in Figure 7.21. The designs varied in heart valve root 
mounting techniques and suitability for use in RWT but all had the potential to 
function successfully.   
 
(a) 
 
(b) 
 
(c) 
Figure 7.21 Conceptual Designs for the Heart Valve Root Holder (a) Design 
involved Sandwiching of Myocardium between the Two Flanges and Attaching 
Aorta to the Spigot with Cable Tie (b) Design involved Suturing of Myocardium and 
Aorta onto the Spigots (C) Design involved Attaching Myocardium and Aorta on to 
the Spigots with Cable Ties  
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7.8.1.1.1 Design 1 
Design 1 (Figure 7.21 (a)) used two spigots connected with three connecting 
rods. The myocardial (muscle) side of the heart valve root could be sandwiched 
between the two flanges and attached to the spigot. The wall could be attached to 
the other spigot with cable ties. However, it was thought that problems may arise as 
a myocardium might get damaged due to the clamping pressure of the two flanges. 
The design may have a relatively low reliability due to heart valve root damage during 
the mounting and the number of parts involved. 
7.8.1.1.2 Design 2 
This design (Figure 7.21 (b)) was based on suturing of the heart valve root onto 
the spigots. This design would be relatively robust because of the lack of any axial 
movement. The reliability of the design would depend largely on the suturing 
technique to mount the heart valve root on spigots and the type of suture and needle 
used to make it. Repeated expansion and contraction in a cyclic environment may 
cause leakage from the suturing line. This design would require a higher level of skill 
than the previous designs due to the required mounting technique (suturing) of the 
heart valve root on the spigots. In addition, this design may require a longer time to 
mount the heart valve root on the spigots. 
7.8.1.1.3 Design 3 
This design consisted of two spigots with two connecting rods. The wall and 
myocardial of the heart valve root was attached to the spigots with cable ties (Figure 
7.21 (c)). The wall side spigot was free to slide axially on the connecting rods. This 
was the simplest of all the conceptual designs. 
7.8.1.1.4 Concept Screening 
The proposed concepts were examined, evaluated and filtered with respect 
to the design objectives, the concept design closest to meeting the design 
specification was determined prior to proceeding with further optimisation. All the 
conceptual designs were scored out of 5 for each criteria, compared and ranked on 
the basis of the features listed in Table 7.4. 
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Table 7.4 Concept Screening and Ranking 
Selection Criteria Ideal score Design 1 Design 2 Design 3 
Easy heart valve root 
mounting 
5 2 1 5 
Simplicity of design 5 2 3 4 
Ease of use 5 2 2 5 
Number of parts 5 3 4 4 
Cost Suitability 5 4 2 4 
Easy to manufacture 5 2 4 5 
Final Score 30 15 16 27 
Rank  3 2 1 
 
The final design selected was design 3. Design 3 ranked highest; hence closest 
to meet the design specification due to the simplicity in the design and heart valve 
root mounting. The cable tie heart valve root mounting technique had been used in 
other experimental techniques (competency testing, pulsatile flow testing, dilation 
testing) and was a proven reliable concept. 
7.8.1.2 Detailed Heart Valve Root Holder Design  
The detailed design and 3D model, based on the conceptual design was created 
for the heart valve root holder using SolidWorks (Dassault Systèmes, Waltham, MA, 
USA). The engineering drawings used to manufacture the holder are presented in 
Appendix C. 
The heart valve root holder design comprised of two spigots, connected and 
supported by two connecting rods. One spigot was connected with the threaded 
valve holder flange from the original valve holder, and the other spigot slid axially on 
the two rods. In order to test the valve performance the inflow and outflow pressure 
from the heart valve root needed to be measured. For this 1/8“ British Standard Pipe 
(BSP) stainless steel push in fittings were assembled into the sliding spigot and the 
output pressure transducer was connected as shown in Figure 7.22.  
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Figure 7.22 Heart Valve Root Holder for Biological Heart Valve Root with 
Pressure Measurement Assembly 
7.8.1.3 Heart Valve Root Holder Feasibility Test  
The aim of the valve holder feasibility test was to check the design stability and 
the amount of time required to mount the heart valve root in the holder. A total of 3 
porcine aortic roots were fixed in glutaraldehyde as described in Chapter 2. The fixed 
heart valve roots were mounted on the holder with cable ties as shown in Figure 7.23.  
 
Figure 7.23 Representative Image of Heart Valve Root Mounting On the RWT 
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As described in Chapter 2 Section 2.4.7.3, a cable tie gun (part no: STHV, Panduit 
Europe Ltd) was used to tension and cut the cable ties. The cable ties were sufficiently 
tight to prevent axial movement along the spigot and stop them being pushed out 
under pulsatile flow conditions. The RWT was run for 30 min at various possible test 
conditions to check valve holder and root stability. It was found that the heart valve 
root holder and heart valve root mounting were appropriate and the valve was 
closing and opening fully for all the test conditions. 
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Figure 7.24 (a) Schematic Diagram showing Inflow and Outflow Pressures 
during the Porcine Aortic Heart Valve Root Testing in the RWT (b) Movement of the 
Aorta and the Valve Opening and Closing from the Outflow Side 
Following the successful trial with the fixed heart valve roots, 3 cellular porcine 
aortic heart valve roots were mounted on the same holders with cable ties (Figure 
7.23).  
The RWT was run for all possible test frequencies (1, 2 and 3.3 Hz). During this 
testing, a major issue was identified. The aorta was collapsing and it was difficult to 
view the valve closing from the outflow side (Figure 7.24). It was identified that the 
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sliding spigot had an orifice which allowed fluid flow to the outflow chamber, this was 
open to the air and thus not controlling the aorta pressure (Figure 7.25 (a)). Also the 
aorta pressure was less than 10 mmHg for all the tested conditions, which was much 
lower than physiological pressure and not enough to keep the aorta dilated. To 
resolve this problem, it was necessary to both modify the heart valve root holder 
design (Section 7.8.1.4) and the RWT itself (Section 7.8.2). 
7.8.1.4 Modified Heart Valve Root Holder Design 
The modification comprised of a viewing window made of Perspex fitted on the 
outer side to view and record valve dynamics. This also closed the orifice and 
maintained the pressure. The complete heart valve root holder assembly, including 
pressure measuring system, Perspex viewing window and spigots is presented in 
Figure 7.25 (b). 
 
Figure 7.25  (a) First version of Heart Valve Holder (b) Modified Heart Valve 
Root Holder for Biological Heart Valve Root Mounted in the RWT with Pressure 
Measurement Assembly 
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  Modification of RWT to Control Physiological Pressure of the Aorta during 
Fatigue Testing of Biological Heart Valve Roots  
The complex physiology of the left ventricle involves three-dimensional 
dynamic myocardial contraction, which cannot be mimicked with the inflow chamber 
of the RWT, and only involved application of a uniform and simultaneous pressure on 
the whole ventricle. Similarly, atrial contraction-expansion movement was absent, as 
the outflow (left atrium) chamber was open to air and not subject to any external 
load. Even though the heart valve root holder was modified, it was difficult to 
maintain the physiological test scenario in keeping the aorta dilated. The aorta of the 
human aortic heart valve root has mean pressure of 70 ± 20 mmHg. To compensate 
for this, compliance was added to the aorta by means of a vertical column, as shown 
in Figure 7.26.  
 
Figure 7.26 Physical Model Illustrating the Application of External Load 
(Pressure) on the Aorta by Attaching a Vertical Column 
The compliance chamber provided an external load (pressure) to the aorta and 
also an excess volume area for fluid to move into during the forward stroke or positive 
part of the cycle. 
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Figure 7.27 Schematic Diagram of Modified RWT  
All valve holders were connected to the vertical column (compliance chamber) 
via BSP push-in fittings, 3 way connectors and flexible tubing. The vertical column was 
filled with 75 % test solution, the top void contained air. A flange mounted analogue 
pressure gauge was mounted on top of the column. The pressure column of test fluid 
provided mean pressure to the atrial side of the heart valve root, which was 
connected to the moving spigot (Figure 7.27).   
7.8.2.1 Validation of Modified RWT  
In order to validate the modified RWT design, a test was run with cellular 
porcine aortic heart valve roots. Three cellular aortic heart valve roots were mounted 
on three modified heart valve root holders as per the procedure described in the 
section 7.8.1.3. Upon ensuring the attachment of the heart valve roots to the holders, 
the whole assembly was secured into the RWT. The holders with heart valve roots 
were placed in station 1, 3 and 5 (Figure 7.8). The remaining three stations (2, 4, 6) 
had valve holders with blanking plates (Figure 7.8).  
All the holders were connected to the compliance chamber via 1/8” BSP push-
in fittings, 3 way connectors and flexible tubing. The RWT’s tank was filled with test 
solution (0.9 % (w/v) saline with 0.04% sodium azide (v/v)). The compliance chamber 
was filled with 75 % test solution, the top void contained air. 
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Figure 7.28 Representative Pressure Waveforms Measured for Cellular 
Porcine Aortic Heart Valve Roots during Real Time Fatigue and Durability Testing   
The inflow and outflow pressure transducers were mounted as shown in Figure 
7.8. Both pressure transducers were calibrated as per the procedure described in 
Section 7.6.2. The RWT was run for 30 minutes for all possible test frequencies (1, 2 
and 3.3 Hz). The pressure tuning was performed as described in the section 7.6.4 to 
control transvalvular pressure across the valve (100 ± 20 mmHg) for at least 95 % of 
the test cycles. The generated pressure due to the addition of the compliance 
chamber was recorded with an analogue pressure transducer and it was 
approximately 75 ± 5 mmHg. This set-up enabled the aorta to remain inflated and to 
attain physiological pressure conditions as described in Table 7.2. The compliance 
chamber simulated the native compliance of the aorta by allowing it to contract and 
dilate depending on the fluid volume and without compliance here, the aorta was 
unnaturally collapsed (Section 7.8.1.3). This meant that the inflow negative pressure 
generated by the driving mechanisms was sufficiently dampened by the addition of 
the compliance chamber on the outflow side in the RWT. 
Representative pressure waveforms captured during the testing are displayed 
in Figure 7.28. Also, valve dynamics were captured using a high speed video camera 
which showed the valve fully opened and closed for all the applied test conditions.  
However, difficulties were encountered during the mounting of the heart valve 
roots. Due to limited space between two stations, it took an average 10 minutes to 
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mount each holder with heart valve roots in the RWT. It was also difficult to 
manipulate the heart valve roots once they were mounted in the RWT. Therefore, it 
was decided to redesign the blanking plates. 
7.8.2.2 Modification of Blanking Plates 
For easy manipulation of the heart valve roots in the RWT and to create space 
between two mounted holders in the RWT, the blanking plates (Figure 7.15) were 
modified. The new design consisted of a blank plate with o- ring seal, connected to 
the threaded flange from the existing valve holder (Figure 7.29).  
 
Figure 7.29 Blanking Plate Designs and Assemblies. Top: First Version of the 
Design. Bottom: Modified Design 
This new blanking plate design was slim, easy to mount and clean. A modified 
RWT with blanking plates is shown in Figure 7.30. 
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Figure 7.30 Modified RWT with Modified Blanking Plates 
  Summary of the Test Method: Fatigue and Durability Testing of Biological 
Heart Valve Roots in the RWT 
An in vitro real time fatigue and durability testing method for biological heart 
valve roots has been developed. The methodology included, heart valve root 
mounting in the RWT, controlling physiological pressure across the test root and 
associated processes to achieve the physiological valve dynamics. The main features 
of the method are summarised below. 
 The RWT was adapted for any type of biological heart valve roots.  
 Pressure and amplitude could be controlled and reproduced in the RWT.  
 The amplitude and bypass valve were adjusted in an attempt to set the 
maximum transvalvular pressure of 100 ± 20 mmHg for 95% or more of the test 
cycles, and the minimum transvalvular pressure was maintained for at least 5% 
of each cycle.  
 The outflow pressure (aorta pressure) value (70 ± 20 mmHg) was achieved by 
adding compliance on the wall side and the amplitude/bypass valve of the RWT 
was adjusted until the outflow waveform was correct. 
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 The test resulted in full opening and closing of the valve.  
 Compliance of the aorta was essential for modelling the dynamic system. This 
enabled the system to incorporate and vary the effect of arterial elasticity. 
7.9  Discussion and Conclusion Following Method Development for Biological 
Heart Valve Roots 
A RWT was purchased that was originally designed for testing standard frame 
mounted or mechanical valves. The RWT was validated and characterised in order to 
understand its behaviour and therefore determine a protocol so that it could be 
employed to test biological heart valve roots. A heart valve root holder was designed, 
optimised and manufactured to adapt the RWT for use with biological heart valve 
roots. The RWT is now understood and can be used for the testing of any type of 
biological heart valve root.  
The aortic valve is located between the left ventricular outflow tract and the 
ascending aorta in the heart. The complex in vivo left ventricular physiology that 
involves a three-dimensional dynamic myocardial contraction with ventricular 
twisting cannot be mimicked with the proposed RWT approach. Similarly, atrial 
contraction was absent, as the outflow side of the heart valve root was not subject 
to any external load and is only provided with a controlled filling pressure through 
the vertical column (compliance). Despite such constraints, results were satisfying 
both in terms of pressure wave morphology and numerical values. The transvalvular 
pressures and aorta pressures were in agreement with the expected values. 
The results demonstrated the proper functioning of the aortic valve with a 
hydrodynamic behaviour comparable to the in vivo conditions. The pressure 
waveforms were influenced by two main controls, which affected the overall 
behaviour of the test valve: the presence of the bypass valve between the inflow and 
outflow chamber, which has introduced local resistances and inertial effects and 
helped to control reverse (closing) pressure on the test valve.  
Due to the pumping mechanism, a large negative closing pressure was 
experienced by the test heart valve root which caused aorta occlusions. The design 
of the biological heart valve root holder and addition of compliance with vertical fluid 
column helped to control physiological pressure across the heart valve root. During a 
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forward piston stroke or positive part of the input cycle, test fluid was fed back to 
vertical column which added positive pressure in the aorta (outflow side) and 
regulated some of the negative inflow pressure.  
In summary, the result showed that the RWT can apply physiological test 
conditions and create forces on the heart valve leaflets, creating a controllable 
environment that will be necessary in the fatigue testing of biological heart valve 
roots.  
Having developed an in vitro real time fatigue method from this study using 
fixed and cellular porcine aortic heart valve roots, the method was further used for 
six cellular and six decellularised porcine aortic heart valve roots (Chapter 8).  
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 In vitro Real Time Fatigue Assessment of Cellular and 
Decellularised Porcine Aortic Heart Valve Roots 
8.1 Introduction  
The real time fatigue of cellular and decellularised porcine aortic heart valve 
roots under physiological cyclic pressures and heart rate conditions was evaluated in 
the real time wear tester (RWT) using the in vitro test methodology developed in 
Chapter 7. The real time fatigue of porcine aortic heart valve root leaflets was 
assessed by high speed camera imaging of the leaflet dynamics and through 
qualitative visual assessment at the end of fatigue assessment in the RWT. For a 
quantitative assessment of the fatigue of the cellular and decellularised porcine 
aortic heart valve roots, their hydrodynamic performance was evaluated under 
pulsatile flow following cyclic conditions in the RWT, and material properties 
evaluated through tensile testing. In addition, a competency test of heart valve roots 
was assessed at several intervals (pre-test, mid-test, post-test) to monitor the effect 
of cyclic loading on the leaflet competency and to eliminate sample to sample 
variability.  
This study comprised of a feasibility study followed by a primary study which 
fully investigated the effect of decellularisation on the in vitro real time fatigue of 
porcine aortic heart valve roots. The feasibility study was conducted to assess the 
efficiency and limitations of experimental test methods which included real time 
fatigue, pulsatile flow and uniaxial tensile tests.  
8.2 Aim and Objectives 
The aim of the study was to fully investigate in vitro real time fatigue of 
decellularised porcine aortic heart valve roots under physiological cyclic pressures 
and heart rate conditions and compare it with cellular porcine aortic heart valve roots 
to derive the effect of decellularisation. 
The main objectives were: 
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1. To determine real time fatigue, pulsatile flow performance and uniaxial tensile 
properties of the leaflets of cellular porcine aortic heart valve roots within 10 
consecutive days to evaluate feasibility and efficiency of the experimental 
methods and techniques.  
2. To determine and compare real time fatigue of the cellular and decellularised 
porcine aortic heart valve roots under physiological cyclic loading conditions 
[physiological pressures and heart rate (frequency)] in the RWT. 
3. To determine and compare the effect of physiological cyclic loading conditions on 
competency of the cellular and decellularised porcine aortic heart valve roots. 
4. To determine and compare the effect of physiological cyclic loading conditions on 
pulsatile flow performance of the cellular and decellularised porcine aortic heart 
valve roots following cyclic fatigue assessment in the RWT. 
5. To determine and compare the uniaxial tensile properties of the cellular and 
decellularised porcine aortic heart valve root leaflets following real time cyclic 
fatigue and pulsatile flow performance assessment. 
8.3 Study Experimental Design   
 
Figure 8.1 Flow Chart Indicating Cellular Porcine Aortic Heart Valve Roots In 
Vitro Performance Assessment Sequence used in the Feasibility Study  
Prior to undertaking a primary study on the decellularised porcine aortic heart 
valve roots to investigate fatigue under cyclic loading conditions, a feasibility study 
was conducted to learn about the possibilities and limitations of the experimental 
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test plan used to derive real time fatigue of cellular and decellularised porcine aortic 
heart valve roots. In addition, the test plan was used to check the practicability of 
experimental techniques, for example the stability of the aortic heart valve root for 
1.2 million cycles in the RWT, multiple mounting and dismounting of the heart valve 
root in the RWT and complexity of consecutive test procedures (real time fatigue, 
pulsatile flow and uniaxial tensile) within 10 consecutive days.  
The feasibility study was conducted using three cellular porcine aortic heart 
valve roots. The heart valve roots were assessed for in vitro real time cyclic fatigue, 
post-test hydrodynamic (pulsatile) and post-test biomechanical (uniaxial tensile 
properties of leaflets) performance within 10 consecutive days. The test plan for the 
feasibility study is shown in Figure 8.1. Pulsatile flow performance of the cellular 
aortic heart valve roots was not assessed prior to the fatigue assessment due to 
concerns of causing damage to the heart valve roots and also the complexity of the 
test.  In addition, pulsatile flow performance data for the cellular aortic heart valve 
roots is available in Chapter 3 for comparison. 
Following a review of the results and observations from the feasibility study 
described in the Section 8.6.1., the study plan was optimised and test conditions were 
refined to assess the effect of decellularisation on the fatigue of the porcine aortic 
heart valve roots (primary study) within 10 consecutive days. 
To minimise growth of contaminating bacteria and fungi during the fatigue 
assessment in the RWT, the cellular heart valve roots were treated with 150 ml 
Cambridge antibiotics and amphotericin B solution as per the procedure described in 
Chapter 2 Section 2.4.3 for the primary study. Also, to eliminate sample variability, a 
within-sample design (repeated measures) was accepted and competency 
assessment was added in the primary study test plan, whereby each aortic heart 
valve root was used as their own control for competency assessment. The 
competency (pre-test, mid-test and post-test) of the heart valve roots was measured 
three times to monitor the effect of cyclic loading conditions on the leaflet 
competency during fatigue assessment in the RWT (Figure 8.2). The advantages of 
the competency assessment method were being more straightforward and less time 
consuming than other biomechanical performance measurements. 
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Figure 8.2  Flow Chart Indicating Cellular and Decellularised Porcine Aortic 
Heart Valve Roots Performance Assessment Sequence used in the Primary Study  
The competency (pre-test) of each heart valve root was evaluated before 
fatigue assessment in the RWT. In sets of three, the heart valve roots were then 
cycled for 680,000 to 880,000 cycles (mid-test) at 120 bpm heart rate (2 Hz 
frequency) in the RWT to assess real time fatigue. Following fatigue, the heart valve 
roots were removed from the RWT for the competency assessment (mid-test). Then 
following competency, the heart valve roots were mounted straight back in the RWT 
for further fatigue testing. The fatigue test in the RWT was terminated at 1.2 million 
cycles and hydrodynamic performance [competency (post-test) and pulsatile flow] of 
each heart valve root was evaluated. Following evaluation of the hydrodynamic 
performance, biomechanical performance (uniaxial tensile) of the leaflets (radial and 
circumferential) from each heart valve root was evaluated.  
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8.4 Materials  
All the cellular porcine aortic heart valve roots were dissected from hearts 
obtained from M & C Meats, Crossgates, Leeds and John Penny & Sons, Rawdon, 
Leeds, UK. within 4 hours of slaughter.  
The decellularised porcine aortic heart valve roots were prepared by  Timothy 
Munsey and Dr Helen Berry in the Faculty of Biological Sciences (University Of Leeds) 
using an established low concentration sodium dodecyl sulphate (SDS) based 
decellularisation protocol (Booth et al., 2002, Korossis et al., 2005, Wilcox et al., 
2005).  
The heart valve root storage and defrosting procedures are described in 
Chapter 2 Section 2.4.4.  
Phosphate buffered saline (PBS) was used to store the heart valve roots in 
between tests and to keep them hydrated during testing.  
 Feasibility Study 
For the feasibility study, three cellular porcine aortic heart valve roots (A1, A3 
and A5) were dissected a day before testing and stored in 150 ml PBS at 4 °C until 
testing. The sizes (internal diameter) of all the cellular aortic heart valve roots were 
measured with obturators and they had a mean diameter of 21 ± 1 mm. 
The test solution used in the cyclic fatigue test was 0.9 % (w/v) saline. 
 Primary Study 
For the primary fatigue study, all the cellular porcine aortic heart valve roots 
were treated with 150 ml Cambridge antibiotics and amphotericin B solution as 
described in Chapter 2 Section 2.4.3 to minimise growth of contaminating bacteria 
and fungi during the fatigue testing in the RWT.  
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Table 8.1 Details of Cellular and Decellularised Porcine Aortic Heart Valve 
Roots Assessed Including Identification Number and Valve Size 
Cellular Aortic Heart Valve Roots Decellularised Aortic Heart Valve Roots 
Identification 
Number 
Valve Size 
(mm) 
Identification 
Number 
Valve Size 
(mm) 
Set 1 Set 1 
AC1 23 AD1 21 
AC2 23 AD2 20 
AC3 24 AD3 22 
Set 2 Set 2 
AC4 22 AD4 21 
AC5 23 AD5 22 
AC6 23 AD6 22 
  
All the cellular porcine aortic heart valve roots were stored in this 150 ml 
treatment solution and used immediately for testing. Six cellular and six 
decellularised porcine aortic heart valve roots were used in this study, as before. The 
sizes (internal diameter) of all the cellular and decellularised heart valve roots were 
measured with obturators (Table 8.1).  
The test solution used in the cyclic fatigue assessment was 0.9 % (w/v) saline 
with 0.04% sodium azide (v/v) to retard bacterial growth. In the pulsatile flow 
assessment, 0.9 % (w/v) saline was used. 
8.5 Methods 
 Methods used in Feasibility Study 
8.5.1.1 Real Time Fatigue  
The real time fatigue of cellular porcine aortic heart valve roots was investigated 
under physiological cyclic pressures (pressure across the closed valve and aorta 
pressure) and heart rate conditions. Three porcine cellular aortic heart valve roots 
were mounted on the heart valve root holders with cable ties as described in the 
Chapter 7 Section 7.8.1.3. Upon ensuring the attachment of the heart valve root to 
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the holder, the whole assembly was secured into the RWT. The holders with heart 
valve roots A1, A3 and A5 were placed in station 1, 3 and 5 respectively; and the 
remaining stations 2, 4 and 6 were blanked off with blanking plates (Figure 8.3). All 
the heart valve root holders were connected to the compliance chamber (vertical 
column) as described in Chapter 7 Section 7.8.2.  
 
Figure 8.3 Aortic Heart Valve Root Mounting in the RWT (a) Front View (b) 
Side View 
The RWT’s tank was filled with the test solution (0.9 % (w/v) saline).The vertical 
column was 75 % filled with test solution and the remaining top void contained air. 
The inflow and outflow pressure transducers were mounted and calibrated as 
described in Chapter 7 Section 7.6.2. The outflow transducer was always connected 
at station 5. The input waveform was a sine wave (S50) with heart rate 120 bpm (2Hz). 
The bypass valve and amplitude of the input sine wave were adjusted (pressure 
tuning process Chapter 7, Section 7.6.3) to achieve full valve closing and opening. The 
amplitude and bypass valve were adjusted to maintain a target peak transvalvular 
pressure difference of -100 mmHg over the closed valves for over 95% of the test 
cycles and to maintain the pressure at -100 mmHg or greater for 5% or more of each 
cycle duration.  
Typical waveforms of the tuned RWT are shown in Figure 8.4, showing a peak 
transvalvular pressure difference greater than -100 mmHg which was maintained 
across the closed heart valves for 95% or more of total test cycles, and at least 5% of 
each cycle. The outflow pressure (aorta pressure) was between 77 to 108 mmHg. The 
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mean pressure on the top of the vertical column (compliance chamber) was 92 ± 15 
mmHg. The RWT was run for a maximum of 1.2 million cycles. During testing, the 
heart valve roots were checked daily for any artery leakage and alteration of 
transvalvular pressure difference across the closed valve. 
 
Figure 8.4 Representative Pressure Waveforms of the Tuned RWT at Heart 
Rate 120 bpm during Real Time Fatigue Assessment of Cellular Porcine Aortic Heart 
Valve Roots   
The real time fatigue of cellular porcine aortic heart valve root leaflets was 
assessed by high speed camera at 500 frames/sec imaging of the leaflet dynamics 
and through qualitative visual assessment at the end of testing in the RWT.  
8.5.1.2 Hydrodynamic Performance under Pulsatile Flow  
Following fatigue assessment in the RWT, more detailed examination of the 
cellular aortic heart valve roots was undertaken under pulsatile flow to assess 
hydrodynamic performance. The heart valve roots were detached from the RWT 
holder and mounted in the pulsatile flow simulator.  
All the heart valve roots were initially tested at minimum compliance in the 
pulsatile flow simulator with heart rates of 60, 72, 80 and 100 bpm with 
corresponding stroke volumes of 60, 70 and 80 ml to determine the peak flow 
conditions required for testing at maximum compliance, which are detailed in Table 
8.2. The detailed test procedure was described in Chapter 2 Section 2.4.7.4.   
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Table 8.2 Test Conditions Used in the Pulsatile Flow Performance of Cellular 
Porcine Aortic Heart Valve Roots (Maximum Compliance Condition) 
Heart Rate (bpm) Mean Peak Flow (mL .s-1) 
60 237 
72 335 
80 370 
100 516 
 
The systemic pressure was held between 120 mmHg to 80 mmHg. The 
hydrodynamic parameters [transvalvular pressure difference during forward flow, 
the root mean square (RMS) forward flow (QRMS) and effective orifice area (EOA)] 
were evaluated. The opening and closing of the valve was recorded with a high-speed 
camera at 500 frames/sec at the maximum compliance condition with heart rate 72 
bpm. The EOA is presented as the mean ± 95% confidence limits. 
8.5.1.3 Uniaxial Tensile Properties of the Heart Valve Root Leaflets  
The effect of cyclic loading on the material properties of the leaflets were 
characterised using uniaxial tensile testing methods in both circumferential and radial 
directions from each cellular porcine aortic heart valve root, following fatigue and 
pulsatile flow assessment. The detailed procedure for the uniaxial tensile testing is 
described in Chapter 2, Section 2.4.8.2.3.1.3. The tensile material parameters [elastin 
phase slope, collagen phase slope, failure strain and ultimate tensile stress (UTS)] 
were calculated from the stress-strain graphs. All the data is presented as the mean 
± 95% confidence limits. 
The leaflet from one of the cellular aortic heart valve roots was not tested in 
the radial direction for uniaxial tensile testing because two of the leaflets had 
deteriorated during the cyclic fatigue and pulsatile flow test. Hence only two radial 
and three circumferential cellular aortic leaflet specimens were used. 
  Methods used in Primary Study 
8.5.2.1 Real Time Fatigue 
The real time fatigue of cellular and decellularised porcine aortic heart valve 
roots was investigated under physiological cyclic pressures and heart rate conditions 
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following the procedure described in the Section 8.5.1.1. The heart valve roots were 
tested in sets of 3. Following the results of the feasibility study, the axial movements 
of all the sliding spigots were restricted by mounting cable ties on the connecting 
rods for the heart valve root holders as shown in Figure 8.5 (b) to prevent detachment 
of the heart valve roots from the fixed spigot. The detailed test conditions are 
described in the Section 8.5.1.1.    
 
Figure 8.5 Heart Valve Root Mounting (a) with Free Axial Movement of the 
Sliding Spigot (used in the Feasibility Study) (b) and Restricted Axial Movement of 
the Sliding Spigot (used in the Primary Study ) during the Fatigue Assessment in the 
RWT 
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Figure 8.6 Front View of Valve Closed Phase Showing Belly Region (red), 
Commissure Region (green) and Free Edge (black) 
The real time fatigue of the aortic cellular and decellularised heart valve root 
leaflets was assessed by high speed camera at 500 frames/sec imaging of the leaflet 
dynamics and through qualitative visual assessment at the end of testing in the RWT. 
Any leaflet damage was identified and reported with respect to three leaflet 
regions: near the commissures, at the free edge, and in the belly region (Figure 8.6). 
8.5.2.2 Hydrodynamic Performance I: Competency (Pre-test, Mid-test, Post-
test)…. 
The competency of each cellular and decellularised porcine heart valve root was 
measured in terms of leakage flow rate by applying a static back pressure of 120 
mmHg. The time taken for the test fluid to drop to 80 mmHg was recorded and 
leakage flow rate was calculated.  
 
Figure 8.7 Aortic Heart Valve Root Mounting during Mid-test and Post-test 
Competency Assessment (Top View)   
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During pre-test competency assessment, the myocardium side of the heart 
valve root was unsupported as described in Chapter 2 Section 2.4.6.1.3. However, 
during the mid-test and post-test competency assessment, the myocardium of the 
heart valve root was kept attached to a fixed spigot with the threaded flange from 
the heart valve root holder for the RWT (Figure 8.7), due to concerns that the heart 
valve root would deteriorate if removed from the spigot. The wall side of the spigot 
(sliding) was detached to enable heart valve root attachment to the static leakage 
tester.  
The detailed procedure for competency testing is described in Chapter 2 Section 
2.4.6.1.3. The heart valve root was classified as competent if the pressure head had 
not dropped to 80 mmHg within a cut off time period of 30 min or leakage flow rate 
≤ 0.85 mL.s-1.  
8.5.2.3 Hydrodynamic Performance II: Pulsatile Flow (Post-test) 
Following real time fatigue and post-test competency assessment, more 
detailed examination of the cellular and decellularised aortic heart valve roots was 
conducted under pulsatile flow to assess hydrodynamic performance.   
After completing post-test competency, the wall side of the heart valve root 
was detached from the static leakage tester. Before mounting the heart valve root in 
the pulsatile flow simulator, the threaded flange (Figure 8.7) was removed but the 
fixed spigot has kept attached. To enable mounting of the heart valve root with the 
fixed spigot, the pulsatile flow simulator and valve root holder for the RWT was 
modified (Figure 8.8). 
All the heart valve roots were initially tested at minimum compliance in the 
pulsatile flow simulator with heart rate 60, 72, 80 and 100 bpm with corresponding 
stroke volumes 60, 70 and 80 ml to determine the peak flow conditions required for 
the testing at maximum compliance, which are detailed in Table 8.3. The detailed test 
procedure was described in Chapter 2 Section 2.4.7.4.   
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Figure 8.8 Heart Valve Root Mounting with Fixed Spigot attached in the 
Pulsatile Flow Simulator 
   
The systemic pressure was held between 120 mmHg to 80 mmHg. The 
hydrodynamic parameters were evaluated as described in Section 8.5.1.2. The 
opening and closing of the valve was recorded with a high speed camera at 500 
frames/sec at the maximum compliance condition with heart rate 72 bpm. 
Table 8.3 Test Conditions Used in the Pulsatile Flow Performance of Cellular 
and Decellularised Porcine Aortic Heart Valve Roots (Maximum Compliance 
Condition) 
Heart Rate 
(bpm) 
Mean Peak Flow (mL.s-1) 
Cellular Aortic  
Heart Valve Roots 
Decellularised Aortic 
Heart Valve Roots 
60 237 260 
72 335 352 
80 370 401 
100 516 577 
  
8.5.2.4 Uniaxial Tensile Properties of the Leaflets (Post-Test) 
Following pulsatile flow assessment, the uniaxial tensile properties of leaflets in 
the circumferential and radial directions from each cellular and decellularised porcine 
242  
Chapter 8 
aortic heart valve root were evaluated. The detailed procedure for uniaxial tensile 
testing is described in Chapter 2, Section 2.4.8.2.3. The tensile material parameters 
were calculated from the stress strain graphs. 
The leaflets from two of the cellular aortic heart valve roots were not subject to 
uniaxial tensile testing because the leaflets were torn during the cyclic fatigue and 
pulsatile flow test and it was difficult to prepare an adequate size of specimen for the 
uniaxial tensile testing. Hence these samples were omitted and four cellular heart 
valve roots were used. 
 Statistical Analysis 
All the hydrodynamic and biomechanical performance data for the cellular and 
decellularised aortic heart valve roots are presented as the mean ± 95% confidence 
limits and statistical significance between the cellular and decellularised aortic heart 
valve roots performance was determined using Student’s t-test. A significance level 
of p < 0.05 was applied. Statistical analyses were performed using SPSS for Windows 
(version 21.0; SPSS, Inc., USA). 
8.6 Results 
 Feasibility Study 
8.6.1.1 Real Time Fatigue 
The targeted transvalvular pressure difference (-100 mmHg) across the closed 
cellular aortic heart valve root was not maintained throughout the experiment due 
to two of the heart valve roots becoming detached from their spigots. The myocardial 
side of heart valve root A1 completely detached from the fixed spigot between 
345,000 to 432,000 cycles. The RWT was stopped and heart valve root A1 was re-
attached to the fixed spigot with cable ties and the fatigue testing continued. After 
632,537 cycles, another heart valve root (A5) completely detached again from the 
myocardial side. Again the RWT was stopped and heart valve root A5 was re-attached 
and the fatigue testing continued. In both cases the heart valve roots became 
detached from the spigot between the hours of 5 pm and 9 am the next day, leading 
to failure in controlling the transvalvular pressure difference across the remaining 
attached heart valve roots. Due to time limitations, the fatigue assessment was 
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aborted at 823,053 cycles instead of the planned 1.2 million cycles. Hence, the initial 
attempt at running the fatigue test for 1.2 million cycles in the RWT with cellular 
porcine aortic heart valve roots was unsuccessful. At the end of this test, no sign of 
macroscopic damage was observed in the leaflets of any heart valve roots. 
It was observed that within the first hour of fatigue assessment in the RWT the 
transparent test fluid became grayish in appearance. Also, as the heart valve roots 
were tested for a longer period of time in the RWT, a problem was identified where 
a yellow fungal infection (Figure 8.9) in the heart valve roots was observed after 
approximately 600,000 cycles. 
 
Figure 8.9 Infected Cellular Porcine Aortic Heart Valve Root during Fatigue 
Testing in the RWT 
8.6.1.2 Hydrodynamic Performance under Pulsatile Flow 
The mean transvalvular pressure difference versus mean RMS flows for cellular 
porcine aortic heart valve roots for the heart rates tested is shown in Figure 8.10.  
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Figure 8.10 Mean Transvalvular Pressure Difference versus Mean RMS Flow 
for Cellular (n=3) Porcine Aortic Heart Valve Roots - Data fitted with second order 
polynomial trend line - The error bars indicate 95 % confidence limits 
 
Figure 8.11 Leaflet Tear of the Cellular Porcine Aortic Heart Valve Root A5  
The mean EOA with 95% confidence limits for the cellular porcine aortic heart 
valve roots at 72 bpm was 2 ± 0.21 cm2. Complete opening and closing was observed 
for all the heart valve roots. A tear in the leaflet belly region was observed in one of 
the heart valve roots (A5; Figure 8.11). 
8.6.1.3 Uniaxial Tensile Properties of the Cellular Aortic Leaflets 
The mean thickness and tensile parameters of the cellular and decellularised 
aortic heart valve root leaflets is given in Table 8.4. 
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Table 8.4 Mean Thickness and Mean Tensile Parameters (Collagen Phase 
Slope Ec, Elastin Phase Slope Ee, Ultimate Tensile Stress (UTS), Failure Strain ɛf) ± 95 
Confidence Limits for the Cellular Porcine Aortic Heart Valve Root Leaflet specimens  
 Radial Circumferential 
Number of Specimens 2 3 
Thickness (mm) 0.38 ± 0.90 0.37 ± 0.15 
Collagen Phase Slope Ec (MPa) 1.27 ± 2.21 42.03 ± 22.02 
Elastin Phase Slope Ee (MPa) 0.02 ± 0.03 0.04 ± 0.05 
UTS (MPa) 0.49 ± 0.10 9.09 ± 1.42 
Failure Strain ɛf 0.57 ± 0.27 1.03 ± 0.23 
 
8.6.1.4 Discussion 
Based on the results and observations from the feasibility study with three 
cellular porcine aortic heart valve roots, the refinements described below were 
incorporated into the test plan and test conditions for the primary study. 
 To minimise growth of any bacteria and/or fungi during the fatigue testing in the 
RWT, the cellular heart valve roots were treated with 150 ml Cambridge antibiotic 
and amphotericin B solution as described in Chapter 2 Section 2.4.3 and 0.04 % 
sodium azide was added in the test solution (saline) to retard bacterial growth. 
 During the fatigue assessment in the RWT, detachment of the heart valve roots 
on the myocardial side from the fixed spigot was seen twice in two different heart 
valve roots. Loosening of the heart valve root was attributed to myocardium 
thinning due to deterioration and simultaneous dynamic pulsatile motion of the 
wall when dynamically pressurised in the axial direction with respect to the heart 
valve root clamping [Figure 8.13(b)].  
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Figure 8.12 Free Body Diagram of the Clamping of Myocardium of the Heart 
Valve Root on the Fixed Spigot 
The free body diagram of the myocardium clamping on the fixed spigot is shown 
in   Figure 8.12. When the heart valve root was dynamically pressurised, the heart 
valve root was under axial tensile load, the tendency of the two surfaces [soft 
biological tissue (myocardium) and delrin (fixed spigot)] to slip against one another is 
resisted by the friction between these surfaces. The frictional resistance is equal to 
the coefficient of friction multiplied by the clamping force between the myocardium 
and the fixed spigot. After a few days of cyclic testing in the RWT, the heart valve root 
started to deteriorate which softens and thins the myocardium. Due to myocardium 
deterioration, the frictional resistance between the two surface decreased and hence 
the tensile load was exceeded the frictional resistance which made the clamping 
loose [Figure 8.13 (b)] 
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Figure 8.13 Cellular Aortic Heart Valve Roots Mounting (a) Before Fatigue 
Assessment in the RWT showing Un-deformed Myocardium (b) During Fatigue 
Assessment in the RWT showing Loosened Myocardium (c) with Restricted Axial 
Movement of the Sliding Spigot  
 The test condition was refined, comprising of the restriction of axial movement 
of the sliding spigot and hence axial movement of the heart valve root during 
fatigue assessment in the RWT [Figure 8.13 (c)]. A cable tie was tied around the 
connecting rods and near to the sliding spigot as shown in Figure 8.13 (c), keeping 
the heart valve root uncompressed. Under the dynamic pressure, part of the 
tensile load experienced by the heart valve roots was equilibrated by restriction 
of axial movement of the sliding spigot. 
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 Fatigue assessment of the heart valve roots was mostly based on the visual 
inspection or image analysis of high speed videos of the leaflets following RWT 
cycling.  For a quantitative assessment of the heart valve roots performance, the 
heart valve roots were tested under pulsatile flow conditions, following fatigue 
assessment. However, due to the complexity, length of the pulsatile flow test and 
concerns around mounting of the heart valve root in the pulsatile flow simulator, 
the pulsatile flow performance of the heart valve roots was not evaluated before 
their fatigue assessment in the RWT and hence it was difficult to clarify whether 
the fatigue of the heart valve roots directly affected hydrodynamic performance. 
Therefore, a competency assessment was added to the experimental design at 
several intervals (pre-test, mid-test, post-test). This also eliminated sample to 
sample variability. 
 A leaflet tear was seen during the pulsatile flow assessment in one of the heart 
valve roots. The leaflet may have torn due to the application of over pressure 
during dismantling of the heart valve root from the RWT holder and subsequent 
mounting of the heart valve root back in the pulsatile flow simulator. Hence, it 
was decided to keep the myocardium side of the heart valve root attached to the 
fixed spigot and instead separate the aorta side from the sliding spigot after 
completing the RWT fatigue assessment.  
To enable mounting of the heart valve root still attached to the fixed spigot in 
the pulsatile flow simulator for further assessment, the fixed spigot and flange for the 
pulsatile flow simulator were modified. The following modification was involved: 
1. The fixed spigot of the RWT was 80 mm in diameter compared to the 40 mm 
diameter spigot of the pulsatile flow simulator. Therefore to mount the fixed 
spigot with the heart valve root attached in the pulsatile flow simulator, it was 
required to modify the mounting flange of the pulsatile flow simulator. 
Consequently, four equally spaced 6 mm diameter blind holes for M6 socket cap 
head screw were produced in the flange for the aortic section of the pulsatile flow 
simulator [Figure 8.14 (a)] to mount the fixed spigot, with the heart valve root 
attached from the RWT. 
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2. Four equally spaced through holes were drilled in the fixed spigot to enable its 
mounting in the pulsatile flow simulator. Also to make the assembly water tight 
an ‘O’ ring with an internal diameter of 36 mm was fitted on the back of the fixed 
spigot [Figure 8.14 (b)]. 
 
Figure 8.14 Modification in the (a) Flange for the Aortic Test Section of the 
Pulsatile Flow Simulator (Front View) (b) Fixed Spigot from the Heart Valve Root 
Holder for the RWT (Back View) (C) Mounting of the Fixed Spigot on the Flange 
(Front View)     
 Primary Study 
8.6.2.1 Real Time Fatigue of Cellular and Decellularised Porcine Aortic Heart 
Valve Roots 
The targeted transvalvular pressure difference (-100 mmHg) across the closed 
heart valve root was maintained throughout the fatigue testing in the RWT. Once the 
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target number of cycles was reached all the heart valve root holders were removed 
from the RWT with the heart valve roots still attached and visually examined. There 
was no sign of detachment of the heart valve roots from the spigots. A small amount 
of yellow staining on the cellular heart valve root walls was observed. Detailed high 
speed video examination of all the cellular and decellularised porcine aortic heart 
valve roots at a maximum of 1.2 million cycles are listed in Table 8.5 and Table 8.6 
respectively along with the image of each heart valve root in the fully closed phase, 
captured with a high speed camera.  
Table 8.5 Valve Fully Closed Images (where LC: left coronary leaflet, RC: right 
coronary leaflet and NC: non-coronary leaflet) and Visual Examinations of the 
Cellular Porcine Aortic Heart Valve Roots at Maximum 1.2 Million cycles  
Cellular Porcine Aortic Heart Valve Roots 
Valve ID 
Number 
Valve Fully Closed Heart Valve Root Visual Examinations 
AC1 
 
All leaflets of this heart valve root 
remained intact with no sign of 
macroscopic damage. 
AC2 
 
All the leaflets of this heart valve root 
showed signs of macroscopic damage 
after 889,669 cycles. All leaflets had 
tear near to leaflet attachment area, 
although it is not clearly visible for the 
right coronary leaflet in the image.  
AC3 
 
All leaflets of this heart valve root 
remained intact with no sign of 
macroscopic damage. 
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Cellular Porcine Aortic Heart Valve Roots 
Valve ID 
Number 
Valve Fully Closed Heart Valve Root Visual Examinations 
AC4 
 
All leaflets of this heart valve root 
remained intact with no sign of 
macroscopic damage. 
 
 
AC5 
 
All the leaflets of this heart valve root 
showed signs of macroscopic damage. 
The right coronary leaflet contained a 
large tear in the belly region. The non-
coronary and left coronary leaflet 
contained a tear in each near to the 
leaflet attachment area. The tear in the 
non-coronary leaflet appeared at 
approximately 1 million cycles whereas 
the tears in the other two leaflets were 
observed at approximately 1.2 million 
cycles.  
AC6 
 
All leaflets of this heart valve root 
remained intact with no sign of 
macroscopic damage. 
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Table 8.6 Valve Fully Closed Images (where LC: left coronary leaflet, RC: right 
coronary leaflet and NC: non-coronary leaflet) and Visual Examinations of the 
Decellularised Porcine Aortic Heart Valve Roots at Maximum 1.2 Million cycles  
Decellularised Porcine Aortic Heart Valve Roots 
Valve ID 
Number 
Valve Fully Closed Heart Valve Root Examination 
AD1 
 
Two leaflets of this heart valve root 
showed signs of macroscopic damage 
after 864,712 cycles. The non-coronary 
and left coronary leaflets contained a 
tear in each leaflet. These tears were 
situated near the free edge and in both 
cases adjacent to the leaflet 
attachment area.  
AD2 
 
All leaflets of these heart valve roots 
remained intact with no sign of 
macroscopic damage. 
 
AD3 
 
AD4 
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Decellularised Porcine Aortic Heart Valve Roots 
Valve ID 
Number 
Valve Fully Closed Heart Valve Root Examination 
AD5 
 
Signs of leaflet damage were observed 
after 861,151 cycles. Two of the 
leaflets (non-coronary and left 
coronary) contained a tear in each 
leaflet. These tears were situated near 
the free edge and in both cases 
adjacent to the commissure of the 
leaflet. 
AD6 
 
All leaflets of this heart valve root 
remained intact with no sign of 
macroscopic damage. 
 
 
8.6.2.2 Hydrodynamic Performance of Cellular and Decellularised Porcine Aortic 
Heart Valve Roots 
8.6.2.2.1 Hydrodynamic Performance I: Competency 
The pre, mid and post-test mean leakage flow rates for the cellular and 
decellularised aortic heart valve roots are shown in Table 8.7. 
All the cellular aortic heart valve roots were fully competent prior to fatigue 
testing, with mean leakage flow rates of less than 0.85 mL.s-1. The majority of the 
cellular aortic heart valve roots were competent during the mid-test competency 
assessment, except cellular heart valve root AC6   (mean leakage flow rate 16.67  
mL.s-1). However, the post-test competency assessment showed that the majority of 
the cellular aortic heart valve roots were regurgitant. The post-test competency of 
the cellular aortic heart valve roots AC3 and AC5 could not be measured as the valves 
were leaking faster than the static pressure applied. 
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Table 8.7 Pre, Mid and Post- Test Mean Leakage Flow Rates (FL) of Each 
Cellular and Decellularised Porcine Aortic Heart Valve Roots  
Cellular  
Aortic Heart Valve Roots 
Decellularised  
Aortic Heart Valve Roots 
Valve 
ID 
Number 
Leakage Flow Rate (mL.s-1) Valve 
ID 
Number 
Leakage Flow Rate (mL.s-1) 
Pre-
test 
Mid-
test 
Post-
test 
Pre-
test 
Mid-
test 
Post-
test 
AC1 <0.85 <0.85 4.36 AD1 2.05 xxx xxx 
AC2 <0.85 <0.85 1.53 AD2 0.88 0.99 <0.85 
AC3 <0.85 <0.85 xxx AD3 1.61 4.73 6.02 
AC4 <0.85 <0.85 1.19 AD4 <0.85 <0.85 <0.85 
AC5 <0.85 <0.85 xxx AD5 2.24 21.31 1.23 
AC6 <0.85 16.67 9.96 AD6 1.64 1.23 1.66 
   xxx - not measured   
The majority of decellularised aortic heart valve roots were regurgitant (with 
mean leakage flow rate > 0.88 mL.s-1) during pre and mid - test competency 
assessment. The decellularised heart valve root AD5 had the highest mean leakage 
flow rate 21.31 mL.s-1 during the mid-test competency assessment, however, this was 
reduced to 1.23 mL.s-1 during the post-test competency assessment. It was not 
possible to measure the mid-test and the post-test leakage flow rates for the 
decellularised aortic heart valve root AD1 as the valve was leaking faster than the 
static pressure applied. Four out of the six decellularised aortic heart valve roots were 
regurgitant during post-test competency assessment. 
8.6.2.2.2 Hydrodynamic Performance II: Pulsatile Flow  
The mean transvalvular pressure difference versus mean RMS flow for the 
cellular and decellularised porcine aortic heart valve roots under the tested heart 
rates is shown in Figure 8.15.  
The pulsatile flow performance of the cellular porcine aortic heart valve roots 
AC2 and AC5 could not be determined as all the leaflets were too damaged for testing 
to be completed. 
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Figure 8.15 Mean Transvalvular Pressure Difference versus Mean RMS Flow 
for Cellular (n=4) and Decellularised (n=6) Porcine Aortic Heart Valve Roots - Data 
fitted with second order polynomial trend line - The error bars indicate 95 % 
confidence limits 
The pulsatile flow performance of the cellular porcine aortic heart valve roots 
AC1 and AC6 could not be determined at the heart rate of 100 bpm as the 
myocardium side of the heart valve root detached from the spigot when this 
condition was applied. 
The EOA averaged over the four heart rate conditions for all the cellular and 
decellularised porcine aortic heart valve roots is shown in Table 8.8. 
Table 8.8 Effective Orifice Area for Each Cellular and Decellularised Porcine 
Aortic Heart Valve Root Averaged over 4 Heart Rate conditions 
Cellular Aortic Heart Valve Roots Decellularised Aortic Heart Valve Roots 
Valve  
ID Number 
Effective Orifice Area 
(EOA) 
cm2  
Valve  
ID Number 
Effective Orifice 
Area (EOA) 
cm2  
AC1 1.88 AD1 1.88 
AC2 xxx AD2 2.10 
AC3 1.88 AD3 2.16 
AC4 2.22 AD4 2.11 
AC5 xxx AD5 1.91 
AC6 2.68 AD6 2.18 
xxx – not measured  
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The mean EOA for the decellularised porcine aortic valve heart valve roots (2.06 
± 0.11 cm2) was not significantly different to the cellular porcine aortic heart valve 
roots (2.23 ± 0.21 cm2 ) (P=0.08, Student’s t-test). 
Fully opened and fully closed Images of all the tested porcine cellular and 
decellularised aortic heart valve roots are shown in Figure 8.16 and Figure 8.17 
respectively.  
Cellular Aortic Heart Valve Roots 
Valve ID 
Number 
Valve Fully Opened Valve Fully Closed 
AC1 
  
AC3 
  
AC4 
  
AC6 
  
 (a) (b) 
Figure 8.16 (a) Valve Fully Opened and (b) Valve Fully Closed Images of Cellular 
Porcine Aortic Heart Valve Roots at Heart Rate 72 bpm, captured from the Front 
View by a High-Speed Camera with a Leaflet Tear in AC4 Highlighted 
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Decellularised Aortic Heart Valve Roots 
Valve ID Number Valve Fully Opened Valve Fully Closed 
AD1 
  
AD2 
  
AD3 
 
 
AD4 
 
 
AD5 
 
 
AD6 
 
 
 (a) (b) 
Figure 8.17 (a) Valve Fully Opened and (b) Valve Fully Closed Images of 
Decellularised Porcine Aortic Heart Valve Roots at Heart Rate 72 bpm, captured 
from the Front View by a High-Speed Camera with a Leaflet Tears Highlighted in 
AD1 and AD5 
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The majority of the cellular porcine aortic heart valve roots showed 
synchronous leaflet opening and closing characteristics. The fully open leaflet 
configuration was circular in shape [Figure 8.16(a)]. The non-coronary leaflet in 
cellular heart valve root AC6 did not open completely. During the closing phase, all 
the valves were observed to close completely with no visible leakage orifice [Figure 
8.16 (b)]. A large tear was detected near the leaflet attachment area of the left 
coronary leaflet of the cellular heart valve root AC4 which was not seen in the post-
test fatigue assessment in the RWT.  
The majority of the decellularised porcine aortic heart valve roots showed 
synchronous leaflet opening and closing characteristics. The right coronary leaflet in 
decellularised heart valve root AD5 did not open completely [Figure 8.17(a)]. The 
decellularised heart valve roots AD1, AD2, AD3 and AD4 showed excellent closed 
leaflet configuration, with perfect coaption at the free edge of the leaflets [Figure 
8.17(b)]. However, the decellularised aortic heart valve root AD5 and AD6 had minor 
central leakage orifices. The majority of the cellular and decellularised aortic heart 
valve roots had a fully opened leaflet configuration, except cellular heart valve root 
AC6 and decellularised heart valve root AD5.  
8.6.2.3 Uniaxial Tensile Properties of the Cellular and Decellularised Aortic 
Leaflets….. 
The mean thickness ± 95 % confidence limits and mean tensile parameters with 
± 95 % confidence limits for the cellular and decellularised porcine aortic heart valve 
root leaflet specimens are shown in Table 8.9 and Table 8.10 respectively. 
Table 8.9 Mean Thickness ± 95 % confidence limits for the Cellular and 
Decellularised Porcine Aortic Heart Valve Root Leaflet Radial and Circumferential 
specimens – p (<0.05) value shows significant difference between cellular and 
decellularised aortic heart valve roots 
 
Specimen 
Direction 
Average Thickness (mm) p 
Value Cellular Decellularised 
Number of Specimens  4 6  
Aortic Heart Valve 
Root Leaflet 
Radial 0.57 ± 0.23 0.28 ± 0.05 0.002 
Circumferential 0.74 ± 0.26 0.32 ± 0.06 0.01 
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Student’s t-test showed significant difference in thickness of the cellular and 
decellularised leaflet specimens in the radial (p=0.002) and circumferential (p=0.01) 
directions. 
The initial linear region of the stress-strain curve was used to derive the elastin 
phase modulus and it was not distinct for one decellularised radial and one 
decellularised circumferential leaflet specimen. Hence these samples were omitted 
and five decellularised samples were used for the mean elastin phase slope 
calculation. 
The tensile leaflet parameters (collagen phase slope, elastin phase slope, UTS 
and failure strain) for the decellularised aortic heart valve roots were significantly 
different to the cellular aortic heart valve roots in the circumferential direction 
(p<0.05, Student’s t-test). However, in the radial direction, all the leaflet tensile 
parameters for the decellularised aortic heart valve roots were similar to the cellular 
aortic heart valve roots (p>0.05, Student’s t-test).  
Table 8.10 Tensile Parameters (Collagen Phase Slope Ec, Elastin Phase Slope Ee, 
Ultimate Tensile Stress σUTS, Failure Strain ɛfailure) ± 95 % Confidence Limits for 
Cellular and Decellularised Radial (R) and Circumferential (C) Aortic Leaflet 
Specimens  and Number of Test Specimens (N) *-Statistical significant difference 
(p<0.05) for decellularised versus cellular aortic heart valve roots.   
Porcine Aortic Heart Valve Roots 
Tensile Parameters 
for Leaflets 
Cellular 
 
Decellularised 
p value 
N  N  
Radial 
Ec (MPa) 4 0.93 ± 0.98 6 2.47 ± 1.60 0.10 
Ee (MPa) 4 0.02 ± 0.01 5 0.03 ± 0.01 0.07 
σUTS (MPa) 4 0.46 ± 0.36 6 1.06 ± 0.68 0.11 
ɛfailure 4 1.03 ± 0.38 6 1.04 ± 0.17 0.92 
Circumferential 
Ec (MPa) 4 8.59 ± 7.92      6 53.44 ± 8.99* 0.00001 
Ee (MPa) 4 0.02 ± 0.01 5 0.31 ± 0.25* 0.02 
σUTS (MPa) 4 2.48 ± 0.66 6 9.31 ± 1.64* 0.00003 
ɛfailure 4 0.60 ± 0.25 6 0.27 ± 0.07* 0.002 
 Discussion 
The function of the decellularised porcine aortic heart valve roots was similar 
to the function of cellular porcine aortic heart valve roots throughout the cyclic 
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testing in the RWT. No detachment of the cellular or decellularised heart valve roots 
from any of the spigots was detected, indicating that the restriction of axial 
movement was appropriate. The aorta of the cellular and decellularised heart valve 
roots maintained its integrity under cyclic pressures in the RWT for 1.2 million cycles. 
The high speed video analysis showed that the regions of leaflet failures in the cellular 
porcine aortic heart valve roots were near the commissure and belly region, whereas 
in the decellularised porcine aortic heart valve roots the leaflet failures were near the 
commissure region only. It was also observed that in the cellular heart valve roots the 
leaflet damage progressed towards the free edge and resulted in a large tear 
compared to the decellularised heart valve roots. Interestingly the regions of leaflets 
failure observed in both cellular and decellularised were consistent with in vivo 
(Ishihara et al., 1981, Hilbert et al., 1992, Wells and Sacks, 2002, Piñón et al., 2015) 
and in vitro accelerated (Sacks and Smith, 1998, Smith et al., 1999) fatigue induced 
leaflet tears seen in bioprosthetic porcine heart valves.    
 
Figure 8.18 Tear in Explanted Bovine Pericardial Trifecta Heart Valve (Piñón et 
al., 2015) 
A study by Piñón et al. (2015) showed that a glutaraldehyde treated bovine 
pericardial Trifecta heart valve (21-mm, St Jude Medical, Inc) had failed in 71-year old 
female after 3 years of implantation in the aortic position due to a large tear in the 
non-coronary leaflet as shown in Figure 8.18. However, the Trifecta valve did not 
show any sign of fatigue at 200 million cycles (equivalent of 5 years) in accelerated 
wear testing. 
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The in vitro accelerated fatigue and in vivo studies reported by Sacks and 
colleagues (Sacks and Smith, 1998, Sacks and Schoen, 2002) indicated significant 
changes in porcine bioprosthetic heart valves collagen fiber architecture due to 
shearing of the fibers. These studies also showed similarity in tissue damage location 
in the bioprosthetic heart valve leaflet between in vitro Figure 8.19 (a) and in vivo 
Figure 8.19 (b) studies.  
  
Figure 8.19 The Structural Damage (indicated with arrow) in Porcine 
Bioprosthetic Heart Valve leaflet (a) Subjected to in vitro Accelerated Fatigue (b) 
Explanted from Patient  
Leaflet tear was the main cause of early structural valve deterioration in 
pericardial bioprosthetic heart valves. The Ionescu-Shiley bovine pericardial valve 
(Shiley, Inc, Irvine, CA, USA) and the Hancock pericardial xenograft valve (Medtronic,. 
Minneapolis, MN) failed in vivo and the causes were early leaflet wear and tear near 
the commissural regions where the leaflets were sewn to the supporting frame 
(Ishihara et al., 1981, Hilbert et al., 1992). The “wear and tear” phenomenon leading 
to valve failure has been reported in another study by (Mohammadi et al., 2006). The 
freestyle stentless bioprosthetic aortic heart valve roots were explanted in 10 
patients after 10.9 ± 3.9 years of implantation due to leaflet tears, located at the 
leaflet base (n = 4) or in the vicinity of the commissure region of leaflets (n = 6) 
(Mohammadi et al., 2006).  
All these studies highlight the importance of mechanical stress as one of the 
main instigators of valve deterioration. In particular, the frequent bending and shear 
stress in the leaflets during valve opening and closing were thought to be responsible 
for the development of tears in the bioprosthetic heart valves (Ishihara et al., 1981).  
262  
Chapter 8 
In this study the leaflet structural deterioration was likely due to either leaflet 
impingement with the heart valve root mounting spigot or to fatigue induced 
deterioration. In addition, the lack of physiological dilation of the aorta may be an 
additional cause of the failures in the leaflet belly due to excessive flexion. The in vitro 
RWT setup accelerated cellular death (necrosis) within a few hours of testing in the 
cellular aortic heart valve roots due to (toxic) sodium azide in the test solution [0.9 % 
(w/v) saline with 0.04% sodium azide (v/v)] and the lack of oxygen supply (hypoxia); 
therefore, only the matrix material was tested in the RWT. Necrosis is appended by 
the release of enzymes (proteinases and matrix metalloproteinases), that are stored 
by lysosomes, which are capable of digesting cell components or the entire cell itself 
(Merrick, 2002). Excessive amounts of these enzymes could damage extracellular 
matrix proteins (collagen) surrounding the cells which form a highly organised fibrous 
structure in the cellular heart valve root leaflets. In addition, cell membranes in 
cellular heart valve roots may have been damaged soon after harvesting due to 
handling and processing (Kitagawa et al., 2001). Hence the tears in the cellular heart 
valve root leaflets after fatigue testing in the RWT may have been the result of cell 
necrosis. The decellularised porcine aortic roots tested in the RWT were devoid of 
cells and exhibited similar fatigue damage (tears in the leaflets). This might be 
expected since neither type of porcine aortic heart valve root (cellular and 
decellularised) had any living cells present to help "repair" the damaged collagen that 
would occur under normal conditions in vivo in the heart. Once the decellularised 
heart valve root is implanted into the human body for use as a replacement heart 
valve, it is believed that leaflet fatigue will not be permanent due to leaflet 
regeneration and repair. In vivo, it is anticipated based on evidence from a study 
(Paniagua Gutierrez et al., 2015) on decellularised porcine aortic valve roots 
implanted in sheep that host cells will populate the leaflets and remodel the matrix.  
All six cellular aortic heart valve roots were competent (leakage rate  <0.85 
mL.s-1) before the fatigue testing. After these heart valve roots were cycled for 
680,000 to 880,000 cycles in the RWT, the competency (mid-test) of one of the 
cellular heart valve roots (AC6) was altered. Cellular heart valve root AC6 
demonstrated severe regurgitation with a leakage rate of 16.67 mL.s-1 whilst the 
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remaining five heart valve roots were competent having a leakage rate <0.85 mL.s-1. 
After 1.2 million cycles of cyclic testing in the RWT, all the cellular aortic heart valve 
roots were regurgitant and the mean leakage flow rate was 4.26 mL.s-1 for four of the 
heart valve roots whilst two of the heart valve roots leaked faster than the static 
pressure applied. It was not possible to apply static pressure on these two cellular 
heart valve roots because the leaflets had deteriorated following cyclic loading in the 
RWT. A similar phenomenon was observed with the decellularised heart valve roots. 
During pre-test and mid-test competency assessment five out of six decellularised 
heart valve roots were not considered competent (having a leakage flow rate> 0.85 
mL.s-1); however the mean leakage flow rates were 1.68 mL.s-1 (mid-test) and 2.32 
mL.s-1 (post-test). After 1.2 million cycle cyclic testing in the RWT, the heart valve root 
AD2 appeared to be competent, although this was not case in the pre-test and mid-
test competency assessment. Two out of the six decellularised aortic heart valve 
roots were competent following 1.2 million cycles of testing, whereas three roots 
were regurgitant with a mean leakage rate of 2.97 mL.s-1. Decellularised heart valve 
roots AD1 and AD5 had the highest regurgitant flow rates at the point mid-test. This 
data agreed well with the high speed image analysis from the cyclic testing in the 
RWT as the tears in the leaflets of decellularised heart valve roots AD1 and AD5 could 
be seen. 
It was not possible to investigate the cellular aortic heart valve roots AC2 and 
AC5 under pulsatile flow conditions as the leaflets were severely damaged due to the 
cyclic loading. During the pulsatile flow assessment of cellular aortic heart valve root 
AC4, a tear near the leaflet attachment region of the leaflet was seen. On the other 
hand, it was possible to determine the pulsatile flow performance of all the 
decellularised aortic heart valve roots, including the heart valve roots AD1 and AD5 
which had damaged leaflets due to cyclic loading in the RWT. The decellularised 
porcine aortic heart valve roots showed comparative functionality to the cellular 
heart valve roots under in vitro pulsatile flow conditions in terms of effective orifice 
area and valve opening and closing behaviour. The pressure/ flow characteristics of 
the cellular and decellularised aortic heart valve roots showed that at low flow rates 
the transvalvular pressure difference was very similar, but at higher flow rates the 
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cellular heart valve roots performed better. However, at higher flow rates, only two 
of the cellular heart valve roots (AC3 and AC4) were tested for pulsatile flow 
performance. The pulsatile flow performance of the remaining two cellular heart 
valve roots AC1 and AC6 could not be obtained at the higher flow rate conditions as 
the clamping of the heart valve root onto the spigot failed.  
The mean thickness of the cellular aortic leaflet specimens was 0.57 ± 0.28 mm 
in the radial direction and 0.74 ± 0.26 mm in the circumferential direction, which 
were greater (leaflet thickness in radial direction: 0.52 ± 0.11 mm and in 
circumferential direction: 0.63 ± 0.013 mm) when it was compared with the control 
data derived in this study (Chapter 3). The thickness of decellularised aortic leaflet 
specimens was significantly lower than the thickness of the cellular leaflet specimens 
in the radial and circumferential directions (p<0.05, Student’s t-test). This possibly 
occurred due to leaflet swelling of the cellular aortic heart valve roots. In the cellular 
aortic valve leaflet, the spongiosa layer contains a high concentration of 
glycosaminoglycans (GAGs). These GAGs contain a large number of negative charged 
groups which attract more positively charged ions cations (i.e. sodium ions) (Setton 
et al., 1998) from the test fluid (saline + 0.04 % sodium azide) into the leaflets, 
producing an imbalance of the total mobile ion concentration between the inside and 
the outside of the leaflets. The resultant imbalance of ions between inside and 
outside-tissue fluid would likely have given rise to an osmotic pressure which caused 
the tissue to swell. All cellular leaflets likely underwent swelling compared to 
decellularised leaflets due to exposure to the test solution. However, only minimal 
leaflet swelling occurred when decellularised leaflets were exposed to the same test 
solution, this may have been due to the significantly lower GAG content in the 
decellularised leaflets since SDS was used as a detergent during decellularisation. SDS 
has been reported to remove GAG’s from tissue (Vafaee et al., 2016).   
The decellularised aortic leaflets were significantly stronger and stiffer in the 
circumferential direction compared to the cellular aortic leaflets. The cellular heart 
valve roots may be degenerating during fatigue assessment in the RWT due to loss of 
cellular viability. The degeneration is both a molecular event (breaking of molecular 
chains) and a tissue level event (loss of strength and integrity). Thus, uniaxial tensile 
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testing (e.g., loss of strength) was used to assess degeneration of the cellular and 
decellularised aortic leaflets after cyclic fatigue in the RWT. The degeneration of the 
cellular aortic leaflets was clearly seen from the tensile parameters in this study 
which were lower than the tensile parameters derived in Chapter 3 (control data) for 
the fresh cellular aortic leaflets (Table 8.11).  
Table 8.11 Tensile Parameters (Collagen Phase Slope Ec, Elastin Phase Slope 
Ee, Ultimate Tensile Stress σUTS) ± 95 % Confidence Limits for the Cellular Aortic 
Leaflets Following Cyclic Testing in the RWT and for the Fresh Cellular Aortic Leaflets 
(Chapter 3) 
Tensile Leaflet Parameters for the Porcine Aortic Heart Valve 
Roots 
 
Following Cyclic 
Testing in the RWT 
(Current Study) 
Fresh Cellular 
Leaflets (Control 
Data; Chapter 2) 
Radial 
Ec (MPa) 0.93 ± 0.98 1.42 ± 0.52 
Ee (MPa) 0.02 ± 0.01 0.03 ± 0.01 
σ UTS (MPa) 0.46 ± 0.36 0.70 ± 0.26 
Circumferential 
Ec (MPa) 8.59 ± 7.92 22.07 ± 6.44 
Ee (MPa) 0.02 ± 0.01 0.81 ± 0.82 
σUTS (MPa) 2.48 ± 0.66 4.17 ± 0.85 
 
However, this was not a case for the decellularised aortic leaflets. The collagen 
phase slopes (radial: 2.47 ± 1.60 MPa, circumferential: 53.44 ± 8.99 MPa) and elastin 
phase slopes (radial: 0.03 ± 0.01 MPa, circumferential: 0.31 ± 0.25 MPa) determined 
in this study for decellularised aortic leaflets were higher than the collagen phase 
slopes (radial: 1.5 MPa, circumferential: 42.9 MPa) and elastin phase slopes (radial: 
0.002, circumferential: 0.003 MPa) reported in a previous study by Korossis et al. 
(2002) on porcine aortic heart valve roots decellularised with a similar protocol that 
had not been tested in the RWT. This showed that the decellularised aortic leaflets 
maintained their integrity. 
Structural valve degeneration due to calcification was not considered in this 
study. Therefore direct comparison of fatigue in the RWT with in vivo clinical data 
may be inappropriate.   
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8.6.3.1 Limitations and Recommendations 
The following limitations and recommendations could be drawn from the real 
time fatigue testing of cellular and decellularised heart valve roots in the RWT: 
 The cellular and decellularised heart valve roots were degenerating during fatigue 
testing, possibly due to the absence of growth factors and the absence of the 
biological environment. Therefore, further studies are recommended by 
simulating the biological environment during fatigue testing of cellular and 
decellularised heart valve roots.  
 The in vitro RWT setup accelerated cellular death during testing of cellular aortic 
heart valve roots due to the presence of toxic sodium azide in the test solution 
and the lack of oxygen supply. 
 Structural morphology of cellular and decellularised leaflets could be assessed 
after fatigue testing in the RWT by histochemical analysis to determine the 
microstructural damages due to cyclic loading. 
 The heart valve roots could be cycled in fluids with physiological viscosity to 
assess the effect of shear stress on the wall and leaflets.  
 Further long term studies are warranted to understand effect of decellularisation 
on the valve function for at least 200 million cycles as described by the ISO 5840 
(2015). 
8.7 Conclusion 
A real time in vitro fatigue assessment along with hydrodynamic performance 
and uniaxial tensile performance (leaflets) of the cellular and decellularised porcine 
aortic heart valve roots was performed for the first time in this study. Four cellular 
and four decellularised aortic heart valve roots showed no mechanical sign of 
damage, whereas two cellular and two decellularised aortic heart valve roots 
exhibited signs of macroscopic failure. The site of the fatigue on the decellularised 
porcine aortic leaflets was identical to the cellular porcine aortic leaflets. The uniaxial 
tensile results revealed leaflet tissue swelling, loss of stiffness (collagen and elastin 
phase) and loss of strength in the cellular aortic heart valve roots leaflets compared 
to the decellularised porcine aortic leaflets in the circumferential direction. Overall, 
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the results from this study suggested that the SDS decellularised porcine aortic heart 
valve roots showed fatigue similar to cellular porcine aortic heart valve roots and 
further long-term fatigue evaluation of the decellularised porcine aortic heart valve 
roots is warranted. 
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 Discussion, Conclusions and Future Work 
9.1 General Discussion 
Worldwide, heart valve disease affects more than 100 million people of all ages 
(Dangas et al., 2016) and is treated by repair or replacement valve surgery. Currently 
heart valve replacements comprise of mechanical prostheses, bioprostheses, 
cryopreserved allografts (human donor) and the pulmonary autograft in the aortic 
position (Ross procedure); and have many disadvantages such as the lack of ability to 
grow, repair and remodel and therefore no lifetime solution exists for the young 
patient (Pibarot and Dumesnil, 2009). Tissue engineered (including decellularised) 
heart valve roots have the potential to overcome many of the drawbacks associated 
with existing valve replacements. Favourable initial results from the implantation of 
decellularised porcine and human heart valves have been shown in various studies 
(Lichtenberg et al., 2006, Costa et al., 2005, Dohmen, 2012, Elkins et al., 2001), 
however, other studies have been less successful and have led to  death of several 
patients (Ruffer et al., 2010, Simon et al., 2003). Malfunctioning of the valve and 
incomplete decellularisation of the porcine tissue were identified as contributory 
factors to their failure (Simon et al., 2003, Ruffer et al., 2010). These studies 
emphasised the need for complete decellularisation of the porcine tissue and for 
quantitative pre-clinical evidence of the porcine heart valve roots to evaluate its 
function and understand its structural properties prior to implantation.   
Previous studies (Korossis et al., 2002, Vafaee et al., 2016, 2014) have 
developed a decellularisation protocol for porcine and human heart valve roots with 
a view to manufacturing and supplying decellularised allograft heart valve roots and 
decellularised porcine heart valve roots for clinical use, replacing severely damaged 
heart valves. The decellularised allograft heart valve roots were developed to 
minimise the immune response to cryopreserved allograft heart valves and hence 
overcome the limitations of degeneration over time. However, decellularised 
allograft heart valve roots suffer from limitations of availability in sizes suitable for 
young patients. To address this problem, “off the shelf” decellularised porcine heart 
valve replacements in a range of sizes have been developed. The decellularisation 
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process involves repeated cycles of low concentration sodium dodecyl sulphate (SDS) 
in the presence of proteinase inhibitors and hypotonic buffer wash cycles. The 
decellularised human and porcine heart valve roots were developed on the basis of 
the hypothesis that removal of the major cellular immunogenic components had 
been achieved without adverse effects on the extracellular matrix (ECM). To 
determine whether the ECM had been affected as a result of the low concentration 
SDS decellularisation treatment, it was essential to assess the in vitro functional 
performance of decellularised heart valve roots. The hydrodynamic and 
biomechanical performance of low concentration SDS decellularised porcine aortic 
(Wilcox et al., 2005, Korossis et al., 2002) and pulmonary (2011) heart valve roots 
have been previously evaluated, however in vitro functional performance of low 
concentration SDS decellularised human aortic and pulmonary heart valve root has 
not been evaluated before. 
All prosthetic heart valves have to conform to ISO 5840 (2015)  and FDA (2010) 
standards, extensively evaluating in vitro functional performance prior to clinical 
implantation. However, the ISO 5840 (2015) and FDA (2010) standards were 
established based on mechanical and bioprosthetic heart valves and their suitability 
as test methods for biological heart valve roots is questionable. Biological heart valve 
roots such as allografts and decellularised heart valve roots exhibit highly time 
dependent viscoelastic behaviour. Therefore, standard test methods described by 
ISO 5840 (2015) and FDA (2010), more specifically an accelerated fatigue test method 
is not appropriate and a real time fatigue test method is required. The evaluation of 
in vitro functional performance of the decellularised heart valve roots is advisable 
before moving to in vivo clinical trial. Therefore, a portfolio of robust in vitro test 
methods (Chapter 2 and 7) was developed, optimised, and applied to investigate 
biomechanical, hydrodynamic and real time fatigue performance of the 
decellularised heart valve roots to predict their mechanical safety and reliability 
before they can be used in clinical studies (Figure 9.1).  
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Figure 9.1 In Vitro Test Methods Developed to Assess Performance of 
Biological (Decellularised) Heart Valve Roots  
The hydrodynamic performance of the heart valve roots was characterised in 
terms of competency under static back pressure and pulsatile flow parameters. To 
measure competency of the aortic and pulmonary heart valve roots under static back 
pressure, a static leakage test rig (Jennings, 2001) was modified, where the vertical 
cylindrical Perspex column was replaced with a longer vertical Perspex column which 
was able to apply a maximum pressure of 120 mmHg. An evaluation study using 
porcine pulmonary heart valve roots indicated that the competency assessment 
method lacked physiological boundary conditions (specifically a lack of annulus 
support) (Chapter 3). To address this problem, the competency assessment method 
was modified for decellularised and cellular human pulmonary heart valve roots by 
adding a delrin ring for annulus support (Chapter 5). To assess hydrodynamic 
performance of heart valve roots under pulsatile flow, the pulsatile flow simulator 
used in previous studies (Fisher et al., 1986, Jennings, 2001, 2014) was optimised. The 
optimised pulsatile flow simulator was capable of mounting cellular and 
decellularised human pulmonary and aortic heart valve roots. 
The biomechanical performance was characterised in terms of root 
circumferential expansion (dilation); uniaxial tensile parameters for wall and leaflets; 
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and suture pull-out load for the wall and myocardium. The uniaxial tensile testing 
method was used to determine wall and leaflet material properties of the heart valve 
roots rather than the biaxial tensile testing method, due to it being a relatively 
straightforward method. Circumferential expansion (dilation) was chosen as the 
indicator of wall stiffness due to its direct representation of the overall arterial 
compliance. Cylindrical Perspex tubes of different sizes were designed for the dilation 
test set up to accommodate heart valve root sizes with diameters ranging from 20 
mm to 32 mm. This test set up enabled the measurement of circumferential 
expansion of the human decellularised and cellular aortic and pulmonary heart valve 
roots in terms of percentage dilation with respect to internal static pressure. The 
material properties of each of the heart valve root components (wall and leaflets) 
were evaluated using uniaxial tensile tests to assess how the component material 
properties affect the function of the valve as a whole. The material testing of heart 
valve roots is often confounded by local complexities introduced at sample-grip 
interfaces (i.e., bending, preloading, cross-section area measurement, stress 
concentrations, tearing). This study developed a suture technique to clamp the tissue 
specimen with specially designed titanium grips in order to avoid excessive 
accumulation of stress near the clamp during uniaxial tensile testing. This produced 
satisfactory results, avoiding specimen rupture close to the grips. Also heart valve 
root specimens are compressible and hence they change their thickness depending 
on the vertical force applied on them during thickness measurement. A repeatable 
and accurate thickness measurement technique was developed for heart valve tissue 
specimens.  
Currently in vitro fatigue and durability of replacement heart valves is evaluated 
in an accelerated fatigue tester according to the ISO 5840 (2015) standard which is 
not suitable for replacement heart valves with viscoelastic properties. The real time 
fatigue assessment at physiologic conditions (e.g. heart rates <200 bpm), to cycle 
counts less than 200 million cycles is recommended by ISO 5840 (2015) for 
replacement heart valves which have components manufactured from viscoelastic 
materials. However, the ISO 5840 (2015)  standard does not define the test 
equipment and detail test method for real time fatigue assessment. With the 
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potential use of decellularised heart valve roots and increased use of biological 
scaffolds in heart valve tissue engineering, there is a need for a new method to 
evaluate fatigue and durability of the scaffolds and decellularised heart valve roots. 
Therefore in this study, a novel in vitro real time fatigue assessment method was 
developed in a real time wear tester (RWT) which replicated physiological 
transvalvular pressure across the closed valve for at least 95 % of the test cycles. 
During fatigue assessment, it is essential to regulate physiological transvalvular 
pressure across the closed valve to attain radial expansion of the leaflets (Lockie et 
al., 1993). In addition, arterial contraction-expansion movement (dilation) was 
achieved by producing the physiological mean pressure of 70 ± 20 mmHg within the 
aorta by modifying the heart valve root holder and adding compliance by a vertical 
pressure column. Arterial wall dilation is an important property which helps to 
transmit stress from the leaflets to the wall (Thubrikar, 2018) and thereby reduces 
fatigue and eventual structural failure of the valve leaflets (Sutton et al., 1995).  The 
validated method was able to evaluate the fatigue of three heart valve roots mounted 
in the RWT per test for a maximum of 1.2 million cycles (Chapter 8). However, the 
fatigue assessment method for biological heart valve roots in the RWT requires 
enhancement due to the lack of flow data through the heart valve root and lack of 
dilation within the aorta. 
The methodologies developed and data derived in this study will provide 
evidence-based standards of practice and the foundation for further research in the 
development of the next generation replacement biological heart valve roots such as 
decellularised heart valve roots. In addition, it would be useful to revise the test 
protocols described by ISO 5840 (2015) to include a real time fatigue test method for 
biological heart valve roots or for tissue based scaffolds.           
The in vitro test methods developed were validated by deriving hydrodynamic 
and biomechanical performance of cellular porcine aortic and pulmonary heart valve 
roots (Chapter 3) and then applied to address several research questions in an effort 
to more fully describe the functional performance of decellularised human aortic and 
pulmonary heart valve roots prior to clinical studies.  
These research questions included:  
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Effect of decellularisation on human aortic and pulmonary heart valve roots 
(Chapter 4 and Chapter 5) 
 The study showed that neither pulsatile flow parameters nor wall material 
properties of the human aortic and pulmonary heart valve roots were significantly 
affected by the low concentration SDS decellularisation treatment. In addition, the 
circumferential expansion properties of decellularised human aortic heart valve roots 
were similar to cellular aortic heart valve roots. However, decellularisation 
significantly altered circumferential expansion properties of human pulmonary heart 
valve roots. In addition, some of the directional material properties of the aortic and 
pulmonary leaflets and the hydrodynamic performance under static back pressure of 
human aortic and pulmonary heart valve roots were altered due to decellularisation. 
The changes in leaflet material properties after decellularisation may be due to the 
significant reduction of glycosaminoglycan (GAGs) and removal of cells reported by 
Vafaee et al. (2016). The loss of GAGs in the decellularised leaflets, may have led to 
loosening of the fibrous structure, and uncrimping of the circumferentially aligned 
collagen fibers. This could potentially cause an earlier than normal recruitment and 
reorientation of the collagen fibers in the direction of applied strain during tensile 
testing (Williams et al., 2009). Previous research studies on decellularised tissues has 
shown similar findings in bone tissue (Banse et al., 2002), ligaments (Herbert et al., 
2016) and soft tissue (Freed and Doehring, 2005). It is expected that the leaflets of 
the decellularised roots will recellularise in vivo and regain their physiological tensile 
properties. In addition, the magnitude of changes in decellularised leaflet material 
properties may not be large enough to influence the performance of the heart valve 
roots in vivo, as these decellularised human and aortic pulmonary heart valves 
showed excellent hydrodynamic performance under pulsatile flow conditions, 
compared to cellular pulmonary heart valve roots.  
There was a concern that the processing step (scraping) used during 
decellularisation (2014) may have had an adverse effect, particularly the functional 
biomechanical performance (dilation and competency) of human pulmonary heart 
valve roots, as studies have shown that the adventitia layer provides structural 
support and protects vessels from overstretch (Lu et al., 2004, Laflamme et al., 2006). 
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Therefore, a subsequent paired comparison of pulmonary heart valve roots with and 
without decellularisation, and with a physiological competency test model, was 
performed. The paired comparison showed no significant difference in the functional 
biomechanical performance of the decellularised and cellular human pulmonary 
heart valve roots.  
In summary, this study has performed for the first time a comparison of in vitro 
biomechanical and hydrodynamic performance of low concentration SDS 
decellularised cryopreserved aortic and pulmonary human heart valve roots (Vafaee 
et al., 2016) with conventionally used cryopreserved aortic and pulmonary human 
heart valve roots and provided valuable pre-clinical data that can support clinical 
studies of decellularised porcine pulmonary heart valve roots. 
Effect of 12 months implantation in sheep on material properties of 
decellularised porcine pulmonary heart valve roots (Chapter 6) 
Low concentration SDS decellularised porcine pulmonary heart valve roots have 
been developed (2014) and have been implanted in sheep for 12 months (Berry et 
al., 2017)  with a view to their clinical use as right ventricle outflow tract replacements 
in the Ross procedure. This study evaluated the material properties of decellularised 
porcine pulmonary heart valve roots following 12 months implantation in sheep. In 
addition, the effect of cryopreservation and decellularisation was evaluated on the 
material properties of cellular porcine pulmonary heart valve roots as the heart valve 
roots were decellularised and cryopreserved before being implanted in sheep.  
The study showed that the material properties of the 12 months explanted 
decellularised porcine (ExpDCP Porcine) pulmonary heart valve root wall in the axial 
and circumferential directions were similar to non-implanted decellularised 
cryopreserved porcine (DecellCP) pulmonary heart valve root wall. However, the 
tensile leaflet material properties of DecellCP pulmonary heart valve roots appeared 
to alter following 12 months of implantation in sheep. But the majority of ExpDCP 
porcine pulmonary root wall and leaflet material parameters (stiffness and strength) 
showed a decreasing trend which indicated that the ExpDCP porcine pulmonary root 
wall and leaflets were becoming more like cellular ovine. Indeed, it was observed in 
the histological and the immunohistochemical analysis that the wall and leaflets of 
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the decellularised porcine pulmonary heart valve roots were repopulating with ovine 
cells following 12 months implantation in sheep (Berry et al., 2017).  In addition, the 
low concentration SDS decellularised treatment combined with cryopreservation 
processing had a minimal effect on porcine pulmonary heart valve roots. 
Effect of decellularisation on the fatigue of porcine aortic heart valve roots 
(Chapter 8) 
To derive the effects of low concentration SDS decellularisation on fatigue of 
porcine aortic heart valve roots, preclinical in vitro real fatigue assessment of low 
concentration SDS decellularised porcine aortic heart valve roots (Wilcox et al., 2005) 
under physiological cyclic pressures and heart rate conditions for a maximum of 1.2 
million cycles was evaluated and compared with cellular porcine aortic heart valve 
roots for the first time. Results showed that there was no significant difference 
between the fatigue properties of decellularised and cellular porcine aortic heart 
valve roots. Four cellular and four decellularised aortic heart valve roots showed no 
mechanical sign of damage, whereas two cellular and two decellularised aortic heart 
valve roots exhibited signs of macroscopic fatigue damage (tear). The fatigue damage 
in all cases was near to the commissure and/or belly region, it may have been due to 
excessive flexion or due to the lack of physiological dilation of the aorta during 
testing. In vivo, dilation of the aortic heart valve root is assumed to transmit the stress 
from the leaflets to the wall and thereby reduces fatigue and eventual structural 
failure of the valve leaflets (Thubrikar, 2018), as detailed in Chapter 1 Section 1.5. 
Remarkably the regions of leaflet failure observed were consistent with in vivo 
(Ishihara et al., 1981, Hilbert et al., 1992, Wells and Sacks, 2002, Piñón et al., 2015) 
and in vitro accelerated (Smith et al., 1999, Sacks and Smith, 1998) fatigue induced 
leaflet tears seen in bioprosthetic porcine heart valves. However, in bioprosthetic 
porcine heart valves (stented and scentless), the dilation of the wall is either limited 
or eliminated due to the fixation process or presence of stent (Raghavan, 2008). The 
performance of the decellularised aortic heart valve roots under pulsatile flow 
following fatigue testing was comparable to cellular aortic heart valve roots. The 
material properties of the cellular porcine aortic heart valve root leaflets were altered 
following cyclic fatigue testing and showed a loss of stiffness (in both collagen and 
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elastin phases) and a loss of strength in the cellular aortic heart valve roots leaflets 
compared to the decellularised porcine aortic leaflets in the circumferential 
direction, possibly due to swelling of the cellular aortic heart valve root leaflets. The 
cellular aortic leaflets consists of the spongiosa layer with highly concentrated 
negative charged groups in glycosaminoglycans (GAGs) which attract positively 
charged sodium ions (Setton et al., 1998) from the test fluid (saline + 0.04 % sodium 
azide) into the leaflets. This produced an imbalance of ions causing the leaflets to 
swell. Conversely, the leaflet swelling in decellularised leaflets was minimum, though 
they were exposed to the same test solution due to the fact that GAG content was 
significantly removed during the decellularisation process (2014, Booth et al., 2002, 
Gilbert et al., 2006, Vafaee et al., 2016).   
Overall, the results from this study suggested that the SDS decellularised 
porcine aortic heart valve roots showed fatigue similar to cellular porcine aortic heart 
valve roots.                                                                                               
9.2  Limitations and Future Work 
The limitations of this research and considerations for future work are 
described below. 
1. Sample size and variability  
The human aortic and pulmonary heart valve roots used in this research came 
from NHS BT TES, Speke, Liverpool; from elderly donors, and were not suitable for 
clinical use. In addition, due to the limited availability of human samples, the study 
was conducted with a relatively low number of samples (n=4) in each group. Sample 
variability is a common concern when conducting experiments with soft tissue. The 
heart valve roots from different human donors showed a wide range of variability 
within the groups (cellular and decellularised) due to their age, size, sex and health 
condition of the donor. For any future studies assessing the effect of decellularisation 
on the human heart valve roots it is recommended that a minimum of six samples 
should be used in each group. It is also recommended to perform a statistical power 
analysis to verify whether the non-significant differences between the groups are due 
to lack of relationship between the groups or due to lack of statistical power. 
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2. Test fluid  
The fluid used in the pulsatile flow simulator and RWT was 0.9 % (w/v) saline 
and 0.9 % (w/v) saline + sodium azide 1 % (w/v) solution. These solutions had lower 
density and viscosity compared to blood (density of saline: 1.0045 g/mL, viscosity of 
saline: 0.001 Pa.s; density of blood: 1.060 g/mL, viscosity of blood 0.0035 Pa.s at body 
temperature), but it was transparent for the benefit of visualisation of leaflet 
dynamics and ease of cleaning the systems. For future studies in a pulsatile flow 
simulator and RWT, the use of potential test fluids could be explored which are a 
closer to a blood analogue. 
3. Mounting of the heart valve root  
The mounting procedure of the heart valve roots, using the cable tie method in 
the pulsatile flow simulator and RWT, could be improved to reduce damage to the 
heart valve root by developing an alternative more robust clamping method.  
4. In vitro real time fatigue assessment method  
The cellular heart valve roots were treated with 150 mL Cambridge antibiotics 
+ 2.5 mL amphotericin B to reduce infection during testing in the RWT. An improved 
method for treating cellular heart valve roots could be investigated and this would 
create less opportunity for initial contamination and allow the experiments to run 
longer with less risk of fungal infection. 
The flow through the heart valve root in the RWT is currently not known. A 
study involving a flow probe in the flow loop of the RWT would enable more insight 
into the dynamic environment in which the heart valve roots can be tested.  
The in vitro fatigue of decellularised porcine aortic heart valve roots was similar 
to cellular porcine aortic heart valve roots. The fatigue damage (tear) in all cases was 
near to the leaflet attachment area, it may have been due to excessive flexion or due 
to the lack of physiological dilation of the aorta during testing. To improve 
physiological dilation or compliant movement of the aorta during fatigue testing in 
the RWT, additional compliance could be added. This could be achieved by replacing 
the existing compliance chamber with an electronically controlled compliance 
chamber to control the volume of air within the compliance chamber. In addition, to 
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gain more insight into the effect of cyclic loading and leaflet failure, it is 
recommended to use histochemical characterisation of the leaflets following fatigue 
assessment. This will help to investigate, on a microscopic level, what the effect of 
cyclic loading on collagen and the elastin fibre network in the leaflets is.  
An extended duration of fatigue testing could provide more information as to 
the effects of decellularisation on the heart valve structure. Cellular tissue viability 
over a longer period of time may be a major hurdle to this proposed future work, 
therefore this would have to be further evaluated by developing and use of culture 
medium to retain viability of cellular heart valve roots. Also continuous monitoring of 
the leaflet dynamics with synchronised pressure measurements would help in the 
assessment of the leaflet failure mode.  
A negative inflow pressure was recorded during the reverse stroke of the pump 
as a result of the resistance to forward flow through the bypass valve. A possible 
solution is to use a larger diameter bypass valve or more than one bypass valve. A 
larger orifice will result in less resistance to the flow and lower negative pressures 
generated by the suction effect. 
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Figure 9.2 Proposed Schematic Diagram of Flow Loop for the RWT  
The heart valve roots under test were not isolated from the inflow side from 
one another during real fatigue testing which meant it was not possible to control 
pressure across each closed heart valve individually. To address the limitations with 
the RWT, the flow loop for the RWT could be redesigned as shown in Figure 9.2. 
This proposed flow loop design in Figure 9.2 for the RWT consists of three 
isolated Perspex valve chambers A1, A2 and A3. The pulsatile flow pump pumps the 
test fluid through the heart valve roots which are placed in the heart valve chambers 
A1, A2 and A3. The flow from each heart valve root is monitored by the flow probes 
F1, F2 and F3, connected to the outflow side of the chambers. The inflow and outflow 
pressure of the heart valve root can be measured with inflow (P1, P3, P5) and outflow 
(P2, P4, P6) pressure transducers. The pressure across each heart valve root could be 
controlled individually with pressure regulating valves (V1, V2 and V3). The other 
elements of the flow loop are the electronically controlled compliance chamber and 
temperature controller which are used to add resistance to the circuit and to control 
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the temperature of test fluid during testing. The fluid flow would pass through the 
heart valve roots (mounted in the aortic position) by opening the valves during the 
forward stroke; and during the reverse stroke the fluid flow would pass through the 
mitral valve and back to the valve chambers.   
9.3 Conclusion 
In summary this thesis has provided important contributions to the field of 
heart valve replacement:  
1. A portfolio of in vitro pre-clinical test methods was developed where 
hydrodynamic and biomechanical performance assessment methods for 
biological heart valve roots including decellularised heart valve roots were 
optimised. 
2.  A novel fatigue assessment method was developed for biological heart valve 
roots and real time in vitro fatigue assessment of the cellular and decellularised 
porcine aortic heart valve roots was evaluated for the first time in this study, 
where decellularised porcine aortic heart valve roots showed fatigue similar to 
cellular porcine aortic heart valve roots.  
3. A full functional performance of cryopreserved decellularised human aortic and 
pulmonary heart valve roots was compared for the first time in a systematic way 
with conventionally used cryopreserved human aortic and pulmonary heart valve 
roots, evaluating the effect of decellularisation. 
4. The in vitro material properties of cryopreserved decellularised porcine 
pulmonary heart valve roots was evaluated following trans-species implantation 
of decellularised porcine pulmonary heart valve roots for 12 months. 
Impact of this research: 
These studies provided valuable pre-clinical functional performance data that 
will contribute to the safety and effectiveness of decellularised human and porcine 
heart valve roots, which will support clinical translation and commercialisation of SDS 
decellularised heart valve roots. Following the translation of the decellularisation 
protocol into a good manufacturing practices-compatible process for donor 
cryopreserved human heart valve roots in collaboration with NHSBT Tissue & Eye 
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Services, developed in vitro test methods will be applied to access their functional 
performance with a view to future clinical use. A sterilisation process will be 
developed for the decellularised porcine heart valve roots and in vitro test methods 
will be applied to assess functional performance of the decellularised porcine heart 
valve roots post-sterilisation. 
The developed in vitro pre-clinical test methods for biological heart valve roots 
will help in the refinement of in vivo large animal studies and improve translation 
outcome of large animal studies. In addition, the methods and the data from this 
research has the potential to help in the revision of ISO 5840 (2015) by including such 
testing for decellularised heart valve roots. 
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 Appendix B: Engineering Drawings for Tissue Specimen Holder and Adaptors for the Uniaxial Tensile Tester 
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 Appendix C: Engineering Drawing for Heart Valve Root Holder for the RWT………… 
 
